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Abstract / Resumen 
Pathophysiology of Primary Coenzyme Q10 Deficiencies. Molecular 
Characterisation of COQ4 gene. 
Primary Coenzyme Q10 (CoQ10) deficiencies are a group of rare conditions genetically 
caused by autosomal recessive biallelic mutations in one of the COQ genes required in 
CoQ10 biosynthesis pathway. The associated clinical manifestations are highly 
heterogeneous and mainly affect central and peripheral nervous system, kidney, 
skeletal muscle and heart.  
The first part of this thesis is focused on studying the primary CoQ10 deficiency 
syndrome.  
Firstly, we present an updated and comprehensive review of all the clinical 
manifestations associated to each of the pathogenic variants in the COQ genes described 
in the literature. With this, we describe patterns of symptoms related with the age of 
onset of the disease for each COQ gene and even, when possible, for each mutation 
involved in primary CoQ10 deficiency, as an attempt to establish genotype-phenotype 
correlations.  
Secondly, we report new cases of primary CoQ10 deficiency due to mutations in COQ4 
and COQ7, expanding phenotypes and genotypes associated to these disorders. We 
worked with different in vitro cellular models with mutations in COQ4, COQ6 or COQ7, 
which accumulate diagnostic intermediates, specific for each COQ defect. Moreover, we 
demonstrate that treatment with 4-hydroxybenzoate (4-HB) analogues is effective in 
some of the cases. 2,4-dihydroxybenzoic acid (2,4-dHB) decreases DMQ10 accumulation, 
increases CoQ10 levels and ameliorate respiratory function in COQ7 mutant fibroblasts. 
Vanillic acid (VA) restores CoQ10 biosynthesis and respiration in COQ6 KO cells. 
In the second part of the thesis, we focused on human COQ4 protein, which has an 
essential role in CoQ10 biosynthesis.  
In our work, we demonstrate that human COQ4 protein is essential for CoQ10 
biosynthesis in cells. We have generated a human COQ4 KO cell line, which has a 




profound deficiency in CoQ10 levels and a great respiratory defect, rescued with CoQ10 
treatment or WT COQ4 expression. Moreover, the lack of COQ4 protein produces the 
accumulation of a specific intermediate. We also found that most of the mutations 
described in patients are hypomorphic, fully recovering CoQ10 biosynthesis in the COQ4 
KO cells when overexpressed.  
With proteomics studies, we identified all the COQ proteins (except for COQ8A) 
copurifying with COQ4 after immunocapture. This fact provides evidence for the 
mammalian CoQ biosynthesis complex and its composition. Moreover, we observed 
that the lack of COQ4 or COQ6 proteins alters the levels of other COQs proteins, 
probably modifying the stability of the biosynthetic complex.   
In this context, yeast CoQ head-modifying enzymes have been resolved in discrete loci, 
so-called CoQ domains, adjacent to ER-mitochondria contact sites 1,2. Mitochondrial 
DNA (mtDNA) maintenance and distribution seems to depend on endoplasmic reticulum 
(ER) -mitochondria contacts 3, and cholesterol levels in these sites are reported to be 
key for this issue 4. We explored these relationships with our COQ4 KO model.  We found 
that the lack of COQ4 led to a slight decrease of mtDNA copy number, with no effect on 
mtDNA transcription and a very subtle effect on mtDNA-encoded translation. Regarding 
mtDNA replication, the lack of COQ4 or COQ6 induced a faster mtDNA recovery rate 
after an induced depletion. In order to find the molecular mechanism explaining this 
surprising phenotype, we studied cholesterol content and distribution of nucleoid 
proteins in density gradients. We found that total cholesterol levels were not altered in 
mitochondria, but we found subtle differences between COQ4 KO and control cells in 
terms of nucleoid proteins (TFAM and ATAD3) distribution in these gradients. This fact 
may be behind the fast mtDNA recovery after induced depletion. However, there is still 
a lot of work to be done to better understand the relationship between CoQ biosynthesis 
and mtDNA metabolism.  
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Fisiopatología de las Deficiencias Primarias de Coenzima Q10. Caracterización 
Molecular del Gen COQ4. 
Las deficiencias primarias de coenzima Q10 (CoQ10) son un grupo de enfermedades raras 
genéticas causadas por mutaciones bialélicas recesivas en uno de los genes COQ 
requeridos en la ruta de biosíntesis de CoQ10, a nivel enzimático o regulador. Las 
manifestaciones clínicas asociadas son muy heterogéneas y afectan principalmente al 
sistema nervioso central y periférico, a los riñones, al músculo esquelético y al corazón. 
La primera parte de esta tesis se centra en el estudio del síndrome de la deficiencia 
primaria en CoQ10. 
En primer lugar, hemos realizado una revisión actualizada y exhaustiva de todas las 
manifestaciones clínicas asociadas a cada una de las variantes patogénicas en los genes 
COQ descritas en la literatura. En ella, describimos patrones de síntomas relacionados 
con la edad de aparición de la enfermedad para cada gen COQ e incluso, para cada 
mutación, cuando es posible. Con estos patrones, hemos intentado establecer 
correlaciones genotipo-fenotipo para la deficiencia primaria en CoQ10. 
En segundo lugar, hemos descrito nuevos casos de deficiencia primaria de CoQ10 debido 
a mutaciones en los genes COQ4 y COQ7, ampliando los fenotipos y genotipos asociados 
a estos trastornos. Hemos trabajado con diferentes modelos celulares in vitro con 
mutaciones en COQ4, COQ6 y COQ7, que acumulan intermediarios diagnósticos, 
específicos para cada defecto COQ. Además, demostramos que el tratamiento con 
análogos del 4-hidroxibenzoato (4-HB) es eficaz para mejorar la deficiencia de CoQ10 y 
el defecto respiratorio en nuestros modelos celulares humanos: el ácido 2,4-
dihidroxibenzoico (2,4-dHB) para la deficiencia en COQ7 y el ácido vainillínico (VA) para 
los defectos en COQ6. 
En la segunda parte de la tesis, nos hemos centrado en la proteína COQ4 humana, que 
tiene un papel esencial en la biosíntesis de CoQ10. 
En nuestro trabajo, demostramos que la proteína COQ4 humana es esencial para la 
biosíntesis de CoQ10 en las células. Hemos generado una línea celular humana KO en 
COQ4, que tiene una gran deficiencia en CoQ10 y en la respiración mitocondrial. Estos 
defectos son rescatados con un tratamiento con CoQ10 o con la expresión del gen COQ4 




WT. Además, la falta de proteína COQ4 produce la acumulación de un intermediario 
específico de la ruta de síntesis. También encontramos que la mayoría de las mutaciones 
descritas en pacientes son hipomórficas, capaces de recuperar completamente la 
biosíntesis de CoQ10 en las células COQ4 KO cuando son sobreexpresadas. 
Con estudios de proteómica, hemos podido identificar todas las proteínas COQ (excepto 
COQ8A) copurificando con COQ4, lo que es una evidencia más de la existencia del 
complejo de síntesis de CoQ en mamíferos. Además, observamos que la falta de 
proteínas COQ4 o COQ6 altera los niveles de otras proteínas COQs, probablemente 
modificando la estabilidad del complejo biosintético. 
Se ha descrito que las enzimas modificadoras de la cabeza de CoQ en levadura resuelven 
en loci discretos, denominados dominios CoQ, que se encuentran adyacentes a los sitios 
de contacto entre el retículo endoplásmico (ER) y las mitocondrias 1,2. Además, el 
mantenimiento y la distribución del ADN mitocondrial (mtDNA) depende de estos 
contactos ER-mitocondria 3, y los niveles de colesterol en estos sitios parecen ser clave 
para ello 4. En la última parte de la tesis, hemos explorado estas relaciones en nuestro 
modelo COQ4 KO. La falta de COQ4 produce una ligera disminución del número de 
copias de mtDNA, sin efecto sobre la transcripción de mtDNA y un efecto muy sutil sobre 
la traducción de proteínas codificadas por el mtDNA. Con respecto a la replicación del 
mtDNA, la falta de COQ4 o COQ6 induce una tasa de recuperación más rápida del mtDNA 
después de una depleción inducida. Para encontrar el mecanismo molecular de este 
sorprendente fenotipo, hemos estudiado el contenido de colesterol y la distribución de 
proteínas de los nucleoides en gradientes de densidad. Los niveles de colesterol total 
parecen no estar alterados en las mitocondrias de las células COQ4 KO. Sin embargo, 
hemos encontrado diferencias sutiles entre COQ4 KO y las células control en la 
distribución de proteínas de los nucleoides (TFAM y ATAD3) en estos gradientes. Este 
hecho podría estar detrás de la rápida recuperación del mtDNA después de la depleción 
inducida. Sin embargo, todavía queda mucho trabajo por hacer para comprender mejor 
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The term mitochondria was first coined in 1898 by the German microbiologist Dr Carl 
Benda. By using a light microscope, he observed long granulated chains during 
spermatogenesis and named them mitochondrion. This word derives from the Greek 
mitos, meaning thread, and chondrion, meaning grain 5. It is widely accepted that, 
together with chloroplasts, mitochondria originated from a facultative anaerobic α-
proteobacterium that was endocytosed by a primitive methanogenic archaebacterium 
during eukaryotic evolution 6. This endosymbiotic event provided the bioenergetic 
means for large variations in the shape, size and function of eukaryotic cells to evolve, 
leading to the creation of multicellular organisms with specialised cell types. 
Mitochondria contain their own DNA, the mitochondrial DNA (mtDNA), which over the 
course of evolution was reduced through horizontal gene transfer into nuclear DNA 
(nDNA), but still encodes for a subset of the mitochondrial proteins (See Chapter 5).  
Mitochondria are membrane-enclosed organelles of eukaryotic cells, vital for producing 
the energy needed for all biological processes. Commonly known as “the powerhouse 
of the cell”, mitochondria  are specialised in adenosine triphosphate (ATP) production 
by a process called oxidative phosphorylation (OXPHOS), for  which oxygen is required7. 
These organelles are in the centre of the cellular energy metabolism, as they also host 
essential biochemical processes such as the tricarboxylic acid (TCA) cycle or Krebs cycle, 
urea cycle and β-oxidation of fatty acids, which are intimately linked to OXPHOS. In 
addition, mitochondria play a critical role in other cellular pathways, such as the 
regulation of calcium homeostasis, the production of reactive oxygen species (ROS), 
autophagy and apoptosis or programmed cell death.  
I1.1. Mitochondrial architecture and dynamics 
Mitochondria have an extremely developed membrane system, composed by two 
membranes known as mitochondrial inner and outer membranes, fact that is considered 
evidence of the endosymbiotic theory. Both the outer and the inner membranes,  





Figure I.1. Mitochondrial architecture and dynamics.  
(A) Cartoon representation of mitochondrion. (B) Electron micrograph of a mitochondrion (Taken from 
Alberts et al., 20158). (C) Computer model generated from segmented tomograms of bovine heart 
mitochondrion (Taken from Gustafsson et al., 20169). (D) Mitochondrial network shown in a light 
micrograph of chains of living mammalian cell in culture (stained with rhodamine 123) (Taken from Alberts 
et al., 20158). 
together with membrane protein complexes, work to transform biomolecules, such as 
sugars, lipids and proteins, into chemical energy in the form of ATP. These two 
membranes have distinct biochemical properties and functions, and they divide the 
organelle into two separate compartments: the matrix (inside the inner membrane) and 
the intermembrane space (IMS), between the two membranes (Figure I.1.A, B and C) 8.  
The outer mitochondrial membrane (OMM) has a similar composition to the cell plasma 
membrane. It contains a large number of integral proteins called porins or voltage-
dependent anion channels (VDAC), that make it permeable to small molecules (< 5 kDa) 
and ions. Therefore, the IMS has the same ionic composition and pH than the cytoplasm, 
and there is no electrochemical gradient across the OMM. A dedicated translocase of 





Moreover, mitochondria can interact with other cellular structures through contacts 
that are established on the OMM, such as the endoplasmic reticulum (ER)-mitochondria 
contact sites. Mitochondria-ER contacts are specific and specialised domains in which 
many processes occur, such as the exchange of lipids between the two membrane 
systems or the induction of mitochondrial fission (see Chapter 5).   
The inner mitochondrial membrane (IMM) is more complex and shares many 
characteristics with the bacterial cell membrane, such as the presence of cardiolipin14, 
among others. It has a high protein concentration and low permeability, being only 
permeable to O2, carbon dioxide (CO2), and water (H2O). Specific mitochondrial carriers 
exist to transport proteins and other molecules through the IMM. This controlled 
permeability allows the generation and maintenance of an electrochemical gradient 
across the IMM, known as the proton-motive force (PMF), which is essential for ATP 
synthesis 7 and other mitochondrial functions such as Ca2+ uptake through the 
mitochondrial calcium uniporter (MCU) 15. IMM is forming highly folded invaginations 
called cristae, enhancing the surface in which the OXPHOS machinery is installed 16,17. 
Continuous with the cristae membrane, there is the boundary membrane region, which 
is thought to contain the machinery for protein import (translocase of the inner 
membrane, TIM), new membrane insertion and respiratory complexes assembly.  
The IMS is crucial for several mitochondrial functions, such as the exchange of proteins, 
lipids and metal ions between the matrix and the cytosol 18–20. It contains the 
mitochondrial intermembrane space assembly (MIA) for oxidative protein folding 21. 
Cytochrome c, a protein involved in electron transfer on the IMM, is also located in the 
IMS, and its release into the cytoplasm triggers apoptosis. The IMS also contains other 
proteins such as Cu/Zn superoxide dismutase, which detoxifies superoxide (O2·−), a 
potentially harmful by-product of oxygen metabolism. 
Mitochondrial matrix is a viscous, protein-rich compartment. It contains multiple copies 
of the mtDNA genome packed with specific proteins in the so-called nucleoids, as well 
as the replication, transcription and translation machineries for expression and 
maintenance of the mtDNA. It also contains pools of ions and proteins involved in many 
different processes, such as the catabolism of pyruvate, fatty acids and amino acids, the 




TCA cycle, the biosynthesis of coenzyme Q (CoQ) and steroids, the biosynthesis of haem 
moieties and iron-sulphur (Fe-S) clusters, etc 22.  
Mitochondria form a markedly dynamic tubular network, constantly dividing, fusing and 
changing shape or position, for what they are often associated to the microtubules of 
the cytoskeleton (Figure I.1.D) 23. Mitochondrial fusion produces elongated tubular 
mitochondria, optimising mitochondrial function by spreading metabolites, protein and 
mtDNA throughout the entire mitochondrial compartment. Fission produces small 
spherical mitochondria, allowing the segregation and isolation of dysfunctional 
mitochondria. Fusion and fission are both driven by membrane remodelling enzymes 
which are part of the dynamin family of large GTPases, including Dynamin-related/-like 
protein 1 (Drp1), mitofusin (MFN) and optic atrophy 1 (OPA1) proteins. Fusion and 
fission events in the mitochondrial network are balanced, in order to adapt 
mitochondrial morphology to the metabolic needs of the cell. The regulation of 
mitochondrial dynamics is crucial for mitochondrial function and quality control 23–26. 
I1.2. Energy transduction in mitochondria: the OXPHOS system 
Energy transduction in mitochondria starts with the catabolism of pyruvate (from 
carbohydrates), fatty acids (from fats) and amino acid (from proteins), which are 
imported to mitochondria by specialised mitochondrial carriers, and are degraded to 
acetyl-coenzyme A (CoA) (Figure I.2) 27. The pyruvate dehydrogenase complex 
decarboxylates pyruvate to acetyl-CoA, also producing a molecule of CO2 and a molecule 
of reduced nicotinamide adenine dinucleotide (NADH). Fatty acids are activated as fatty 
acyl-CoA, and broken down completely by a cycle of reactions (beta-oxidation of fatty 
acids) that trims two carbons at a time from its carboxyl end, generating a molecule of 
acetyl-CoA, a molecule of NADH and a molecule of reduced flavin adenine dinucleotide 
(FADH2) for each turn of the cycle 8.  
The acetyl groups are incorporated to the TCA cycle to form citric acid, which is gradually 
oxidised. The energy of these oxidations is stored in the form of three molecules of 
NADH, a molecule of FADH2 and a molecule of guanosine triphosphate (GTP) for each 





oxidation of the acetyl-CoA. NADH and FADH2 produced during this oxidative process 
feed electrons into de electron transport chain (ETC) in the IMM (Figure I.2) 8.  
 
Figure I.2. General overview of mitochondrial metabolism.  
Main metabolic pathways are shown in red. The outer and inner membranes are indicated with dashed 
and continuous lines, respectively. The ATP synthase and the complexes of the respiratory chain are blue 
and green, respectively. Known and unknown carrier proteins are shown in yellow and purple, 
respectively. Green arrows indicate electron flux, blue arrows indicate proton pumping and the curly red 
arrow indicates oxygen conversion to water (Taken from Kunji and Robinson, 201027). 
 
In the process of electron transport, subsequent redox reactions occur spontaneously 
from a pair with lower or more negative redox potential (NADH/NAD+), to a pair with a 
higher or more positive redox potential (Figure I.3). Each complex of the system has a 
higher affinity for electrons (or higher redox potential) than the previous one, being the 
molecular oxygen the acceptor with the highest electron affinity of all. The electrons 
finally combine with O2 to form H2O, a low energy molecule. The energy released during 
the electron transport results in pumping H+ out of the matrix, across the IMM 8.  
This process generates an electrochemical gradient across the IMM, which causes a 
PMF. Two components define the PMF: an electrical membrane potential (ΔΨ) and a 
chemical pH gradient (ΔpH), which tends to drive H+ back to the matrix. The ATP 
synthase or complex V uses this force to rotate and generate ATP from adenosine 
diphosphate (ADP) and inorganic phosphate (Pi). The whole process is called oxidative 
phosphorylation (OXPHOS) (Figure I.4) 8.  






Figure I.3. Standard free-energy change 
for the transfer of each of the two 
electrons donated by an NADH molecule.  
NADH dehydrogenase (complex I) and 
cytochrome b-c1 (complex III) complexes 
each pump two H+ per electron. 
Cytochrome oxidase (complex IV) pumps 
one H+ per electron. Pink arrows indicate 
electron flux, black arrows indicate proton 
flux. (Taken from Alberts et al., 20158). 
 
The mitochondrial respiratory chain (MRC) is composed by three large enzymatic 
complexes embedded in the IMM, which pump electrons to the IMS and contribute to 
the PMF: Complex I, Complex III and Complex IV; the ATP synthase or Complex V, which 
uses this force to generate ATP; two small mobile electron carriers, to support electron 
transfer between complexes: coenzyme Q or ubiquinone (CoQ) and cytochrome C (CytC) 
(Figure I.4); and other protein complexes or enzymes that feed the chain with electrons: 
Complex II and other enzymes giving electrons to CoQ (dihydroorotate dehydrogenase, 
mitochondrial glycerol-3-phosphate dehydrogenase, electron transport flavoprotein 
dehydrogenase (ETFDH), proline dehydrogenase 1 and 2, sulphide-quinone 
oxidoreductase, see Introduction, Section I2.3) 28. 
 
Figure I.4. Schematic representation of mitochondrial respiratory chain and OXPHOS.  
Electrons are donated to CI or CII by the electron carriers NADH and FADH2 respectively, and then flow to 
CIII and CIV, with the help of CoQ and CytC (pink arrows). Finally, electrons reach Complex IV and are 
passed onto the terminal electron acceptor O2, which is reduced to H2O. Electron transport provides 
energy to complexes I, III and IV to pump protons across the IMM, generating the PMF. The PMF drives 
H+ back down its gradient through CV (FoF1-ATP synthase), which harnesses the energy of this movement 







Complex I is also known as NADH dehydrogenase complex or NADH:ubiquinone 
oxidorreductase (Complex I, CI, EC1.6.5.3). It is the largest complex, with 45 subunits 
constituting a L-shaped enzyme, with a hydrophilic arm, facing the matrix, and a 
membrane embedded hydrophobic arm. CI catalyses the electron transfer from NADH 
to the lipid-soluble electron carrier CoQ through the matrix arm, through a non-
covalently bound flavin mononucleotide (FMN), one 2Fe-2S cluster and six 4Fe-4S 
clusters (Figure I.5) 29. The energy derived from the transfer of two electrons from NADH 
to ubiquinone is used to pump 4 H+ to the IMS, through the membrane arm. Ubiquinone 
receives 2 electrons, and also takes up 2 H+ from the matrix to be fully reduced. This 






Figure I.5. Structure and 
reactions catalyzed by 
mammalian complex I.  
NADH is oxidized by a FMN at the 
top of the hydrophilic domain. 
Electrons are then passed along a 
chain of iron–sulfur clusters 
(ending in cluster N2) to reduce 
CoQ in the Q-binding site. Four 
protons are transferred from the 
matrix to the IMS for each NADH 
oxidized. The reduced FMN also 
reacts with O2 to form ROS. The 
fourteen subunits of the core 
enzyme are shown in color. 












Complex II is also named succinate dehydrogenase or succinate:ubiquinone reductase 
(Complex II, CII, EC1.3.5.1): CII is a component of the TCA cycle that catalyses the 
electron transfer from succinate to ubiquinone, through a flavin adenine dinucleotide 
(FAD), the 2Fe-4S, 4Fe-2S and 3Fe-4S clusters and one haem  (Figure I.6) 30,31.  CII 
contains the dimeric TCA enzyme succinate dehydrogenase, and three other small 
hydrophobic subunits embedded in the crista membrane. CII does not pump H+, so it 
does not contribute to the PMF 8. That is why sometimes it is not considered as a part 
of the MRC, but as one of the many dehydrogenases that donate electrons to CoQ in the 




Figure I.6. Structure and 
reactions catalyzed by porcine 
complex II.  
Electron transfer occurs from 
succinate to ubiquinone via a 
FAD, three iron-sulphur clusters 
(2Fe-4S, 4Fe-2S and 3Fe-4S) and 
one haem (heme b). (Adapted 












Cytochrome c reductase, cytochrome b-c1 complex or ubiquinol:cytochrome c 
oxidoreductase (Complex III, CIII, EC1.10.2.2) are other names for CIII. It is a dimeric 
complex, and each of the monomers contains three cytochrome haems and one 2Fe-2S 
cluster. CIII catalyses the electron transfer from a two-electron carrier (CoQH2) to a one-
electron carrier (CytC) by the Q cycle (Figure I.7). In the process of electron transfer, 
protons are vectorially translocated to the IMS 32–35. Each CoQH2 in the intermembrane 
side of the IMM passes two electrons to CIII, one to reduce one CytC and the other one 
to a molecule of oxidised CoQ in the matrix side of the IMM, reducing it to 
semiubiquinone. This semiubiquinone will be fully reduced to ubiquinol when another 
CoQH2 molecule transfers again a pair of electrons to CIII, one to reduce a second CytC 
molecule, and the other one to the semiubiquinone on the matrix side. Thus, two CoQH2 
molecules (IMS side) are required to eventually reduce two CytC and one CoQ (matrix 
side). Simultaneously, 2 H+ are transported to the intermembrane space per cycle, so 4 
H+ are translocated per pair of electrons transported through CIII to CytC. The net effect 
of the electron pair transfer is that one molecule of CoQH2 is oxidised to CoQ, and two 
molecules of oxidised CytC are reduced. CytC is a small soluble protein, located in the 
IMS, which carries electrons, one at a time, to Complex IV 8.  
 
Figure I.7. The Q-cycle through complex III.  
Successive oxidation of two CoQH2 (IMS side), resulting in the reduction of one CoQ and two cytochrome 
c(matrix side). The electron transfer pathways through the co-factors are represented with red arrows, 
and the proton transfer with blue arrows. (Adapted from Wikström et al., 201535). 
 





Complex IV is the cytochrome c oxidase complex (COX) or succinate:cytochrome c 
oxidoreductase (Complex IV, CIV, EC1.9.31). It contains two cytochrome haems and 
three copper atoms. CIV accepts electrons, one at a time, from reduced CytC and 
transfers them to O2, producing H2O (Figure I.8). Coupled with the reduction by four 
electrons of O2 to two molecules of H2O, 4 H+ are pumped to the IMS 8,36.  
 
Figure I.8. Reactions catalyzed by complex IV.  
Electron transfer occurs from cytochrome c to O2 via copper centre CuA, then haem a and finally to haem-
a3-CuB centre-haem (pink arrows). Proton pumping is represented with green arrows. (Adapted from 
Alberts et al., 20158). 
Complex V 
Complex V is the ATP synthase, H+-transporting two-sector ATPase or FoF1-ATPase 
(Complex V, CV, EC 3.6.14). This complex uses the PMF generated by the respiratory 
complexes CI, III and IV to produce ATP from ADP and Pi. It is composed of two distinct 
domains: the membrane-intrinsic proton-translocating domain (Fo) and the membrane-
extrinsic matrix-protruding catalytic domain (F1), and both are connected through 
central and peripheral stalks. In the IMM, dimers of the ATP synthase are formed by the 
association of their membrane domains. These dimers are localized at the region of 





H+ from the IMS pass through the F0 region, driven by the PMF. This leads to 
conformational changes that cause the clock-wise rotation of the central stalk. The 
central stalk transmits the rotational energy of the motor to the catalytic domain of F1, 
producing conformational changes that allow the catalysis and release of one molecule 
of ATP per 3 H+ translocated, approximatively (Figure I.9) 37–39. F1 contains five types of 
subunits: α3, β3, γ, δ and ε. The conversion of ADP+Pi to ATP occurs at the catalytic sites 
of β subunits, which can exist in three different conformations: the open form, which 
does not bind neither substrate nor product; the loose form that binds ADP and Pi 
weakly; and the tight form, which binds a molecule of ATP. Most of the ATP produced 
by the OXPHOS system is translocated by ADP/ATP carrier proteins into the cytosol, 
where it is used as the chemical energy supply in a myriad of other cellular reactions. 
 
 
Figure I.9. Structure and ATP synthesis function of bovine ATP synthase.  
The ATP synthase is found in the IMM, with the F1 region in the mitochondrial matrix and the FO region 
accessible from the IMS. The PMF drives protons across the c-ring (blue arrow), inducing a clockwise 
rotation of this subunit that is transferred to the central stalk (orange arrow). The rotation induced 
conformational changes in the catalytic crown of F1 region, that catalyses the conversion of ADP+Pi to ATP 










MRC complexes interact with each other forming higher order structures with different 
stoichiometries, called supercomplexes (SCs). Blue Native Gel Electrophoresis (BN-
PAGE) of digitonin treated mitochondria has revealed SCs with different molecular size 
and subunit composition, including III2IV1, I1III2, I1III2IV1, and I2III2IV1–2 40–42. The 
supercomplex I1III2IV1 has been called the respirasome, and the supercomplex I2III2IV2 
has been named as respiratory megacomplex. High-resolution cryo-electron microscopy 
(cryo-EM) structures of the respirasome of several mammalian species, including 
human, have been resolved in the last years 43–46. However, their mode of assembly and 
specific roles are not known yet 36,41–44,47.  
It has been proposed that CoQ is organised in different pools, being each of them specific 
and essential for each respiratory-active super assembly 48,49. However, this fact is 
controversial, since CoQ can be experimentally reoxidised more rapidly by alternative 
quinol oxidases outside the SCs than by CIII inside these SCs 50,51. This would indicate 
substrate channelling does not occur, but instead CoQ diffuses freely, constituting one 
single pool 50,51.  
I1.3. Other mitochondrial functions 
Besides their function in ATP production metabolism, mitochondria also have a plethora 
of other functions, including many metabolic pathways. Mitochondria participate in 
amino acid metabolism. Some anabolic and catabolic pathways of all the 20 amino acids 
are associated with mitochondria 52.  Additionally, some steps of the synthesis and 
degradation of nucleotides 53 and fatty acids 54 also occur inside mitochondria. The 
biosynthesis of CoQ 28, steroids 55 and cardiolipin 14 take place inside this organelle as 
well. Moreover, mitochondria play a pivotal role in iron metabolism56. The incorporation 
of iron into haems 57 and Fe-S clusters 58,59 also takes part in the mitochondria.  
Mitochondria have an important role in calcium storage and signalling. Mitochondrial 
Ca2+ uptake is performed through the mitochondrial calcium uniporter (MCU) 15. 





Mitochondria are key players in both programmed cell death by apoptosis and necrotic 
cell death. Apoptosis occurs in response to stress, such as DNA damage, growth factor 
withdrawal or oxidative stress. During apoptosis, the OMM is permeabilised and several 
IMS proapoptotic proteins, such as CytC, are released to the cytosol 60. Necrosis is 
triggered by excessive production of ROS, and Ca2+ overload of the mitochondrial matrix. 
Necrosis death is characterised by permeabilisation of the IMM, by opening the 
mitochondrial permeability transition pore (MPTP). This leads to the dissipation of the 
IMM potential, ion deregulation, mitochondrial and cellular swelling, activation of 
degradative enzymes, failure of the plasmatic membrane and cell lysis 61–63.  
I1.4. Mitochondrial diseases: an overview 
Mitochondrial diseases are a group of rare genetic disorders with very heterogeneous 
origins, leading to a total or partial mitochondrial dysfunction of the OXPHOS system, 
the main source of ATP in cells. Therefore, clinical manifestations typically involve 
organs with high energetic demands, such as brain, muscle, eye, heart or kidney. They 
are highly heterogenous, both genetically and clinically, and they can affect virtually any 
organ and may present at any age 64,65. Genetically, they are further complicated by the 
involvement of both nuclear and mitochondrial genomes coding for essential 
mitochondrial proteins.  
Their estimated prevalence is 1 out of 5,000 people, being as a whole, the most frequent 
cause of inherited metabolic disease 66,67. Several studies have shown that nuclear 
genetic defects are the main cause of childhood mitochondrial disease whereas mtDNA 
mutations are more prevalent in adult cases 64. 
Genetics of mitochondrial diseases and molecular diagnosis 
Mitochondria are under the control of two different genetic programmes, the nuclear 
and the mitochondrial genome. Thus, mitochondrial diseases can be due to mutations 
in nDNA, with autosomal and X-linked inheritance, or in the mtDNA, maternally 
inherited. Some rare sporadic cases of diseases caused by de novo mutations in either 
mtDNA or nDNA genes have also been found 65.  




The nuclear genome encodes around 1,500 proteins that are involved in mitochondrial 
structure and function 69. Around 300 nuclear genes encoding mitochondrial proteins 
have been associated with mitochondrial diseases to date (Figure I.10) 64,68,70. These 
proteins can be classified as: MRC subunits, MRC assembly factors, proteins involved in 
mtDNA maintenance, replication and transcription, factors involved in mitochondrial 
protein synthesis, protein import machinery, proteins involved in mitochondrial 
dynamics, motility, membrane integrity and protein quality control, or other proteins 
participating in mitochondrial metabolism, such as the biosynthesis of lipids and 
cofactors, the iron metabolism, etc. 64,65,68,70–72.  
 
 
Figure I.10. Genes linked to mitochondrial disease.  
All of the genes reported to date in which mutations have been shown to cause mitochondrial diseases. 
They are classified by their specific function in (A) genes directly involved in OXPHOS biogenesis or (B) 
genes with a secondary impact on OXPHOS is secondary, likely involving additional cellular functions. 







The mitochondrial genome only has 37 genes, but the mtDNA can exist in multiple copies 
in each cell, and different populations of mtDNA molecules can coexist in the same cell 
(heteroplasmy) (See Chapter 5, section 5.1.2). Therefore, in patients with mutations in 
the mitochondrial genome (Figure I.10), the pathological variant can be in homoplasmy 
or different levels of heteroplasmy, which complicates the inheritance pattern and the 
clinical outcome.  
In general, the higher the percentage of heteroplasmy is, the more severe the disease 
is, and critical threshold level above 60-80% of heteroplasmy is required to trigger the 
OXPHOS defects in specific tissues. However, it depends widely on the patient’s 
background, the mutation, the disease, the tissues or organs affected, etc. Moreover, 
the percentage of heteroplasmy can vary among tissues, and the mutation load 
increases with age, complicating even more the picture. Currently, more than 250 
pathogenic mtDNA mutations have been identified (Mito-MAP database, 
www.mitomap.org) and can be classified as: large-scale rearrangements (partial 
deletions or duplications), that are usually sporadic; and point mutations, that are 
usually maternally inherited 65,73.  
The development of next-generation sequencing (NGS) technologies has revolutionised 
the diagnosis of genetic disorders in general, and mitochondrial diseases in particular. 
Mitochondrial disorders are particularly amenable to such strategies, as they are very 
heterogeneous 72. Over the past decade, different NGS approaches have been 
successfully implemented 70:  
i. Whole mtDNA sequencing allows the identification of any mtDNA variant and its 
accurate heteroplasmy levels. 
ii. Targeted gene panels sequence a specific list of genes encoding respiratory chain 
components or known disease-associated genes, or even more expansive panels, 
known as the MitoExome which included all genes listed in the MitoCarta 
database. 
iii. Whole exome sequencing (WES) analyses only the exons (around 1.6 % of the 
total genome) and allows the identification of pathogenic variants in the protein-
coding region of any gene, which is the most common case (85%).  




iv. Whole genome sequencing (WGS) extends the analysis to the whole genome, 
being helpful to detect variations outside the exons. 
v. RNA sequencing (RNA-Seq) transcriptomics is sometimes implemented to 
complement WGS and aid in variant prioritisation, when no clear variants are 
initially identified. 
Clinical and biochemical features of mitochondrial diseases 
From the clinical point of view, mitochondrial diseases are characterised by a wide range 
of symptoms, severity, age of onset and outcome, which hinders the diagnosis. Typically, 
organs and tissues with a high metabolic demand are the most affected. The most 
common clinical presentations affect the central nervous system (CNS) 
(encephalopathy, migraine, epilepsy, dementia, ataxia, dysphagia, etc.), the cardiac 
muscle (heart muscle weakness), the respiratory system (hypoventilation, apnea, 
pneumonia) and the skeletal muscle, although ophthalmoplegia, optic atrophy, 
blindness, deafness and diabetes are also usual (Figure I.11). The broad spectrum of 
clinical symptoms can be classified  as particular syndromes, such as MELAS 
(Mitochondrial encephalomyopathy, lactic acidosis, and stroke- like episodes), MERRF 
(Myoclonic epilepsy with ragged red fibres), LHON (Leber hereditary optic neuropathy), 
NARP (Neuropathy, ataxia, and retinitis pigmentosa), Leigh Syndrome (progressive 
neurodegenerative disorder with basal ganglia lesions) and Pearson Syndrome 
(refractory sideroblastic anaemia, vacuolisation of bone marrow precursors and 
exocrine pancreatic dysfunction). Nonetheless, many patients do not fit into this 
syndromic classification 70. Patients with adult-onset disease usually display myopathy 
with a variable involvement of the CNS, while early-onset patients mostly present Leigh 
syndrome, which can be caused by mutations in over 75 different genes 74. 
Patients with mitochondrial diseases often manifest a deficiency in one or more OXPHOS 
complexes, which can be measured biochemically or histochemically from patients’ 
tissue biopsy or cell culture. ATP levels are usually decreased as result of an impaired 
OXPHOS function. Also, lactic acid is commonly increased in blood and/or cerebrospinal 






Figure I.11. Clinical Features of Mitochondrial Disease.  
Mitochondrial dysfunction can cause a range of neurological and non-neurological symptoms. The 
spectrum of tissues involved varies between the mutation (mtDNA or nDNA), heteroplasmy, and age of 
onset and thus makes it difficult to predict dis- ease progression. (Extracted from Russell et al., 202064). 
 
 




Treatments and therapies 
Treatment of mitochondrial diseases is still very challenging, due to several 
characteristics of these kind of defects:  
i. they are highly heterogeneous both clinical and genetically; 
ii. they are very often multisystemic, so difficult to address all the dysfunctions 
at once; 
iii. it is difficult for a drug to cross the blood brain barrier and reach the brain, 
which is very often affected; 
iv. the double membrane surrounding mitochondria make it difficult to deliver 
bioactive molecules to the specific mitochondrial compartment;  
v. mtDNA is present in multiple copies in each cell 
vi. and it has no recombination systems;  
vii. mitochondria cannot import nucleic acids, impeding the use of CRISPR/Cas9-
based techniques, or equivalent technologies.  
Nowadays, clinical treatments for mitochondrial diseases are mostly symptomatic, and, 
very often, they lack effectiveness. Therapies that are used today in clinical practices 
include some pharmacological and dietary supplementation, such as vitamins (thiamine, 
riboflavin, folinic acid, and others), CoQ, aminoacids (arginine), lipoic acid, and other 
components, taken in cocktails of three or four supplements 75. These pharmacological 
agents are usually complemented with treatment of the symptomatic complications and 
supportive care, and exercise can also be beneficial 76,77.   
Recent advancements in molecular genetics and biochemical methodologies, have 
provided better understanding of the aetiology and pathogenesis of mitochondrial 
diseases and substantially improved diagnosis. This knowledge has also helped to 
develop new promising therapies that target different pathological mechanisms of the 
mitochondrial dysfunction, aiming to change the course of the disease 64,73,75,78. Some 





i. Enhancing ETC function with treatments: Some mitochondrial treatments 
strengthen the function of the ETC by increasing the levels of its components 
(CoQ, idebenone) or utilisation rate of its substrate (thiamine). Among them, 
CoQ (in its ubiquinone or ubiquinol forms) is the most commonly used. It has a 
relatively high effectivity and little side effects, even when high doses are applied 
79. It has been proven especially effective in patients with primary CoQ deficiency 
(See Chapter 1) 80. In fact, The European Medicine Agency (EMA) has recently 
approved ubiquinol (CoQ10H2) as an orphan drug for the treatment of primary 
CoQ10 deficiency 79. Idebenone, a CoQ10 analogue, was also defined by the EMA 
as an orphan drug for LHON (Leber hereditary optic neuropathy) treatment 75,81.  
ii. Decreasing ROS: antioxidants have been proven useful to reduce the excess of 
ROS produced in a pathological context. For example, the redox modulator 
KH176  has been shown to reduce ROS levels and protect OXPHOS-deficient 
human cells against redox stress 82. This drug has been approved by the EMA as 
an orphan drug for treatment of MELAS and Leigh Syndrome, and it is being 
tested on clinical trials for a range of mitochondrial diseases.  
iii. Deoxynucleotide triphosphate (dNTP) bypass: supplementation of dNTPs has 
been shown to be successful in several in vitro and in vivo models of disorders 
characterised by defects in mtDNA replication and dNTP pool metabolism, which 
causes a decrease in the mtDNA copy number, multiple deletions or point 
mutations of mtDNA, consequently affecting OXPHOS activity 53,75,83–85. 
iv. Mitochondrial biogenesis activation: The stimulation of mitochondrial 
biogenesis is considered one of the most promising approaches for 
mitochondrial disease. Increasing mitochondrial biogenesis is driven by the 
activation of peroxisome proliferator-activated receptor γ coactivator 1 α 
(PGC1α), which can be targeted by AMPK, SIRT1 or peroxisome proliferator-
activated receptors (PPARs). Currently, PGC1α stimulators (benzafibrate, a PPAR 
agonist), epicatechin and RTA 408 (isoprenoid that activates NRF2)) are under 
clinical study to assess their effectivity in different mitochondrial disease 
patients 75,77. Positive results have been reported on several mouse models of 
mitochondrial diseases using other compounds, such as the AMP analogue 5-




aminoimidazole-4-carboxamide 1-β-D-ribofuranoside (AICAR) (AMPK agonist) 86, 
NR (a NAD+ precursor) and PARP1 (an inhibitor of NAD+ consuming enzymes). 
These last two drugs act by increasing NAD+ concentration, which activate SIRT1 
and other sirtuins 87,88.   
v. Manipulating mitochondrial dynamics: In mouse models, moderate 
overexpression of Opa1, the master regulator of mitochondrial cristae 
morphology, has been proven to significantly ameliorate mitochondrial damage 
induced by drugs, surgical denervation 89, OXPHOS dysfunction due to CI or CIV 
defects 90 and also mtDNA depletion 91.  
vi. Inhibition of mTORC1: mTORC1 plays essential roles in a vast number of cellular 
metabolic (mainly anabolic) pathways, including activation of protein 
translation, immune response, nucleotide and lipid synthesis, and glucose 
metabolism, and, in parallel, inhibition of catabolic pathways, such as autophagy 
and lysosomal biogenesis 81,92. Treatment with rapamycin, an inhibitor of 
mTORC1 was beneficial for fly and mouse models with mitochondrial 
dysfunction 93–95.  
vii. Scavenging specific toxic compounds: Mitochondrial diseases are sometimes 
characterised by accumulation of different toxic metabolites. For example, 
hydrogen sulphide (H2S) is accumulated in patients with ethylmalonic 
encephalopathy, a fatal infant disease due to mutations in ETHE1, one of the 
enzymes involved in sulphide degradation  96. Treatment with N-acetylcysteine 
and metronidazole partially corrected the pathogenic effects of H2S 
accumulation in patients with ethylmalonic encephalopathy and in an Ethe1 
knock-out (KO) mouse model 97. 
viii. Heteroplasmy shift: the recent development of new techniques for genome 
editing have allowed the development of strategies that aim to modify 
heteroplasmy levels is by selectively cleaving mutated mtDNA 98. Mitochondrially 
targeted endonucleases 99, TALENs (transcription activator-like effector 
nucleases) 100,101 and ZNFs (zinc-fingers nucleases) 102–104 have been shown to 
selectively eliminate pathogenic DNA, decreasing the heteroplasmy percentage 





ix. Gene therapy: the expression of genes, such as the wild type (WT) form of a 
defective gene or other therapeutic genes, delivered by adeno-associated viral 
vectors (AAVs) targeted to specific tissues is a very promising strategy for some 
mitochondrial diseases 75,81. In this context, AAVs have been used to deliver 
therapeutic genes in several mouse models and some clinical trials 81,105–107.  
Many other strategies for mitochondrial disease therapy are being studied and 
developed, such as ketogenic diet, enzyme replacement therapies, hypoxia, bypass of 
electron chain defects by expression of xenogenes, mtDNA replacement or 
mitochondrial donation. 
I2. Coenzyme Q 
I2.1. Coenzyme Q structure and properties 
Coenzyme Q (CoQ) or ubiquinone is the only endogenously synthetised redox-active 
lipid. It is especially abundant in mitochondrial membranes, but it is found in virtually all 
endomembranes, plasma membrane and serum lipoproteins. Its chemical structure is a 
benzoquinone ring as a redox-active head group, and a polyisoprenoid chain, which 
gives hydrophobicity to the molecule (Figure I.12.A). The length of the lipid tail varies 
depending on the species. CoQ has 6 isoprene units in Saccharomyces cerevisiae (CoQ6), 
while in humans it has mainly 10 (CoQ10), although a small subset of molecules has 9 
units (CoQ9). The main form found in mice is CoQ9, but also low amounts of CoQ10 are 
present in their membranes.  
CoQ was first described by Cain and Morton in 1955 108. Soon after, its main function in 
the mitochondrial ETC was proposed by Crane and cols., who also demonstrated its 
redox proprieties 109. CoQ is in a permanent balance between a completely reduced 
form (CoQH2 or ubiquinol) and a completely oxidised form (CoQ or ubiquinone), through 
oxidation-reduction cycles (Figure I.12.B). When this redox cycle occurs by a two-step 
transfer of one electron each, as it happens during the Q-cycle in the ETC, a semiquinone 
free radical (or semi-ubiquinone, CoQ·-) intermediate is produced 32,33. This intermediate 
is particularly relevant also in the plasma membrane antioxidant system, generated by 
the reduction of CoQ by cytochrome b5 reductase. This semiquinone maintains vitamin 
C and α-tocopherol in a reduced state in the plasma membrane 110,111. 






Figure I.12. Structure and redox forms of coenzyme Q.  
(A) Chemical structure of CoQ. (B) Redox cycle of its head group, in CoQ oxidized form (ubiquinone) can 
be reduced to ubiquinol (CoQH2) by two steps of one electron each, through semi-ubiquinone radical 
form, or by one reaction of two electrons, without the semi-ubiquinone intermediate (Adapted from 
Alcázar-Fabra et al., 2018112). 
 
I2.2. Coenzyme Q biosynthesis and distribution  
Most of the CoQ is endogenously synthesised by a set of nuclear-encoded proteins that 
reside in the mitochondria, through a pathway that is not completely understood yet. 
Most of the work on CoQ biosynthesis has been performed in the yeast model. The 
isoprenoid side chain comes from the mevalonate pathway in extramitochondrial 
membranes. Yeast Coq1p assembles the polyprenyl tail, determining the number of 
isoprene units. The quinone head is synthesised from tyrosine in the cytosol and linked 
to the polyprenylated tail by Coq2p in mitochondria. The rest of the reactions take place 
in a multiprotein biosynthetic complex localised in the matrix side of the IMM, consisting 
in sequential modifications of the aromatic ring. Coq6p and Coq7p are hydroxylases; 
Coq3p and Coq5p are methylases; Coq4p, Coq8p, Coq9p, and Coq10p are proteins with 
regulatory function (See Chapter 4, section 4.1)). 
Levels of CoQ are quite stable in cells but its concentration varies among different tissues 
and organs, depending on the dietary conditions and age 113–116. Although CoQ is mainly 
endogenously synthetised in mitochondria and then distributed to other cell 





Experimental biophysical studies and computational molecular dynamics prediction 
models have showed how, in the IMM, CoQ is mainly located either close to the 
membrane-water interface, with its relatively small head group being shadowed by the 
bigger polar heads of phospholipids, or stabilised in the middle of the bilayer. During the 
process of electron transfer, CoQ rapidly translocates from one side to the other of the 
inner membrane bilayer, with a rate that varies depending on the redox state of the 
molecule. This process enables the interaction with the reducing and oxidising sites in 
the proteins of the ETC complexes, located close to the membrane surfaces 118,119. 
I2.3. Coenzyme Q functions in mitochondrial and extramitochondrial membranes 
CoQ is an essential component of the MRC. In addition to this central role in the energy 
metabolism, CoQ is also involved in a big number of other cellular functions, and it is 
even probable that some of them are still unknown.  
CoQ is a key node in the mitochondrial respiratory chain 
The major function attributed to CoQ is the transport of electrons in the MRC, 
contributing to generate the membrane potential coupled to OXPHOS. CoQ is a unique 
compound that receives electrons from Complex I, Complex II and other 
dehydrogenases, and transfer them to Complex III in the MRC (Figure I.13) 49,120.  
CoQ accepts electrons from NADH in CI, through a FMN, one 2Fe-2S cluster and six 4Fe-
4S clusters. The CoQ binding site of CI is in the interface of both hydrophilic and 
hydrophobic arms of the L-shaped NADH dehydrogenase enzyme (Figure I.5). Very 
interestingly, CoQ bound to its specific site at CI may contribute to the proton 
translocation to the IMS 121. Complex II or succinate dehydrogenase is a component of 
the TCA cycle that provides electrons from succinate to CoQ, through a FAD, the 4Fe-4S, 
2Fe-2S and 3Fe-4S clusters and one haem 30.  CIII catalyses the electron transfer from 
CoQH2 to CytC by the Q cycle 33, a mechanism that enables the sequential reduction of 
CytC by two reduction steps of one electron each (Figure I.7). The Q-cycle is an essential 
step for proton translocation and hence energy conservation (see section I1.2). 
 













































































































































































































































































































































































































































































































The NADH to O2 pathway (catalysed by CI, CIII and CIV) and the succinate to O2 pathway 
(catalysed by CII, CIII and CIV) are the two main electron flux pathways through the MRC 
that result in generation of the PMF that is utilised to produce ATP. However, there are 
many other dehydrogenases delivering electrons to the CoQ, producing CoQH2 that can 
be efficiently reoxidised by CIII in the ETC (Figure I.13). Some of these dehydrogenases 
and the processes in which are involved are: 
i. Dihydroorotate dehydrogenase (DHODH), a key enzyme for pyrimidine 
biosynthesis 123, which can influence the reactive oxygen species (ROS) 
production by CoQH2 accumulation in skeletal muscle, thus partially contributing 
to ROS signalling in mitochondria 124. 
ii. Mitochondrial glycerol-3-phosphate dehydrogenase (GPDH) 125, a tissue-specific 
component of mitochondria connecting glycolysis, OXPHOS and fatty acid 
metabolism126. 
iii. Electron transport flavoprotein dehydrogenase (ETFDH), a key enzyme involved 
in the fatty acid β-oxidation and branched-chain amino acid oxidation 
pathways127 
iv. Proline dehydrogenase 1 (ProDH), an enzyme required for proline and arginine 
metabolism128. 
v. Probably, hydroxyproline dehydrogenase (or proline dehydrogenase 2), involved 
in the glyoxylate metabolism129. 
vi. Sulphide-quinone oxidoreductase (SQOR)130 during hydrogen sulfide (H2S) 
detoxification, a gas modulator of relevant cellular processes which is toxic in 
excess  131.  SQOR which oxidises H2S in the first step of its catabolism in the 
mitochondria 131–133. 
CoQ participates in reactive oxygen species production. 
The MRC is the major source of reactive oxygen species (ROS) within the cell 134. ROS are 
mainly produced in the form of superoxide (O2·−) that is transformed to hydrogen 
peroxide (H2O2) by the manganese superoxide dismutase (MnSOD) in the mitochondrial 




matrix or released to the IMS and the cytosol to be further detoxified by the copper-zinc 
superoxide dismutase (CuZn-SOD) 135,136.  
Overall, uncontrolled and aberrant mitochondrial ROS production can cause damage to 
cellular components inducing the accumulation of lipid peroxides, carbonylated proteins 
and mtDNA mutations. This damage can lead to mitochondrial dysfunction. Also, 
mitochondrial ROS can produce the release of CytC via the mitochondrial outer 
membrane permeabilisation (MOMP), as well as opening of the MPTP of the IMM, 
leading to apoptotic and necrotic cell death, respectively. Very interestingly, ROS 
production, by inducing lipid peroxidation, has been even proposed to influence the 
organisation of the mitochondrial respiratory complexes in SCs 137.  
However, mitochondria-derived ROS also have a beneficial redox signalling role, being 
physiologically produced at low concentrations in response to environmental stresses 
138. ROS signalling can regulate life- and health-span 139,140, enabling communication 
between the mitochondria, the cytosol and the nucleus.  
There are at least ten different points of ROS production in the MRC, but the FMN site 
or the CoQ-binding site in Complex I and the CoQ0 site in Complex III are the most 
important ones141,142. It is widely accepted that the accumulation of reduced CoQ 
generates superoxide through the retrograde electron transport (RET), driving electrons 
throughout Complex I to NAD+, a mechanism that balances the CoQ/CoQH2143,144. 
Complex III is also capable of producing ROS under certain conditions134,145. The CoQ·-
/CoQ couple formed during the Q cycle is highly reducing, thus capable of donating an 
electron to O2, forming O2·-. 
CoQ participates in the plasma membrane redox system. 
CoQ is reduced at the plasma membrane by several NAD(P)H-oxidoreductases. These 
include the NADH-cytochrome b5 reductase (b5R), the NAD(P)H:quinone reductase 1 
(NQO1),  the NADH-ferricyanide reductase 146 and the Ferroptosis Suppressor Protein 1 
(FSP1)147,148, amongst others 111,149. There is also evidence for the existence of a NADH-
dependent CoQ reductase involved in proton translocation to the lysosome 150.  
b5R (EC 1.6.5.5, ascorbate free radical reductase) is a FAD-containing monomeric 





membrane, forming CoQ·-. NQO1 (EC 1.6.99.2) is a homodimeric enzyme with a non-
covalently bound FAD that is involved in the transfer of two electron from NADH to CoQ, 
resulting in no CoQ·- radical production 111,149. Recently, the FSP1 CoQ oxidoreductase 
has been described to be recruited to the plasma membrane to reduce CoQ, which 
functions as a radical-trapping antioxidant that suppresses the propagation of lipid 
peroxides. This pathway prevents cell death by ferroptosis, in parallel to the traditional 
function of the glutathione peroxidase 4 (GPX4) 147,148.  
The CoQ-dependent transport of electrons across plasma membrane is important for 
the regulation of cytosolic NAD+/NADH ratio, the regeneration of other antioxidants 
such as α-tocopherol and ascorbate 151, the maintenance of the antioxidant capacity of 
membranes, the inhibition of the propagation of lipid peroxidation 147,148, among others.  
CoQ is a potent endogenously synthesised, lipid-soluble antioxidant 
In line with the previous section, the ability to sustain continuous oxidation/reduction 
cycles makes CoQ not only a great electron carrier for different cellular processes, but 
also a potent membrane antioxidant, which protects lipids, proteins and nucleic acids 
from harmful oxidative damage 120,152,153. In membranes, CoQH2 has been shown to 
prevent both initiation and propagation of lipid peroxidation 154,155 and, indirectly, to 
regenerate other antioxidants, such as α-tocopherol and ascorbate 151. The high 
efficiency of CoQ against oxidative stress may be related to its ubiquitous distribution, 
its localization in the core of membranes and the availability of diverse dehydrogenases, 
able to efficiently regenerate the molecule. 
CoQ participates in the regulation of the opening of the mitochondrial transition pore 
The IMM has a low permeability to ions and solutes, which allows the electron and 
proton gradient to be maintained. MPTP is a protein complex located on the IMM that 
controls permeability of this membrane. However, its exact composition is still unknown 
61–63. The MPTP is involved in regulating cell death by apoptosis, since a prolonged 
opening of this pore results in a loss of membrane potential, a dramatic increase in ROS 
production and the release of pro-apoptotic proteins and CytC outside the 
mitochondria156.  




CoQ and analogues have been reported to inhibit apoptosis by preventing the opening 
of the MPTP 157–160, being this fact independent to the free radical scavenging property 
of CoQ 161. 
CoQ is a cofactor of uncoupling proteins 
Uncoupling proteins (UCPs) are a family of carriers with 5 different isoforms (UCP1-5), 
whose role is to produce a controlled dissipation of the electrochemical proton gradient 
by transporting H+ across the IMM from the cytosol into the mitochondria. This 
phenomenon uncouples the mitochondria and produces a heat release, being important 
for thermogenesis 162,163. CoQ acts as a cofactor for some of these UCPs, interacting with 
them in the lipid bilayer and regulating their function. CoQ would subtract H+ from the 
fatty acids and move them to the H+ acceptor group of the UCPs, in charge of directing 
them towards the mitochondrial matrix 164.  
I2.4. Coenzyme Q10 deficiency: a mitochondrial disease 
Since CoQ main function is the electron transport in the MRC, contributing to ATP 
generation in the OXPHOS system, CoQ10 deficiency mainly leads to different degrees of 
mitochondrial dysfunction, with energy deficiency. CoQ10 deficiency in humans 
manifests with a broad spectrum of clinical phenotypes, affecting different organs, 
tissues and systems, mainly central and peripheral nervous system, kidney, skeletal 
muscle and heart.  
Patients with CoQ10 deficiency have reduced levels of CoQ10 in tissues, which can be 
primary or secondary. Primary CoQ10 deficiencies are caused by mutations in one of the 
genes participating in the CoQ10 biosynthesis pathway at the enzymatic or regulatory 
levels. Secondary CoQ10 deficiencies are caused by defects not directly linked to CoQ10 















Primary CoQ10 deficiency syndrome is a rare condition, genetically caused by autosomal 
recessive biallelic mutations in one of the COQ genes participating in the CoQ10 
biosynthesis pathway. The main aim in this project is the study of the pathophysiology 
of primary CoQ10 deficiency, with a special focus on the still poorly characterised COQ4 
gene. For this purpose, the following specific aims have been proposed: 
i. Study of phenotypic or genetic patterns of all primary CoQ10 deficiency patients 
reported in the literature so far (described in Chapter 1).  
ii. Determination of the pathophysiology of primary CoQ10 deficiency by using in 
vitro cell models with defects in COQ7, COQ6 and COQ4 (described in Chapter 2).  
iii. Characterisation of human COQ4 by studying its subcellular localization and its 
function in CoQ10 biosynthesis and mitochondrial respiration (described in 
Chapters 3 and 4).  
iv. Study of the relationship between CoQ10 biosynthesis (or COQ4 function) and 
mtDNA metabolism (described in Chapter 5). 
 
  
















Materials and Methods 
M1. Literature review and patient classification 
We performed an extensive review of all primary CoQ10 deficiency published cases, 
obtained by Pubmed search using search terms PDSS1, PDSS2, COQ2, COQ3, COQ4, 
COQ5, COQ6, COQ7, COQ8A, ADCK3, COQ8B, ADCK4 and Coenzyme Q10 deficiency. We 
compiled the information about clinical manifestations (classified by organ and tissue 
affected), age at onset, pathogenic variants found and functional validation. Information 
about CoQ10 treatment and response was also obtained. 
The patterns and frequency of clinical manifestations were evaluated for each primary 
CoQ10 deficiency-causing gene, as a whole, and also stratified by age at onset.  
M2. Cell culture methods 
M2.1. Cell lines and maintenance 
All cells were cultured at 37°C in an incubator with an atmosphere at 5% CO2. They are 
described in Table M.1. Cell culture media are specified in next sections. 
Patient Fibroblasts 
Skin fibroblasts derived from skin biopsies from the patients with COQ4 (P105, P108 and 
P109) and COQ7 (P102 and P112) mutations were kindly provided by our collaborators 
from different hospitals (Table M.1). Informed consents for biological sample collection 
and genetic studies were obtained in origin from all the subjects involved in our studies 
in agreement with the Declaration of Helsinki. Two different controls were used, a 
neonatal control: HDF Neo (Human Dermal Fibroblasts, neonatal) (Sigma Aldrich) and 
an adult control (B003). Patient and control fibroblasts were cultured in Gibco™ 1g/L 
glucose DMEM (Dulbecco's Modified Eagle Medium) supplemented with 10% (v/v) Fetal 
bovine serum (FBS) and 1% (v/v) Gibco® Antibiotic-Antimycotic (Ab). P105 patient 
fibroblasts showed difficulty in growing, so they were grown in 1g/L glucose DMEM 
supplemented with 20% (v/v) of FBS, 1% Ab and 10 μM uridine (Sigma). All the 
experiments were performed with cells with passage numbers lower than 15.  




Continuous cell lines 
Human HEK293T-Rex/Flp-In ™ (Thermo Fisher Scientific) cells were cultured in Gibco™ 
4.5g/L glucose DMEM supplemented with 10% (v/v) FBS and 1% (v/v) Ab (complete High 
glucose medium). These cells contain a single stably integrated flippase recognition 
target (FRT) site at a transcriptionally active genomic locus (Figure M.1.A). When they 
are co-transfected with pcDNA5 plasmid, carrying the gene of interest and an FRT site, 
together with pOG44, expressing the flippase, the flippase mediates the recombination 
between the genomic and the plasmid FRT sites, introducing the gene of interest in the 
genome of the transfected cell (Figure M.1.B). 
 
 
Figure M.1. HEK 293T-Rex/Flp-In cells genomic background and protein expression system.  
(A) HEK 293T-Rex/Flp-In cells contain two stably, independently integrated plasmids. pFRT/lacZeo plasmid 
is in a transcriptionally active genomic locus and introduces a single FRT (Flp Recombination Target) site 
and stably expresses the lacZ-Zeocin™ fusion gene under the control of the SV40 promoter. pcDNA™6/TR 
plasmid stably expresses the Tet repressor (TetR) gene under the constitutive human cytomegalovirus 
(CMV) promoter. Parental HEK 293T-Rex/Flp-In cells are, thus, resistant to blasticidin and zeocin.  
(B) The pcDNA™5/FRT/TO vector contains our gene of interest (COQ4) under a tetracycline/doxycycline 
inducible promoter (CMV fused to TetO2), a single FRT site for Flp recombinase-mediated integration and 
a hygromycin resistance gene for selection. The Flp recombinase is expressed from the pOG44 plasmid, 
which must be co-transfected with pcDNA5 into Flp-In™ T-REx™ mammalian host cells.  
 
 




Uridine 10 μM (Sigma) was added to the medium for cells defective in COQ4 and COQ6 
genes (and their controls), in order to compensate the reduced synthesis of pyrimidine 
derivatives due to a decrease in the activity of the dihydroorotate dehydrogenase, which 
is CoQ-dependent. For some experiments, cells were incubated in DMEM medium with 
2mM glucose, to induce respiratory function. 
Table M.1. List of cell lines used in this project. 
Cell line Description Source 
HDF Neo Neonatal control skin fibroblasts Sigma Aldrich 




UPO, Sevilla, Spain 
P102 patient fibroblasts 
Skin fibroblasts derived from a 
patient carrying biallelic mutations in 
COQ7 (NM_016138.5):  
c.161_161delG and c.319C>T 
Hospital 
Universitario la Fe de 
Valencia, Spain 
P112 patient fibroblasts 
Skin fibroblasts derived from a 
patient carrying a homozygous 
mutation in COQ7 (NM_016138.5):  
c.3G>T 
Hospital Costa del 
Sol, Marbella, Spain 
P105 patient fibroblasts 
Skin fibroblasts derived from a 
patient carrying biallelic mutations in 
COQ4 (NM_016035.5):  
c.23_33delTCCTCCGTCGG and 
c.532+6 T>A 







P108 and P109 patient fibroblasts 
Skin fibroblasts derived from twin 
patients carrying a homozygous 
mutation in COQ4 (NM_016035.5):  
c.437T>G 
The Azrieli Faculty of 
Medicine,  
Bar Ilan University, 
Safed, Israel 
HEK293T-COQ6 KO HEK293T knocked out in COQ6 
Dr. Leonardo Salviati 
laboratory 165 
HEK293T-Rex/Flp-In ™ 





HEK293T-Rex/Flp-In knocked out in 
COQ4 
This study 
Transfected HEK293T-COQ4 KO 
COQ4 KO transfected with pcDNA5 




When required, supplemental molecules were added to the culture medium, prediluted 
in ethanol 100%. The conditions of the treatments are detailed in Table M.2. In the case 
of CoQ10, the ethanol stock was prediluted in the FBS before preparing the complete 
medium. All these reagents were purchased from Sigma.  




Table M.2. Reagents used for cell treatment and conditions. 










CoQ10 Coenzyme Q10 
CoQ 
supplementation 




De novo CoQ 
labelling 
10000X 7.2 nM 3 days 
VA Vanillic acid 
CoQ biosynthesis 
bypass 



















1000X 100 μM 1-3 days 
DOX Doxycycline 
Induction of the 
transgene 
expression 
1000X 0.1-5 ng/ml 24h 
 
M2.3. Co-transfection of HEK293T-Rex/Flp-In ™ cells with pCDNA5 and pOG44 
plasmids 
Before the transfection with pcDNA5/pOG44 plasmids, HEK293T-Rex/Flp-In ™ cells were 
grown in High glucose DMEM supplemented with 10% Tetracycline Free FBS (Tet-FBS), 
1% Ab, 10μM uridine, 15 µg/mL of Blasticidin (Blasticidin S HCl, 10 mg/mL, Thermo 
Fischer Scientific) and 100 µg/mg Zeocin (Zeocin™ Selection Reagent, 100 mg/mL, 
Thermo Fischer Scientific).  
Transfections were carried on 6-well plates, with 70-80% confluent cells and 
Lipofectamine 3000 reagent (Invitrogen) (LFA). For this purpose, cells were seeded 1 day 
before transfection at a confluency of 40% in High glucose medium without antibiotics. 
At least 3 wells were seeded per cell line and each of them would be transfected with 
pOG44+pcDNA5-gene+LFA (reaction of interest), pOG44+LFA and only LFA (negative 
controls), respectively.  
On the day of transfection, a DNA-tube was prepared for each transfection reaction. In 
each tube, 300 µL of Gibco® Opti-MEM® (Thermo Fischer Scientific) were mixed with 
1350ng of pOG44 and 150 ng of pcDNA5-gene plasmids (ratio pCDNA5-gene of 




interest:pOG44 = 1:9). For the control reactions, no DNA or only pOG44 was mixed with 
Opti-MEM. 3 µL of P3000 reagent (included in the LFA 3000 kit) were added to the 
reactions tubes (2 µL / µg of DNA). Then, a LFA mix tube was prepared, with 300 µL of 
Opti-MEM and 3.6 µL of LFA per transfection reaction. Within the following 5 minutes, 
300 µL of LFA mix were added to each DNA-tube and gently mixed. A 20 minutes 
incubation at room temperature (RT) was performed to allow the formation of LFA-DNA 
complexes. After that, wells were washed with warm sterile phosphate-buffered saline 
(PBS), and the 600 µL of each LFA-DNA tube were added to each well. This step was 
followed by a 4 hours incubation at 37°C, to let the complexes transfect the cells.  
Then, 600 µL of DMEM 30% Tet-FBS 15 µg/mL Blasticidin were added to each well. 24h 
after transfection, the medium was removed, and 2 mL of DMEM 10% Tet-FBS, 1% Ab, 
15 µg/mL Blasticidin were added to each well. 48h after transfection, the medium was 
changed to a selective one, to select transfected clones. The selective medium was a 
High glucose DMEM supplemented with 10% Tet-FBS, 1% Ab, 10 µM uridine, 15 
µg/mL of Blasticidin and 100 µg/mg of Hygromycin B (Sigma). 
M2.4. Generation of a COQ4 KO cell model 
Paired nickases 3-plasmid strategy was chosen to increase the specificity of the genomic 
DNA modifications. gRNAs target sequences were designed to target COQ4 exon 2 (Table 
M.3), using the CRISPR-design tool from Zhang Lab (http://crispr.mit.edu), which is no 
longer available. Potential off-target sites of the different pairs of gRNAs were analysed 
with the same tool, using 4 different combinations of Forward and Reverse gRNA.  
All plasmids were purchased from Sigma-CRISPR Products and are detailed in Table 
M.12. Each gRNA sequence was contained in a pU6-gRNA plasmid (Table M.3, Figure 
M.2.B). Cas9 nickase (Cas9D10A) and GFP (green fluorescent protein) sequences were 
both included in the pCMV-Cas9D10A-GFP plasmid (Table M.12, Figure M.2.A). CMV 
(cytomegalovirus) promoter would allow strong transient expression of Cas9-D10A, co-
expressed with GFP from the same mRNA via a 2A peptide linkage. This would enable 
tracking of transfection efficiency and enrichment of genome editing activity in cell 
populations via fluorescence activated cell sorting (FACS). 
 





Figure M.2. CRISPR plasmids. 
Paired nickases CRISPR/Cas9 3 plasmid strategy was used to generate the COQ4 KO in a HEK 293T-Rex/Flp-
In wild type background, transfecting these cells with a pCMV-Cas9D10A-GFP, which expresses the 
nickase-GFP (A), and two pU6-gRNA plasmids (B), each one with a different target sequence (Table M.3). 
 
 
Table M.3. gRNAs target sequences. 
gRNA target 
sequence 
Orientation Target ID Sequence 5’-3’ 
gRNA1 Fw HSL0002175793 UGGUGCGAGUAUAGCGGGCCGG 
gRNA2 Fw HSL0002175797 CUUUCUGCAGCGGGGAGGUGGG 
gRNA3 Rv HSL0002175798 CUGUUGGCCGCCGGCUCCGCGG 
gRNA4 Rv HSL0002175799 GCCGCCGGCUCCGCGGCGAUGG 
 
Transfection 
CRISPR plasmids transfection protocol was adapted from Ran et al., 2013166. 
Transfections with the 4 combinations of plasmids containing the gRNAs were 
performed (named CRISPR 1-4 reactions), together with the pCMV-Cas9D10A-GFP 
plasmid. Two transfection controls were also performed. The negative control was 
transfected with no DNA, and served as GFP negative control for FACS; the positive 
control was only transfected with the pCMV-Cas9D10A-GFP plasmid, and served as GFP 
positive control for FACS. The genome editing activity was also tracked using CRISPR 
controls. The CRISPR negative control was transfected with the CRISPR/Cas9 negative 
control (pU6-gRNA/CMV-Cas9-GFP), and was used as a control for no genome editing 
activity; and the CRISPR positive control was transfected with the two CRISPR/Cas9 
nickase EMX1 positive control plasmids (pU6-EMX1-s4 and pU6-EMX1-as4), together 








Table M.4. Conditions for transfection with CRISPR plasmids. 
Reaction Plasmid DNA ng Number of reactions 
Transfection - Control - - 3 
Transfection + Control pCMV-Cas9D10A-GFP 311.32 3 
CRISPR Reaction 1 
pU6-gRNA1 94.34 
3 pU6-gRNA3 94.34 
pCMV-Cas9D10A-GFP 311.32 
CRISPR Reaction 2 
pU6-gRNA1 94.34 
3 pU6-gRNA4 94.34 
pCMV-Cas9D10A-GFP 311.32 
CRISPR Reaction 3 
pU6-gRNA2 94.34 
3 pU6-gRNA3 94.34 
pCMV-Cas9D10A-GFP 311.32 
CRISPR Reaction 4 
pU6-gRNA2 94.34 
3 pU6-gRNA4 94.34 
pCMV-Cas9D10A-GFP 311.32 
CRISPR + Control 
pU6-EMX1-s4 94.34 
3 pU6-EMX1-as4 94.34 
pCMV-Cas9D10A-GFP 311.32 
CRISPR – Control pU6-gRNA/CMV-Cas9-GFP 311.32 3 
 
Transfections were carried on 24 well plates, with 70-90% confluent HEK293T-Rex/Flp-
In cells and LFA 3000. Cells were seeded 1 day before transfection at a density of 3·105 
cells in 1 mL High glucose medium without antibiotics per well. On the day of 
transfection, a DNA-tube was prepared for each transfection reaction. In each tube, 100 
µL of Opti-MEM were mixed with the amounts of plasmids specified on Table M.4 
(plasmids were mixed at equimolar ratios and the maximal amount of DNA used was 
500 ng). For transfection control reactions, no DNA or only pCMV-Cas9D10A-GFP were 
mixed with Opti-MEM. Then, a LFA mix tube was prepared, with 100 µL of Opti-MEM 
and 2 µl of LFA per transfection reaction. Within the following 5 minutes, 100 µL of LFA 
mix were added to each DNA-tube and gently mixed. After 20 minutes incubation at RT, 
cells were washed with warm sterile PBS and the 200 µL of each LFA-DNA tube were 
added to each well. Cells were incubated with the LFA-DNA complexes for 4 hours at 
37°C. Then, 300 µL of DMEM 30% Tet-FBS per well were added. 24h after transfection, 
500 µl of DMEM 10% Tet-FBS were added to each well.  
Isolation of clonal cell lines by FACS and clone expansion  
The transfected population was FACS sorted for GFP expression 48 h after transfection. 
Cells were resuspended in high glucose phenol red–free DMEM supplemented with 10% 




Tet-FBS and 1% antibiotics, dissociated and filtered with a 70 µm cell strainer. GFP-
positive single cells were sorted and collected in cytometer tubes with complete High 
glucose medium supplemented with 10 μM uridine. Then, they were diluted in order to 
get 100 cells/ml and seeded in 96 well plates (100 µL of complete DMEM with uridine + 
10 µL of cell dilution per well), to get 1 single cell per well. 1 plate was seeded per 
transfection reaction, and the rest of the cell dilutions were also seeded into 24 well 
plates as pools. Single colonies could be isolated from these pools too. The isolated 
clones and pools were grown into populations over a period of 1 month. Populations 
were expanded, and DNA was harvested from the 80% of cells of confluent 12-well 
plates with a DNeasy Blood & Tissue Kit (Qiagen). The remaining 20% of cells was used 
to continue expanding the populations. 
Genotyping of the clones 
Genomic DNA was amplified with COQ4 primers (EMX1 primers for the positive controls) 
spanning the target cut site (Table M.11, primers #4, #5, #6 and #7). PCR was performed 
with KOD Hot Start Master Mix (Novagen), following the manufacturer’s protocol. 2.5 
µL of the PCR product were ran in a 1,8% agarose gel, and differences on the size of the 
products could be observed. Amplicons were gel-purified and A-tailed with Taq 
polymerase (HorsePower Taq polymerase, Canvax). They were then ligated into pGEMT 
Easy Vector (Promega) and transformed into DH5α bacteria using standard molecular 
biology techniques. A minimum of 5 bacterial clones were sequenced per each tested 
cell line (See sections M4.8, M4.10, M4.12-14). 
M2.5. Assessment of mitochondrial respiratory function using Seahorse 
Extracellular Flux Analyzer 
General protocol 
Oxygen consumption rate (OCR) was determined using a Seahorse XF24 Extracellular 
Flux Analyzer (Agilent) following the manufacturer’s instructions. The protocol was 
optimised for each cell line, detailed in Table M.5. Cells were seeded at an optimal 
density onto Seahorse 24-well plates, 1-3 days previous to the assay (depending on the 
experiment) (Table M.5). The day of the experiment and prior to the measurements, 




medium was removed and cells were washed twice with Seahorse XF base medium 
(bicarbonate-free medium) supplemented with glucose (2 mM, 1g/l or 4.5 g/L), 2 mM 
glutamine and 1 mM sodium pyruvate. After the second wash, 500 µL/well of base 
medium were added and the plate was incubated for 1 hr at 37°C without CO2.  
The cartridge was pre-hydrated one day before the assay with Seahorse XF Calibrant 
Solution, and incubated overnight (o. n.) at 37°C. The day of the assay, while cells were 
incubating with the base medium, the injection cartridge was loaded with the 
respiratory modulators of choice. In our case, we wanted to measure the OCR, so we 
used the Mito-Stress Test, using inhibitors of the respiratory chain (oligomycin (OL), 
carbonyl cyanide-4-trifluoromethoxy-phenylhydrazone (FCCP), rotenone (Rot) and 
antimycin A (AntA)) at an optimised concentration (Table M.5). We loaded the four ports 
of the cartridge A, B, C and D with 56, 62, 69 and 76 µL of 10X stocks of OL, FCCP, Rot 
and AntA, respectively (volumes are optimised by taking into account the well volume 
increment after the addition of each compound). The cartridge was introduced into the 
Analyzer and calibrated. Finally, the cell plate was introduced into the Analyzer as well, 
and the Mito-Stress assay was run. OCR was measured under basal conditions, and after 
the sequential injection of oligomycin, FCCP, rotenone and antimycin A. To normalize 
respiration rates, cells were harvested and counted after the assay.   
Table M.5. Optimal Seahorse parameters for each cell line 
Optimised parameter Fibroblasts HEK cell lines 
Seeding cell density (cells/well) 50· 103 30· 103 
Number of days between seeding 
and the assay 
1 
2 (or 3, in experiments with 
2mM glucose medium) 
Glucose concentration in Seahorse 
XF base medium 
1 g/L 
4.5 g/L (or 2mM in specific 
experiments) 
Oligomycin final concentration 4 µM 1 µM 
FCCP final concentration 1 µM 0.2 µM 
rotenone final concentration 1 µM 1 µM 
antimycin A final concentration 2.5 µM 2.5 µM 
 
i. Fibroblasts particularities 
In some experiments, 9 days before seeding the Seahorse plate, cells were treated with 
2,4-dHB or with CoQ10 (See Materials and Methods, Section M2.2).  
 




ii. HEK cell lines particularities 
Seahorse plates must be poly-D-lysine pre-coated before seeding, in order to ameliorate 
the attachment of the cells. For this purpose, they were incubated with 200 µL of a filter-
sterile poly-D-lysine (Sigma) solution (50 µg/mL) for 30 min at 37°C. After incubation, 
the solution was removed and the plates were dried in the tissue culture hood. The 
solution can be used twice. 
For Seahorse experiments with 2mM glucose medium, cells were seeded onto the 
Seahorse plates with high glucose DMEM medium, and 48h later, medium was replaced 
with 2mM glucose DMEM medium. Cells were incubated in these conditions for  
additional 24 hours. Prior to the measurements, medium was replaced with Seahorse 
XF base medium supplemented with 2mM glucose, and the washes were not performed 
because cells were very delicate at this time and detached easily. 
Analysis of the results 
The measurement of OCR after the sequential addition of inhibitors of the respiratory 
chain, like oligomycin (inhibitor of ATP synthase), FCCP (uncoupling agent), rotenone 
(inhibitor of CI) and antimycin A (inhibitor of CIII), allows to determine different 
important parameters of mitochondrial function (Figure M.3). 
These parameters are: 
i. Non-Mitochondrial respiration: Minimum rate measurement after injection of 
all ETC inhibitors.  
ii. Basal respiration: Mitochondrial OCR under resting conditions. It is calculated as 
the value of the last rate measurement before oligomycin injection minus the 
non-mitochondrial respiration. 
iii. Maximal respiration: Maximal utilization of mitochondrial respiration after the 
addition of an uncoupling agent (FCCP). Mitochondria are forced to respire more, 
trying to compensate the loss of mitochondrial membrane potential. It is 
calculated as the value of the maximum rate measurement after FCCP injection 
minus the non-mitochondrial respiration rate. 




iv. Spare respiratory capacity: Measurement of the cells' ability to respond to an 
energetic demand. It is an indicator of cell fitness or flexibility. It is calculated as 
the value of the maximal respiration minus the basal respiration.  
v. Coupled or ATP-linked respiration: OCR coupled to ATP production. It is 
calculated as the value of the last rate measurement before oligomycin injection 
minus the minimum rate measurement after oligomycin injection.  
 
 
Figure M.3. Seahorse Mitostress 
test OCR profile.  
Example of an oxygen 
consumption rate assay with 
Seahorse, with serial injections of 
oligomycin, FCCP, and 
rotenone/antimycin A. The assay 
reports key parameters, including 
basal respiration, ATP-linked 
respiration, maximal respiration 
and spare respiratory capacity 
(taken from Seahorse Analyzer 
manufacturer’s protocol).  
 
M2.6. In vivo mitochondrial translation assay 
The in vivo analysis of mitochondrial translation products was performed following 
protocols previously described (Figure M.4) 167–170. Briefly, HEK cells were seeded two 
days before the experiment on 60 mm diameter culture dishes, being at least 80% 
confluent the day of the assay. They were washed three times with warm methionine 
(Met) and cysteine (Cys)-free DMEM (2 mL per plate), and incubated for 5 minutes with 
the third wash. Then, cells were incubated with 2 ml of labelling medium (Met and Cys-
free DMEM, supplemented with 96 µg/ml Cys, 2mM GlutaMAX, 1mM sodium pyruvate, 
10% of dialysed FBS and 1% of Ab) for 10 min at 37°C.  Later, the cytosolic protein 
translation inhibitor emetine (Sigma, 25 mg/ml in PBS) was added to each plate to a final 
concentration of 100 µg/ml and plates were incubated for 30 min at 37°C. Then, 10 µL 
of 33 µCi/µL 35S L-methionine (L-Methionine, [35S]-Cell Labelling Grade, PerkinElmer) 




were added to each plate, to get a final concentration of 166.6 µCi/mL per plate. Cells 
were incubated for 1h at 37°C and afterwards, harvested in 1 mL of cold PBS and washed 
4 times by centrifuging at 10,000g for 30 s.  
Cell pellets were lysed in 45 µL of PBS supplemented with 0.1% of n-dodecyl-β-D-
maltoside (DDM), 1x protease inhibitors cocktail (PIC) (cOmplete™ Mini EDTA-free 
Protease Inhibitor Cocktail, Roche) and 50 units of benzonase for 1h on ice. Then, SDS 
(sodium dodecyl sulphate)  was added to a final concentration of 1% and samples were 
vortexed and left 5 min at RT. 30 µg of protein of each sample were ran onto a Novex™ 
18% Tris-Glycine precast SDS polyacrylamide gel (Invitrogen) for 2h at 100V. Gel was 
fixed with 20 % methanol, 10 % acetic acid solution and dried under vacuum at 80°C for 
2h.  
To visualise the bands corresponding to the radiolabelled mitochondrial translation 
products, the dried gel was exposed to a Storage Phosphor Screen (GE Healthcare) for 
at least 48h at RT. The screen was then developed with Amersham Typhoon (GE 
Healthcare), and the images analysed by using Fiji-ImageJ 171. 
 
 
Figure M.4. In vivo analysis of mitochondrial 
translation. 
(A) Cells are incubated with radiolabelled 
methionine and a cytoplasmic  translation 
inhibitor. (B) Typical pattern of pulse-labeled 
mitochondrial translation products in human 
cultured cells, shown here for immortalized 
myoblasts. The 13 mitochondrially synthesized 
proteins are indicated at the left of the panel: 
ND subunits of Complex I, COX subunits of 
Complex IV, ATP subunits of Complex V, cyt b 
subunit of Complex III (Adapted from Sasarman 
et al., 2012170). 
 




M2.7. mtDNA copy number depletion and recovery rate after ethidium bromide 
treatment and withdrawal 
Cells were seeded at  a confluency of 2.5% and 1 day after, ethidium bromide (EtBr) 
(Sigma) was added to the plate at a final concentration of 100 ng/mL. Treatment was 
extended for 4  days, when cells reached the 10% of their original mtDNA copy number 
before the treatment. After the treatment, 4 washes with fresh medium of 1 hour each 
were done and then,  cells were collected and seeded in different percentages of 
confluency for each time point of the recovery assay. 5 M CoQ10 was added to the 
recovery medium for some experimental conditions. Every 24h , cells were harvested in 
cold PBS and pellets stored at -20°C. These samples were used to determine the mtDNA 
copy number (See M4.7) and for protein extraction and quantification by western blot 
(See M3.3). The mtDNA copy number data was represented as a percentage, considering 
the mtDNA quantification of the cells before EtBr treatment as the 100%. 
M3. Biochemical methods 
M3.1. Total protein extraction and quantification 
Cell lysates were prepared by adding to fresh or frozen cell pellets 50 to 500 µL of Lysis 
solution (2% DDM, 1x PIC in PBS), depending on the pellet volume. After 15 min rotating 
at 4˚C, the lysates were centrifuged at 20,000 x g at 4˚C for 20min and the cleared 
supernatants were kept (stored at -20˚C or used immediately).  
Protein was measured in triplicates with Bradford Protein Assay (BioRad) in 96 well 
microplates, using a Pierce (bovine serum albumin) BSA Standards (2mg/ml, Thermo 
Fischer Scientific) curve. 10 µL of NaOH 1M, 2.5 µL of sample and 200 µL of 1X Bradford 
reagent were added per well, and after a 5 min incubation at RT, in the dark, absorbance 
at 595 nm was measured with a POLARstar Omega microPlate Reader 
Spectrophotometer (BMG LABTECH). 




M3.2. Protein gel electrophoresis 
SDS-PAGE 
Total cell protein lysates were separated through polyacrylamide gel electrophoresis in 
denaturing conditions (SDS-PAGE). After protein quantification, 10-100 µg of each 
protein sample were mixed with 2x Laemmli Sample Buffer (2XSB), containing 4% SDS, 
20% glycerol, 10% β-mercaptoethanol, 0.004% bromophenol blue and 125 mM Tris-HCl 
at pH 6.8, at a 1:1 ratio. Samples were incubated at 42°C for 45 minutes. 
The samples were then resolved on 12% SDS-PAGE mini-gels using the Mini-PROTEAN 
Tetra cell (Bio-Rad) at 100 V for 2 hours in running buffer TGS (25 mM Tris, 192 mM 
glycine, 0.1% SDS, pH 8.3) (Bio-Rad). As a standard, 5 μl of Precision Plus Protein all blue 
or dual color standards (Bio-Rad) was loaded. 
Blue Native-PAGE 
Blue native polyacrylamide gel electrophoresis (BN-PAGE) was used for the separation 
of mitochondrial complexes in non-denaturing conditions after as the solubilisation of 
the mitochondrial membranes using neutral mild detergents such as DDM or 
digitonin172–174.  
Mitochondrial enriched fractions were obtained by resuspending the cell pellets in 200 
µL of cold PBS and incubating at 4°C for 10’ with one volume of cold 8 mg/mL digitonin. 
Digitonin breaks the cell membrane and enriches the sample in mitochondria. After two 
washes with 1 mL of cold PBS and centrifugations at 10,000 x g for 10 min at 4˚C, the 
mitochondria-enriched samples were resuspended in 100 µL of a Solubilization Buffer, 
containing 1.5 M aminocaproic acid, 50 mM Bis-Tris/HCl at pH 7 and 1 % DDM (stronger 
detergent) or 2 % digitonin (milder detergent). After an incubation at 4°C for 5 min, 
samples were centrifuged at 18,000 x g at 4˚C for 30’, to remove the insoluble material. 
Cleared supernatants were mixed with 10 µL of sample buffer (750 mM aminocaproic 
acid, 50 mM Bis-Tris/HCl pH 7, 0.5 mM ethylenediaminetetraacetic acid (EDTA) and 5 % 
Serva Blue-G250). Samples were stored at -80˚C or loaded directly to run BN-PAGE. 
Samples were run through a 3-12 % Native-PAGE gel (NativePAGE™ Novex™ Bis-Tris 
Gels, Thermo Fisher Scientific) at 150 V and 4˚C. The cathode buffer was 50 mM Tricine, 




15 mM Bis-Tris, 0.02 % Serva Blue-G250, pH 7.4 and the anode buffer 50 mM Bis-Tris, 
pH 7.4. The cathode buffer requires a constant supply of negative charges (from the 
Serva Blue-G250) to keep the proteins negatively charged, which ensures their 
electrophoretic mobility and their separation in the gel according to molecular weight 
differences. After 1h of running, the cathode buffer was substituted by a similar buffer 
with lower amount of dye (0.002% Serva Blue-G250), to allow a better visualization of 
the samples during the electrophoresis. 
After first dimension (1D), run in native conditions, a denaturing second dimension (2D) 
was performed to separate the different subunits from the native complexes. For that, 
each lane was cut, denatured with 1 % SDS and 1 % β-mercaptoethanol for 1 hour at RT 
and then run through a 4-12 % SDS-PAGE gel (NuPAGE® Novex® Bis-Tris Protein Gels, 1.0 
mm, 2D-well, Thermo Fisher Scientific). 
M3.3. Western blotting and immunodetection 
Western blotting analysis was performed after electrophoresis. The gel was blotted onto 
a methanol-activated polyvinylidene difluoride (PVDF) membrane (Immobilon. 
Millipore). Semi-dry transfer was performed with a Trans-Blot® SD Semi-Dry Transfer Cell 
(Bio-Rad) at 25 V for 1 hour, in transfer buffer TG (25 mM Tris-HCl, 192 mM Glycine, 20 
% methanol (v/v) and 0.025 % SDS) (Bio-Rad). 
The membrane was blocked with 5% milk in TTBS (TBS (Tris-buffered saline) with  0.05% 
Tween-20) for 1h at RT, and subsequently washed three times in TTBS for 10 min. After 
the washes, it was incubated at 4˚C o.n. with different specific antibodies diluted at the 
appropriate concentrations in 5% milk in TTBS (Table M.6). After three washes in TTBS, 
the membrane was incubated for 1-2h at RT with the species-appropriate secondary 
antibody, diluted 1:5000 in 5% milk in TTBS (Table M.6), which is conjugated with 
horseradish peroxidase (HRP), essential for the following detection. After three more 
washes with TTBS, membranes were developed with Immobilon Crescendo Western 

















Company Catalog number 
COQ4 Polyclonal Rabbit 1/1000 Sigma HPA042945 
COQ5 Polyclonal Rabbit 1/1000 Proteintech 17453-1-AP 
COQ6 Polyclonal Rabbit 1/1000 Proteintech 12481-1-AP 
COQ7 Polyclonal Rabbit 1/1000 Proteintech 15083-1-AP 
β-actin Monoclonal Mouse 1/2000 Sigma A2228 
β-tubulin Monoclonal Mouse 1/10000 Sigma T5201 
TOM20 Monoclonal Mouse 1/500 abcam ab56783 
ATAD3 Monoclonal Mouse 1/1000 Santa Cruz sc-376185 
LDH-A Polyclonal Goat 1/1000 Santa Cruz sc-27230 
FLAG Monoclonal Mouse 1/1000 Sigma F3165 
HA Monoclonal Rat 1/1000 Roche 11 867 431 001 
HSP60 Polyclonal Rabbit 1/10000 abcam ab46798 




Mouse 1/500 abcam ab110412 
COXI Monoclonal Mouse 1/1000 abcam ab14705 
COXII Monoclonal Mouse 1/10000 abcam ab110258 
TRUB2 Polyclonal Rabbit 1/1000 Proteintech 19891-1-AP 
TFAM Monoclonal Mouse 1/1000 Santa Cruz sc-376672 
LRPPRC Polyclonal Rabbit 1/1000 abcam ab97505 
TUFM Polyclonal Mouse 1/1000 Abnova H0000728-4 
NDUFS3 Monoclonal Rabbit 1/1000 abcam ab177471 
NDUFA9 Monoclonal Mouse 1/1000 abcam ab14713 
VDAC Monoclonal Mouse 1/2000 abcam ab14734 
MRPS18B Polyclonal Rabbit 1/1000 Proteintech 16139-1-AP 






Company Catalog number 
anti-Goat Rabbit 1/5000 Sigma 401504 
anti-Rabbit Goat 1/5000 Cell Signaling #7074 
anti-Mouse Horse 1/5000 Cell Signaling #7076 
anti-Rat Goat 1/5000 Santa Cruz sc-2032 
M3.4. Immunostaining of fixed cells for fluorescence confocal analysis 
Immunofluorescence labelling was used to study the subcellular localisation of COQ4 
protein. Cells were seeded on poly-D-lysine-coated 24x24 mm glass coverslips in a 6-well 
plate. The next day, cells were washed with PBS three times, fixed with 4 % (w/v) 
paraformaldehyde (PFA) in DMEM-only for 15 minutes at 37 ˚C, washed again three times, 
and permeabilised for 5 minutes at RT in PBSS buffer (PBS, 5% FBS) with 0.3 % (v/v) Triton 
X-100 (Fisher Bioreagents) (PBSST). After three washes of 5 min with PBS, the coverslips 
were incubated with the anti-FLAG primary antibody (Anti-FLAG® M2 mouse antibody, 
Sigma) 1:1000 in PBSST, either for 1.5 hours at RT or overnight at 4 ˚C in a wet chamber. 
After washing, the coverslips were incubated with the secondary antibody Alexa fluor®488 




anti-mouse (Invitrogen) 1:1000 in PBSS, for 1 hour at RT. At the same time, in order to 
visualise the mitochondrial network, an anti-TOMM20 Alexa Fluor®568 (ab210841, abcam) 
was also added at a 1:50 dilution. After the incubation, samples were washed again, 
protected from light. Slides were mounted using ProLong Gold antifade with 4',6-diamidino-
2-phenylindole dihydrochloride (DAPI, Invitrogen). The fluorescence was detected with a 
confocal laser microscope (Confocal Microscope Leica SPE, Leica Microsystems). 
M3.5. Cell subfractionation  
Mitochondria and mitochondria associated membranes (MAMs) purification  
The mitochondrial isolation procedure was adapted from the one described by 
Fernández-Vizarra et al. 168. The starting material could vary depending on the final 
purpose for the mitochondria, but it was usually 5-10 T175 flasks (175 cm2 flasks) at 80-
90% confluency. All the process was performed on ice, and sometimes in the cold room. 
Cells were harvested by banging the flasks, pelleted at 1,000g for 5 min at 4°C and 
washed twice with cold PBS. Pellets were weighed and volume of cell pellet was 
estimated (1 g of cells = 0.8 ml wet volume).  
Cells were resuspended in 9 volumes of hypotonic buffer (HB: 20 mM 4-(2-
hydroxyethyl)-1-piperazineethanesulfonic acid (HEPES) pH 7.8, 5 mM KCl, 1.5 mM 
MgCl2, 2 mM dithiothreitol (DTT), 1 mg/ml BSA, 1 mM phenylmethylsulfonyl fluoride 
(PMSF) and PIC), and homogenized by 20 strokes using a tight-fitting 15 ml Dounce 
homogenizer. The homogenate was immediately mixed with 2 ml of 2.5x MSH buffer for 
every 3ml of HB added previously (2.5XMSH: 525 mM Mannitol, 175 mM Sucrose, 20 
mM HEPES pH 7.8, 5 mM EDTA, 1 mg/ml BSA, 2 mM DTT, 1 mM PMSF, PIC), in order to 
make the medium isotonic.  
The homogenate was centrifuged at low speed (1,000 g for 10 min at 4°C) to remove cell 
debris, unbroken cells and nuclei. The supernatant was collected and centrifuged again 
at low speed. This second supernatant was then spun at 10,000 g for 10 min at 4°C with 
a Sorvall LYNX 6000 Superspeed Centrifuge (Thermo Scientific). The supernatant was 
kept as the cytosolic fraction, while the pellet, containing crude mitochondria, was 
washed 3 times with 1x MSH and kept on ice until used.  




Further purification was sometimes performed in order to get pure mitochondria. For 
this purpose, crude mitochondria resuspended in 1x MSH were loaded onto a 1.5-1 M 
sucrose gradient (2 and 10 ml respectively) in 10 mM HEPES pH 7.8/ 5 mM EDTA/ 2 mM 
DTT. The gradients containing the mitochondria were spun in polypropylene tubes (14 x 
95mm, Beckman 331374) at 40,000 g for 30 min at 4°C in SW 40 Ti Rotor (Beckman 
Coulter) in an Optima L-90K Ultracentrifuge (Beckman Coulter). After the spin, 
mitochondria were forming a neat band in the interphase between 1.5 and 1 M sucrose. 
Slightly above this band, there was another small band corresponding to the 
mitochondrial associated membranes (MAMs) fraction. Both fractions were transferred 
into clean tubes and washed with 1x MSH.  
Mitochondria solubilization with DDM  
Crude or pure mitochondria were resuspended in 2X Lysis buffer (40 mM HEPES pH 7.8, 
150 mM NaCl, 10 mM EDTA, 4 mM DTT, 4x PIC) to get 10 mg/ml protein. 1 volume of 
0.8% n-dodecyl-β-D-maltoside (DDM) was added and tubes were incubated in the roller 
at 4°C for 20 min. Samples were spun at 2,000g for 10 min at 4°C, and supernatant (SN) 
was ready for subsequent procedures. 
Submitochondrial localisation by a mild trypsin treatment 
Aliquots with 200 µg of fresh crude mitochondria were resuspended in 100 µL of a 
hypotonic buffer (20 mM HEPES, pH 7.6), and trypsin was added to a final concentration 
of 5 µg/mL. The reactions were incubated at 30°C during different times, 0, 1, 10, 20 and 
60 min. After the incubation time, the reactions were stopped by the addition of 1 µL of 
100 mg/mL of Pefabloc (Sigma), a trypsin inhibitor, and 2XSB. 15 µL per sample were run 
on an SDS-PAGE gel. This assay was adapted from the literature 175.  
Iodixanol gradients 
Top-down iodixanol (IOD) gradient centrifugation of pure mitochondria was carried out 
as described in the literature 4,176. Sometimes, a digitonin pre-treatment was performed 
in order to separate membranes and soluble components, by using a digitonin (µg) to 
protein (µg) ratio of 2/1 in PBS supplemented with PIC. After a 10-minute incubation on 




ice, digitonin pre-treated samples were centrifuged at 14,000 g for 10 min at 4°C to 
obtain a membrane enriched pellet and associated components and a supernatant 
containing soluble components. 
Briefly, pure mitochondria or digitonin pre-treated membrane enriched fraction were 
lysed with 0.4% DDM. Samples (total DDM lysates, membrane enriched DDM lysates or 
digitonin-treated soluble components) were loaded on a 20–42.5% iodixanol gradient 
prepared in 20 mM HEPES pH 7.8, 1 mM EDTA, 50 mM NaCl, 2 mM DTT, 0.05% DDM and 
protease inhibitors) and centrifuged at 100,000 g for 14 h. Fractions (500 µL) were 
collected by punching a small hole into the bottom of the tube. 
M3.6. Lipid compounds quantification 
Lipids extraction  
The extraction was performed following standard procedures of our laboratory 177. 
Frozen pellets from cells or mitochondria were thawed on ice and resuspended in 200 
µL of PBS. Protein was measured and 0.5 mg of total cell homogenate or 40 µg of 
mitochondrial protein were aliquoted for extraction into 1.5 mL polypropylene tubes in 
a total volume of 100 µL in PBS. When the starting material were iodixanol fractions, 
100 µL of each fraction were used. To estimate the CoQ10 recovery of the extraction 
process, 50 pmol of CoQ6 was added as an internal standard (5 µL of 10 µM CoQ6 in 
ethanol).  Disruption of membranes was performed by adding SDS (1% final 
concentration, 5 µL of 20% SDS) and 1 min of vortexing. Lipids were dispersed with an 
alcohol cocktail (ethanol-isopropanol 95:5) added to the disrupted biological sample 
(ratio 1:2 v/v, 220 µL of alcohol cocktail) and 1 min of vortexing. The samples underwent 
subsequent triplicated hexane extraction (dispersed sample:hexane ratio 3:5 v/v, 500 
µL of hexane and 1 min of vortexing, followed by a 1,000 g 4°C 5min centrifugation). 
Hexane fractions were mixed and dried under vacuum, and then reconstituted in 
ethanol prior to high-performance liquid chromatography (HPLC) analysis. 
Quinones HPLC detection 
CoQ10 content was analysed by the injection of lipid extracts in HPLC as described by 
Rodríguez-Aguilera et al., 2017 177. These measurements were performed at the 




Laboratory of Cellular Physiopathology and Bioenergetics (Pablo de Olavide University, 
Sevilla, Spain), mainly by Ana Cortés Rodríguez. A guard cell was installed before or after 
the injection valve, depending on the experiment (after the injection valve when 
oxidation of the whole sample was required before chromatographic separation). 
Separation was performed in C18 ReversePhase-HPLC columns (5 µm, 150 × 4.6 mm) 
with 20 mM AcNH4 pH 4.4 in methanol (solvent A) and 20 mM AcNH4 pH 4.4 in propanol 
(solvent B). A gradient method with an 85:15 solvent mixture (A:B ratio), and a flow rate 
of 1.2 mL/min, was used as starting conditions. The mobile phase turned to a 50:50 ratio, 
starting in minute 6 and completed in minute 8, as the flow rate decreased to 1.1 
mL/min. After 20 min (run time) at 40 °C, the columns were re-equilibrated to the initial 
conditions for three additional minutes. 
CoQ10 levels were analysed and detected by electrochemical detector (ECD) (channel 1 
set to −700 mV and channel 2 set to +500 mV), UV-vis detector (set to 275 nm) and 
radio-flow detector (LB 509 with a solid cell YG 150 Al-U4D (Berthold Technologies)) 
when needed. 
Analysis of CoQ10 Biosynthesis 
CoQ10 biosynthesis rate was assessed by measuring the incorporation of 14C-4-HB, 
precursor of the benzoquinone ring. 14C-4-HB was chemically synthesized from 14C-
tyrosine by Fernández-Ayala et al., 2005 117. Cells were seeded on 100 mm diameter 
culture dishes in a density of 3·105 cells/dish (5·103 cells/cm2), 24 h before the addition 
of 14C-4-HB. Cell cultures were incubated with 7.2 nM 14C-4-HB for 72 hours (72 pmol of 
14C-4-HB in 10ml of medium). In some cases, cells were also grown with unlabelled 4-HB 
in the same conditions. Labelled-CoQ10 content was analysed by lipid extract injection 
in HPLC as described above.   
CoQ10 biosynthesis Intermediates characterisation 
These analyses were performed at the Mass Spectrometry Laboratory (Instituto de la 
Grasa, Sevilla, Spain), by Alicia Sánchez García and José Julián Ríos. Samples were 
analysed in an HPLC-APcI-MS system. This equipment is composed of a UHPLC Dionex 
Ultimate 3000RS (Thermo Fisher Scientific) coupled to a high-resolution mass 




spectrometer with a Time-of-Flight (TOF) analyser, micrOTOF-QII (Bruker Daltonics), 
equipped with an APcI (Atmospheric Pressure Chemical Ionization) source. 
Chromatographic separation was performed as described previously 177. The injection 
volume was 30 µl and the flow rate was 1 ml / min. The reverse phase column used was 
a Mediterranea SEA18 (3 µm, 200 x 4 mm) (Teknokroma). A 0.4 ml / min post-column 
split was directly introduced into the APcI source. The parameters of the APcI source 
used were the following: 4000 V (capillary voltage), 6000nA (intensity of the corona), 2.5 
bar of nebulization pressure, 4 l / min of drying gas flow, 220 ºC of drying temperature 
and 300 ºC source vaporization temperature. The mass spectrometer operated in 
positive mode, detecting the compounds in full scan in a mass range m / z of 50-1800.  
A specific database with the compounds of interest was prepared for the occasion (see 
Table 4.7), including the elemental composition and the name of the compounds, and 
sometimes other data such as the retention time. 
Data analysis was done by using the DataAnalysis 4.1 software (Bruker Daltonics), and 
the automatic detection from the database was carried out with the TargetAnalysisTM 
1.2 (Bruker Daltonics). This program identifies a compound according to two aspects: 
the mass accuracy of the compound, and the SigmaFitTM criteria. The SigmaFitTM 
algorithm provides a numerical comparison between the experimental and theoretical 
isotopic pattern, with smaller values indicating a closer match between theoretical and 
measured isotopic patterns 178. Only those results with mass accuracy error and mSigma 
values within the tolerance limits (5 ppm (parts per million) and 50, respectively) were 
considered as confident results.  
Cholesterol quantification 
Cholesterol was quantified using a fluorometric enzymatic kit, Amplex® Red Cholesterol 
Assay Kit (Invitrogen) according to the manufacturer’s instructions. Briefly, the assay 
measures the production of hydrogen peroxide (H2O2) after the oxidation of cholesterol 
by the enzyme cholesterol oxidase. The production of H2O2 is measured by the 
appearance of fluorescence, since, in the presence of HRP, the non-fluorescent Amplex 
Red reagent reacts in a 1:1 stoichiometry with H2O2 to produce highly fluorescent 
resorufin. For measuring total cholesterol levels (and not only free-cholesterol), a 




cholesterol esterase is also added to the reaction mix, so cholesterol esters are 
transformed in free-cholesterol and fatty acids, and this free-cholesterol can be 
quantified as well. 
Cholesterol esters cholesterol esterase Cholesterol + fatty acids 
Cholesterol + O2 cholesterol oxidase Cholest-4-ene-3-one + H2O2 
H2O2 + AmplexRed HRP Resorufin (fluorescent) 
Lipid extracts from different origins were used to measure cholesterol levels: 
i. Samples from IOD gradients: the 20% of this extract was used for each 
measurement of cholesterol.  
ii. Samples from mitochondria: Lipid extract from 10 µg of crude mitochondria was 
used for each measurement. 
iii. Samples from homogenates: Lipid extract from 20 µg of total homogenates was 
used for each measurement. 
Cholesterol-containing samples were diluted 1:5 in the 1X Reaction Buffer from the kit. 
A volume of 40 μL of the diluted sample was used for each reaction. 10 μL of catalase 
100U/mL (Sigma) were pipetted in each well. Catalase was utilised to consume 
endogenous peroxides of the solvent/sample, to reduce the background and increase 
sensitivity179. After this, 40 μL of the diluted samples, controls and STD curve were added 
to the catalase-containing wells, followed by incubation for 15 min at 37°C. Afterwards, 
50 μL of a working solution (300 μM Amplex® Red reagent, 2 U/mL HRP, 2 U/mL 
cholesterol oxidase, 0.2 U/mL cholesterol esterase) were added to each microplate well, 
followed by incubation for 30 or longer min at 37°C, protected from light. The 
fluorescence was measured by using the scanner Amersham Typhoon (GE Healthcare), 
with the microplate tray and the Cy3 filter (excitation: 532  nm, emission: 570 nm) and 
quantified by ImageQuant TL v 5.2 (GE Healthcare). 
M3.7. Mitochondrial respiratory function assessment 
For respiratory complexes enzymatic activity measurements, cell samples were 
harvested and digitonised, in order to obtain a mitochondrial membranes-rich fraction. 
Then, enzymatic activities were measured spectrophotometrically in 96-well 
microplates, measuring the kinetics for 2 or 3 minutes. Complexes I, II, III and IV 
activities, and citrate synthase activity were measured by adapting the protocol 




previously described 180. CoQ-dependent activities (complexes I + III and II + III) were 
measured according to García-Corzo et al., 2014181. 
Digitonisation of cultured cells for enzymatic assays 
Fresh pellets of 5·106 cells were harvested and washed twice with PBS. Pellets were 
resuspended in 400 μL of buffer A (20 mM MOPS (3-(N-morpholino)propanesulfonic 
acid) KOH pH 7.4, 250 mM sucrose) and the same volume of 0.2 mg/mL of digitonin in 
buffer A was added. After incubation at 4°C for 5 min, samples were microfuged at 5,000 
g, for 3 min at 4°C. Resulting pellets were resuspended in 600 μL of buffer B (20 mM 
MOPS KOH pH 7.4, 250mM sucrose, 1 mM EDTA-Na4) and, after incubation at 4°C for 5 
min, microfuged at 10,000xg, for 3 min at 4°C. The mitochondria enriched fraction 
(pellet) was stored at -80°C. Right before starting the measurements, samples were 
thawed on ice and resuspended in 200 μL of potassium phosphate (KP) buffer (10 mM, 
pH 7.4). For lysis, samples were frozen in liquid nitrogen and thawed at 37°C, for 3 cycles. 
Protein concentration was measured as previously described (see M3.1).  
Complex I activity measurement 
Complex I activity (rotenone-sensitive NADH-CoQ oxidoreductase) was measured at 
30°C, following the disappearance of NADH as a decrease in absorbance at 340 nm 
(extinction coefficient= 6.81 mL ·nmol−1 ·cm−1). 20 µL of each sample were incubated 
with the reaction mixture (20 mM KP buffer pH 8, 0.2 mM NADH, 1 mM sodium azide 
(NaN3), 1 mg/mL BSA) for 2 minutes at 30 ° C. The reaction was started with 50 µM of 
CoQ1 and the kinetics was measured for 2 minutes. Then, 5 µM rotenone were added, 
and the variation in absorbance was measured. CI specific activity was represented as 
nmol of NADH consumed per min and per mg of protein, rotenone sensitive.  
Complex II activity measurement 
Complex II activity (succinate dehydrogenase) was measured at 30°C, following the 
disappearance of the oxidized artificial electron acceptor 2,6-dichlorophenolindophenol 
(DCPIP), as a decrease in absorbance at 600 nm (extinction coefficient= 19 
mL·nmol−1·cm−1). 15 µL of each sample were incubated with 15 µL succinate (1.63 




mg/mL in 10mM KP buffer pH 7.4) for 30 min at 4°C. Then, samples were incubated with 
the reaction mixture (50 mM KP buffer pH 7, 1.5 mM potassium cyanide (KCN), 0.1 mM 
DCPIP) for 2 minutes at 30°C. The kinetics was measured both before and after the 
addition of 50µM of CoQ1. CII specific activity was represented as nmol of DCPIP 
consumed per min and per mg of protein. 
Complex III activity measurement 
Complex III activity (decilubiquinone (DBH2):cytochrome c oxidoreductase) was 
measured at 30°C, following the reduction of cytochrome c, as a variation in absorbance 
at 550 nm (extinction coefficient= 21 mL·nmol−1·cm−1). 10 µL of each sample were added 
to the reaction mixture (50 mM KP buffer pH 7.4, 2 mM NaN3, 1 mg/mL BSA, 50 µM 
cytochrome c, 50 µM reduced DBH2) and the kinetics was measured for 2 minutes at 
30°C.  CIII specific activity was represented as nmol of cytochrome c reduced per min 
and per mg of protein. 
Complex IV activity measurement 
Complex IV activity (cytochrome c oxidase) was measured at 37°C, following the 
oxidation of cytochrome c, as a variation in absorbance at 550 nm (extinction 
coefficient= 18.5 mL ·nmol−1 ·cm−1). 10 µL of each sample were added to the reaction 
mixture (50 mM KP buffer pH 7, 100  µM reduced cytochrome c) and the kinetics was 
measured for 3 minutes at 37°C. CIV specific activity was represented as nmol of 
cytochrome c oxidized per min and per mg of protein. 
CoQ-dependent activities measurement 
Complex I+III and II+III activities were measured at 30°C, following the reduction of 
cytochrome c, as a variation in absorbance at 550 nm (extinction coefficient= 21 mL 
·nmol−1 ·cm−1).  
i. For CI+III activity measurement, 8 µL of sample were added to the reaction 
mixture (100 mM KP buffer pH 7.4, 5% BSA, 0.5 mM KCN, 0.1 mM cytochrome c) 
in the presence or absence of 25 µM rotenone, incubating 4 min at 30°C. The 
reaction began with the addition of 0.2 mM of NADH and the absorbance was 




monitored for 3 min at 30°C. The activity was represented as the rotenone 
sensitive activity.  
ii. For CIl+III activity measurement, 8 µL of sample were added to the reaction 
mixture (75 mM KP buffer pH 7.4, BSA 1%, 0.5 mM KCN, 0.3 mM succinate, 25 
µM rotenone), incubating 10 min at 30 ° C. The reaction began with the addition 
of 0.1 mM cytochrome c and the absorbance was monitored for 3 min at 30°C. 
CI+III and II+III specific activities were represented as nmol of cytochrome c reduced per 
min and per mg of protein. 
Citrate synthase activity measurement 
Citrate synthase (CS) activity was measured at 30°C, following the appearance of 
thionitrobenzoic acid (TNB), proportional to the amount of liberated CoA, as a variation 
in absorbance at 412 nm (extinction coefficient= 13.8 ml ·nmol−1 ·cm−1). 5 µL of sample 
were incubated with the reaction mixture (75 mM Tris-HCl pH 8, 100 μM DTNB (5,5'-
dithiobis (2-nitrobenzoic acid)), 0.1 % Triton X-100 and 400 μM acetyl-CoA) for 2 min. 
The reaction began with the addition of 0.5 mM oxaloacetate and the absorbance was 
measured for 2 min at 30 ° C. CS specific activity was represented as nmol of CoA formed 
per min and per mg of protein. The specific activities of each complex (nmol/min/mg 
prot) were normalized by the specific activity of CS.  
M3.8. Detection of COQ4 interaction partners 
COQ4 protein affinity purification 
For isolation of FLAG or HA-tagged COQ4 or untagged COQ4 with their interaction 
partners, immunocapture using an anti-FLAG, an anti-HA or an anti-COQ4 antibody was 
performed. Transfected cells with COQ4-FLAG-Strep tags (COQ4-FS), COQ4-HA or with 
untagged COQ4 were grown and doxycycline treated for the induction of the transgene 
(0.1 ng/mL, 24 h). Non-transfected COQ4 KO cells were also used for all the procedure, 
as a negative control. Cells were collected, and 15 mg of cell protein were resuspended 
in PBS with PIC (PBSi) and treated with 0.5 mg/ml digitonin for 10 min at 4°C, in order to 
get a mitochondria-enriched fraction. Samples were centrifuged at 11,000 g for 5 min 
and pellets were washed with PBSi. Then, they were resuspended in 330 µL of 




solubilisation buffer (PBSi with 10 % (w/v) glycerol, 1X lipid stock (10X stock: 0.9 mg/ml 
1-palmitoyl-2-oleoyl-glycero-3-phosphocholine (POPC), 0.3 mg/ml 1-hexadecanoyl-2-
(9Z-octadecenoyl)-sn-glycero-3-phosphoethanolamine (POPE), 0.3 mg/ml 1-palmitoyl-
2-oleoyl-sn-glycero-3-phospho-(1'-rac-glycerol) (POPG), Avanti Polar Lipids) and 1.5 % 
(w/v) DDM), and incubated for 30 minutes at 4°C. Lysates were centrifuged at 16,900 x 
g for 10 min. Clear supernatants were filtered using spin-X-centrifuge filters, 0.22 µm 
cellulose acetate (Costar) or ultrafree -MC durapore 0.22 µm PVDF filters (Millipore). 
Samples were incubated with 40 µL of agarose beads crosslinked to the antibody of 
interest, o.n. at 4°C in rotation.  
i. For FLAG-tagged protein purification, EZview red anti-FLAG M2 affinity gel 
(Sigma-Aldrich) was used.  
ii. For HA-tagged protein purification, HA-Tag (C29F4) rabbit mAb sepharose bead 
conjugate (Cell Signaling Technology) was used. 
iii. For untagged COQ4 purification, rabbit anti-COQ4 antibody (HPA042945, Atlas 
Antibodies) was crosslinked to agarose beads the day before the experiment by 
using the Pierce Crosslink Immunoprecipitation Kit (ThermoScientific), following 
the manufacturer’s instructions.  
The unbound material was collected and affinity resins were washed 5 times with wash 
buffer containing PBSi, 10% glycerol, 1 x lipid stock and 0.05 % (w/v) DDM. Bound 
material was eluted in different ways.  
i. For FLAG-tagged proteins, a native elution was performed by using 30 µL of 150 
µg/mL FLAG peptide (Sigma-Aldrich) in wash buffer, for 4h at 4°C.  
ii. For HA-tagged proteins and untagged COQ4, a denaturing elution was 
performed by using 200 mM glycine at pH 2.5 with 0.05% (w/v) DDM, for 30 min 
at RT. The eluate was neutralised with Tris Base. 
The presence of specific proteins in the eluates was analysed by SDS-PAGE, WB and 
immunodetection, and by mass spectrometry (MS). 




Crosslinking of mitochondrial proteins  
For crosslinking experiments, 0.5 - 2 mM disuccinimidyl suberate (DSS) were added to 
crude mitochondria, for 30-120 min at RT. Then, the reaction was quenched by using 
200 mM ammonium bicarbonate 15 min at RT. Crosslinked mitochondria were washed 
twice with PBS. Then, immunoprecipitation was performed as described above, starting 
with the resuspension of crosslinked mitochondria with solubilization buffer.  
Stable isotope labelling by amino acids in cell culture  
SILAC (stable isotope labelling by amino acids in cell culture) is a simple and efficient 
approach of quantitative proteomics which allows an accurate relative quantification of 
the proteomes from two different cell populations (Figure M.5) 182–184. Essential amino 
acids labelled with stable non-radioactive isotopes, 15N- and 13C- labelled arginine (R10) 
and lysine (K8), are added to an amino acid deficient cell culture medium. Through 
normal metabolic processes, the cells grown in this heavy (H) medium replace the 
natural (light, L) amino acids (14N and 12C arginine and lysine, R0 and K0) with the heavy 
ones, which are fully incorporated into the newly synthetized proteome after 8-10 
doublings (Figure M.5.A). SILAC amino acids do not have effects on cell morphology, 
metabolism or growth rates and allow the two differentially labelled cell pools to be 
equally mixed in a single sample and then analysed by mass spectrometry (MS), 
remaining fully distinguishable.  
In this study, SILAC was used to compare COQ4-defective cell line to the same cell 
overexpressing different tagged or untagged forms of COQ4, in order to identify COQ4 
interactors. The two cell lines to be compared by SILAC MS were grown in H-DMEM 
containing R10 and K8 and in L-DMEM containing R0 and K0 (Sigma-Aldrich), for at least 8 
doublings. Both SILAC media also contained proline, to avoid the conversion of the 
excess of arginine to proline, and 10% dialyzed FBS, to prevent the dilution of heavy 
isotopes. Full incorporation of heavy amino acids was checked before the experiments. 





Figure M.5. Overview of SILAC protocol.  
The SILAC experiment consists of two distinct phases—an adaptation (A) and an experimental (B) phase. 
(A) During the adaptation phase, cells are grown in light (L) and heavy (H) SILAC media until cells grown in 
the H medium have fully incorporated the heavy amino acids (red star). The two SILAC cell pools are then 
fully distinguishable by MS (black dot (L) and red star (H) peptides, respectively). (B) In the experiment 
phase, the two cell populations (control and experiment) that are differentially labelled are expanded and 
during the experiment, they can be mixed and processed as a single sample. In our case, we performed 
affinity purification of COQ4-FS protein, and analysed the eluted fraction. Samples were reduced and 
alkylated, resolved by SDS-PAGE and trypsin digested. Resulting peptides were as a single pool by MS for 
protein identification and quantification (Adapted from Ong et al., 2006183). 
 
Quantitative proteomics with SILAC labelling 
Each quantitative proteomics analysis was based on two SILAC experiments, namely exp. 
1 and exp. 2, one in which the overexpressing cell line (COQ4-FS, COQ4-HA or COQ4) 
was H-labelled and the control cell line (COQ4 KO) unlabelled, and the second one with 
reverse labelling, respectively. For each experiment, equal portions of the differentially 
labelled H and L cells were mixed (Figure M.5.B), and protein immunoprecipitation was 
performed as described above (with or without crosslinking, and with or without 
mitochondria purification).   
Eluted samples were prepared for MS by reducing and alkylating the cysteine residues. 
Reduction was done by adding tris(2-carboxyethyl)phosphine (TCEP) (5 mM final 
concentration, Sigma-Aldrich) dissolved in gel sample buffer (40 % (w/v) glycerol, 200 




mM Tris pH 9, 4 mM EDTA pH 8, 4 % (w/v) SDS), and incubating at 37 °C for 30 min. 
Samples were brought to RT and alkylation was performed by adding iodoacetamide (15 
mM final concentration) and incubating in dark at RT for 30 minutes. Then DTT (25 mM 
final concentration) was added to quench the excess of iodoacetamide. Proteins were 
then resolved by SDS-PAGE in 10-20% acrylamide Novex Tris-Glycine Mini Gel, 
WedgeWell format (Invitrogen) electrophoresis. Next, the gel was stained with 
Coomassie Brilliant Blue R-250 185 in order to visualize the protein bands. Each lane of 
the gel was cut in eleven 0.6 mm slices, which were sent to the mass spectrometry 
facility at the MRC-Mitochondrial Biology Unit (Cambridge, UK), where they performed 
all the following steps of proteins digestion, MS and protein identification and 
quantification. 
Briefly, proteins were digested with trypsin and the resulting peptides analysed by liquid 
chromatography mass spectrometry (LC-MS) employing an LTQ XL-Orbitrap system 
(Thermo Fisher Scientific), as described previously 186. Proteins were identified by 
Andromeda and quantification of heavy to light (H/L) ratio was calculated with 
MaxQuant 187. Ratio was based on reciprocal labelling duplicate SILAC experiments. The 
median peptide ratio was taken to be the protein ratio, using at least two ratio counts 
for each peptide. The ratios from each experiment were plotted as the log2 value on a 
scatter plot, at the x and y axes, respectively, each protein represented by a point.  
In the scatter plot, proteins unaffected by experimental conditions cluster around the 
origin.  Proteins with a consistent increase or decrease in abundance occur in the top 
right or bottom left quadrants, respectively. Points in the two other quadrants represent 
proteins with irreproducible results within replicates. Those in the top left quadrant 
contain exogenous contaminants. A diagonal line from the top right to bottom left 
represents a perfect correlation between the two experiments.  
Statistically significant proteins (P < 0.05) in one or both orientations of labelling were 
identified with Perseus 188. The significance of the enriched proteins was calculated 
based on significance B with permutation-based False Discovery Rate (FDR) control 189, 
considering a Benjamini-Hochberg FDR<5%. 





Mitoplasts from COQ4 KO and COQ4 KO-overexpressing COQ4-FS (induced with 
doxycycline) were affinity purified using anti-FLAG beads, as described above. Protein 
eluates were methanol-chloroform precipitated, dried under vacuum (Speed Vac) and 
send to the proteomics facility of the Pablo de Olavide University (Seville, Spain), where 
they performed all the following steps of sample digestion, LC-MS and protein 
identification.  
Briefly, protein pellets were resuspended in urea 6 M, 50 mM ammonium bicarbonate. 
Disulphide bonds were reduced adding DTT 10 Mm, 50 mM ammonium bicarbonate to 
protein solution and incubating for 60 min at RT. For carbamidometylation of cysteine –
SH groups, iodoacetamide 30 mM, 50 mM ammonium bicarbonate was added to 
samples and incubated in the dark for 30min. 
Samples were digested overnight at 37°C using trypsin bovine (Sequencing Grade 
Modified Trypsin, Promega) in a ratio 1:12 enzyme-substrate. Reaction was stopped 
using formic acid to 0.5%. OMIX C18 tips (Agilent Technologies) were used for 
concentrating and desalting peptide extracts. Samples were dried and resuspended in 
0.1% trifluoroacetic acid and injected in a nano-HPLC system. 
Protein digested samples were separated in a Thermo ScientificTM Easy nLC system 
using a 50 cm C18 Thermo Scientific™ EASY-Spray™ column. The following solvents were 
employed as mobile phases: Water 0.1% Formic Acid (phase A) and Acetonitrile, 20% 
H2O, 0.1% Formic Acid (phase B). Separation was achieved with an acetonitrile gradient 
from 10% to 35% over 120 min, 35% to 100% over 1 min, and 100% B over 5 min at a 
flow rate of 200 nL/min. 
A Thermo ScientificTM Q Exactive™ Plus Orbitrap™ mass spectrometer was used for 
acquiring the top 10 MS/MS spectra in DDA (Data-dependent acquisition) mode. LC-MS 
data were analysed using the SEQUEST® HT search engine in Thermo Scientific™ 
Proteome Discoverer™ 2.2 software using static carbamidomethylation (C), dynamic 
oxidation (M) and acetylation (C, H, K, S, T, Y) modifications. Data were searched against 
the Uniprot Human protein database and results were filtered using a 1% protein FDR 
threshold 189. 




The list of identified proteins was analysed by gene name, to eliminate replicated 
results. Venn diagrams of the resulting lists were generated by using the Venny 2.1 tool 
190. We subjected the protein list (by gene names) to a Gene Ontology (GO) PANTHER 
overrepresentation analysis, by cellular component, biological process and molecular 
function, using a Homo sapiens reference list containing all genes in the GO database 
191–193. In order to simplify the results, similar GO terms were fused. 
M4. Molecular biology methods 
M4.1. Nucleic acid extraction and quantification 
Total genomic DNA was extracted from cell pellets, by using the Promega Wizard 
Genomic DNA Purification kit (Promega), following the manufacturer's protocol. When 
the pellets were very small, all the volumes of the standard protocol were divided by 3. 
Dry DNA pellet was reconstituted in milliQ H2O.  
Total RNA was extracted from cell pellets, by using the TRIzol Plus RNA Purification 
System (Invitrogen-ThermoFisher Scientific), following the manufacturer's protocol. Dry 
RNA pellet was reconstituted in RNAase free milliQ H2O.  
DNA and RNA concentrations were measured using a NanoDrop One UV-Vis 
Spectrophotometer (Thermo Scientific). Good quality samples had a 260 nm / 280 nm 
ratio between 1.6-2.0 for DNA and between 1.8-2 for RNA. Additionally, to check RNA 
integrity, 0.5 μg of RNA was run on a 1% TBE-agarose gel to observe the 18S and 28S 
ribosomal RNA bands. 
M4.2. Polymerase chain reaction (PCR) amplification 
PCR was performed in order to amplify DNA fragments for different purposes (cloning, 
sequencing, checking ligations, etc.) and from different origins (genomic DNA, cDNA, 
plasmid, bacteria colony). DNA was amplified with HorsePower Taq polymerase kit 
(Canvax Biotech), using the manufacturer’s protocol. The PCR amplification set-up is 
detailed in Table M.7 and the thermocycler conditions were optimised for each specific 
reaction (Table M.8). 
 
 




Table M.7. Standard PCR assay. 
Reagent Volume (μL) 20 μL/reaction Final concentration 
10x PCR buffer 2 1x 
MgCl2 25mM 2 2.5 mM 
dNTP 10mM mixture 1.6 0.8 mM 
Primer Forward (Fw) 10 µM 1.5 0.75 
Primer Reverse (Rv) 10 µM 1.5 0.75 
DNA template 0.2-10 1.75-2.5 ng/μL 
Horse-Power-Taq DNA 
polymerase (5 U/μL) 
0.2 0.05 U/μL 
milliQ H2O to 20  
 
Table M.8. Cycling conditions for PCR. 
Step Temperature (°C) Time Number of cycles 
Initial 
denaturation 
95 5 min 1x 




30 s 0.8 mM 
Elongation 72 1 min / Kb 0.75 
Final elongation 72 10 min 0.75 
Hold 4 ∞ - 
 
M4.3. Agarose gel electrophoresis 
Agarose gel electrophoresis was used for the separation of DNA or RNA in fragments of 
varying sizes. 1 % agarose gels were used for general applications, 0.7-0.8 % when 
resolving large fragments (>5 kb) and 1.5 % for small fragments (<0.5 kb). Gels were cast 
with the appropriated percentage (w/v) of agarose low melting point (Sigma-Aldrich) 
dissolved in 50 mL / 100 mL of Tris/Borate/EDTA (TBE) buffer (89 mM Tris-borate, 100 
mM boric acid, 2 mM EDTA) and 1x RedSafe™ dye (20,000X, iNtRON biotechnology). 
DNA samples were mixed with loading dye (6X) at a 5:1 volume ratio and were always 
run alongside the GeneRuler 1 kb DNA Ladder (Termo Scientific). Gel electrophoresis 
was performed at voltage of 80-100 V with TBE as running buffer, in a ReadySub-Cell GT 
Horizontal Electrophoresis System (Bio-Rad). Bands were visualized with a ChemiDocTM 
XRS+ Imaging System (Bio-Rad).  
M4.4. Retrotranscription of RNA 
Purified RNA (40 µL) was treated with DNase I Amplification Grade (Sigma-Aldrich), to 
remove any DNA traces. Briefly, 5 µL of 10x reaction buffer and 5 µL of DNase were 
added to the RNA and incubated at RT for 15 min. Then, 5 µL of stop solution were added 




and samples were incubated for 10 min at 70°C. 1 µg of DNase-treated RNA was 
retrotranscribed with the iScript kits (Bio-Rad), to obtain the complementary DNA 
(cDNA).  
iScript Reverse Transcription Supermix was used when cDNA was needed for 
subsequent gene expression analysis by Real-time quantitative PCR (RT-qPCR), while 
iScript Select cDNA Synthesis Kit was used when cDNA was needed for subsequent 
cloning (Tables M.9 and 10). 
Table M.9. cDNA synthesis reaction. 
iScript Reverse Transcription Supermix 
Reagent Volume (μL) 
5x iScript Reaction Mix 4 
iScript Reverse Transcriptase 1 
milliQ H2O To 20 
RNA template (1 µg) variable 
iScript Select cDNA Synthesis Kit 
Reagent Volume (μL) 
5x iScript Select Reaction Mix 4 
iScript Reverse Transcriptase 1 
Oligo (dT)20 primer 2 
milliQ H2O To 20 
RNA template (1 µg) variable 
 
Table M.10. cDNA synthesis reaction protocol. 
Step Temperature (°C) Time 
Priming 25 5 min 
Reverse Transcription 46 20 min 
RT inactivation 95 1 min 
Hold 4 ∞ 
M4.5. Real-time quantitative PCR 
To perform a relative quantification of gene expression levels, RT-qPCR was performed 
by using the iTaq Universal SYBR Green Supermix, following the instructions and 
protocol provided by the manufacturer. Generally, an amount of first-strand cDNA 
equivalent to 50 ng of starting RNA was used. Samples were loaded in 96-Well Reaction 
Plates (Bio-Rad) and the RT-qPCR was performed in CFX Connect Real-Time PCR 
Detection System (Bio-Rad). The relative quantification was calculated by using the          
2-ΔΔCp method 194.  




M4.6. In vitro studies of spliceogenicity of patients’ variants 
Reverse Transcription- Semi-quantitative PCR  
Semi-quantitative PCR was performed by using an amount of first-strand cDNA 
equivalent to 150 ng of starting RNA. We used the standard PCR protocol, but with a 25-
cycle amplification protocol, to ensure that the PCR amplification remained in the 
exponential phase.  
The RT-PCR products were analysed by agarose gel electrophoresis. The relative 
amounts of the different forms were determined by densitometry, using the Fiji-Image 
J 171 and expressed as a percentage. After electrophoresis, bands were excised from the 
gel for cloning and sequencing. 
Minigene constructs expression and analysis of the transcripts 
Minigene constructs expression and analysis were performed by our collaborators from 
Dr Eva Trevisson’s laboratory in Padova. Briefly, the ß-globin minigene was developed 
by Forzan et al., 2010 195, by cloning the ß-globin gene in a pcDNA™3.1/Hygro(+) vector 
(Thermo Fischer Scientific), with a polylinker containing the restriction sites for enzymes 
XhoI, NotI and HindIII in the intron 2 of ß-globin gene. The patient’s genomic DNA 
fragment carrying the c.532+6 T>A variant was amplified with primers with the same 
restriction sites and subsequently cloned inside the ß-globin minigene.  
The COQ4 fragment amplified consisted in the exon closest to the intronic variant to 
analyse and a portion of 100 bp of flanking intronic regions upstream and downstream. 
For comparison, the WT equivalent sequence was also cloned in the minigene vector. 
WT and mutant plasmids were used for transfection in HEK293 cells that do not express 
ß-globin, in addition with the empty ß-globin vector, as negative control. 24 hours after 
transfection, total RNA was extracted, retrotranscribed and the resulting cDNA was 
amplified with a semiquantitative-PCR, using specific primers for the ß-globin gene, 
designed on exon 2 (forward) and exon 3 (reverse).  





RNA from control and patient fibroblasts pellets was extracted from 175 cm2 of cells 
grown in 1g/L glucose DMEM supplemented with 20% (v/v) of FBS, 1% Ab and 10 μM 
uridine. Total RNA was extracted and quantified as described in section M4.1. Samples 
were submitted to Novogene Europe (Cambridge, United Kingdom) with a total RNA 
quantity of at least 2 μg.  
Novogene prepared the libraries and performed the paired-end sequencing of the 
samples with Illumina NovaSeq 6000, with a read length of 150 nt. They analysed the 
results, mapping the obtained sequences to the human reference genome GRCh38 
assembly. Data was visualised with the Integrative Genomics Viewer (IGV) software 
(Broad Institute and UC San Diego)196, focusing on COQ4 transcript and counting the 
reads for each exon. 
M4.7. mtDNA copy number determination 
DNA from frozen cell pellets was extracted using the Promega Wizard Genomic DNA 
Purification kit. mtDNA copy number was measured by RT-qPCR, using Taqman probes 
for a nuclear (APP, probe: Hs02339796_cn, Applied Biosystems) and a mitochondrial 
gene (COXI, probe: Hs02596864_g1, Applied Biosystems), using the Mix qPCR TaqMan® 
Gene Expression Master Mix (Applied Biosystems), following the manufacturer’s 
instructions.  
20 ng of genomic DNA were used per reaction, and for each sample, three technical 
replicates were added to the plate. RT-qPCR was run in an ABI PRISM® 7900HT Sequence 
Detection System (Applied Biosystems). The relative quantification was calculated by 
using the 2-ΔΔCp method 194, using the nuclear gene APP for normalisation.  
M4.8. Purification of PCR products from agarose gels  
Agarose-embedded DNA fragments were purified using the NucleoSpin® Gel and PCR 
Clean-up kit (Macherey-Nagel). Briefly, a high-salt binding buffer was added to the cut-
out gel band, and it was heated to dissolve the agarose. The mixture was then applied 
to the spin column, where, in the presence of chaotropic salt, DNA binds to the silica 
membrane. Contaminations were removed by washing steps with ethanolic Wash Buffer 




NT3. Finally, the pure DNA was eluted under low salt conditions with slightly alkaline 
Elution Buffer NE (5 mM Tris/HCl, pH 8.5). 
M4.9. DNA digestion and plasmid dephosphorylation 
DNA plasmids were digested at 37 °C for 1 h with the Anza Restriction Enzymes system 
(Thermo Scientific) according to manufacturer’s instructions. After digestion, vectors 
were dephosphorylated (to avoid self-ligation) by adding 1 μL of the Anza™ Alkaline 
Phosphatase to the reaction and incubating at 37°C for 30 minutes. DNA fragments were 
then separated on 1 % (w/v) agarose gels, and the bands corresponding to the fragments 
of interest (the linearised vector or the insert) were excised from the gel and purified. 
M4.10. DNA ligation 
PCR products amplified with Taq polymerase, which leaves a A-overhang, were cloned 
directly into the pCR2.1 (Invitrogen) or the pGEM®-T Easy vector, following the 
manufacturer’s protocol. In the case of blunt-end fragments, A-tailing was performed 
before ligation. For this, the purified DNA fragments were incubated at 72°C for 20 
minutes with 0.2 mM of dATP (Sigma) and the HorsePower Taq polymerase kit (Canvax 
Biotech): 1X PCR Reaction Buffer, 2.5mM MgCl2 and 0.5 u/ μL of HorsePower Taq 
polymerase, in nuclease-free water to a final volume of 10 μL. 
The restriction enzyme -digested inserts and vectors, were ligated using  Anza™ T4 
DNA Ligase Master Mix (Thermo Scientific). Ligation reactions of 20 μL containing 5 μL 
of Anza™ T4 DNA Ligase Master Mix were set up at a 1:5 vector:insert ratio, with 50 ng 
of linearised vector, and incubated at RT for 1 h, or 4°C o.n. Ligation products were then 
transformed into DH5α chemically competent bacteria.  
M4.11. Site directed mutagenesis 
Site directed mutagenesis (SDM) was performed by using the QuikChange II XL Site-
Directed Mutagenesis kit (Agilent), following the manufacturer's protocol. These 
oligonucleotides are specified in Table M.11. 
 




M4.12. Transformation of E. coli  
Chemically competent E. coli DH5α bacteria were used for plasmid transformation and 
maintenance. For transformation, they were taken from the stock at -80°C and thawed 
on ice. Plasmids or ligation products to be transformed were added to the cells (1-5 μL, 
5-100 ng), with subsequent incubation on ice for 10 min. A heat shock was performed 
at 42°C for 45 seconds, and samples were returned to ice immediately after, for 10 min. 
500 µL of LB (10 g/L tryptone, 5 g/L yeast extract, 5 g/L NaCl) were added and incubated 
30 min at 37°C, with 200 rpm shaking. Different dilutions were plated in LB plates with 
100 μg/ml ampicillin, and grown 24h at 37°C to visualize the results. 



































5 Rv TCGACCTCGGAGTTGACTTT 






























17 Rv GGTAAGAAGTGGGCTAGGGC 
18 
qPCR-hAct 
Fw CTCGCTGTCCACCTTCCA Actin 



















25 Rv TCCCCGGATTGCGGCAGCCGCCCTCGACCT 
26 hcoq4 
mutSTET 
Fw AGGTCGAGGGTCTCTGTCGAAATCCGGGGACGCTC phospho 
mutant M2 27 Rv GAGCGTCCCCGGATTTCGACAGAGACCCTCGACCT 
28 hcoq4 
mutAAEA 
Fw CCAGGTCGAGGGCCTCTGCCGCAATCCGGGGACGC phospho 
mutant M3 29 Rv GCGTCCCCGGATTGCGGCAGAGGCCCTCGACCTGG 
 


























































































































M4.13. Plasmid preparation 
Bacteria colonies carrying a plasmid of interest were grown o.n. in 5 mL of LB medium 
supplemented with 100 μg/ml ampicillin or 50 µg/mL of kanamycin (depending on the 
plasmid resistance gene, see Table M.12), at 37 °C with shaking at 200 rpm. DNA 
plasmids from the overnight cultures were isolated using the QIAprep Spin Miniprep kit 
(Qiagen). Briefly, bacterial cultures were lysed and centrifugated. Cleared lysates were 
then applied to the spin columns, where DNA binds to the membrane. Impurities were 
washed and pure DNA was eluted in elution buffer. 
M4.14. Sequencing 
All the constructs were checked by DNA Sanger sequencing (STAB VIDA company). 
M4.15. Plasmids, primers and tags used in this project 
Primers and plasmids used in this project are listed in Table M.11 and Table M.12, 
respectively.  
All primers for standard PCR were designed with Primer3 tool 197,198, and posterior 
manual optimisation. All primers for SDM were designed using the tool provided by 
Agilent (www.agilent.com/genomics/qcpd) 199. All primers were synthesised by STAB 


















Table M.12. List of plasmids used in this project. 
Plasmid name Description Source 
pU6-gRNA1 
(Forward) 
U6-gRNAs plasmids expressing guide sequences to human 
COQ4 exon 2 under U6 promoter. pUC origin and KanR gene for 












Cas9-D10A nickase plasmid co-expressing GFP under CMV 
promoter. pUC origin and KanR gene for multiplication and 
selection in bacteria. (CAS9D10AGFPP-1EA) 
pU6- EMX1-s4 CRISPR/Cas9 nickase EMX1 positive control: 2 U6-gRNAs 
plasmids expressing guide sequences to human EMX1 under U6 
promoter. pUC origin and KanR gene for multiplication and 






CRISPR/Cas9 negative control: U6-gRNA/CMV-Cas9-GFP 
plasmid expressing a non-targeting guide sequence under U6 
promoter and co-expressing Cas9 and GFP under CMV 
promoter. pUC origin and KanR gene for multiplication and 
selection in bacteria. (CRISPR06-1EA) 
pcDNA™5/ 
FRT/TO 
Inducible expression vector designed for use with the Flp-In™ 
T-REx™ System (CMV/TetO2 promoter, for Tet/DOX-regulated 
expression of the gene of interest; FRT site for Flp 
recombinase-mediated integration; Hygromycin resistance 
gene for selection of stable cell lines; pUC origin and AmpR 
gene for multiplication and selection in bacteria) 
Invitrogen 
pOG44 
Flp recombinase gene under CMV promoter, pUC origin and 
AmpR gene for multiplication and selection in bacteria 
pcDNA5-FS 
Linker-FLAG-linker-Strep-STOP tag sequences cloned with XhoI 
and ApaI in pcDNA5 multicloning site (MCS), for C-terminal 
tagging of proteins. Genes of interest must be cloned with XhoI 
and no stop codon in 3' 





COQ4 WT gene sequence cloned in pcDNA5-FS. Amplified from 
cDNA with primers #1 and #2 and digested with HindIII and 
XhoI 
This study. Dr. 
Gloria Brea Calvo, 
UPO, Seville, Spain 
pcDNA5-
COQ4-HA 
COQ4-HA-stop sequence cloned in pcDNA5-FS. Amplified from 
pcDNA5-COQ4-FS with primers #1 and #3, to introduce HA tag, 




Untagged COQ4 sequence with two stop codons in pcDNA5-
COQ4-FS. Obtained by SDM with primers #20 and #21 
pcDNA5-
COQ4-FS-M1 
COQ4-FS in pcDNA5 with M1 phospho-mutation introduced by 
SDM from pcDNA5-COQ4-FS in two rounds, with primers #22 
and #23, and #24 and #25 
pcDNA5-
COQ4-FS-M2 
COQ4-FS in pcDNA5 with M2 phospho-mutation introduced by 
SDM from pcDNA5-COQ4-FS with primers #26 and #27 
pcDNA5-
COQ4-FS-M3 
COQ4-FS in pcDNA5 with M3 phospho-mutation introduced by 





COQ4-HA in pcDNA5 with patients' mutations introduced by 
SDM from pcDNA5-COQ4-HA, with primers #30 to #65 
 




Table M.12. List of plasmids used in this project (Continued). 
Plasmid name Description Source 
pcDNA5-COQ4-HA 
Iso b 
COQ4-HA Iso b splice variant (missing exon 3) sequence cloned 
in pcDNA5. Amplified from P105/HDF Neo cDNA with primers 




COQ4-HA Iso c splice variant (missing exon 5) sequence cloned 
in pcDNA5. Amplified from P105/HDF Neo cDNA with primers 
#1 and #3, and digested with HindIII and XhoI 
pcDNA5-COQ4-HA 
Iso d 
COQ4-HA Iso d splice variant (missing exons 3 and 5) sequence 
cloned in pcDNA5. Amplified from P105/HDF Neo cDNA with 
primers #1 and #3, and digested with HindIII and XhoI 
pcDNA5-COQ4-HA 
Iso e 
COQ4-HA Iso e splice variant (missing exons 3 to 5) sequence 
cloned in pcDNA5. Amplified from P105/HDF Neo cDNA with 
primers #1 and #3, and digested with HindIII and XhoI 
 
Table M.13. Tag sequences used for fusion proteins generation. 








CTGGC (linker 1) 
GATTACAAGGACGACGATGACAAG (Flag) 
GGCGGAGCCGCTGGA (linker 2) 
TGGAGCCACCCCCAGTTCGAGAAG (Strep) 
















M5. In silico analysis of gene and protein sequences and protein structures 
M5.1. Sequence analysis 
Reference sequences were retrieved from NCBI Refseq 200 and UniprotKB 201 databases. 
Different tools were used for sequence analysis.  
Multiple alignment 
BioEdit 202 + Clustal W 203 were used for the multiple alignment of sequences and 
visualization.  
Translation initiation site prediction 
We predicted translation initiation sites (TIS) of mRNA sequences using NetStart1.0 204 
and ATGpr 205 tools. 




RNA secondary structure prediction 
We used the RNAfold server206 to predict the secondary structure of the pre-mRNA that 
would contribute a state of minimum free energy. As input, we used a sequence 
containing the mutated nucleotide and 100 or 200 nucleotides flanking it upstream and 
downstream.  
Protein secondary structures prediction 
Secondary structures of proteins were predicted by JPred 207. 
MTS prediction 
Prediction of a mitochondrial targeting signal (MTS) and cleavage sites of proteases was 
performed using MitoMiner 208 and MitoFates 209. 
Phosphorylation prediction 
Human COQ4 sequence and some COQ4 ortholog sequences (mouse, zebra fish, yeast 
and worm) were aligned and subjected to different in silico analysis for phosphorylation 
prediction. Potentially phosphorylatable residues (Ser, Thr, Tyr) were analyzed in terms 
of conservation. Residues that were conserved in at least 2 of these species (human’s, 
among these two) were analyzed by different in silico phosphorylation prediction tools 
or phosphorylation databases. The tools used were the following: GPS 3.0 (Group Based 
Prediction System 210, score>6, cut off>6, threshold medium, all the kinases), PHOSIDA 
(phosphorylation site database 211), DISPHOS 1.3 (Disorder-Enhanced Phosphorylation 
Sites Predictor 212, score>0.5), NetPhos 2.0 (Generic phosphorylation sites in eukaryotic 
proteins 213), NetPhosK 1.0 (kinase specific eukaryotic protein phosphorylation sites 214), 
KinasePhos 2.0 215 and PhosphositePlus 216.  For each selected residue, the number of 
tools for which the phosphorylation prediction was positive was counted and considered 
to be the score for that residue (tools score: 0-7). Phosphorylation at a site depends on 
many factors, including the structure and solvent accessibility of the phosphorylation 
site, and it is thought that it predominantly occurs in regions of intrinsic disorder. 
Information about 3D structure was also taken into account as a supplemental score for 
each residue. Protein structures for human, mouse and yeast were modelled using the 




only COQ4 ortholog protein structure which is crystallized (PBD: 3KB4). The models with 
the highest coverage of the sequence were selected (Human: positions 38-256; mouse: 
positions 39-257; yeast: positions 85-303). We considered the position of the residue in 
the 3D structure of the models to give it an additional score. When the residue was on 
the surface of the protein, in a disordered region, the score was the highest, and when 
it was totally buried within a conformational ordered region of the protein structure, 
the score was zero (3D structure score: 0-2). We also considered the solvent accessibility 
predicted by JPred, giving the maximum score when the residue was exposed in a 
disordered region and the minimum score when it was buried and in an ordered region, 
calculated using different accessibility cut offs (solvent accessibility score: 0-4). The 
residues with the highest scores were selected for ulterior experimental studies. 
Prediction of mutations’ pathogenicity 
Different complementary online software for pathogenicity prediction were employed: 
SIFT 217 (available at https://sift.bii.a-star.edu.sg/) and PolyPhen-2 218 (available at 
http://genetics.bwh.harvard.edu/pph2/) for missense variants;  SPiCEv2.1 219 (available 
at https://sourceforge.net/projects/spicev2-1/ ) for splicing variants; and CADD v1.6 220 
(available at https://cadd.gs.washington.edu/ ). SIFT score <0.05 was considered 
pathogenic. PolyPhen-2 score >0.05 was considered probably damaging, using the 
HumVar data set. Spliceogenicity of the variants was predicted with a prediction tool 
called SPiCE. Splicing Prediction in Consensus Elements (SPiCE) has been developed by 
Leman et al., 2018 219 as a protocol for variant spliceogenicity prediction. It combines in 
silico predictions from SpliceSiteFinder-like and MaxEntScan and uses logistic regression 
to define optimal decision thresholds. These thresholds were defined as two probability 
thresholds to set optimal sensitivity and specificity: optimal sensitivity threshold 
(ThSe=0.115) and optimal specificity threshold (ThSp=0.749). ThSe is designed to give 
the highest detection rate while allowing false positives, and ThSp is designed to 
minimize false positives while allowing false negatives. SPiCE gives a P probability for a 
given variant. When P is above the 2 optimal thresholds, the variant is classified as 
variant with high probability to alter splicing; the region in between the two thresholds 
is defined for variants with medium probability to alter splicing; and the variants with a 




P under the two thresholds are predicted to have low probability to alter splicing. CADD 
score > 20 was considered pathogenic. 
M5.2. Protein homology modelling  
Human COQ4 structure was modelled using its sequence obtained from UniProt 
database (Q9Y3A0). SWISS-MODEL 221 server was used to construct a homology model 
of human COQ4, using the PDB (Protein Data Bank) structures 3KB4, 3MSQ and 6E12 as 
templates. The structures were visualised by using UCSF Chimera software 222. For the 
visualization of the conservation mapped on the structure, we used the AL2CO 
method223 through the UCSF Chimera software 222 
Human COQ7 structure was modelled from its sequence obtained from UniProt 
database (Q99807). SWISS-MODEL 221 server was used to generate a homology model 
of the human COQ7. As a template, we used a ferritin (PDB: 5HJH), which has a 15% 
sequence identity to COQ7. The model was generated using the same specifications than 
224 and it was visualised by using UCSF Chimera software 222 
M6. Statistical analysis 
All results were expressed as mean ± SD, unless otherwise specified. Data analysis was 
performed with GraphPad Prism 8.0. Samples were assumed to come from a normal 
distribution. In the case of comparison between two groups, we used unpaired two-
tailed t-test with a Welch’s correction. Multiple samples were compared using a one-
way (1 group) or two-way ANOVA (2 or more groups), with Sidak’s, Tukey’s or Dunnett’s 
multiple comparison post-hoc test (depending on the nature of the data and the 













Chapter 1.  
Clinico-Genetic aspects of primary CoQ10 deficiency:  
a literature review 
1.1. Introduction 
1.1.1. Primary CoQ10 deficiencies 
Primary CoQ10 deficiency syndrome is a very rare condition, genetically caused by 
autosomal recessive biallelic mutations in one of the genes participating in the CoQ10 
biosynthesis pathway. To date, ten genes encoding CoQ10 biosynthetic proteins have 
been shown to have pathogenic variants causing human CoQ10 deficiency: PDSS1, 
PDSS2, COQ2, COQ4, COQ5, COQ6, COQ7, COQ8A, COQ8B and COQ9 112,225. 
Up to date, over 275 patients from 180 families have been described in the literature 
(Table 1.3). It has been estimated a worldwide total of 123,789 individuals (1 in 50,000) 
affected by primary CoQ10 deficiencies, being only 1,665 (less than 1 in 3,000,000) due 
to known pathogenic variants, taking into account the frequency of the different known 
or predicted pathogenic variants in given populations 226.  
Clinical symptoms associated to primary CoQ10 deficiency 
Primary CoQ10 deficiency patients manifest a broad spectrum of clinical phenotypes. 
Different organs, tissues and systems can be involved in a highly variable way, depending 
on the affected gene, the age of onset and the specific defect on the gene, among other 
causes that are still not entirely known. Genetic factors, including hypomorphic 
mutations or polymorphisms that affect the susceptibility to the disease; epigenetics; 
compensation mechanisms; maternal effect; aging and/or environmental factors, 
amongst others, could determine the moment and the tissues affected during 
development or during life, and thus, influence the outcome of each genetic defect in 
each individual. 
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While mutations in some COQ genes can affect different organs (e.g. COQ2, COQ4), 
pathogenic variants of other COQ genes show a more specific phenotype (e.g. COQ8A, 
COQ8B). Even more, mutations in the same COQ gene can cause very variable clinical 
phenotypes with different age of onset (e.g. COQ2, COQ4) (Figure 1.1). The age of onset 
may generally range from birth to early childhood (PDSS1, PDSS2, COQ2, COQ4, COQ5, 
COQ6, COQ7, COQ9), or from childhood to adolescence (COQ8A, COQ8B), but there are 
also some adult-onset cases (COQ8A 227,228; COQ8B 229).  
The systems mainly affected are the central and peripheral nervous system, kidney, 
heart and skeletal muscle (Figure 1.1 and Table 1.1) 112:  
i. Central nervous system (CNS) manifestations: CNS is often affected in these 
patients, showing a wide range of clinical manifestations, including 
encephalopathy, developmental delay (DD), intellectual deficiency (ID), 
cerebellar ataxia (CAt), seizures (Sz), hypotonia (Ht), nystagmus (Ny), dysarthria 
(Dy), dystonia or epilepsy (Ep), among others. These symptoms have been 
reported in patients with mutations in any of the described COQ genes, being 
less frequent in patients with pathogenic variants of COQ6 and COQ8B, in whom 
the renal involvement predominates112,230.  
ii. Peripheral nervous system (PNS) and sensory organs (SO) manifestations: Less 
common than CNS manifestations, PNS and SO related symptoms have been 
reported in several cases of primary deficiencies. Sensorineural hearing loss 
(SNHL) is the most frequent PNS phenotype in primary CoQ10 deficiency patients, 
in most of the cases associated with steroid resistant nephrotic syndrome (SRNS) 
231–237. Some patients also presented peripheral neuropathy, optic atrophy (OA) 
and/or visual dysfunction 235,238–242.  
iii. Renal manifestations: Steroid resistant nephrotic syndrome (SRNS) is quite 
common in primary CoQ10 deficiency patients, specifically in those with 
pathogenic variants of PDSS2, COQ2, COQ6 and COQ8B 243–245. It generally starts 
as proteinuria and derives to end-stage renal disease (ESRD) within childhood, if 
not treated 245. Other less frequent renal manifestations are chronic kidney 





iv. Cardiac manifestations: Heart is often affected in primary CoQ10 deficiency. The 
most common heart manifestation is hypertrophic cardiomyopathy (HCM). It is 
particularly frequent in COQ4 250–252 and COQ7 239,240 patients.  Other 
cardiopathies less frequently found are valvulopathies (Vp), bradycardia, heart 
failure (HF), cardiomegaly, septal defects or heart hypoplasia (HHyp) 112.  
v. Muscle manifestations: Skeletal muscle manifestations are not common in these 
patients. Isolated myopathy has not been found in individuals with molecularly 
confirmed primary CoQ10 deficiency, and the majority of the patients with a 
predominantly muscular phenotype have been associated with secondary CoQ10 
deficiency 253,254. Myopathy has been described in some patients with a broader 
multisystem phenotype. Other muscular manifestations include exercise 
intolerance (EI), muscle weakness (MW) and muscle fatigue (MF) 112,255. 
vi. Other manifestations: Other more heterogeneous clinical findings have also 
been reported in patients affected by mutations in the different COQ genes 
(Figure 1.1 and Table 1.2). Among them, respiratory system alterations are the 
most frequent. Respiratory distress (RD) and apnea seem to be characteristic of 
COQ4 250–252, COQ7 239,240, COQ9 246,247,256 and some COQ2 257 patients. Oedema 
is only present in cases with nephrotic syndrome, so it is frequent in probands 
with pathogenic variants of genes with renal involvement 258. Less frequent 
clinical findings include dysmorphic features, metabolic pathologies (diabetes 
mellitus (DM), obesity and hypercholesterolemia), thyroid disease (goiter, 
hypothyroidism) and circulatory problems (cyanosis, hypertension (HT), livedo 
reticularis (LR)), among others 112. It should be considered that some of these 
symptoms could be secondary consequences of a more general defect. 
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Table 1.1. Main clinical manifestations in primary CoQ10 deficiency and abbreviations. 
Affected tissue, organ or system  
CNS PNS / SENSORY 
ORGANS 
KIDNEY MUSCLE HEART 









- Developmental delay (DD) 



















































- Epilepsy (Ep) 
- Seizures (Sz) 
EYE MOVEMENT DISORDERS HEARING MYOPATHY 
- Nystagmus (Ny) 
- Saccadic eye movements (SEM) 
- Slow ocular pursuit 
- Hearing 
impairment 
- Hearing Loss (HL) 
- Sensorineural 
hearing loss (SNHL) 
- Myopathy 
MOVEMENT DISORDERS HYSTOLOGY 
- Chorea 




- Deteriorated ambulation (DAmb) 
- Gait instability (GI) 
- Impaired Handwriting (IH) 
- Muscle stiffness (MS) 
- Myoclonus (My) 
- Opisthotonos 
- Tremor (Tr) 
- Spams 
- Pyramidal syndrome 










- Delayed visual 
maturation 




- Retinopathy (Rp) 
- Rod-Cone 
dysfunction 
- Visual aureas 
- Visual dysfunction 
- Exotropia 
- Strabismus 
- Non-visual pursuit 
(nVP) 







MOVEMENT DISORDERS ARRHYTHMIA 
- Chorea 




- Deteriorated ambulation (DAmb) 
- Gait instability (GI) 
- Impaired Handwriting (IH) 
- Muscle stiffness (MS) 
- Myoclonus (My) 
- Opisthotonos 
- Tremor (Tr) 
- Spams 
- Pyramidal syndrome 
- Spasticity (Sp) 
- Bradycardia 



















- Renal cysts 
STRUCTURAL LESIONS 
- Basal ganglia lessions (BGL) 
- Cerebellar atrophy (CAt) 
- Cerebellar hypoplasia (CHyp) 
- Cerebral atrophy 
- Cerebral Hypoplasia 
- Leigh-like Syndrome (LS) 
- Multifocal global ischemic events (MGIE) 
- Stroke-like lessions (SLL) 
- Thalamic hypoplasia (THyp) 
ASPECIFIC SIGNS 
- Headaches 
- Hypotonia (Ht) 
- Migraine 
DISEASES/CONDITIONS 
- Autosomal recessive cerebellar ataxia 2 
(ARCA2) 







Table 1.2. Other clinical manifestations in primary CoQ10 deficiency and abbreviations. 





















































































Figure 1.1. Organs and systems involved in primary CoQ10 deficiencies.  
Organs and systems affected in individuals with primary CoQ10 deficiency, associating specific clinical 
manifestations with the genes involved in each one. For abbreviations refer to Tables 1.1 and 1.2. For 
frequency of each symptom linked to a specific gene refer to Table 1.3. (Adapted from Alcázar-Fabra et 
al., 2018 112). 
 
Pathophysiology of Primary CoQ10 Deficiencies. Molecular Characterisation of COQ4 gene 
104 
 
Biochemical findings in primary CoQ10 deficiency patients 
Primary CoQ10 deficiency patients can show a high concentration of lactate, pyruvate,  
growth differentiation factor-15 (GDF-15) and fibroblast growth factor-21 (FGF-21) in 
plasma or serum259. CoQ10 levels in skeletal muscle biopsies might be reduced, as well 
as the enzymatic activities of complex I+III and/or II+III 260. Biochemically, CoQ10 
deficiency can also be detected in cultured fibroblast which, together with skeletal 
muscle, are the preferred diagnosis tissues 261. However, sometimes fibroblasts do not 
show reduction while muscle does 261 and vice versa. CoQ10 levels can also be measured 
on white blood cells (WBC), but it has been shown WBC CoQ10 levels alone are not 
reliable to diagnose primary CoQ10 deficiency in the setting of nephrotic syndrome 262. 
There are concerns about CoQ10 plasma measurements for diagnosis since it seems to 
be influenced by the amount of plasma lipoproteins (carriers of CoQ in circulation) and 
the dietary intake. Recently, urine CoQ10 measurement as a non-invasive approach has 
been proposed 263 but further research needs to be done to establish this specimen for 
CoQ10 deficiency diagnosis in the clinical setting. 
It is important to note that biochemical analysis is unable to distinguish between primary 
and secondary CoQ10 deficiencies 260. Of note, de novo synthesis can also be measured 
by radioactive precursor incorporation in fibroblasts 177,264, which is especially useful to 
discriminate between primary and secondary deficiencies.  
Pathogenesis in primary CoQ10 deficiency 
The pathogenesis of primary CoQ10 deficiency is far from being simple, and our 
understanding is still scarce. The reduced OXPHOS activity and an increase of ROS 
production are certainly crucial factors. However, the wide spectrum of CoQ functions, 
the unclear roles of some COQ gene products and the considerable phenotypic 
variability, suggest that other mechanisms contribute to the pathogenesis of the 
disease. Some of the proposed pathogenic mechanism are described below: 
i. In cultured cells it has been found that, severe CoQ deficiencies lead to great 
defects in energy production with no major increase in oxidative stress. In 
contrast, mild CoQ defects cause a significant increase in ROS production without 





ii. CoQ is required for the biosynthesis of pyrimidine nucleotides since it is an 
essential co-factor for the dihydroorotate dehydrogenase (DHODH)123. De novo 
pyrimidine synthesis is impaired in CoQ10 deficiency, further contributing to the 
development of the disease 266.  
iii. CoQ is also an electron acceptor of the sulphide-quinone oxidoreductase 
(SQOR)130 during hydrogen sulfide (H2S) detoxification. Sulphide oxidation 
pathway has been described to be tissue-specifically defective in primary CoQ10 
deficiency, leading to an accumulation of H2S, and thus, an alteration of protein 
S-sulphydrilation promoting changes in vasorelaxation, inflammation and ROS 
production 131–133,267–269.  
iv. CoQ10 deficiency cells also show increased mitophagy, being proposed as a 
protective mechanism in disease pathogenesis 270, although other authors 
defined it as detrimental 271.  
v. CoQ deficiency has also been linked to development of insulin resistance in 
human and mouse adipocytes, as a result of increased ROS production via 
complex II 272. 
vi. The disparity on the age of onset and tissues affected, and the specificity of some 
symptoms associated to certain genes, suggest that COQ genes may be involved 
in other processes and the molecular mechanism of the disease would also be 
dependent on these yet unknown functions.  
Genotype-phenotype correlations in primary CoQ10 deficiency 
Genotype-phenotype correlations are arduous to establish in this kind of rare diseases, 
for which the number of diagnosed patients is very low and the complexity of the clinical 
manifestations hinders the task.  
COQ8A and COQ8B have the highest number of families with pathogenic variants 
reported. In the case of COQ8A some studies have tried to find clues about genotype-
phenotype correlations in this condition with no clear conclusions 273–275. Some 
mutations (like c.895C>T, p.Arg299Trp) produced a disease with varied age of onset and 
severity, while patients harbouring other pathogenic variants (such as c.1042C>T, 
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p.Arg348Ter) presented similar age of onset and severity of the disease 274. 
Multisystemic involvement beyond ataxia was found more prevalent in missense than 
biallelic loss-of-function variants, for which the phenotype was more frequently found 
to be an isolated ataxia 275. This would suggest a possible gain-of-function or dominant- 
negative mechanism for missense variants in contrast to loss-of-function variants 275. 
Preliminary associations between missense variants in specific domains and specific 
phenotypic outcomes have been proposed. For example, missense variants in the 
COQ8A protein-specific KxGQ domain seem to be associated with clinical signs reflecting 
cortical (developmental delay and epilepsy) and pyramidal tract dysfunction 275. In the 
case of COQ8B, residual activity of mutated versions of COQ8B from patients has been 
studied by expressing these variants in yeast, and no correlations between residual 
activity of CoQ biosynthesis (CoQ levels) and severity of the symptoms were found 276. 
Also, a COQ8B polymorphism (c.521A > G, p.His174Arg), present in 50% of the European 
population, has been found to affect the stability of the protein and could represent a 
risk factor for secondary CoQ10 deficiencies or for other complex traits276. 
For COQ2 patients (22 families described), with a wide clinical spectrum, it has been 
proposed that the severity of the disease correlates with the enzymatic residual activity 
of the COQ2 protein and hence CoQ levels, as shown by expressing mutant proteins in 
yeast 277. To date, no clear correlations have been observed for COQ6 and COQ4 
patients.  
Only a few families with mutations in PDSS1, PDSS2, COQ5, COQ7 or COQ9 have been 
described in the literature, being very hard to establish any association. Studies in two 
different patients’ fibroblasts with COQ7 pathological variants showed that there seems 
to be a correlation between the residual levels of CoQ10 and COQ7 protein, and the 
severity of the disease. The fibroblasts from the patient with the most severe phenotype 
showed a drastic CoQ10 deficiency 239, while the patient with the milder phenotype had 
only a 30% decrease in CoQ levels in skin fibroblasts 238. In the case of COQ9, studies in 
two different knock-in mouse models 278,279 suggested that the degree of stability and 
residual stability of the CoQ complex is crucial for determining the disease severity, 





Diagnosis of primary CoQ10 deficiency 
The diagnosis of primary CoQ10 deficiency is established with the identification of 
biallelic pathogenic variants in any of the genes coding for one of the proteins directly 
involved in CoQ10 biosynthesis 255. Genome or specific gene sequencing is performed 
when there is suspicion of mitochondrial disease. Typically, it is suspected by the 
conjunction of a particular and compatible clinical picture of mitochondrial disease 
together with the laboratory findings described above (decreased levels of CoQ10 or 
reduced combined activities of complex I+III and II+III in mitochondria of skeletal muscle 
of patients). Biochemical analysis alone is not a definitive diagnosis. Only a genetic test 
(using NGS approaches, either genes panels or WES/WGS) will definitively determine 
the molecular diagnosis of these pathologies 255. It should bear in mind, that for each 
new potentially pathogenic variant of the COQ genes that is identified by NGS, a 
functional validation is necessary.  
Management of primary CoQ10 deficiency patients 
Considering the wide clinical spectrum of this condition, any individual with a diagnosis 
of primary CoQ10 deficiency should be assessed, in order to establish the severity of the 
disease. Importantly, a genetic consultation is recommended for other family members 
and for recurrence risk of patient’s parents.  Based on the genetic defect identified in 
the patient, a specific follow-up should be programmed 112.  
Being CNS manifestations very frequent, every patient with a diagnosis of CoQ10 
deficiency should undergo periodical neurological examinations, even if normal at 
diagnosis. Evaluation should include an electroencephalogram (EEG) analysis and a brain 
magnetic resonance imaging (MRI). Also, peripheral nervous system should be assessed 
for the possible presence of peripheral neuropathy in patients with PDSS1 and COQ7 
mutations. 
Patients with mutations in PDSS1, PDSS2, COQ2, COQ4, COQ6, COQ7, COQ8A and COQ8B 
may have eye involvement due to optic atrophy (OA), retinopathy (Rp), retinitis 
pigmentosa (RP) and even cataracts 112. They should, therefore, be screened at diagnosis 
and during the follow-up.  Audiometry is necessary in COQ6 patients who almost 
invariably manifest SRNS, but should also be performed in patients with mutations in 
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PDSS1, PDSS2, COQ4, COQ7 and COQ8A who may sometimes manifest this phenotype 
112. 
Individuals harbouring mutations in PDSS1, PDSS2, COQ2, COQ6, and COQ8B may 
manifest renal involvement with SRNS, whose onset may vary from early childhood to 
adolescence. Tubulopathy has been reported rarely. These patients thus need to 
undergo periodical renal function tests with urine analysis for proteinuria and 
nephrological evaluations for the risk of evolving to ESRD 112.  
A cardiologist examination with echocardiogram should be performed in patients with 
COQ4, PDSS2, COQ2, COQ7 and COQ9 mutations (who may present with a severe early-
onset cardiomyopathy) and should also be considered in individuals with mutations in 
PDSS1, COQ6, COQ8A and COQ8B to exclude the presence of a valvulopathy or septal 
defects 112.  
Treatment of primary CoQ10 deficiency 
Exogenous CoQ10 supplementation is the only therapeutic option currently available for 
CoQ10 deficiency. In general, patients respond quite well to CoQ10 supplementation, but 
this is not always the case. Barriers for tissues CoQ10 delivery have been found due to its 
high molecular weight and poor aqueous solubility, but at high doses, dietary 
supplementation increases CoQ10 levels in all tissues, including heart and brain, 
especially with certain formulations 280,281. It also increases in circulating low-density 
lipoproteins, where it functions as an efficient antioxidant together with α-tocopherol 
282,283. Recently, the EMA approved ubiquinol as an orphan drug for the treatment of 
primary CoQ10 deficiency 79. 
CoQ10 supplementation at high doses has been demonstrated to be effective for the 
treatment of both primary and secondary CoQ deficiencies 284. It is crucial to start the 
supplementation as soon as possible to get favourable outcomes and to limit irreversible 
damage in critical tissues such as the kidney or the CNS 255. Different doses of CoQ10 have 
been employed for the treatment of primary CoQ10 deficiencies, ranging from 5 
mg/kg/day 285 to 30-50 mg/kg/day for both adults and children 286. In mouse models of 
this condition even higher doses (up to 200 mg/kg/day) have been used 287. With regards 





designed randomized, controlled human trials, although doses as high as 3000 mg/day 
have been used in shorter clinical trials 79,288.  
Except for COQ8A patients, most individuals with primary forms show a good response 
to CoQ10 treatment, which is usually evident after 10-20 days 286. Different formulations 
of CoQ are now available, both in the oxidized and the reduced forms, although most of 
the data available have been obtained in patients treated with ubiquinone. 118 cases of 
the 276 reported ones (43%) were treated with CoQ10 supplementation. The outcome 
of the treatment will be discussed in the next sections. 
Alternatively to CoQ10 supplementation, some 4-HB analogues have been proposed as 
potential bypass molecules with higher bioavailability than CoQ 289. These molecules 
provide the defective chemical group and can reactivate endogenous CoQ biosynthesis. 
They have only been tested in yeast, mammalian cell cultures and mouse models of 
primary CoQ10 deficiency, but have still not been used for patient’s treatment, as it will 
be discussed in Chapter 2 (section 2.1.1).  
1.1.2. Secondary CoQ10 deficiencies 
CoQ10 deficiency can also occur in conditions not directly linked to mutations in the COQ 
genes. These secondary deficiencies are more common than the primary ones 290,291, 
and might exacerbate the phenotype of the conditions to which they are associated. 
They can be related to oxidative phosphorylation (OXPHOS) defects, other impaired 
non-OXPHOS mitochondrial processes, or even to a dysfunction in non-mitochondrial 
functions 291.  
How these defects lead to CoQ10 deficiency is still unknown, and multiple and very 
diverse factors are thought to contribute. Some of these factors are the diverse 
biological functions and metabolic pathways in which CoQ is involved inside and outside 
the mitochondria, and the different mechanisms that can modulate CoQ levels by 
regulating CoQ biosynthesis or CoQ turnover 120,291,292. Due to the high diversity of 
disorders that can be accompanied by secondary CoQ10 deficiency, genotype-phenotype 
correlations are difficult to establish, and will primarily depend on the nature of the 
condition and the mutated gene. 
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Disorders associated to secondary CoQ10 deficiency 
The clinical spectrum of secondary CoQ10 deficiencies is highly dependent on the 
pathology they derive from. Muscular manifestations in these disorders are myopathies 
with muscular weakness, hypotonia, exercise intolerance or myoglobinuria. It is clear 
that isolated mitochondrial myopathies are frequently associated with CoQ10 secondary 
deficiencies and not with primary deficiencies 253,254. CNS can be also affected in 
secondary CoQ10 deficiencies, presenting ataxia with neurological decline 225,290. 
However, there is also a high variability of secondary CoQ10 deficiency presence among 
different patients suffering from the same disorders. This would suggest different 
susceptibility to the development of CoQ10 deficiencies among different individuals. 
Genetic factors, such as additive hypomorphic mutations or specific polymorphisms, 
have been proposed to be involved 253,276,290,291.  
Amongst OXPHOS pathologies, secondary CoQ10 deficiency was found more common in 
mtDNA depletion syndromes due to nuclear DNA mutations (e.g. POLG, MPV17, SUCLA2 
or FBXL4 291,293. Moreover, comparative omic studies performed in mouse models of 
OXPHOS dysfunction caused by nuclear-encoded essential factors for mtDNA 
maintenance (Twinkle, Tfam, Polrmt, Lrpprc and Mterf4) showed a general 
downregulation of CoQ9 biosynthesis proteins, leading to a secondary CoQ9 deficiency 
294. Other examples of nuclear genes that when mutated, lead to OXPHOS defects with 
secondary CoQ10 deficiency are: complex III assembly factor BSC1L  295; complex I subunit 
NDUFS4 296,297; or EARS2, which encodes for the mitochondrial aminoacyl-tRNA 
synthetase specific for glutamate 298,299. Low CoQ10 levels have also been observed in 
OXPHOS diseases due to point mutations in mtDNA-encoded genes (e.g. MT-TL1 or MT-
TK) 253,291,300. Other very variable non-OXPHOS diseases may display secondary CoQ10 
deficiency as well, but the mechanisms involved are still elusive 291:  
i. Mutations in ETFDH-encoded flavoprotein-ubiquinone oxidoreductase, and in 
the electron transfer flavoprotein (ETFA and ETFB), cause multiple acyl-CoA 
dehydrogenation deficiency (MADD) associated with decreased levels of CoQ10 
301,302. These enzymes are essential for mitochondrial fatty acid β-oxidation, 





noted that not all MADD patients have CoQ10 deficiency 303,304, suggesting 
difference in susceptibility among different patients.  
ii. Mutations in APTX gene, coding for the single-stranded DNA repair aprataxin, 
cause ataxia with ocular motor apraxia 305,306, with CoQ deficiency in muscle and 
fibroblasts 291,307.  
iii. Also, it has been shown that patients with Friedrich ataxia can show a decrease 
of CoQ content in skeletal muscle as a consequence of the mutation in FXN gene, 
which encodes for frataxin, a protein regulating iron transport into 
mitochondria291.  
iv. Mutations in ANO10 gene, coding for a member of the anoctamin family of 
transmembrane proteins with calcium-activated chloride channel activities, 
cause spinocerebellar ataxia associated to CoQ10 deficiency in skeletal muscle, 
plasma and cerebrospinal fluid 308–310.  
v. Another channelopathy with mutations in SCN2A-encoded voltage gated sodium 
channel (Nav1.1) was found to present CoQ10 deficiency in muscle, suggesting 
that CoQ might have a role in CoQ in calcium signalling 291.  
vi. A patient with GLUT1 transporter deficiency caused by a heterozygous mutation 
in the SLC2A1 gene showed reduced CoQ10 levels 311. However, this is not a 
common feature in GLUT1 deficiency syndrome 312, indicating that possibly other 
factors would be involved in the CoQ10 defect in this patient.  
vii. Patients with mutations in NPC1, with Niemann-Pick C disease presented a 
reduction of CoQ10 biosynthesis probably because of the characteristic 
accumulation of cholesterol, which may  down-regulate HMG-CoA reductase 
and, consequently, reduce mevalonate and CoQ synthesis 291,301,313. Something 
similar was observed in fibroblasts from familial hypercholesterolemia patients, 
in which the mevalonate pathway was dysregulated, resulting in increased 
cholesterol levels and CoQ10 deficiency 314.  
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Mechanisms of secondary CoQ10 deficiency 
The mechanisms underlying CoQ10 secondary defects remain largely unknown, but 
several explanations have been proposed:   
i. The rate of CoQ degradation could be increased rate as response to other 
dysfunctional processes, like a non-functional respiratory chain 290,291.  
ii. CoQ biosynthesis pathway could be dysregulated by an interference with its 
signalling regulatory pathways 290,291. This could occur because of the 
malfunctioning of components involved in these signals, or because the 
signalling pathways activated for a response to certain defect may intrinsically 
lead to a down-regulation of CoQ synthesis.   
iii. Severe mitochondrial deficiencies would cause secondary CoQ deficiency by 
interfering with the import and formation of mature forms of the COQ proteins 
in the mitochondria 315. 
iv. Certain pathologic environments could lead to a reduction of the stability of the 
CoQ biosynthetic complex. In this context, a recent study in yeast described the 
localization of the Coq proteins in specific foci in the IMM, named CoQ domains 
1. The definition of the CoQ domains implies that the spatial localization 
dimension is essential for CoQ complex formation. These CoQ domains, in yeast, 
are spatially and functionally related to ERMES (endoplasmic reticulum-
mitochondria encounter structure) complex 1,2 and the loss of ERMES structure 
impairs respiration through reduction of CoQ levels in mitochondria. This could 
be a mechanism of secondary CoQ deficiency, since many mitochondrial 
disorders produce a disturbance in IMM structure, which could lead to an 
impairment in CoQ domain formation and CoQ biosynthesis 316. Mitochondrial 
structure disturbances are also observed in aged mitochondria. It has not been 
demonstrated yet that CoQ domains in mammals are related to ER-
mitochondrial contacts.  
v. A general deterioration of mitochondrial function could imply CoQ reduction as 





Mouse models with secondary CoQ9 deficiency 
The study of some secondary CoQ9 deficiency mouse models has provided evidence for 
the understanding of these deficiencies. One example is Parl-/- mouse model. PARL 
(coding for Presenilin Associated Rhomboid Like protein) is an IMM intramembrane 
protease from the rhomboid family 317. Parl-/- mouse model shows a phenotype similar 
to Leigh syndrome, with a severe complex III defect caused by the disappearance of 
mature Ttc19, a factor required for complex III stability 318. Moreover, Parl-/- brain 
mitochondria show a significant decrease of CoQ biosynthesis associated with a 
reduction of Coq4 and other Coq peptides, and swollen mitochondria with abnormal 
cristae 319. Another example is Mfn2-/- mouse model. MFN1 and MFN2 are mitochondrial 
outer membrane proteins that mediate outer membrane fusion and thus, are important 
for mitochondrial network dynamics. Studies in Mfn2-/- mouse model suggested that 
MNF2 protein is required for maintaining CoQ biosynthesis in mice 320. 
 
1.2. Results and discussion 
Primary CoQ10 deficiency patients manifest a broad spectrum of clinical phenotypes, 
affecting different organs, tissues and systems (Figure 1.1).  
Currently, over 275 patients from 180 families have been reported to have a primary 
CoQ deficiency with mutations in one of the COQ genes (Table 1.3). Pathogenic variants 
of PDSS1, PDSS2, COQ2, COQ4, COQ5, COQ6, COQ7, COQ9, COQ8A and COQ8B have 
been associated to primary CoQ deficiency in the literature. In this section, we have 
comprehensively reviewed all primary CoQ10 deficiency published cases, in order to 
provide an overview of the different patterns of the age of onset, clinical presentation 
and course of the disease, depending on the defective gene. The patterns of clinical 
presentation and evolution have been evaluated as a whole, for each COQ gene involved 
in primary CoQ10 deficiency. This work has been submitted and is now under review321.  
It is important to note that the evaluation of the frequency of some specific 
manifestations is probably being underestimated because some features are not 
reported homogeneously among the different published reports. Also, the number of 
primary CoQ10 deficiency patients reported is small, and the number of patients with 
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pathological variants in the different genes varies widely. This number is especially 
reduced for PDSS1, PDSS2, COQ5, COQ7 and COQ9 genes, so higher frequencies found 
for some symptoms in these cases can be due to the sampling effect. 
1.2.1. General clinical symptoms associated to primary CoQ10 deficiency 
Primary CoQ10 deficiency patients manifest a wide range of clinical phenotypes, affecting 
several organs, tissues and systems in a highly variable way (Figures 1.1, 1.2, 1.3). The 
systems mainly affected are the central and peripheral nervous system, kidney, heart 
and skeletal muscle (Figure 1.2 and Table 1.3). A complete picture of the frequency of 
all the described symptoms can help to better understand any potential trend in the 
development of the disease depending on the affected gene.  
To make these analyses of frequency openly available to the community, we have 
created a web-based platform that will be periodically updated with the new literature: 
https://coenzymeQbiology.github.io/clinic-CoQ-deficiency. Heatmap representation of 
the frequency of symptoms will give a visual and convenient overview of the disease 
according to the affected gene. The continuous update of the platform will permit a 
quasi-real-time overview of the research in the field. With this resource, we aim to 
contribute not only to a better understanding of the genotype-phenotype correlations 
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PDSS1 
 







ID (2), DD (1) 
PNSN (2), OA 
(2), SNHL (2) 
SRNS and  
ESRD (1) 
 Vp (2) LR (2), Obesity (2), 
HT (1) 










8yo* (1),  
8-12yo (2), 
NK (2) 
ARCA2 (3), ID (3), Ht 
(2), LS (1), Sz (1) 
Sp (1), Dystonia (1), 
Ny (1), Pyramidal  
syndrome (1), 
Cerebral palsy (1), 
DD (1), 
Encephalopathy (1) 
SNHL (4), RP 
(2), Myopia 
(2), Visual  
Dysfunction 





 HCM (2) Edema (2), Neonatal 
Pneumonia (1), HT 
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1 3  Early 
childhood 
(3) 
14-22yo (3) ID (3), ARCA2 (3), 
CAt (3), Dy (3), Ny 
(3), My (2), Sz (2),  
DD (2), SEM (1), Tr 
(1), Sp (1) 




3 3 F (1),  
M (2) 




Ht (3), DD (3) 
BGL (1), Cerebral 
atrophy (1), 
Encephalopathy (1), 



















(2), HT (1), 
Dysmorphic 
features (1), LHyp 
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Sz (3), Ht (2), LS (2), 
CAt (1), CHyp (1), 
Dystonia (1), MGIE 
(1), MS (1), BGL (1), 
Opisthotonus (1) 
 Renal cysts 

















liver (1), HT (1) 







Table 1.3. Clinical manifestations in primary CoQ10 deficiency (continued). 
Gene F P Sex 
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Ht (6), Ny (3) 
DD (2), Dystonia (2), 
My (2), SLL (2), BGL 
(1), CAt (1), MS (1), Tr 
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HCM (3),  
Bradycardia 
(1) 
Edema (11), DM (6), 
RF (5), 
Oligohydramnios 
(4), LF (3), Apnea 
(2), Hyper-
cholesterolemia (2), 
RD (2), Cholestatic 
Liver (1), CLD (1), HT 
(1), Respiratory 
infections (1) 






26 35 F (20),  
M (14),  
NK (1) 
Birth (19),  
<1yo (11),  
4yo (1),  
8-9yo (3),  
NK (1) 
<4do* (7),  
1mo-3yo* (12),  
7yo* (1),  
8yo (1),  
14-18yo (3),  
27-28yo (2),  
NK (1) 
Sz (24), Ht (19), DD 
(18), Encephalopathy 
(11), CHyp (10), Sp (8), 
CAt (8), Cerebral 
atrophy (6), DAmb (6), 
Dystonia (6), ID (6), 
BGL (5),  
ARCA2 (4), Dy (2), 
Dysdiadochokinesia 
(2), Dysmetria (2), LS 
(2), SLL (2), Spasms 
(2), Tr (2), My (1), 
Cerebral hypoplasia 






























RD (14), Apnea (9) 















22 301 F (8) 
M (10) 
NK (12) 
2mo-<1yo (8),  
1-2yo (7),  
3-4yo (7),  
6-10yo (4),  
NK (4) 
5-6yo* (2), 
17yo* (1),  
NK* (2),  
0.5-1.5yo (3),  
2-10yo (11),  
11-17yo (3),  
27yo (1), NK (7) 
DD (3), Sz (2) 
ARCA2 (1), ID (1), Ny 
(1) 
SNHL (18), OA 
(1), Exotropia 
(1), Pt (1) 
SRNS (26),  





















Table 1.3. Clinical manifestations in primary CoQ10 deficiency (continued). 
Gene F P Sex 















Kidney Muscle Heart Other 
COQ8A 
55 77 F (41),  
M (33),  
NK (3) 
1-4yo (35),  
5-11yo (19),  
13-15yo (4),  
18-20yo (4),  




3-11yo (14),  
13-25yo (22),  
26-54yo (32),  
81yo (1),  
NK (6) 
ARCA2 (70), CAt (62), ID 
(35), Tr (33), Dy (27), 
Dysmetria (21), Sz (25), GI 
(16), Dystonia (14), My 
(14), SEM (14), DD (13), IH 
(11), Ny (9), 
Dysdiadochokinesia (8), Sp 
(8), Ht (7), SLL (6), Migraine 
(5), Depression (3), Chorea 
(2), CHyp (2), 
Encephalopathy (2), 
Pyramidal syndrome (1), 
Slow ocular pursuit (1) 
Strabismus (4),  
Pt (3), SNHL (2), 
Visual dysfunction 
(1), Cataracts (1), 
Visual aureas (1), 
Rod-Cone 
dysfunction (1) 
























41 79 F (32),  















Sz (6), ID (4), Headaches 

































Edema (16), HT (11), 
Goiter (2), CD (1), 








Recurrent otitis (1), 
Splenomegaly (1) 
 F (5) 229,243,276,362–369 
Numbers between brackets indicate the number of patients with the specific manifestation. * These patients died at the indicated age. 
Abbreviations: ho: hours old; do: days old; wo: weeks old; mo: months old; yo: years old; NK: not known; F: Number of Families; P: Number of Patients; LA: Lactic Acidosis; 
CoQ deficiency (WBC: White Blood Cells, F: Fibroblasts, M: Muscle). For Clinical Manifestations abbreviations, refer to Tables 1.1 and 1.2.






Figure 1.2. Frequency of symptoms related to 
the most commonly affected organs and 
systems in primary CoQ10 deficiency, for each 
COQ gene involved.  
Symptoms related to central nervous system 
(CNS) (A), peripheral nervous system (PNS) and 
sensory organs (B), renal system (C), heart (D) 
and muscle (E) are sorted in a decreasing order 
of frequencies. Total number of patients for 
each gene is indicated at the bottom of the 
heatmaps. For Clinical Manifestations 






CNS is often affected in these patients, showing a wide range of clinical manifestations 
(Figure 1.2.A). These symptoms have been reported in patients with mutations in any of 
the described COQ genes, being less frequent in COQ6 and COQ8B patients. The most 
common are the following: 
i. Disorders or conditions: 
The most frequently CNS-related disorders reported are encephalopathy and ARCA2 
(autosomal recessive cerebellar ataxia-2, or autosomal recessive ataxia due to CoQ10 
deficiency), but also, less frequently, cerebral palsy or sporadic multisystem atrophy 
(MSA). 
Encephalopathy is defined as a broad spectrum of brain manifestations, often not 
described in detail in case reports. It has been found in patients with mutations in each 
of all the ten genes involved in primary CoQ10 deficiency. It has been mainly found in 
COQ4 (11/35, 31%) 250–252,336,339–341, COQ2 (9/30, 30%) 241,242,249,257, COQ5 (3/3, 100%) 326 
and COQ9 (3/7, 43%) 246–248 patients. It has also been observed in some PDSS1 (2/3, 67%) 
241, PDSS2 (1/7, 14%) 323, COQ7 (1/3, 33%) 240, COQ8A (2/77, 2.6%) 273,370 and COQ8B 
(1/79, 1.3%) 364 probands.  
Progressive cerebellar atrophy and ataxia, also called ARCA2 is a neurodegenerative 
disorder defined by an ataxic phenotype with movement disorders, sometimes 
accompanied by intellectual disability (ID), epileptic seizures (Sz), tremor (Tr), dysarthria 
(Dy), dysmetria, dysdiadochokinesia, saccadic eye movements (SEM), dystonia or 
spasticity (Sp) 274,275. It is the main phenotype in COQ8A patients (70/77, 91%). The only 
family affected by a mutation in COQ5 up to now also showed a cerebellar ataxic 
phenotype similar to COQ8A patients (3/3, 100%) 326. A subgroup of COQ4 patients with 
childhood-onset also presents this phenotype (5/35 14%) 251,335,338. Cerebellar ataxia has 
also been observed in some patients harbouring pathogenic variants of PDSS2 (3/7, 43%) 
285,325 and COQ6 (1/30, 3%) 233 genes. 
 
 




ii. Cognitive and behavioral deficits 
Developmental delay is defined as a delay in reaching one or more milestones, 
categorised into motor, cognitive, speech, emotional, social and communication 
skills371. When there is a delay in several of these skills, it is called global DD. It has been 
found in patients with mutations in each of the ten genes involved in primary CoQ10 
deficiency, mainly in COQ4 (18/35, 51%)250–252,336,372,373, COQ5 (2/3, 67%) 326, COQ7 (3/3, 
100%) 238–240 and COQ9 (6/7, 86%) 246–248,327 patients. It has also been observed in some 
probands with mutations in PDSS1 (1/3, 33%) 322, COQ8A (13/77, 17%) 350,352,354,370, 
PDSS2 (1/7, 14%) 323, COQ6 (3/30, 10%)231,233,258, COQ2 (2/30, 7%) 242,334 and COQ8B 
(1/79, 1.3%) 363.  
Intellectual disability (ID) is a generalized neurodevelopmental disorder characterized 
by significantly impaired intellectual and adaptive functioning374. It was found in a 
variable number of cases but in patients of almost all the COQ genes: PDSS1 (2/3, 67%) 
241, PDSS2 (3/7, 43%) 245,285, COQ4 (6/35, 17%)251,335,338,341, COQ5 (3/3, 100%)326, COQ6 
(1/30, 3%) 231, COQ7 (1/3, 33%)239, COQ8A (35/77, 45%)227,273,274,344–346,351,352,354–357,360,370 
and COQ8B (4/79, 5%) 229,364,366.  
Note that some patients present the disease and die in infancy, when DD and ID are 
difficult to assess.  
iii. Epilepsy 
Epilepsy and seizures have been reported mainly in COQ4 (24/35, 69%)250–252,336–340, 
COQ2 (12/30, 40%) 232,241,242,257,332,333,  COQ5 (2/3, 67%) 326 and COQ9 (3/7, 43%) 247,248,256 
patients, generally associated with encephalopathy, but also without such association 
in some COQ8A (25/77, 32%) 227,273,274,345,350,357,360, PDSS2 (1/7, 14%) 324, COQ6 (2/30, 
7%) 233 and COQ8B (6/79, 8%) 364,367 patients.  
iv. Hypotonia 
Hypotonia (Ht) is a state of low muscle tone. It can be caused by central or peripheral 
nervous system, as well as by muscle involvement. This feature that has been reported 
mainly in COQ4 (19/35, 54%) 251,252,336,340,341, some COQ2 (6/30, 20%) 242,257,332,333 and in 
all the three published COQ7 patients (3/3, 100%) 238–240. Hypotonia has also been 




especially misleading because of the low number of reported cases (PDSS2 (2/7, 29%) 
323,324, COQ9 (2/7, 29%) 256). Other groups of COQ patients apparently present a lower 
frequency of hypotonia such as COQ8A (7/77, 9%) 354,357,359,370.  
v. Others 
Other alterations of the CNS reported in the literature with variable frequency include 
movement disorders (dysarthria (Dy), dystonia, dysmetria, dysdiadochokinesia, 
myoclonus (My), gait instability (GI), tremor, spasticity, etc.) and eye movement 
disorders (nystagmus (Ny), saccadic eye movements (SEM), slow ocular pursuit), among 
others.  
Brain imaging techniques revealed in some cases structural CNS lesions (cerebral 
atrophy, cerebellar atrophy (CAt), cerebellar hypoplasia (CHyp), basal ganglia lesions 
(BGL), stroke-like lesions (SLL), etc.) Particularly, CAt, which is a hallmark of the ARCA2 
phenotype, is a relevant diagnostic feature since it was universally found at brain MRI of 
a large worldwide cohort of 59 COQ8A patients 275. 
Peripheral nervous system and sensory organs manifestations 
PNS and sensory organs manifestations have also been reported in several cases of 
primary deficiencies (Figure 1.2.B). Sensorineural hearing loss (SNHL) is the most 
frequent PNS phenotype in primary CoQ10 deficiency patients. SNHL is present in over 
half of the reported cases of COQ6 (18/30, 60%) and PDSS2 (4/7, 57%) patients 285,323,325, 
being in all those cases associated with SRNS 231–236. Some probands with PDSS1 (2/3, 
67%) 241, COQ7 (3/3, 100%) 238–240 and COQ8A (2/77, 2.6%) 356 pathogenic variants 
presented SNHL as well, which in these cases was not linked to SRNS. The PDSS1 patients 
that presented SNHL were two siblings that suffered peripheral neuropathy, associated 
with OA and early-onset SNHL 241. All the three COQ7 reported patients presented SNHL, 
and in two cases, they also showed peripheral polyneuropathy and visual dysfunction 
(2/3, 67%) 238–240. Visual dysfunction was also reported in some COQ4 (6/35, 17%) 250,340, 
PDSS2 (2/7, 29%) 285, COQ8A (1/77, 1.3%) 344 and COQ8B (1/79, 1.3%) 364 probands. Optic 
nerve atrophy (OA) was reported in very few individuals with PDSS1 (2/3, 67%) 241, 
PDSS2 (1/7, 14%) 285, COQ2 (1/30, 3%) 242,331,375 and COQ6 (1/30, 3%) 235 pathogenic 
variants. Other less frequent visual impairments such as cataracts 227,285, retinopathy 




(Rp) 242,332, retinitis pigmentosa (RP) 285,323,364 or delayed visual maturation 336 have 
been observed in several cases of COQ patients.  
Renal manifestations 
Renal dysfunction, altered morphology and specific signs and symptoms of renal disease 
have also been reported in the literature. Steroid resistant nephrotic syndrome (SRNS) 
is very frequent in primary CoQ10 deficiency patients (Figure 1.2.C), specifically in those 
with pathogenic variants of PDSS2 (7/7, 100%) 245,285,323,324, COQ2 (26/30, 87%) 
232,241,242,245,257,262,329–331,333,334,375,376, COQ6 (26/30, 87%) 231–233,235,236,342,343,377 and 
COQ8B (65/79, 82%) 229,243,362–365,368. Importantly, it generally starts as proteinuria and 
evolves to end-stage renal disease (ESRD) within childhood, if not treated (Figure 1.2.C).  
The majority of COQ2 patients manifested early-onset nephrotic syndrome (24/30, 80%) 
241,242,245,257,262,329,330,333,334,376, and there was also one family with adolescent-onset and 
slow progression of the isolated renal disease (2/30, 7%) 232. The hallmark manifestation 
of COQ6 pathogenic variants is childhood-onset SNRS (26/30, 87%) 231–233,235,236,342,343,377, 
which in around half of the cases was associated with SNHL (17/30, 57%) 231,233,235,236. 
COQ8B patients mainly manifested SRNS (65/79, 82%) 229,243,362–365,368 due to focal 
segmental glomerulosclerosis (FSGS), some of them associated with edema (16/79, 
20%) 243,362–364and hypertension (HT) (11/79, 14%) 229,364, which in the most part of the 
cases progressed to ESRD (47/79, 59%). All of the patients with PDSS2 (7/7, 100%) 
245,285,323,324 mutations and some of those with PDSS1 (1/3, 33%) 322 variants also 
manifested SRNS.  
Other less frequent renal manifestations are CKD (COQ2 (1/30, 3%) 244, COQ6 (1/30, 3%) 
258, COQ8B (18/79, 23%)229,362,364,366), renal cysts (COQ7 (1/3, 33%) 240, COQ9 (2/7, 29%) 
246,247) or tubulopathy (COQ2 (1/30, 3%)249, COQ9 (1/7, 14%) 248,327).  
Cardiac manifestations 
Heart is often affected in primary CoQ10 deficiency (Figure 1.2.D). Arrhythmia and 
functional and morphological defects have been reported with variable frequency. The 
most commonly reported heart defect is hypertrophic cardiomyopathy (HCM). It is 




but has also been reported in some PDSS2 (2/7, 29%) 285,323, COQ2 (3/30, 10%) 249,328,333, 
COQ9 (1/7, 14%) 248,327 and COQ8B (2/79, 2.5%) 229,243 patients. Other morphological or 
functional heart defects less frequently found are valvulopathies (PDSS1 (2/3, 67%) 241), 
cardiomegaly (COQ4 (3/35, 9%) 250,252,339, COQ9 (1/7, 14%) 246), septal defects (COQ4 
(1/35, 3%) 341, COQ6 (1/30, 3%), COQ8A (1/77, 1%) 370 and COQ8B (2/79, 3%) 364,365) or 
heart hypoplasia (HHyp) (COQ4 (1/35, 3%) 251). Also, arrhythmia (bradycardia) has been 
observed (COQ4 (5/35, 14%) 251,252,340, COQ9 (2/7, 29%) 246,256 and COQ2 (1/30, 3%) 257). 
In some cases, heart failure (HF) has been reported as a fatal outcome (COQ4 (2/35, 
5.7%) 251,252, COQ7 (1/3, 33%) 240 and COQ8B (1/79, 1.3%) 364).  
Muscle manifestations 
Muscle is less commonly affected in these patients (Figure 1.2.E). Myopathy has not 
been described isolated, but in patients with a broader multisystemic phenotype (COQ4 
(2/35, 6%) 250,341, COQ7 (1/3, 33%) 240, COQ8A (1/77, 1%) 358). Other muscular 
manifestations include exercise intolerance (EI) (COQ8A (14/77, 18%) 344,354,356,357), 
muscle weakness (MW) (COQ2 (1/30, 3%)  242, COQ6 (2/30, 7%) 235, COQ7 (3/3, 100%) 
238–240, COQ8A (13/77, 17%) 227,348,354,357, COQ8B (1/79, 1%) 243) and muscle fatigue (MF) 
(COQ8A (3/77, 4%) 227,344,347 and COQ8B (1/79, 1%) 364). Also, hypotonia and respiratory 
alterations may depend on muscular involvement. Some muscle biopsies have shown 
lipid accumulation in this tissue (COQ8A (3/77, 4%) 227,357, COQ2 (1/30, 3%)328), but 
probably this type of study has not been performed for all primary CoQ deficiency 
patients, so the information is still vastly incomplete. Lipid accumulation in mitochondria 
from skeletal muscle was also observed in a patient with adult-onset myopathy and 
CoQ10 deficiency. This patient had an happloinsuficiency of ADCK2 gene, and a mouse 
model mimicking Adck2 happloinsufficiency presented a similar phenotype, with defects 
in fatty acids β-oxidation378. This gene seems to participate in lipid homeostasis, 
regulating mitochondrial CoQ in muscle and organismal fatty acids β-oxidation378. 
Other manifestations 
Other more heterogeneous clinical findings have also been reported in patients affected 
by mutations in the different COQ genes (Figure 1.3 and Table 1.2). Among them, 
respiratory system alterations are the most frequent (Figure 1.3.B). Respiratory distress 




(RD) and apnoea seem to be characteristic of COQ4 (14/35, 40%; 9/35, 26%) 250–252, 
COQ7 (2/3, 67%; None) 239,240, COQ9 (3/7, 43%; 2/7, 29%) 246,247,256 and some COQ2 
(2/30, 7%; 2/30, 7%) 257. Respiratory failure (RF) occurred in some COQ2 (5/30, 17%) 
242,257,332 and COQ4 (5/35, 14%) 250,251,336,340 patients. The liver is affected in a few 
patients harbouring mutated versions of COQ2 (liver failure in 3/30, 10% 241,328; 
cholestatic liver in 1/30, 3% 249), COQ9 (reduced hematopoiesis in liver in 1/7, 14% 246), 
COQ8A (hepatosteatosis in 1/77, 1.3% 353) and COQ8B (hepatomegaly in 1/79, 1.3%) 
(Figure 1.3.A). Edema is only present in cases with nephrotic syndrome, so it is frequent 
in probands with pathogenic variants in genes characterised by renal involvement, such 
as COQ8B (16/79, 20%), COQ2 (11/30, 37%) 232,242,257,262,330,332–334,  COQ6 (2/30, 7%) 233,258 
and PDSS2 (2/7, 29%) 323,324. It is highly likely that many of the COQ6 patients presented 
edema, but this was underreported in the literature. A more exhaustive comprehension 
of these disorders might derive from long-term follow-up studies of patients affected by 
primary CoQ10 deficiencies. Less frequent clinical findings include dysmorphic features 
233,247,341, metabolic pathologies (DM, obesity and hypercholesterolemia)241,249,257,343, 
thyroid disease (goiter, hypothyroidism) 229,363 and circulatory problems (cyanosis, 
hypertension, livedo reticularis)251,340,364, among others (Figure 1.3.C). It should be 
considered that some of these symptoms could be secondary consequences of a more 
general defect. 
1.2.2. Biochemical findings 
Remarkably, most of the reported cases were not accompanied by a biochemical report. 
Some of them were reported to show a high concentration of lactate in plasma or serum 
(56/276, 20%), but the total number of the patients tested is unknown.  When enzymatic 
activities of complex I+III and/or II+III were measured, they generally showed a 
deficiency.  
CoQ10 measurement is the most relevant biochemical assay that should be performed 
when a CoQ10 deficiency is suspected. CoQ10 levels are measured in skeletal muscle 
biopsies or in cultured fibroblast, which are the preferred diagnosis tissues. In some 
cases of the reported cases, CoQ10 levels have been measured on white blood cells 
(WBC), but it has been reported that this measurement is not  reliable to diagnose 







Figure 1.3. Frequency of 
symptoms related to the 
less commonly affected 
organs and systems in 
primary CoQ10 deficiency, 
for each COQ gene 
involved.  
Symptoms related to 
respiratory system (A), liver 
(B) and other symptoms (C) 
are sorted in a decreasing 
order of frequencies. Total 
number of patients for each 
COQ gene is indicated at the 
bottom of the heatmaps.   
For Clinical Manifestations 
abbreviations, refer to 
Tables 1.1 and 1.2. 
 
 
Of note, only in 61 cases of the 276 reported ones (22%) the diagnosis has been 
accompanied by a measurement of CoQ10 levels in muscle, fibroblasts or white blood 
cells. This number is extremely low, just considering that the disease being diagnosed is 
a primary CoQ10 deficiency. Additionally, the methods that are being used for this 
purpose are very heterogeneous, and the control values of CoQ levels also vary from 
one laboratory to another. Efforts in homogenizing these techniques should be made, 
in order to improve biochemical diagnosis and reduce variability. 




1.2.3. Age of onset, age of death and age of last examination  
The age of onset in primary CoQ10 is very variable, but each of the affected genes seems 
to have a distinguishable onset age interval (Figures 1.4.A and 1.5). Moreover, even for 
the same gene, this range can be extensive (Figure 1.5).  
 
 
Figure 1.4. Heatmaps representing the age in which patients first 
manifested (A), died (B) or were examined for the last time (C), 
for each COQ gene involved.  
Age has been represented as the percentage of patients belonging 
to seven different age groups: neonatal (birth), infancy  (before 2 
years of age), childhood (2-10 years old), adolescence (11-18 years 
old), young adulthood (18-25 years old), adulthood (25-65 years 
old) and elderhood (after 66 years old). yo: years old.  
 
The age of onset generally falls between birth and childhood (PDSS1, PDSS2, COQ2, 
COQ4, COQ5, COQ6, COQ7, COQ9), or between childhood and adolescence (COQ8A, 
COQ8B), but there are also some adult-onset cases (COQ8A 227, COQ8B 229) (Figure 1.5). 
Of note, some COQ2 variants have been reported to  increase susceptibility to adult-





Figure 1.5. Age of onset of patients with primary CoQ10 deficiency, for each COQ gene involved. 
Each point represents one patient, and mean age of onset and standard deviation is calculated for each 
mutated gene. 
 
Neonatal onset is more frequent in COQ4 (19/35, 54% of the cases) 240,250,251,336,340,341, 
COQ7 (2/3, 67% of the cases) 239,240 and COQ9 (6/7, 86% of the cases) 246,248,256 patients. 
Also, many COQ2 (11/30, 37% of the cases) 241,249,257,328,332,334, and some PDSS1 (1/3, 
33%) 322 and PDSS2 (3/7, 43%) 245,323,324 patients presented neonatally. It is important to 
mention the marked lethality of the disease course in the neonatal-onset patients, 
almost all of them dying in the neonatal or infantile period, and some of them during 
childhood (Figure 1.4.A and B).  
The majority of the COQ2 patients presented before the age of 2 years (14/30, 47%) 
242,245,262,329,376. This is also true for PDSS1 (2/3, 67%) 241, PDSS2 (4/7, 57%) 245,285 and 
COQ6 (15/30, 50%) 231–233,235,258,343 patients. Some patients with pathogenic variants of 
COQ4 (11/35, 31%) 250,251,340, COQ7 (1/3, 33%) 238, COQ9 (1/7, 14%) 247, COQ8A (23/77, 
30%) 227,273,344,354,356,357,370 and COQ8B (4/79, 5%) 363,366 also presented when they were 
2 years old or before.  
COQ8A patients generally first manifest during childhood (29/77, 38%) 273,274,356,360, as it 
has been equally reported in previous studies 273–275. Childhood-onset also occurs in a 
significant number of COQ8B (28/79, 35%) 229,364,365 and COQ6 (11/30, 37%) 233,235,236 
patients, and in the only reported family with COQ5 defects (3/3, 100%) 326. Some 
patients with COQ2 (2/30, 7%) 262,376 and COQ4 (4/35, 11%) 335,338 mutations also 
presented during childhood.  
Adolescent-onset is the hallmark of COQ8B patients’ presentation (35/79,44%)229,363,364, 
while also some COQ8A (7/77, 9%) 273,274,347 and COQ2 (2/30, 7%) 232 patients presented 




between 11 and 18 years old. Adult-onset is rare, but some patients with COQ8B (11/79, 
14%) 229,363,364 and COQ8A (6/77, 7%) 227,228,273,274 mutations presented when they were 
adults. 
Analysing the age of the last examination, we can infer how patients in the different 
gene groups or onset-ages were able to live beyond childhood, adolescence or 
adulthood (Figure 1.4.C). This is just an approximative observation, since it significantly 
depends on the time when the case was published, which is not homogeneous nor 
explicative. We can see how some patients that present before 2 years old can progress 
at least to childhood (PDSS2, COQ2, COQ4, COQ6, COQ7, COQ9, COQ8A, COQ8B), 
adolescence (PDSS1, COQ2, COQ6, COQ8A) or adult age (COQ8A). Equally, some 
probands that manifested during childhood could achieve the adolescence (COQ2, 
COQ4, COQ5, COQ6, COQ8A and COQ8B), adult (COQ4, COQ5, COQ6, COQ8A and 
COQ8B) or elder age (COQ8A). Some of the patients manifesting during adolescence 
could likewise achieve adult age (COQ2, COQ8A).  
1.2.4. Primary CoQ10 deficiency due to mutations in the different COQ genes 
To shed light on the plethora of symptoms associated with the different cases of primary 
CoQ10 reported, we will discuss the patterns of symptoms at onset (Figure 1.6) and 
general clinical manifestations for each COQ gene. For the genes for which the total 
number of families with affected patients was sufficiently high (>20), the clinical cases 
were additionally stratified by age at onset (0/Birth: neonatal-onset; 0-2 years old (yo): 
infantile-onset; 2–10 yo: childhood-onset; 11–18 yo: adolescence onset; 19-65 yo: adult-
onset). We classified patients with mutations in COQ2 (30 patients from 22 families), 
COQ4 (35 patients from 26 families), COQ6 (30 patients from 22 families), COQ8A (77 
patients from 55 families) and COQ8B (79 patients from 41 families) (Figure 1.7). With 
this classification, in some cases, patients belonging to the same family were split into 
different groups. This happened mainly with COQ8B patients, in which siblings from the 
same family first manifested at different ages. There are a very low number of patients 
with mutations in PDSS1 (3 patients from 2 families), PDSS2 (7 patients from 5 families), 
COQ5 (3 patients from 1 family), COQ7 (3 patients from 3 families) and COQ9 (7 patients 
from 4 families) to do so. Still, we will equally discuss the global clinical features. We will 





Figure 1.6. Symptoms at onset in patients with mutations in the different COQ genes and number of 
patients associated with each first symptom.   
Each graph represents each gene involved in primary CoQ10 deficiency. (A) PDSS1, 3 patients in total; 
(B) PDSS2, 7 patients in total; (C) COQ2, 30 patients in total; (D) COQ4, 35 patients in total; (E) COQ5, 3 
patients in total; (F) COQ6, 30 patients in total; (G) COQ7, 3 patients in total; (H) COQ9, 7 patients in 
total; (I) COQ8A, 77 patients in total and (J) COQ8B, 79 patients in total. For abbreviations refer to 
Tables 1.1 and 1.2. 







Figure 1.7. Age of onset stratification of patients with primary CoQ10 deficiency.  
They are classified by the COQ gene involved: COQ2 (30 patients) (A), COQ4 (35 patients) (B), COQ6 (30 
patients) (C), COQ8A (77patients) (D) and COQ8B (79 patients) (E). In each graph, the whole group of 
patients is represented (All), as well as different groups of patients resulting of age-of-onset stratification 
of the cases (groups 1-4). Each point represents one patient, and mean age of onset and standard 






118 cases of the 276 reported ones (43%) were treated with CoQ10 supplementation. 
The outcome of the treatment will be discussed for these cases in this section (Table 
1.4). 
We also compiled the information about the pathogenicity of the mutations in the 
literature, reviewing three aspects: (i) the segregation of the mutation in the family; (ii) 
the biochemical characterisation of the disturbance of CoQ10 biosynthesis (measuring 
CoQ10 levels, synthesis rate, levels of COQ proteins or COQ transcripts, etc.); (iii) or the 
functional demonstration of the pathogenicity using a model (yeast, human or mouse 
cells, induced pluripotent stem cells (iPSCs), etc.). We analysed in silico the predicted 
pathogenicity of the mutations found in these patients. We used SIFT and PolyPhen-2 
tools to predict the effect of the missense mutations in the protein function, and SPiCE 
tool to predict the spliceogenicity of the variant. Furthermore, a pathogenicity score for 
single nucleotide variants and small insertion/deletions variants was calculated using 
the Combined Annotation Dependent Depletion (CADD v1.6) tool, which integrates 
multiple annotations220. Most variants analysed display a CADD score higher than 20, 
the cut-off of deleteriousness that is usually considered. 
Additionally, we analysed how the pathogenic variants were distributed concerning the 
age of onset of the disease (Figure 1.8). All the pathogenic variants of each gene were 
classified in the onset-age stratified groups, to investigate if some variants can be linked 
to different phenotypic outcomes. Of note, the majority of variants have been described 
only in one family, whereas some of them are more represented within the patient 
cohort. It is not possible to draw definite conclusions for variants that have only been 
described in a reduced number of families. What is more, for compound heterozygous 
genotypes, both variants are considered for the classification, but in the absence of 
functional data, it is not possible to conclude which of them contributes more to the 
phenotype. Only for those few variants that are represented in several families, we have 
analysed the possible link to different clinical pictures. In the cases of frameshift or 
nonsense mutations, when they occur early in the sequence, they could be considered 
as loss-of-function alleles. 
 
 










References # of patients 
treated 
Effect 
PDSS1 3 - - - 
PDSS2 7 2 No benefits (2) 323,324 
COQ2 30 14 
Neuromuscular functions restored (2), 
No benefits (2), 
No benefits on neuromuscular function (3), 
No benefits on renal function (1), 
No deterioration (2), 
Renal function restored (6) 
232,242,257,262,
333,334,376 
COQ4 35 20 
No benefits (7), 
Improvement of Sz or Ep (3), 
Improvement in development (2), 
Improvement of cardiac function (2), 
Stable condition (2), 
Subjective response improvement (2), 
Improvement of ataxia (1), 
Improvement of lactic acidosis (1), 
Muscle improvement (1) 
250,252,335,338–
341 
COQ5 3 3 Improvement of ataxia (3) 326 
COQ6 30 9 
Improved proteinuria (5), 
Improved renal function (3), 
Improved groth retardation (2), 
Improved SNHL (1) 
231–
234,236,258,343 
COQ7 3 3 
No deteroration (2), 
No benefits (1) 
238–240 
COQ9 7 4 
No benefits (3), 
Plasma lactate reduced (1) 
246–248 
COQ8A 77 29 
No benefits (13), 
Improvement of ataxia (9), 
Improvement of tremor and myoclonus (5), 
Improvement in motor abilities (5), 
Slight improvement of cerebellar signs (2), 
Stabilization of the ataxia (2), 
Improvement in fatigue and speech (1), 





COQ8B 79 29 
No benefits (7), 
 Improvement of proteinuria (18), 
 Improvement of edema (1) , 
Better physical fitness and  
reduced fatigue (1), 











Figure 1.8. Age of onset and genotype of patients with pathogenic variants in one of the ten COQ genes 
involved in primary CoQ10 deficiency.  
Each point represents one patient. Coloured circles represent mutations that were found in more than 
one family (each mutation in a different colour, depicted in the legend). Rhombus represent patients 
with mutations that appeared only in one family (in gray) or unknown mutations (in black). Full-filled 
symbols represent homozygous mutations, while half-filled ones design heterozygous mutations.  
Abbreviations: NK: Not known, Homoz: homozygous, Heteroz: heterozygous, mut: mutation. 
 





PDSS1 gene (MIM*607429) is located in the Chr10:26,697,701-26,746,798 
(GRCh38.p13), forward strand. The protein-coding transcript (1,584 base pairs (bp)) 
encodes a 415 amino acid (aa) (12 exons) protein. The gene product, the decaprenyl 
diphosphate synthase subunit 1, is a monomer of the enzyme that elongates the prenyl 
side-chain of CoQ10, in order to assemble the complete polyisoprenoid side chain, the 
first step in CoQ10 biosynthesis 380,381. Defects in this gene is a cause of primary CoQ10 
deficiency (COQ10D2, MIM#614651).  
i. CoQ10 deficiency due to PDSS1 mutations  
Only 3 patients from 2 families with PDSS1 mutations have been reported so far, so little 
information is known to draw a disease picture. The mean age of onset was 1 year old 
(yo) (range birth-2 yo) (Figures 1.5, 1.6.A). These two families manifested very different 
clinical pictures (Table 1.3).  
One family had a birth-onset disease with mainly renal involvement, with a severe SRNS 
that progressed in an ESRD, with death at 16 months old (mo). The patient from this 
family also had a marked DD. We could define her clinical picture as a severe 
multisystem disorder, similar to the primary phenotype of COQ2 patients. This patient 
had two compound heterozygous mutations, one frameshift mutation in exon 7 
(c.661_662insT), producing an early truncated protein (p.Arg221Leufs*16), and one 
missense mutation in exon 12, c.1108A>C (p.Ser370Arg)322 (Table 1.5). 
The other family had two siblings with an infancy onset (1-2 yo), who developed a milder 
disease (Table 1.3). They presented with SNHL, and later in their childhood and 
adolescence, they developed encephalopathy with a mild ID, and associated peripheral 
neuropathy with OA. They also presented a valvulopathy, LR and obesity. They did not 
display any renal involvement, at least at the age of the last examination (14 and 22 yo, 
respectively). They had a homozygous mutation in exon 10 in both PDSS1 alleles, 
c.924T>G (p.Asp308Glu) 241 (Table 1.5).  
ii. CoQ10 treatment and effects 
Regarding CoQ treatment and effects, there is no information about CoQ10 treatment in 




iii. Pathogenicity of the mutations 
There are 3 mutations in PDSS1 related with primary CoQ10 deficiency in the literature 
(Figure 1.8 and Table 1.5). Only one of them has been demonstrated pathogenic in a 
yeast model, c.924T>G (p.Asp308Glu)241. The other two mutations are thought to be 
pathogenic because of the low levels of CoQ10 found in patient’s cells. The frameshift 
mutations would probably lead to a loss-of-function allele. The two missense mutations 
have been predicted pathogenic with SIFT, PolyPhen-2 and CADD tools (Table 1.5). 
Table 1.5. Pathogenic variants of PDSS1 and PDSS2 genes found in patients.  
Gene/ 
protein 





























1 (1) c.661_662insT p.Arg221Leufs* 7  B  - - - 33 322 
1 (2) c.924T>G p.Asp308Glu 10 S B F Pathog. Probably - 22.1 241 






1 (1) c.485A>G p.His162Arg 3 S   Pathog. Probably - 25.1 323 




p.? 8 S   - - low - 323 
2 (2) c.1145C>T p.Ser382Leu 8 S B  Pathog. Probably - 31 
245,
324 
1 (1) c.1151C>A p.Ala384Asp 8 S   
Tole-
rated 
Probably - 29.0 245 
1 (3) NA NA NA  B  Pathog. Probably - - 
285,
325 
Reference sequences correspond to longest transcript. Abbreviations: F: Number of families with each 
variant, P: Number of patients with each variant, aa: amino acid, Ref: references, NA: not available, 
Pathog: Pathogenic. 
PDSS2 
PDSS2 gene (MIM*610564) is located in chr6:107,152,562-107,459,564 (GRCh38.p13), 
reverse strand. Three different protein coding transcripts are annotated, but only the 
longest one is thought to produce PDSS subunit 2. This transcript (3,536 bp) encodes a 
399 aa (8 exons) protein. The gene product, the decaprenyl diphosphate synthase 
subunit 2, together with PDSS1, forms the heterotetramer that assemble the complete 
polyisoprenoid side chain, the first step in CoQ10 biosynthesis. Defects in this gene are a 
cause of CoQ10 deficiency (COQ10D3, MIM#614652).  
 




i. CoQ10 deficiency due to PDSS2 mutations  
7 patients from 5 families with PDSS2 mutations have been reported so far. The 
pathology of PDSS2 deficiency seems to be different from that of PDSS1 deficiency. 
PDSS2 patients presented a multisystemic disorder with mainly renal involvement, all 
of them having SRNS and some of them ending in an ESRD (Table 1.3). However, they 
had a wide range of neurological manifestations within the different families (Leigh-like 
syndrome (LS), ataxia, cerebral palsy, encephalopathy). What is clear is that when SNHL 
was present (in 4 patients of 2 families), it was the first symptom to appear, similarly to 
one of the two PDSS1 families 241 (Figure 1.6.B). The two families with SNHL also had an 
HCM. The disease manifested at a mean age of 6 mo (range birth-2 yo) (Figure 1.5). 
Three families had a birth onset (3/7 patients, 43%), while two families (4/7 patients, 
57%) had an infancy onset (Figures 1.5, 1.6.B).  
Two patients with a birth onset died during infancy, but from different causes (epilepsy 
or ESRD), while the age of the third one is not available. One of these patients presented 
with hypotonia and developed a LS with basal ganglia lesions (BGL) and seizures, passing 
away at 8 mo because of a complication of the epileptic status. He had two compound 
heterozygous mutations, one nonsense variant in exon 6 (c.964C>T), producing an early 
truncated protein (p.Gln322*), and one missense change in exon 8, c.1145C>T 
(p.Ser382Leu) 324. The other patient initially presented with hearing loss (HL), and DD, 
and later manifested an encephalopathy with hypotonia, RP and HCM. He died because 
of a renal dysfunction. He had two compound heterozygous mutations, one missense 
mutation in exon 3, c.485A>G (p.His162Arg), and a 2923bp deletion that affected the 5‘ 
end of exon 8 323. The third patient was described with no other presentation than the 
SRNS, and had a homozygous missense mutation in exon 8, c.1151C>A (p.Ala384Asp)245. 
There were two families with an infancy onset, and with a less severe phenotype. One 
of them had three siblings who presented with nystagmus and HL, and then developed 
visual impairment and an ataxic phenotype, with ID. One of them had HCM. The 
mutations in these patients were not specified 285,325. The other family had one patient 
with cerebral palsy and ID. He had an homozygous missense substitution in exon 8, 
c.1145C>T (p.Ser382Leu), the same that the LS patient presented 245. 




CoQ10 treatment was administered to two of the birth-onset cases, but with no apparent 
benefits (Table 1.4). Two siblings with the ataxic syndrome were treated with 
ubidecarenone, and after 6 months, they improved their motor performance and 
general condition 285.  
iii. Pathogenicity of the mutations 
Five pathogenic variants of PDSS2 have been related to primary CoQ10 deficiency in 
published patients (Figure 1.8). All the mutations were confirmed to segregate within 
the different families (Table 1.5). Only the variants identified in the patients with LS 
(c.964C>T (p.Gln322*) and c.1145C>T (p.Ser382Leu)) were biochemically tested by 
revealing low levels of CoQ10 biosynthesis rate on the patient fibroblasts  324. The 
missense mutation was also found in another unrelated patient 245, but with a different 
disease course (Figure 1.8). The deletion mutation (c.1042_1148-2816del) affects the 
last part of the last exon and have an uncertain molecular effect 323. The missense 
mutation accompanying this deletion, c.485A>G (p.His162Arg), has been predicted to 
be pathogenic with SIFT, PolyPhen-2 and CADD tools. The last variant, the homozygous 
missense mutation in exon 8, c.1151C>A (p.Ala384Asp) 245, has been predicted as 
tolerated by SIFT, but probably damaging by Polyphen-2, whereas it reaches a 
pathogenicity score (29) with CADD, supporting a deleterious effect of this substitution. 
Its pathogenicity should be confirmed by an experimental validation (Table 1.5). 
COQ2 
COQ2 gene (MIM*609825) is located in chr4:83,261,536-83,284,914 (GRCh38.p13), 
reverse strand. The open reading frame contains four in-frame ATG initiation codons 
(termed ATG1-4). Traditionally, ATG1 was considered the first translated codon, 
generating a 421 aa protein with 7 exons. Still, recently, it has been shown that the most 
abundant COQ2 transcript in human cells includes only the most downstream initiation 
codon (ATG4, 1,641 bp), giving rise to a 371 aa protein with 7 exons 277. The gene 
product, the para-hydroxybenzoate polyprenyl-transferase, is the enzyme that catalyses 
the condensation of 4- hydroxybenzoate with polyprenyl-pyrophosphate, generating 
the first membrane-bound CoQ10 intermediate. Defects in this gene are a cause of CoQ10 
deficiency (COQ10D1, MIM#607426).  




i. CoQ10 deficiency due to COQ2 mutations  
30 patients from 22 families with COQ2 pathogenic variants have been reported up to 
date. COQ2 patients manifested a nephrotic syndrome with different degrees of 
severity (Table 1.3). The nephrotic syndrome could be presented either isolated, 
associated with CNS affections, or as a part of a more severe multisystemic disorder.  
a. Age of onset  
COQ2 patients manifested at a mean age of 25 mo (range birth-18 yo) (Figure 1.5). We 
classified the clinical cases by the age of onset in 4 different groups, revealing each of 
them a different clinical picture (Figures 1.7.A, 1.9.A and B).  
Group 1 is the largest one (13/30, 43% of the total number of COQ2 patients). The mean 
age of onset in this group was 2 weeks old (wo)(range birth-4 mo). Group 2 is a small 
group (6/30, 20% of the total number of COQ2 patients), which includes 6 patients from 
5 different families, in whom the mean age of onset was 9 mo (range 5 mo-1 yo). Group 
3 is composed of patients (9/30, 30% of the total number of COQ2 patients) that had an 
infancy (6/9, 78%) or childhood (2/9, 22%) -onset, whose mean age of presentation was 
almost 3 yo (34 mo) (range 1 yo-10 yo). Only one family (Group 4, 2/30, 6.7% of the total 
number of COQ2 patients) manifested during adolescence, with a mean age of 
presentation of 17 yo (range 16-18 yo). 
b. Symptoms at onset 
COQ2 patients mainly displayed a multi-symptom presentation, with a combination of 
different clinical manifestations. However, the hallmark symptom at onset was SRNS 
(21/30, 70%). Other symptoms at onset were diabetes mellitus (DM) (4/30, 13%) 257 or 
respiratory defects (3/30, 10%) 249,332. Other very variable and less frequent symptoms 
at onset were seizures, liver failure (LF), collapse, acidosis, hyperreactivity, oliguria, 






Figure 1.9. Clinical manifestations and genotype of COQ2 patients.  
(A) Symptom frequency found in COQ2 patients, for each age-of-onset group 1-4. (B) Total number of 
patients in each age-of-onset group. (C-F) First symptoms at onset, and the number of patients 
manifesting them, for each age-of-onset group. (G) Age of onset and pathogenic variants of COQ2 
patients. Each point represents one patient. Coloured circles: mutations found in more than one family 
(see the legend). Rhombus: patients with mutations only present in one family (gray). Full-filled symbols: 
homozygous mutations, half-filled symbols: heterozygous mutations.  Abbreviations: Tables 1.1 and 1.2. 




When sorted by age at onset, patients with the earliest onset (group 1) first presented 
with a wide spectrum of different symptoms (SRNS (5/13, 38%)241,257, respiratory defects 
(3/13, 23%) 249,332, DM (4/13, 31%)257, liver failure (1/13, 8%)241, seizures (1/13, 8%)333, 
acidosis (1/13, 8%)328, collapse (1/13, 8%) 241 or hyperreactivity (1/13, 8%)328) (Figure 
1.9.C). For group 2 patients, SRNS was the first symptom in the majority of the cases 
(5/6, 83%)242,245,262,330,331,375. One patient also  presented with Ny and OA 331,375, and 
another one with oedema and proteinuria, which are signs of SRNS (Figure 1.9.D) 334. 
The rest of the patients (groups 3 and 4) first presented with SRNS (9 and 2, respectively) 
(Figure 1.9.E and F) 232,242,244,245,262,329.  
c. Clinical manifestations of the disease  
COQ2 patients presented a nephrotic syndrome with different degrees of severity, being 
isolated, with encephalopathy and seizures, or as a part of a multisystemic disorder 
(Table 1.3). When clinical cases are classified by the age of onset, 4 different groups 
emerged, revealing each of them a distinct clinical picture (Figure 1.9.A and B).  
COQ2 deficiency’s main phenotype is an early-onset severe multisystemic disorder 
(group 1), mainly with renal (SRNS (9/13, 69%)) and CNS involvement (encephalopathy 
(7/13, 54%), epilepsy (2/13, 15%), seizures (10/13, 77%), hypotonia (5/13, 38%), 
dystonia (2/13, 15%), stroke-like lesions (SLL) (2/13, 15%), nystagmus (2/13, 15%)), but 
also with other organs and systems’ features (HCM (3/13, 23%), LF (3/13, 23%), DM 
(6/13, 46%), RF (5/13, 38%)) 241,242,249,257,328,333,334. All patients from group 1 died (13/13, 
100%) (Figure 1.4.B) mainly because of multiorgan failure (7/13, 54%)249,257,333, or a 
complication of the renal (2/13, 15%) 242,330 or neurological (3/13, 23%) status 257,328. 
Infections caused the death of the rest of the patients (2/13, 15%) 332. 
Some patients presented an infancy-onset SRNS that was accompanied by some 
neurological symptoms (group 2), such as encephalopathy (2/6, 33%), DD (2/6, 33%), 
and seizures, nystagmus, hypotonia, myoclonus, CAt, tremor, OA and retinopathy (1/6, 
17% each symptom)242,245,331,334,375.  
Group 3 is composed of patients who had infancy (6/9, 67%) or childhood (2/9, 22%) -





Only one family (group 4) manifested during adolescence an SRNS with a mild CNS 
involvement (epilepsy, mild neurological symptoms). They also had edema (2/2, 100%) 
and hypercholesterolemia (1/2, 50%)232. 
ii. CoQ10 treatment and effects 
CoQ10 treatment was administered to 14/30 (47%) of the COQ2 patients, representing 
all the four groups described (Table 1.4 and 1.6). In the most severe group (group 1), 
4/13 patients were treated. 3/4 normalised glucose and lactate levels, and only one of 
them decreased proteinuria 257. None of these 4 patients had any improvement in 
neurological function. In the group showing SRNS accompanied by encephalopathy 
(group 2), 4/6 patients were treated, and they restored neuromuscular (2/4) and renal 
(2/4) functions 242,262,331,334,375. In the isolated SRNS group (group 3), 4/9 patients were 
treated, and they ameliorated their renal function (2/4), did not get worse (1/4) or did 
not benefit from the treatment (1/4)242,262,376. From the last group (adolescence onset 
SRNS), two patients from the same family restored the renal function after the CoQ10 
supplementation (group 4) 232.  
In general, there is a variable response to CoQ10 treatment, with no obvious correlation 
with the mutations of the patient. Renal function often responds well to treatment. 
i. Pathogenicity of the mutations 
There are 16 reported COQ2 variants that have been associated with primary CoQ10 
deficiency in the literature (Figures 1.8, 1.9.G and Table 1.7). Almost all the mutations 
(13/16, 81%) were confirmed to be segregated on the different families, except the 
variants c.26dupT (p.Ala10Argfs*33), c.731C>T (p.Thr244Ile) and c.1009C>T 
(p.Arg337*). Some of the mutations (8/16, 50%) were tested in a yeast model in a study 
in which a genotype-phenotype correlation for COQ2 patients is established 277.   
Following the age-of-onset stratification of the patients, we analysed the pathogenic 
variations that were represented within the different groups (Figure 1.9.G and Table 
1.6). We observed a correlation in which some variants are associated with more severe 
phenotypes, while others are associated with less severe ones. This fact fits with the 
previous study in which COQ2 variants are associated with the residual CoQ10 synthesis 
ability and the severity of the disease 277.  






















lactate level (3), 
No benefits on 
neurological 
function (3), 
No benefits (1) 
5 (7) c.287G>A p.Ser96Asn 
242,249,257,277,
333 
1 (1) c.368G>A p.Arg123His 334 
1 (1) c.395T>G p.Met132Arg 328 
1 (2) c.755C>T p.Ala252Val 277,332 
1 (1) c.823A>G p.Thr275Ala 334 
1 (1) c.1009C>T p.Arg337* 249,277 
1 (2) c.1047delT p.Asn351Ilefs*15 241 






No benefits on 
renal function (1), 
No deterioration 
(1)  
1 (1) c.368G>A p.Arg123His 334 
1 (1) c.682T>C p.Cys228Arg 330 
2 (3) c.740A>G p.Tyr247Cys 
242,245,277,331,
375 
2 (2) c.823A>G p.Thr275Ala 262, 334 
1 (1) c.1009C>T p.Arg337* 262 





No benefits (1) 
1 (1) c.26dupT p.Ala10Argfs*33 262 
1 (1) c.368G>A p.Arg123His 245 
1 (1) c.440G>A p.Arg147His 242,277 
8 (9) c.533A>G p.Asn178Ser 
242,244,245,262,
277,329 
1 (1) c.551delT p.Leu184fs*14 277,329 
1 (1) c.706C>T p.Leu236Phe 245 
1 (1) c.731C>T p.Thr244Ile 262 
Group 4 2 2 
Renal function 
restored (2) 
1 (2) c.1019G>C p.Gly340Ala 232 
Abbreviations: F: Number of families with each variant, P: Number of patients with each variant, aa: amino 
acid, Ref: references. 
 
We have classified all the variants, but we cannot draw clear conclusions for variants 
that have been only described in a reduced number of families. Otherwise, we can 
discuss the phenotypic severity of the variants the most represented in each group 
(c.287G>A (p.Ser96Asn), c.740A>G (p.Tyr247Cys), c.533A>G (p.Asn178Ser), c.1019G>C 





Table 1.7. Pathogenic variants of COQ2 gene found in patients.  
Gene/ 
protein 































1 (1) c.26dupT p.Ala10Argfs*33 1    - - - 21.8 262 




2 (3) c.368G>A p.Arg123His 2 S   Pathog. Probably - 25.4 245,334 
1 (1) c.395T>G p.Met132Arg 2 S B F Pathog. Probably - 27.7 328 
1 (1) c.440G>A p.Arg147His 3 S B F Pathog. Probably - 31 242,277 
8 (9) c.533A>G p.Asn178Ser 3 S B F 
Tole-
rated 




1 (1) c.551delT p.Leu184fs*14 4 S B  - - - 32 277,329 
1 (1) c.682T>C3 p.Cys228Arg 5 S   Pathog. Probably - 25.3 330 
1 (1) c.706C>T p.Leu236Phe 5 S   Pathog. Probably - 25.1 245 
1 (1) c.731C>T p.Thr244Ile 5    
Tole-
rated 
Probably - 25.2 262 




1 (2) c.755C>T p.Ala252Val 5 S B F Pathog. Probably - 26.5 277,332 
2 (3) c.823A>G p.Thr275Ala 6 S   
Tole-
rated 
Possibly - 23.7 262,334 
2 (2) c.1009C>T2 p.Arg337* 7    - - - 38 
249,262,
277 
1 (2) c.1019G>C p.Gly340Ala 7 S B F Pathog. Possibly - 22.9 232 
1 (2) c.1047delT p.Asn351Ilefs*15 7 S B F - - - 25.7 241 
1. COQ2 has four in-frame initiation codons. The last proposed nomenclature is used (starting from 
ATG4), corresponding to a 371-aa-long protein 277.  
2. The patient with these two variants also carries a novel mutation in MT-ND1 (3754C>A) with 22% 
of heteroplasmy in peripheral blood, which may contribute to the disease 249. 
3. The patient with this mutation in homozygosis also carries an additional homozygous mutation 
in ARSB gene (c.1213 + 1G > A), which may contribute to the disease 330. 
Reference sequences correspond to longest transcript. Abbreviations: F: Number of families with each 
variant, P: Number of patients with each variant, aa: amino acid, Pathog: Pathogenic, Ref: references. 
  




p.Ser96Asn mutation is present in 7 patients from 5 different families corresponding to 
group 1, in homozygous (6/7 patients)242,257,333 or compound heterozygous state (1/7 
patients, with the nonsense mutation p.Arg337*)249. Its pathogenicity has been 
confirmed in a yeast model, where it showed to have very low levels of residual CoQ 
biosynthesis277. We can say that this variant probably leads to a severe infantile 
multisystemic disorder. 
Two families were diagnosed having p.Tyr247Cys variant homozygously, and presented 
a SRNS with neurological symptoms (Group 2)242,245. However, the number of cases is 
small to be able to conclude anything further. 
On the other hand, p.Asn178Ser variant is present in 9 patients from 8 families grouped 
in the isolated SRNS clinical group 3, in homozygosis (2/9 patients) 244,262 or compound 
heterozygosis (7/9 patients, with different missense and frameshift mutations) 
242,245,262,329. Its pathogenicity has been confirmed in a yeast model, where it showed to 
have 50% of residual CoQ10 biosynthesis, compared to the WT allele 277. This pathogenic 
variant seems to be less severe. 
Only one family manifested during adolescence a SRNS (Group 4) with a mild CNS 
involvement. These two siblings had p.Gly340Ala mutation in homozygosis. The 
pathogenicity of this variant has been confirmed in a yeast model, where it showed to 
have a mild effect, retaining almost the 50% of residual CoQ biosynthesis, compared to 
the WT allele232. 
Finally, some variants were found in heterozygous state in patients belonging to 
different groups (p.Arg123His, p.Thr275Ala, p.Arg337*) and predicted pathogenic 
(Table 1.6 and 1.7)245,249,262,334. However, with the available data, it is hard to establish 
the extent to which each of the heterozygous mutations would contribute to the disease 
pathogenesis. p.Arg337* is a nonsense change, but since it is in the last exon, the protein 
only lacks the last 34 amino acids, and its effect on protein function is unknown.  
Of note, some studies predict that specific COQ2 variants increase susceptibility to adult-
onset multisystem atrophy (MSA), with Parkinson’s-like symptoms, particularly in the 





COQ4 gene (MIM*612898) is located in chr9:128,322,544-128,334,072 (GRCh38.p13), 
forward strand. Four different protein-coding transcripts are annotated, but only the 
longest one is thought to produce COQ4 protein. This transcript (1,245 bp) encodes a 
265 aa (7 exons) protein. The gene product of COQ4 appears to play a structural role in 
stabilising a complex that contains most of the CoQ10 biosynthesis enzymes. COQ4 
deficiency leads to a form of primary CoQ10 deficiency (COQ10D7, MIM#616276).  
i. CoQ10 deficiency due to COQ4 mutations  
35 patients from 26 families with COQ4 mutations have been reported so far. COQ4 
patients mainly showed a severe neurological affection, associated with a 
cardiomyopathy (18/35, 51%) and respiratory distress (14/35, 40%) in the majority of 
the cases (Table 1.3).  
a. Age of onset  
The mean age of presentation was 1 yo (range birth-9 yo) (Figure 1.5), being mostly a 
neonatal or infancy (19/35, 54% and 11/35, 31%; respectively) presentation (Figure 
1.10.B). Likewise COQ2, COQ4 patients present different clinical pictures, and we can 
classify them in 3 different groups when stratified by the age of onset (Figures 1.7.B, 
1.10).  
Group 1 is constituted by 25 patients from 18 families (25/35, 71% of the total number 
of COQ4 patients), which include all with birth-onset and some presenting the disease 
within the first months of life. The mean age of onset of patients in this group is 2 wo 
(range birth-4 mo). Group 2 is composed of 4 patients from 4 Chinese families (4/35, 
11% of the total number of COQ4 patients), with a mean age of presentation of 6 mo 
(range 6-8 mo). Group 3 is the one with less severe phenotype (5/35, 14% of the total 
number of COQ4 patients), manifesting at a mean age of 6 yo (range 10 mo-9 yo).  





Figure 1.10. Clinical manifestations and genotype of COQ4 patients.  
(A) Symptom frequency found in COQ4 patients, for each age-of-onset group 1-3. (B) Total number of 
patients in each age-of-onset group. (C-E) First symptoms and the number of patients manifesting them, 
for each age-of-onset group. (F) Age of onset and pathogenic variants of COQ4 patients. Each point 
represents one patient. Coloured circles: mutations found in more than one family (see the legend). 
Rhombus: patients with mutations only present in one family (gray). Full-filled symbols: homozygous 




b. Symptoms at onset 
Patients generally presented with a combination of 1, 2 or 3 clinical manifestations, 
typical of a severe multisystemic disorder (Figures 1.6.D, 1.10.C-E). The most common 
symptoms at onset were hypotonia (8/35, 23%), RD (8/35, 23%), seizures (5/35, 14%), 
acidosis (4/35, 11%), DD (3/35, 9%), motor deterioration (3/35, 9%) and apnea (3/35, 
9%). Other less frequent symptoms at onset were walking difficulty, HCM, bradycardia, 
cerebellar hypoplasia (CHyp) or spasms (2/35, 6% each of them).  
We can define different patterns of symptoms at the onset if we analyse them by the 
age of onset. The majority of COQ4 patients presented at birth (group 1) with a collection 
of different symptoms affecting variable systems and organs (RD (8/25, 32%), hypotonia 
(7/25, 28%), acidosis (4/25, 16%), seizures (4/25, 16%), apnea (3/25, 12%), bradycardia 
(2/25, 8%), HCM (2/25, 8%)) 250–252,336,340 (Figure 1.10.C). Infantile-onset patients (group 
2) presented with DD (2/4, 50%), spasms (1/4, 25%), visual dysfunction (1/4, 25%) and 
hypotonia (1/4, 25%) (Figure 1.10.D) 250,340. Some patients presented during childhood 
(group 3) and their first symptoms were motor deterioration or walking difficulties (3/5, 
60%), tremor (1/5, 20%) and seizures (1/5, 20%), being this onset typical of a cerebellar 
disorder (Figure 1.10.E) 251,335,338.  
c. Clinical manifestations of the disease  
COQ4 patients mainly showed a severe CNS affection, with encephalopathy (11/35, 
31%), seizures (24/35, 69%), hypotonia (19/35, 54%) and CHyp (10/35, 29%), associated 
to HCM (13/35, 37%) and RD (14/35, 40%) (Figure 1.10.A); and a fatal outcome with 
death within the first days (2/35, 6%), months (16/35, 46%) or years of life (2/35, 6%) 
(Table 1.3). Of note, the majority of the identified COQ4 patients are Chinese (17/35, 
49%).  
The main phenotype of COQ4 deficiency is a neonatal-infantile onset encephalo-
cardiomyopathy (group 1) 250–252,336,339–341. The most common cardiac manifestations 
were HCM (13/25, 52%), bradycardia (5/25, 20%), cardiomegaly (3/25, 12%), HF (2/25, 
8%), tachycardia (2/25, 8%); while CNS was mainly affected by hypotonia (16/25, 64%), 
seizures (16/25, 64%), DD (13/25, 52%), encephalopathy (9/25, 36%), CHyp (9/25, 36%), 
BGL (5/25, 20%), amongst other implications. Additionally to cardiac and CNS 




involvement, these patients very often presented RD (14/25, 56%) and apnea (9/25, 
36%). Almost all these patients died (19/25, 76%) (Figure 1.4.B) mainly because of a 
multiorgan failure (7/25, 28%), a complication of the cardiac (4/25, 16%) or respiratory 
(4/25, 16%) functions, or a severe episode of acidosis (3/25, 12%).  
Some patients had a slightly milder outcome (group 2), with an infantile-onset 
encephalopathy mainly with DD (4/4, 100%), dystonia (4/4, 100%), visual dysfunction 
(4/4, 100%), spasticity (3/4, 75%) and seizures (2/4, 50%). The clinical picture is 
characterised by the lack of cardiac and respiratory involvement (Figure 1.10.A) 250,340. 
The less severe phenotype is that of patients manifesting a childhood-onset progressive 
spinocerebellar ataxia (group 3), similar to COQ8A patients’ clinical presentation 
251,335,338. After onset, during their childhood and adolescence, they developed ataxia 
(4/5, 80%), with deteriorated ambulation (DAmb) (5/5, 100%), ID (5/5, 100%), seizures 
(5/5, 100%), spasticity (4/5, 80%), CAt (3/5, 60%), dysarthria (2/5, 40%), 
dysdiadochokinesia (2/5, 40%), dysmetria (2/5, 40%), tremor (2/5, 40%), SLL (2/5, 40%), 
hypotonia (1/5, 20%) and PNSN (1/5, 20%). 
ii. CoQ10 treatment and effects 
CoQ10 treatment was administered to 20/35 (57%) of the COQ4 patients, representing 
all the three groups described (Tables 1.4 and 1.8). In the most severe group (group 1), 
12/25 patients were treated. Most of them did not obtain any benefits from the 
treatment (5/12) 250,252. Small improvements in cardiac function (1/12) 252, seizures 
(2/12) 250,339, acidosis (1/12) 252 or subjective response (1/12) 340 were observed in these 
patients. In group 2, all the 4 patients were treated. Some of them improved the seizures 
condition (1/4), the general response (1/4) or stabilised the disease progression (1/4), 
while others did not experience any amelioration (2/4) 250,340. From the last group, the 
childhood-onset ataxia, 4/5 patients were treated and one of them reported an 
improvement of the ataxic condition, while the outcome of the rest of them was not 
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1 (2) c.202G>C p.Asp68His 252 
1 (2) c.245T>A p.Leu82Gln 252 
1 (1) c.311G>T p.Asp111Tyr 336 
1 (1) c.356C>T p.Pro119Leu 336 
9 (13) c.370G>A p.Gly124Ser 250,339,340 
3 (4) c.402+1G>C ? 250 
1 (1) c.421C>T p.Arg141* 251 
1 (1) c.433C>G p.Arg145Gly 251 
1 (2) c.473G>A p.Arg158Gln 252 
1 (2) c.521_523delCCA p.Thr174del 251 
1 (1) c.533G>A p.Gly178Glu 340 
3 (3) c.718C>T p.Arg240Cys 251,252 
1 (1) 
3.9 Mb deletion of chromosome 










Sz or Ep (1) 
3 (3) c.370G>A p.Gly124Ser 250,340 
2 (2) c.371G>T p.Gly124Val 250,340 
1 (1) c.402+1G>C ? 250 







1 (2) c.164G>T p.Gly55Val 335 
1 (1) c.190C>T p.Pro64Ser 251 
1 (2) c.230C>T P.Thr77Ile 338 
Abbreviations: F: Number of families with each variant, P: Number of patients with each variant, aa: amino 
acid, Ref: references, NK: not known. For Clinical Manifestations abbreviations, refer to Tables 1.1 and 
1.2. 
 
iii. Pathogenicity of the mutations 
There are 22 reported COQ4 mutations associated with primary CoQ10 deficiency in the 
literature (Figures 1.8, 1.10.F, Tables 1.8 and 1.9). Nearly all of them were confirmed to 
segregate within the different families (18/22, 82%), except for the mutations 
c.402+1G>C and c.533G>A (p.Gly178Glu), for which no data were available. The 
















Table 1.9. Pathogenic variants of COQ4 gene found in patients.  
Gene/ 
protein 
Pathogenic variants Validation 


































p.Val8Alafs*19 1 S   - - - 21.1 336 
1 (2) c.155T>C p.Leu52Ser 2 S   Pathog. Probably  - 28.6 251 
1 (2) c.164G>T p.Gly55Val 2 S   Pathog. Probably  - 24.4 335 




p.Arg66Gln 2 S B  Pathog. Probably  - 32 252 
2 (3) c.202G>C p.Asp68His 2-3 S B  Pathog. Probably  high 35 252,337 
1 (2) c.230C>T P.Thr77Ile 3 S B  Pathog. Possibly  - 28.7 338 
1 (2) c.245T>A p.Leu82Gln 3 S B  Pathog. Benign - 24.6 252 
1 (1) c.311G>T1 p.Asp111Tyr 4  B  Pathog. Probably  - 27.2 336 
1 (1) c.356C>T1 p.Pro119Leu 4 S  F Pathog. Probably  - 26.0 336 
12 
(16) 
c.370G>A2 p.Gly124Ser 4 S B F Pathog. Probably  - 24.7 
250,339,
340 
2 (2) c.371G>T p.Gly124Val 4 S   Pathog. Probably  - 24.4 340 
4 (5) c.402+1G>C ? 
Intron  
4 
S B  - - high 33 250 
1 (1) c.421C>T p.Arg141* 5 S B F - - - 41 251 
1 (1) c.433C>G p.Arg145Gly 5    Pathog. Possibly  - 25.1 251 
1 (1) c.469C>A p.Gln157Lys 5  B  
Tole-
rated 
Possibly  - 23.5 337 




p.Thr174del 5 S   - - - 22.1 251 
1 (1) c.533G>A p.Gly178Glu 6 S   Pathog. Probably  medium 33 340 
1 (1) c.550T>C p.Trp184Arg 6 S B  Pathog. Probably  - 26.2 250 
3 (3) c.718C>T p.Arg240Cys 7 S  F Pathog. Probably  - 32 251,252 
1 (1) 
3.9 Mb deletion of Chr 9q34.13, 
including COQ4 gene 
 B  - - - - - 
1. These two missense variants were identified in a patient in the same allele, paternally inherited. 
The maternally inherited COQ4 allele carried the c.22_33delTCCTCCGTCGG deletion 
(p.Val8Alafs*19) 336.  
2. The c.370G>A p.(Gly124Ser) variant in COQ4 has been described as a founder mutation in 
southern Chinese population, being identified in 16 patients from 12 Chinese families 250,339,340. 
Reference sequences correspond to longest transcript. Abbreviations: F: Number of families with each 
variant, P: Number of patients with each variant, aa: amino acid, Pathog: pathogenic, Prob: probability, 







We classified the mutations into the three age of onset groups (Figure 1.10.F). Here, we 
will only discuss the most represented variants, which are the c.718C>T (p.Arg240Cys) 
mutation, found in 3 families; and 3 mutations found in Chinese families, c.370G>A 
(p.Gly124Ser), c.402+1G>C and c.371G>T (p.Gly124Val).  
Three families were diagnosed with p.Arg240Cys variant in homozygous (2/3) 252 or 
heterozygous (1/3) state with the nonsense variant p.Arg141* 251,372, and they all 
presented a fatal neonatal onset encephalo-cardiomyopathy. 
p.Gly124Ser mutation has been described as a founder mutation in the southern 
Chinese population, and it has been described in 16 patients from 12 different 
families250,340. Most of them (13 patients from 9 families) have been associated to the 
most severe phenotype (group 1), in homozygosis (8/13 patients) or heterozygosis (5/13 
patients) with the probably spliceogenous variant c.402+1G>C in 4 of the cases 250. This 
variant has a high probability of altering splicing, predicted with the SPiCE software 
(Table 1.9). The rest of the patients with the p.Gly124Ser mutation (3 patients from 3 
families) are classified in the phenotypic group 2, in homozygosis (1/3 patients) or 
heterozygosis (2/3 patients) with the c.371G>T (p.Gly124Val) variant250,340. These three 
pathogenic variants have all been described in patients with a neonatal-infantile onset 
encephalo-cardiomyopathy or an infancy-onset encephalopathy. 
A patient with haploinsufficiency of COQ4 due to a de novo heterozygous 3.9-Mb 
deletion of chromosome 9q34 presented encephalomyopathic manifestations and 
CoQ10 deficiency in fibroblasts 341.  
All the 5 patients from 3 families with 3 different mutations in homozygosis (p.Pro64Ser, 
p.Thr77Ile and p.Gly55Val) 251,335,338 had a childhood-onset progressive spinocerebellar 
ataxia (group 3). These mutations could be considered less severe than the rest of the 
described COQ4 mutations, but the number of cases is again too small to reach any 
sound conclusion. 
Finally, there are some other variants found in homozygous or heterozygous state in 
patients belonging to the different groups. We have predicted their pathogenicity and 
classified them, but we cannot be certain of how they would contribute to the disease 
pathogenesis because of their low representation (Tables 1.8 and 1.9).  





COQ5 gene (MIM*616359) is located in chr12:120,503,279-120,534,434 (GRCh38.p13), 
reverse strand. Six different protein-coding transcripts are annotated, but only the 
longest one is thought to produce COQ5 protein. This transcript (1,506 bp) codes for a 
327aa (7 exons) protein. The gene product, COQ5, is a methyltransferase required for 
the methylation of 2-polyprenyl-6-methoxy-1,4-benzoquinol (DDMQH2) to 2-
polyprenyl-3-methyl-6-methoxy-1,4-benzoquinol (DMQH2). Defects in this gene have 
been found to cause primary CoQ10 deficiency (COQ10D9, MIM#619028).  
i. CoQ10 deficiency due to COQ5 mutations  
Only 3 patients from 1 family with COQ5 defects have been reported so far. These three 
female siblings presented varying degrees of an early childhood cerebellar ataxic 
phenotype similar to COQ8A patients 326 (Figures 1.5, 1.6.E). The first symptoms they 
manifested were a slow motor development (2/3) with ID (2/3), ataxia (1/3) or 
dysarthria (1/3). The age of last examination was between 14 and 22 years old. They 
mainly presented cerebellar ataxia (3/3), encephalopathy (3/3), generalized tonic-clonic 
seizures (2/3), and cognitive disability (3/3) (Table 1.3).  
ii. CoQ10 treatment and effects 
CoQ10 treatment was administered to the three patients and all of them experienced a 
clinical improvement of their ataxic phenotype.  
iii. Pathogenicity of the mutations 
This family had a biallelic duplication in the COQ5 gene (Table 1.10). This duplication of 
9,590 bp does not alter the original COQ5 open reading frame (ORF) and is located about 
1 kb after the DNA sequence that encodes the COQ5 3′ untranslated region (UTR). The 
duplicated region spans the last four exons of the gene (4-7) and part of the 3’ UTR. This 
duplication creates an abnormal isoform due to an altered splicing event, where the 
original 3′UTR is partially deleted and fused with duplicated exons (exons 4–7), thus 
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9590 bp tandem duplication of the last 
4 exons of COQ5 after 1Kb of 3'UTR  
(base pair positions: Chr 12: 
120,940,150-120,949,950/hg19) 









p.Lys64del 2 S   - - - 22.4 235 
1 (1) c.484C>T1 p.Arg162* 5   F - - - 38 233 
1 (1) c.564G>A1 p.Trp188* 5   F - - - 39 233 
1 (1) c.686A>C p.Gln229Pro 6 S   
Tole-
rated 
Probably - 27.5 235 
2 (7) c.763G>A p.Gly255Arg 7 S  F Pathog. Probably - 32 233,342 
6 (6) c.782C>T p.Pro261Leu 7 S  F Pathog. Probably low 33 232,235 
1 (1) c.804delC 
p.Leu269Trpfs
*13 
8    - - - 32 343 




3 (3) c.1078C>T p.Arg360Trp 9 S   Pathog. Probably - 32 
231,258,
343 
1 (1) c.1154A>C p.Asp385Ala 11    Pathog. Probably - 29.8 245 
2 (2) c.1235A>G1 p.Tyr412Cys 11   F Pathog. Probably - 25.5 245,342 
1 (1) c.1341G>A p.Trp447* 11 S  F - - - 41 233,342 
1 (1) c.1383delG 
p.Gln461fs* 
478 





























1 (1) c.384delG 
p.Gly129Valfs*
17 
4 S   - - - 23.2 247 
1 (1) c.521+1delG 
p.Ser127_Arg 
202del 
Int.5 S B F - - high 24.4 256 
1 (4) c.521+2T>C 
p.Ser127_Arg 
202del 
Int.5 S B  - - high 33 246 
1 (4) c.711+3G>C 
p.Ala203_Asp 
237del 
Int.7 S B  - - high 23.6 246 
1 (1) c.730C>T p.Arg244* 7  B F - - - 46 248,327 
1. These pathogenic variants were found in simple heterozygosis in at least one patient 233,342. 
2. COQ7 c.308C>T polymorphism seems to increase COQ7 protein instability and intensify the effect 
of the mutation. The patient also has a 1555A>G mutation in mtDNA, which may contribute to 
the disease 238. 
Reference sequences correspond to longest transcript. Abbreviations: F: Number of families with each 
variant, P: Number of patients with each variant, aa: amino acid, Prob: probability, Int: Intron, Ref: 
references, UTR: untranslated region, Chr: chromosome, Pathog: pathogenic. 
 





COQ6 gene (MIM*614647) is located in chr14:73,949,926-73,963,670 (GRCh38.p13), 
plus strand. At least three alternatively spliced transcript variants encoding different 
isoforms have been described for this gene. The most represented transcript, the 
longest one (2,109 bp), encodes a 468 aa (12 exons) protein, COQ6 isoform 1 (or a). This 
protein is an evolutionarily conserved FAD-dependent monooxygenase required for the 
C5-ring hydroxylation during CoQ biosynthesis. It catalyses the hydroxylation of 3-
decaprenyl-4-hydroxybenzoic acid (HHB) to 3-decaprenyl-4,5-dihydroxybenzoic acid 
(DHHB). The electrons required for the hydroxylation reaction may be obtained 
indirectly from NADPH via a ferredoxin/ferredoxin reductase system.  
There are two additional transcripts (isoforms 2 or b; and 3 or c), which are present at 
lower levels in cells and encode different proteins. Transcript variant 2 (1,538 bp), 
encodes COQ6 isoform 2 (391 aa, 11 exons), which contains an alternative first exon 
(exon 1b) and lacks exon 3. It is thought that it is not active 342.  The two isoforms differ 
in the use of alternative exon 1a or 1b and the splicing of exon 3 (absent in isoform 2). 
Transcript variant 3 (1,608 bp), encodes COQ6 isoform 3 (443 aa, 12 exons). It differs 
from isoform 1 only for the first exon but it does not rescue CoQ10 biosynthesis in human 
cells lacking COQ6 165.  
Mutations in this gene are associated with autosomal recessive CoQ10 deficiency 
(COQ10D6, MIM#614650), which manifests as nephrotic syndrome with sensorineural 
hearing loss. 
i. CoQ10 deficiency due to COQ6 mutations  
30 patients from 22 families with COQ6 mutations have been reported in the literature 
up to date. COQ6 patients mainly showed a nephrotic syndrome (26/30, 87%), 
associated in most of the cases with sensorineural hearing loss (18/30, 60%) (Table 1.3).  
a. Age of onset  
The disease was first presented in patients at a mean age of almost 3 yo (32 mo) (range 
2 mo-10 yo) (Figure 1.5), having mostly infancy or childhood-onset (15/30, 50% and 




were sorted in 2 different groups, each of them having a slightly different clinical picture 
(Figures 1.7.C, 1.11). 
Group 1 includes 15 patients from 11 families (15/30, 50% of the total number of COQ6 
patients), who first manifested before the age of 2 yo. The mean age of onset of patients 
in this group is 1 yo (range 2 mo-2 yo). Patients with childhood-onset are grouped 
together in group 2, which includes 12 patients from 10 families (12/30, 40% of the total 
number of COQ6 patients). The mean age of presentation was almost 5 yo (range 3 -10 
yo).  
 
Figure 1.11. Clinical manifestations and genotype of COQ6 patients.  
(A) Symptom frequency found in COQ6 patients, for each age-of-onset group 1 and 2. (B) Total number 
of patients in each age-of-onset group. (C-D) First symptoms and the number of patients manifesting 
them, for each age-of-onset group. (E) Age of onset and pathogenic variants of COQ6 patients. Each point 
represents one patient. Coloured circles: mutations found in more than one family (see the legend). 
Rhombus: patients with mutations only present in one family (gray). Full-filled symbols: homozygous 
mutations, half-filled symbols: heterozygous mutations.  Abbreviations: refer to Tables 1.1 and 1.2. 





b. Symptoms at onset 
Patients with COQ6 mutations mainly first presented with SRNS (24/30, 80%) 233,235, but 
in some cases proteinuria (2/30, 7%), edema (1/30, 3%) or SNHL (1/30, 3%) were found 
as first manifestations of the disease (Figures 1.6.F, 1.11.C and D).  
When stratified by the age of onset, patients with infancy onset (group 1) mainly 
presented with SRNS (12/15, 80%), but some patients were firstly found having 
proteinuria (2/15, 13%) 233,343 or edema (1/15, 7%) 258 (Figure 1.11.C). Patients with 
childhood-onset (group 2) presented with SRNS as the first symptom (11/12, 92%) 
233,235,245, and one of them first showed SNHL (1/12, 8%), and he did not develop SRNS 
afterwards 236 (Figure 1.11.D).  
c. Clinical manifestations of the disease  
COQ6 patients mainly showed a SRNS (26/30, 87%), associated in most of the cases with 
SNHL (18/30, 60%) (Table 1.3). Some of them also presented a CNS affection, with 
seizures (2/30, 7%), ataxia (1/30, 3%), exotropia (1/30, 3%), ID (1/30, 3%), nystagmus 
(1/30, 3%), or ptosis (1/30, 3%). These neurological manifestations occur mostly in 
patients manifesting earlier in life (Figure 1.11.A). 
Group 1 had an infantile-onset nephrotic syndrome (14/15, 93%) that evolved, in most 
of the cases, to an ESRD (10/15, 67%). These patients also developed sensorineural 
hearing loss (8/15, 53%) 233,235,245. Group 1’s characteristic is that some of the patients 
(7/15, 47%) also presented a CNS affection, with DD (3/15, 20%) 231,233,258, seizures 
(2/15, 13%) 233, ataxia (1/15, 7%) 233, exotropia (1/15, 7%) 235, ID (1/15, 7%) 231, 
nystagmus (1/15, 7%) 235 or ptosis (1/15, 7%) 231. Other less frequent manifestations are 
OA, MW, cardiovascular abnormalities, septal defects, edema, dysmorphic features or 
hypercholesterolemia (each of them present in 1/15 patient, 7%).  
Patients with childhood-onset (group 2) had an SRNS (11/12, 92%), associated with 
SNHL (8/12, 67%) 233,235,236,245. Some of the patients developed an ESRD (6/12, 50%). One 





ii. CoQ10 treatment and effects 
CoQ10 treatment was administered to 9/30 (30%) of the COQ6 patients from the two 
groups described (Tables 1.4 and 1.11). In general, they responded well to the 
treatment, with some improvements in renal function. 6/15 patients from group 1 were 
treated, and they improved proteinuria (4/6) 231,233,258, renal function (2/6) 231,343, growth 
retardation (2/6) 231,258 and SNHL (1) 233. In group 2, 3/12 patients were treated and only 
1 improved proteinuria 233,234,236.  
Table 1.11. COQ6 patients classified by age of onset. CoQ10 treatment and mutations. 
Group 
1 









3 (3) c.189_191delGAA p.Lys64del 235 
1 (1) c.686A>C p.Gln229Pro 235 
2 (6) c.763G>A p.Gly255Arg 233,342 
3 (3) c.782C>T p.Pro261Leu 232,235 
1 (1) c.804delC p.Leu269Trpfs*13 343 
2 (2) c.1058C>A p.Ala353Asp 233,234,342 






3 (3) c.189_191delGAA p.Lys64del 235 
1 (1) c.763G>A p.Gly255Arg 233,342 
3 (3) c.782C>T p.Pro261Leu 235 
4 (6) c.1058C>A p.Ala353Asp 
233,234,236,
245,342 
1 (1) c.1154A>C p.Asp385Ala 245 
1 (1) c.1235A>G p.Tyr412Cys 245 
1 (1) c.1341G>A p.Trp447* 233,342 
1 (1) c.1383delG p.Gln461fs*478 233,342 
Abbreviations: F: Number of families with each variant, P: Number of patients with each variant, aa: amino 
acid, Ref: references, SNHL: sensorineural hearing loss. 
 
iii. Pathogenicity of the mutations 
Primary CoQ10 deficiency due to COQ6 mutations has been associated with 13 different 
variants in COQ6 (Figures 1.8, 1.11.E, Tables 1.10 and 1.11). Most of them were 
confirmed to segregate with the disease within the different families (8/13, 62%), while 














We classified the variants into the two age of onset groups. Only the most represented 
variants will be discussed here, which are 5: c.189_191delGAA (p.Lys64del), c.763G>A 
(p.Gly255Arg), c.782C>T, (p.Pro261Leu), c.1058C>A (p.Ala353Asp) and c.1078C>T 
(p.Arg360Trp). Some of these variants appear more frequently in group 1, others in 
group 2, while some of them are equally represented in the two groups (Figure 1.14 and 
Table 1.11).  
The p.Gly255Arg missense change was found in 7 patients from 2 families, 6 of them 
classified in group 1  and only 1 in group 2 233. They presented an infantile-onset 
nephrotic syndrome with sensorineural hearing loss and a slight CNS involvement.  
However, the number of cases is small to be able to draw a definite conclusion about 
genotype-phenotype correlation. The pathogenicity of this mutation has been 
confirmed in a yeast model 342, in which the mutant allele retained a low residual CoQ 
biosynthetic function (only 15% of the WT levels).  
The p.Arg360Trp substitution has been reported in 3 patients of 3 families, in 2 cases in 
homozygosis231,258, while in one case in heterozygosis with a frameshift mutation 343. 
This variant has been associated with the most severe phenotype (group 1), but the 
number of patients is still low to be able to define a correlation. 
The p.Ala353Asp variant was reported in 8 patients from 5 families, always in 
homozygosis. They were classified mostly in group 2 (6/8 patients)233,236,245, while two 
patients belonged to group 1 (being in the upper limit of group1, 2 yo) 233. These patients 
mainly presented childhood-onset SRNS, associated with SNHL. The pathogenicity of this 
mutation has been confirmed in a yeast model 342, in which the mutant allele retained 
30% of the WT CoQ biosynthetic function. 
p.Lys64del mutation is described in 6 patients from 6 different families, in heterozygosis 
with the missense mutations p.Pro261Leu (5/6) 232,235 or p.Gln229Pro (1/6) 235. 
p.Pro261Leu was also found in homozygosis in 1 patient 232. Patients with these 
mutations are equally found in group 1 or 2, so they might not contribute to the 
differences in age of onset or clinical presentation. However, the age of presentation of 
these patients in group 1 is closer to the upper limit, 2 yo, while in group 2 is closer to 




a yeast model 232, in which the mutant allele retained a low residual CoQ biosynthetic 
function (only 10% of the WT levels). 
Finally, there are some variants found in homozygosis or heterozygosis in patients 
belonging to the different groups. We have classified them, but we cannot be certain of 
how they would contribute to the disease pathogenesis because of their low 
representation (Table 1.11).  
COQ7 
COQ7 gene (MIM*601683) is located in chr16:19,067,595-19,080,095 (GRCh38.p13), 
forward strand. It has two transcript variants, each one with six exons, differing in the 
first exon. The longest transcript (2,642 bp) encodes a 217 aa long protein, whereas the 
shorter transcript (819 bp) results in a 179 aa protein. The longest one is thought to be 
COQ7 protein, which is a mitochondrial di-iron oxidase responsible for hydroxylating 5-
demethoxyubiquinol (DMQH2) in the presence of NADH, during CoQ10 biosynthesis. 
Mutations in this gene are a cause of primary CoQ10 deficiency (COQ10D8, 
MIM#616733).  
i. CoQ10 deficiency due to COQ7 mutations  
Only 3 patients from 3 families with COQ7 defects have been reported so far. These 
patients presented varying degrees of a neonatal-infancy onset multisystemic disorder, 
with CNS, PNS, renal, muscle and heart involvement (Table 1.3). The mean age of onset 
was 4 mo (range birth -1 yo), and they presented with RD (2/3, 67%) and other 
symptoms, such as cardiomegaly, HF, hypertension, hypotonia or slow motor 
development (1/3, 33% for each symptom) (Figures 1.5, 1.6.G). The main manifestations 
were hypotonia (3/3), DD (3/3), SNHL (3/3), PNSN (2/3), MW (3/3), HCM (2/3) and RD 
(2/3). However, the three families manifested different clinical pictures. 
The most severe case was a Chinese boy, who presented at birth with cardiomegaly, 
heart failure and respiratory distress. He developed an encephalopathy with DD, 
hypotonia, BGL and ptosis. He had SNHL and visual impairment, as well as renal cysts 
and MW, with low muscle bulk. The heart was also affected by an HCM, and he 
experienced HF. He passed away at 1 year of age due to an episode of sepsis. He had 
two compound heterozygous mutations in COQ7, a missense mutation (c.319C>T, 




p.Arg107Trp) and a frameshift variant (c.599_600delinsTAATGCATC, 
p.Lys200Ilefs*56)240. 
The second case was a Syrian boy who debuted at birth, with hypotonia, RD and 
hypertension. The patient developed a complex clinical picture with multiorgan 
involvement, including mild ID, hypotonia, DD. He also had a PNSN, with SNHL and visual 
impairment. He had MW and HCM. Kidney dysplasia resolved alone within the first year 
of life. The age of the last examination was 9 years old. He had a missense homozygous 
mutation (c.422T>A, p.Val141Glu) in COQ7 gene 239. 
The third family presented a less severe phenotype. The patient, a 1-year-old girl, 
debuted with slow motor development and showed spasticity, hypotonia and DD. She 
also presented a PNSN, with SNHL and MW. The age of the last examination was 6 years 
old. She had a missense homozygous mutation (c.332T>C, p.Leu111Pro) in the COQ7 
gene 238.  
ii. CoQ10 treatment and effects 
CoQ10 treatment was administered to the three patients (Table 1.4). The most severe 
one didn’t benefit from the treatment 240, while the two others experienced a 
stabilization of the disease progression, with no improvement but no deterioration 
either 238,239.  
iii. Pathogenicity of the mutations 
4 pathogenic variants of COQ7 have been associated to primary CoQ deficiency in the 
literature so far (Figure 1.8 and Table 1.10). All the mutations segregated within the 
different families. The pathogenicity of the homozygous mutations from the two less 
severe cases was confirmed by expressing the variants in mouse cells KO in Coq7. The 
levels of residual CoQ synthesis were consistent with the severity of the disease 
observed in the patients. The missense mutation from the most severe case, c.319C>T 
(p.Arg107Trp), has been predicted to be pathogenic with SIFT, PolyPhen-2 and CADD 





COQ9 gene (MIM*612837) is located in chr16:57,447,425-57,461,275 (GRCh38.p13), 
forward strand. The protein-coding transcript (1,630 bp) encodes a 318 aa long protein 
(9 exons). The gene product, COQ9, is a lipid-binding protein thought to bind CoQ and 
present it to COQ7 during CoQ biosynthesis. Defects in this gene are a cause of CoQ 
deficiency (COQ10D5, MIM#614654).  
i. CoQ10 deficiency due to COQ9 mutations  
Only 7 patients from 4 families with COQ9 mutations have been reported so far. These 
patients presented varying degrees of a severe neonatal-infancy onset multisystemic 
disorder, with CNS, renal and cardiac involvement (Table 1.3) 246–248,256,327. The mean 
age of onset was 1 mo (range birth-9 mo) (Figures 1.5, 1.6.H). They presented with 
intrauterine growth restriction (IUGR) (3/7, 43%), RD (2/7, 29%), poor respiratory efforts 
accompanied by hypotonia, bradycardia and cyanosis (1/7, 14%) or acute acidosis (1/7, 
14%). They had a profound DD (6/7, 86%), with encephalopathy (3/7, 43%), seizures 
(3/7, 43%), hypotonia (2/7, 29%) and LS (2/7, 29%), among others. There was also renal 
involvement, with renal cysts (2/7, 29%) and tubulopathy (1/7, 14%). The heart was also 
affected with bradycardia (2/7, 29%), cardiomegaly (1/7, 14%) and HCM (1/7, 14%). 
Some patients presented RD (3/7, 43%) and apnea (2/7, 29%). 
ii. CoQ10 treatment and effects 
CoQ10 treatment was administered to four of the patients (Table 1.4). None of them 
experienced any clinical improvement, and one of them reduced the plasma lactate 
levels248.  
iii. Pathogenicity of the mutations 
There are 5 pathogenic variants of COQ9 that have been described in the literature in 
patients with primary CoQ10 deficiency (Figure 1.8 and Table 1.10). There are three 
intronic mutations, one frameshift and one nonsense mutation.  All the mutations were 
confirmed to segregate with the disease within the different families 246,247,256, except 
for the nonsense mutation, whose pathogenicity was confirmed biochemically and by 
heterologous expression of the variant in yeast 248. There are three intronic mutations 
with an in silico predicted high probability to alter splicing events (Table 1.10). The 




pathogenicity of one of these three was confirmed by rescuing the patient’s fibroblasts 
with the expression of WT COQ9 256. 
COQ8/ADCK proteins 
In humans there are five paralogs belonging to the aarF domain-containing protein 
kinase or UbiB protein kinase-like family (ADCK1-5); among them, COQ8A (ADCK3) and 
COQ8B (ADCK4) are highly similar, and both are involved in CoQ10 biosynthesis. Human 
COQ8A and COQ8B protein sequences have a 44.23% of identity and a 66.12% of 
similarity. COQ8A have a longer N-terminal region of 117 aa, while COQ8B has an 
extended C-terminal region of 18 aa. Both proteins contain the conserved kinase motif 
in the region responsible for ATP binding and phosphotransfer reaction. Still, they lack 
the conserved kinase C-term motif, not having canonical protein kinase activity in trans. 
Instead, they have ATPase activity, whose role in CoQ10 biosynthesis still needs to be 
further studied 385. They have also been proved to interact with lipid CoQ intermediates 
and are thought to have a regulatory function, probably redundant being each of them 
specialised in different tissues. In humans, COQ8A expression exceeds COQ8B in several 
tissues with the exception of kidney, in which COQ8B is highly expressed 385.  
COQ8A 
COQ8A gene (MIM*606980) is located in chr1:226,897,536-226,987,545 (GRCh38.p13), 
forward strand. Two different transcript variants are annotated, and only the longest 
one is considered to be the canonical sequence or isoform 1. This transcript (2,866 bp) 
encodes a 647 aa long protein with 15 exons, in which exon 1 is non-coding. Defects in 
this gene are a cause of CoQ10 deficiency (COQ10D4, MIM#612016).  
i. CoQ10 deficiency due to COQ8A mutations  
77 patients from 55 families with COQ8A mutations have been reported so far. COQ8A 
deficiency results in an autosomal-recessive cerebellar ataxia type 2 (ARCA2) (70/77, 
91%), a slowly progressive ataxic syndrome with cerebellar atrophy (62/77, 81%) (Table 
1.3). After the elaboration of this study, a multicentre study of 59 COQ8A patients (39 




disease275. These patients are not included in this study, but the results will be discussed 
and compared. 
a. Age of onset  
The mean age of onset was 6.6 years old (range 6 mo-27 yo) (Figure 1.5), being mostly 
an infancy or childhood presentation (23/77, 30% and 29/77, 38%; respectively) (Figure 
1.15.B). When classified by the age of onset, COQ8A cases were sorted into 4 different 
groups (Figures 1.7.D, 1.12).  
Group 1 includes 24 patients from 17 families (24/77, 31% of the total number of COQ8A 
patients), which are all of the infancy onset cases. The mean age of onset of patients in 
this group is 1.6 yo (19 mo) (range 6 mo-2.5 yo). The majority of the COQ8A patients 
were classified in group 2, with 32 patients from 24 families (32/77, 42% of the total 
number of COQ8A patients) presenting during childhood. The mean age of presentation 
in this group is almost 6 yo (range 3-10 yo). Group 3 includes 9 patients from 8 families 
(9/77, 12% of the total number of COQ8A patients) who first manifested at a mean age 
of 14 yo (range 11-18 years old). 6 patients from 5 families with COQ8A mutations (group 
4) presented when they were adults (6/77, 8% of the total number of COQ8A patients). 
This group of patients first manifested at a mean age of 22.5 yo (range 19-27 yo). 
b. Symptoms at onset 
Patients typically first presented with 1, 2 or 3 clinical manifestations (Figures 1.6.I, 
1.12.C-F) including ataxia (19/77, 25%), gait instability (GI) (11/77, 14%), tremor (11/77, 
14%), dysarthria (8/77, 10%) or slow motor development (8/77, 10%). Other less 
frequent symptoms at onset were impaired handwriting (IH) (6/77, 8%), seizures (5/77, 
6%) or DD (3/77, 4%). The 59 patients from a very recent study, 39 of them, not included 
here, mostly presented with ataxia (68%), DD (22%), tremor (13%), epilepsy (8%) and 
dystonia (7%)275. The differences in frequencies probably derives from the small number 
of patients and the different ways to report the first symptoms in the different reports. 
 









When stratified by age of onset, patients with infancy-onset (group 1) mainly first 
presented with slow motor development (6/24, 25%)  and ataxia (6/24, 25%), but also 
with GI (4/24, 17%), tremor (3/24, 13%), dysarthria (3/24, 13%), DD (2/24, 8%) or 
hypotonia (2/24, 8%)) (Figure 1.12.C) 227,273,346,351,354,356–360,370. Probands with childhood-
onset (group 2) had ataxia (9/32, 28%), GI (4/32, 13%), IH (4/32, 13%), dysarthria (3/32, 
9%), tremor (3/32, 9%), seizures (3/32, 9%) or slow motor development (2/32, 6%) as 
first symptoms (Figure 1.12.D) 273,274,344–352,355–357,360. In the case of an adolescence-onset 
of the disease, the first symptoms were mainly tremor (5/9, 56%), ataxia (2/9, 22%), IH 
(2/9, 22%), myoclonus (1/9, 11%), GI (1/9, 11%) or dysarthria (1/9, 11%) (Figure 1.12.E) 
227,273,274,347,350,352,353,356. Some patients presented when they were adults with GI (2/6, 
33%), gait ataxia (2/6, 33%), dysarthria (1/6, 17%) or seizures (1/6, 17%) (Figure 1.12.F) 
227,228,273,274,350. 
Ataxia, as the first symptom, is equally frequent in all disease onset groups. We can see 
that impaired developmental and cognitive manifestations were more common when 
the disease manifested earlier. In contrast, the opposite trend was observed for other 
symptoms, such as tremor, gait instability, handwriting or speech difficulties, which 
become more frequent as first symptoms when the onset of the disease is later in life 
(Figure 1.12.C-F). 
c. Clinical manifestations of the disease  
COQ8A deficiency results in an autosomal-recessive cerebellar ataxia type 2 (ARCA2) 
(70/77, 91%), a slowly progressive ataxic syndrome with cerebellar atrophy (62/77, 
81%), with variable associated clinical features: ID (35/77, 45%), tremor (33/77, 43%), 
dysarthria (27/77, 35%), seizures (25/77, 32%) and EI (14/77, 18%), amongst others 
(Table 1.3). The clinical severity of the disease varies with its age of onset, the earlier the 
disease appears, the more severe it becomes. We can clearly see this when patients are 
stratified by the age of onset (Figure 1.12.A). 
Figure 1.12. Clinical manifestations and genotype of COQ8A patients.  
(A) Symptom frequency found in patients, for each age-of-onset group 1-4. (B) Total number of patients 
in each age-of-onset group. (C-F) First symptoms and the number of patients manifesting them, for 
each age-of-onset group. (G) Age of onset and pathogenic variants of COQ8A patients. Each point 
represents one patient. Coloured circles: mutations found in more than one family (see the legend). 
Rhombus: patients with mutations only present in one family (gray). Full-filled symbols: homozygous 
mutations, half-filled symbols: heterozygous mutations.  Abbreviations: refer to Tables 1.1 and 1.2. 
 




Patients with the earliest onset (group 1) manifested an infantile-onset cerebellar 
ataxic syndrome with intellectual disability (15/24, 63%) and developmental delay 
(9/24, 38%) 227,273,346,351,354,356–360,370. They also had tremor (8/24, 33%), hypotonia (7/24, 
29%), dysmetria (6/24, 25%), seizures (8/24, 33%), spasticity (6/24, 25%), and nystagmus 
(6/24, 25%). Other less frequent manifestations were dysarthria (5/24, 21%), myoclonus 
(4/24, 17%), SLL (3/24, 13%), strabismus (3/24, 13%), GI (3/24, 13%) or SEM (3/23, 13%). 
Some of them had other systems and tissues affected, having MW (10/24, 42%), EI 
(7/24, 29%), SNHL (1/24, 4%) or cardiac abnormalities (2/24, 8%). 
The majority of the COQ8A patients (group 2) presented a childhood-onset cerebellar 
ataxic syndrome with cognitive impairment (16/32, 50%), tremor (15/32, 47%) and 
speech difficulties (12/32, 38%) 273,274,344–352,355–357,360. They also manifested dysmetria 
(11/32, 34%), seizures (11/32, 34%), SEM (8/32, 25%), GI (7/32, 22%) and dystonia (7/32, 
22%). Other less frequent manifestations in this group were IH (6/32, 19%), 
dysdiadochokinesia (5/32, 16%), myoclonus (4/32, 13%) or SLL (3/32, 9%). Other 
systems were also affected in some patients, manifesting EI (7/32, 22%), MW (1/32, 3%), 
SNHL (1/32, 3%) or visual dysfunction (1/32, 3%). 
Some patients (group 3) manifested an adolescence-onset cerebellar ataxic syndrome 
with tremor (6/9, 67%), speech difficulties (6/9, 67%) and myoclonus (4/9, 44%) 
227,273,274,347,350,352,353,356. They also manifested GI (3/9, 33%), IH (3/9, 33%), dystonia (3/9, 
33%), SEM (3/9, 33%), seizures (2/9, 22%) and dysdiadochokinesia (2/9, 22%). Some of 
them also suffered from MF (1/9, 11%) or MW (1/9, 11%). Other less frequent 
manifestations in this group were DD, dysmetria, migraine, strabismus, slow ocular 
pursuit or hepatosteatosis (1/9, 11% each). 
A few patients (group 4) had an adult-onset cerebellar ataxic syndrome with tremor 
(4/6, 67%) and speech difficulties (4/6, 67%) 227,228,273,274,350. These patients also 
manifested seizures (3/6, 50%), GI (3/6, 50%), dysmetria (3/6, 50%), dystonia (2/6, 33%) 
and myoclonus (2/6, 33%).  Other less frequent manifestations in this group were IH, 
dysdiadochokinesia, migraine, ID, nystagmus, ptosis, spasticity, cataracts, visual aureas 
or MW (1/6, 17% each).  
Generally, COQ8A patients had an ataxic syndrome with cerebellar atrophy, displaying 




stratify by the age of onset. Developmental delay and cognitive impairment are more 
frequent with the youngest ages of onset. Muscle or heart involvement is also more 
frequent in patients that had an earlier presentation. Other symptoms, such as 
dysarthria, dystonia, GI, myoclonus or tremor become more frequent the later in life the 
disease manifests (Figure 1.12.A).   
ii. CoQ10 treatment and effects 
CoQ10 treatment was administered to 29/77 (38%) of the COQ8A patients, representing 
all the four groups described (Tables 1.4 and 1.12). In the youngest onset group (group 
1), 11/24 patients were treated 227,273,346,351,354,357,359. Most of them did not obtain any 
benefits from the treatment (6/11), while the rest experienced some amelioration of 
ataxia (4/11), motor performance (3/11) or cognitive abilities (2/11). In group 2, 13/32 
patients were treated 345,348,351,352,356,360. Some of them did not obtain any benefits from 
the treatment (6/13), and the rest had some improvement of the cerebellar signs: ataxia 
(5/11), motor skills (2/11) tremor (1/11) and myoclonus (1/11). From the adolescence 
onset group 3, 5/9 patients were treated and, except from one, 4/5 reported benefits, 
improving tremor (3/5), ataxia (1/5), motor abilities (1/5), dystonia (1/5), fatigue (1/5) 
and speech (1/5) 227,274,347,352,353. 2/6 patients of group 4 were treated, and only one of 
them reported a slight improvement of the neurological condition 227,228. There seemed 
to be no associations between treatment response and age of disease onset or 
genotype.  
i. Pathogenicity of the mutations 
There are 49 reported COQ8A mutations associated with primary CoQ10 deficiency 
(Figures 1.8, 1.12.G and Tables 1.12 and 1.13). Half of them were confirmed to segregate 
on the different families (27/49, 55%), while the rest of variants were mostly 
biochemically checked (by measuring CoQ10 levels) (29/49, 57%). The pathogenicity of 
some of the variants (7/49, 14%) was confirmed in a yeast model 356,357. The 
pathogenicity of only a few mutations has not been supported by any other evidence 
(6/49, 12%) than the in silico pathogenicity prediction, being almost all of them 
predicted as pathogenic (Table 1.13). 




Only one variant, the c.993C>T, had a CADD score lower than the cut-off to be 
considered pathogenic (20). This variant was identified in a patient in trans with the 
c.1645G>A missense change and it was shown to partially affect splicing, leading to an 
abnormal exon 8 skipping 356. However, this variant showed an allelic frequency of 
approximately 1.6% with 38 homozygous individuals in the European non-Finnish 
population in the gnomAD population database (https://gnomad.broadinstitute.org/) 
and it is reported in the ClinVar database as likely benign. It is possible that this variant 
is a functional polymorphism that, when it appears in combination with other variant, 
may increase the susceptibility to develop a disease, but other studies are required to 
confirm this hypothesis. 
We classified the variants into the 4 age of onset groups (Figure 1.12.G). We will only 
discuss to the most represented variants: c.589-3C>G (p.Leu197Valfs*20), c.895C>T 
(p.Arg299Trp), c.901C>T (p.Arg301Trp), c.1027C>T (p.Gln343*), c.1042C>T (p.Arg348*),  
c.1331_1332insCACAG (p.Glu446Alafs*33), c.1750_1752delACC (p.Thr584del) and 
c.1844G>A (p.Gly615Asp). 
The c.589-3C>G (p.Leu197Valfs*20) frameshift variant in intron 3 was in silico predicted 
as having a high probability of altering splicing (Table 1.13). It was found in 5 patients 
from 4 families; in heterozygosis with p.Arg301Trp in one patient first presenting at 2 
years of age (group 1)351, in heterozygosis with p.Gly615Asp mutation, in 2 families 
presenting during childhood (group 2) 274,351, and in homozygosis in 2 sisters first 
presenting when they were 19 years old (group 4) 273. It seems this splicing mutation is 
less severe when it is found in homozygous state, probably due to the pathogenicity of 
the mutation that accompanies it. The p.Gly615Asp variant was also found in 
homozygosis in a third family with 2 siblings, presenting at the age of 2 and 7 years old 
273. This mutation mainly produces a childhood-onset disease.  
c.895C>T (p.Arg299Trp) was found in 7 patients from 5 families, having most of them a 
childhood-onset (group 2) (5 patients from 3 families)273,360, but some of them with 
infancy (group 1) (1 patient) 360 or adolescence (group 3) (1 patient) onset 273.  
c.901C>T (p.Arg301Trp) was sequenced in 7 patients from 7 families. The majority of 
them (4) presented during childhood (group 2), in heterozygosis with the frameshift 




unique missense mutation (p.Arg410Gln) in one case 350. Additionally, some of these 
patients had an infancy (group 1) (1 patient) 351 or adolescence (group 3) (1 patient) 
onset 352, having this variant in heterozygosis with other mutations.  
The nonsense c.1027C>T (p.Gln343*) mutation was found in 6 patients from 3 families, 
all of them from Israel, with an infancy onset (group 1) 354. In one family the mutation 
was homozygous, while in the other two, it was in compound heterozygosis with the 
p.Ser608Phe variant. A very similar nonsense mutations, c.1042C>T (p.Arg348*), was 
found in 8 patients from 5 families, mainly in homozygosis (5/8). Half of them presented 
during childhood 344,345, while some had infancy (group 1) (2 patients) 344, adult (group 
4) (1 patient) 274 or unknown onset 350. Due to COQ8A regulatory role and to the 
presence of at least another COQ8 protein with a similar function, the lack of residual 
functional protein seems to be compatible with life.  
c.1750_1752delACC (p.Thr584del) deletion variant was found in 5 patients from 4 
families, always in heterozygosis. 3 of them presented during childhood (group 2) 
346,352,356, 1 of them at 2 years of age (group 1) 346 and the age of first presentation of the 
other one is unknown 350.  
Finally, there are some variants found in homozygous or heterozygous state in patients 
belonging to the different groups. We have classified them, but we cannot be certain of 
how they would contribute to the disease pathogenesis, because of their low 
representation (Table 1.12).  
Regarding the recent study of 59 COQ8A patients, multisystemic involvement beyond 
ataxia was more prevalently found in patients with missense variants. Contrarily, 
patients with biallelic loss-of-function variants more frequently presented an isolated 
ataxia275, suggesting a gain-of-function or dominant-negative mechanism for missense 
variants in contrast to loss-of-function variants275. Moreover, they proposed preliminary 
associations between variants in specific domains and phenotypic outcomes: missense 
variants in the KxGQ domain seemed to be associated with clinical signs reflecting 
cortical (developmental delay and epilepsy) and pyramidal tract dysfunction 275. 
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1 (1) c.589-3C>G p.Leu197Valfs*20 351 
1 (2) c.637C>T p.Arg213Trp 273,357 
1 (1) c.811C>T p.Arg271Cys 273 
1 (2) c.815G>T p.Gly272Val 273,357 
1 (1) c.827A>G p.Lys276Arg 358 
1 (2) c.830T>C p.Leu277Pro 359 
1 (1) c.895C>T p.Arg299Trp 227,360 
1 (1) c.901C>T p.Arg301Trp 351 
1 (1) c.993C>T p.Lys314_Gln360del 
273,356,
361 
3 (6) c.1027C>T p.Gln343* 354 
1 (2) c.1042C>T p.Arg348* 344 
1 (1) c.1081_1082dupGTA p.Gln360_Tyr361ins* 273 
1 (2) c.1136T>A p.Leu379* 344 
1 (2) c.1286A>G p.Tyr429Cys 227 
1 (2) c.1506+1G>A p.Val503Metfs*21 359 
1 (1) c.1534C>T p.Arg512Trp 370 
1 (1) c.1645G>A p.Gly549Ser 
273,356,
361 
1 (1) c.1651G>A p.Glu551Lys 357 
1 (1) c.1702delG p.Glu568Argfs* 358 
1 (1) c.1750_1752delACC p.Thr584del 346 
1 (1) c.1805C>G p.Pro602Arg 346 
2 (3) c.1823C>T p.Ser608Phe 354 




No benefits (6), 
Improvement 









1 (1) c.500_521del22insTTG p.Gln167Leufs*36 356 
2 (2) c.589-3C>G p.Leu197Valfs*20 274,351 
1 (3) c.685-690delCTGGCA p.Leu229_Ala230del 349 
1 (1) c.815G>A p.Gly272Asp 273,357 
3 (5) c.895C>T p.Arg299Trp 273,360 
4 (4) c.901C>T p.Arg301Trp 
274,350,
351 
1 (1) c.913G>T p.Asp305Tyr 352 
2 (4) c.1042C>T p.Arg348* 344,345 
1 (2) c.1228C>T p.Arg410* 273 
1 (1) c.1229G>A p.Arg410Gln 350 
3 (3) c.1331_1332insCACAG p.Glu446Alafs*33 274,351 
1 (1) c.1396delG p.Glu466Argfs*11 355 













No benefits (6), 
Improvement 









1 (1) c.1523T>C p.Phe508Ser 273 
1 (1) c.1532C>T p.Thr511Met 352 
1 (1) c.1541A>G p.Tyr514Cys 356 
1 (2) c.1732T>G p.Phe578Val 360 
3 (3) c.1750_1752delACC p.Thr584del 
346,352,
356 
1 (1) c.1805C>G p.Pro602Arg 346 
1 (1) c.1813dupG p.Glu605Glyfs*125 273,357 
3 (3) c.1844G>A p.Gly615Asp 
273,274,
351 
1 (1) c.1844dupG p.Ser616Leufs*114 347 
1 (1) 




2.9Mb duplication of 1q42.11q42.13  





No benefits (1), 
Improvement 
of ataxia (1), 
Improvement 





in fatigue and 
speech (1), 
Improvement 
of dystonia (1) 
1 (2) c.811C>T p.Arg271Cys 227 
1 (1) c.895C>T p.Arg299Trp 273 
1 (1) c.901C>T p.Arg301Trp 352 
1 (2) c.910G>A p.Ala304Thr 227 
1 (1) c.1013C>T p.Ala338Val 353 
1 (1) c.1334-1335del p.Thr445Argfs*52 350 
1 (1) c.1358delT p.Leu453Argfs*24 273 




1 (1) c.1399-3_1408del ? 352 
1 (1) c.1844dupG p.Ser616Leufs*114 347 









1 (2) c.589-3C>G p.Leu197Valfs*20 273 
1 (1) c.811C>T p.Arg271Cys 350 
1 (1) c.911C>T p.Ala304Val 227 
1 (1) c.1000C>T p.Arg334Trp 350 
1 (1) c.1042C>T p.Arg348* 274 
1 (1) c.1511_1512delCT p.Ala504fs* 228 
Abbreviations: F: Number of families with each variant, P: Number of patients with each variant, aa: amino 






















































p.Gln167Leufs*36 3  B  - - - 33 356 
4 (5) c.589-3C>G2 p.Leu197Valfs*20 Int.3 S   - - high 23.0 
273,274,
351 







5 S   - - - 21.1 349 
2 (3) c.811C>T p.Arg271Cys 6 S B  Pathog. Probably - 27.1 
227,273,
350 
1 (2) c.815G>T p.Gly272Val 6  B F Pathog. Probably - 26.0 273,357 
1 (1) c.815G>A p.Gly272Asp 6  B F Pathog. Probably - 26.5 273,357 
1 (1) c.827A>G p.Lys276Arg 6    Pathog. Probably - 29.0 358 
1 (2) c.830T>C p.Leu277Pro 6 S B  Pathog. Probably - 28.2 359 
5 (7) c.895C>T p.Arg299Trp 7 S B  Pathog. Probably - 31 
227,273,
360 
3 (3) c.901C>T p.Arg301Trp 7 S B  Pathog. Probably - 23.5 350 
1 (2) c.910G>A p.Ala304Thr 7 S   Pathog. Probably - 24.8 227 
1 (1) c.911C>T p.Ala304Val 7 S B  Pathog. Probably - 25.0 227 
1 (1) c.913G>T p.Asp305Tyr 7  B  Pathog. Benign - 24.8 352 







 B  - - - 9.753 
273,356,
361 
1 (1) c.1000C>T p.Arg334Trp 8 S   Pathog. Probably - 29.7 350 
1 (1) c.1013C>T p.Ala338Val 8    Pathog. Probably - 24.8 353 
3 (6) c.1027C>T p.Gln343* 8 S   - - - 49 354 











   - - low 18.65 273 
1 (2) c.1136T>A p.Leu379* 9 S B  - - - 43 344 
1 (2) c.1228C>T p.Arg410* 10 S B  - - - 40 273 
1 (1) c.1229G>A p.Arg410Gln 10 S   Pathog. Possibly - 26.8 350 
1 (2) c.1286A>G1 p.Tyr429Cys 11 S B  
Tole-
rated 








p.Thr445Argfs*52 11 S   - - - 32 350 
1 (1) c.1358delT p.Leu453Argfs*24 11    - - - 33 273 
3 (4) c.1396delG p.Glu466Argfs*11 11 S   - - low 33 355 












S B  - - high 33 352 










































p.Ala504fs* 13  B  - - - 33 386 
1 (1) c.1523T>C p.Phe508Ser 13    Pathog. Probably - 29.9 273 
2 (2) c.1532C>T p.Thr511Met 13 S B  Pathog. Probably - 24.9 350,352 
1 (1) c.1534C>T5 p.Arg512Trp 13 S   Pathog. Probably - 23.4 370 
1 (1) c.1541A>G p.Tyr514Cys 13  B F Pathog. Probably - 22.9 356 
1 (1) c.1645G>A p.Gly549Ser 14  B F Pathog. Probably - 26.3 273,356,361 
2 (2) c.1651G>A p.Glu551Lys 14  B F Pathog. Probably - 31 350,357 
1 (1) c.1702delG 
p.Glu568Argfs
* 
15    - - - 34 358 





p.Thr584del 15 S B F - - - 22.5 
346,350,352,
356 
1 (2) c.1805C>G p.Pro602Arg 15    Pathog. Probably - 27.3 346 
1 (1) c.1813dupG 
p.Glu605Glyfs
*125 
15  B  - - - 34 273,357 
2 (3) c.1823C>T p.Ser608Phe 15 S   Pathog. Probably - 31 354 
3 (4) c.1844G>A2 p.Gly615Asp 15 S   Pathog. Probably - 29.9 273,274,351 
1 (2) c.1844dupG 
p.Ser616Leufs
*114 
15 S B  - - - 33 347 
1 (1) 
27.6 kb deletion of 1q42.3 
including exons 1-2 of COQ8A 
 B  - - - - 274 
1 (1) 
29 kb deletion including exons 3 
to 15 of COQ8A1 (Chr1: 
227,150,977-227,195,656, hg19) 
   - - - - 273 
1 (1) 
 
2.9Mb duplication at 
1q42.11q42.13 (including COQ8A) 
   - - - - 348 
1. These pathogenic variants were found in simple heterozygosis in at least one patient 227,273,350. 
2. A patient with these two mutations in heterozygosis in COQ8A also carries two compound 
heterozygous mutations in PAH gene, which may contribute to the disease274. 
3. The variant c.993C>T in COQ8A, which was identified in a patient in trans with the c.1645G>A 
missense change, was shown to partially affect splicing, leading to the production of an 
abnormal transcript with exon 8 skipping 356. However, this variant showed an allelic frequency 
of approximately 1.6% with 38 homozygous individuals in the European non-Finnish population 
in the gnomAD population database (https://gnomad.broadinstitute.org/) and it is reported in 
the ClinVar database as likely benign.  
4. COQ8A c.1398+2T>C6 variant affects a splice donor site, different splice variants are expressed: 
p.Asp420Trpfs*40 and p.Ile467Alafs*22 356. 
5. The patient with this COQ8A mutation in homozygosis also carries an additional homozygous 
mutation in MED25 gene (c.518T>C; p.Ile173Thr), which may contribute to the disease 370. 
6. This variant is named as c.1749_1751delCAC in Chang et al., 2018 352. 
Reference sequences correspond to longest transcript. Abbreviations: F: Number of families with each 
variant, P: Number of patients with each variant, aa: amino acid, Int: intron, Ex: exon, Prob: probability, 
Pathog: pathogenic, Ref: references. 
 





COQ8B gene (MIM*615567) is located in chr19:40,691,529-40,718,207 (GRCh38.p13), 
reverse strand. Two different protein-coding transcripts are annotated, being the 
longest one the canonical sequence (isoform 1). This transcript (2,443 bp) encodes a 544 
aa protein with 15 exons, being exon 1 non-coding. Defects in this gene are a cause of 
nephrotic syndrome with primary CoQ10 deficiency (NPHS9, MIM#615573).  
i. CoQ10 deficiency due to COQ8B mutations  
79 patients from 41 families with COQ8B mutations have been reported until now. 
COQ8B deficiency leads to a steroid-resistant nephrotic syndrome (SRNS) (65/79, 82%) 
with variable neurological involvement (13/79, 16.5%) (Table 1.3).  
a. Age of onset  
The mean age of presentation was 12.5 yo (range 9 mo-32 yo) (Figure 1.5), being mostly 
a childhood or adolescent presentation (28/79, 35% and 35/79, 44%; respectively) 
(Figure 1.13.B). When classified by the age of onset, COQ8B cases were sorted in 4 
different groups (Figures 1.7.E, 1.13).  
Group 1 is the smallest one, including 4 patients from 4 families (4/79, 5% of the total 
number of COQ8B patients), who had an infancy-onset disease. The mean age of onset 
in this group is 1.4 yo (17mo) (range 9 mo-2 yo). Group 2 includes 28 patients from 22 
families (28/79, 35% of the total number of COQ8B patients) that manifested during 
childhood, at a mean age of 7.3 yo (range 3-10 yo). The majority of the COQ8B patients 
had an adolescent onset (group 3), with 35 patients from 28 families (35/79, 44% of the 
total number of COQ8B patients). The mean age of presentation in this group was 14.3 
years old (range 11-18 years old). Adult-onset is less frequent, with 11 patients from 10 
families presenting after 20 years of age (group 4) (11/79, 14% of the total number of 
COQ8B patients). They manifested at a mean age of 24 yo (range 20-32 years old).  
Figure 1.13. Clinical manifestations and genotype of COQ8B patients.  
(A) Symptom frequency found in patients, for each age-of-onset group 1-4. (B) Total number of patients 
in each age-of-onset group. (C-F) First symptoms and the number of patients manifesting them, for 
each age-of-onset group. (G) Age of onset and pathogenic variants of COQ8B patients. Each point 
represents one patient. Coloured circles: mutations found in more than one family (see the legend). 
Rhombus: patients with mutations only present in one family (gray). Full-filled symbols: homozygous 










b. Symptoms at onset 
COQ8B deficiency patients mainly presented with a renal manifestation (Figures 1.6.J, 
1.13.C-F). Patients typically present with SRNS (27/79, 34%), proteinuria (25/79, 32%), 
edema (15/79, 19%), CKD (14/79, 18%), hypertension (8/79, 10%) or headaches (4/79, 
5%). Early detection of proteinuria arose the suspicion of a renal disease367,377,387. The 
majority of the patients firstly referred to the hospitals when they were suffering a 
nephrotic syndrome.  
Patients with infancy-onset (group 1) mainly presented with proteinuria or SRNS (2/4 
each, 50%), in one case with edema (Figure 1.13.C) 243,276,363,366. Childhood-onset (group 
2) was mainly characterised by the detection of proteinuria upon scholar medical tests 
(13/28, 46%) 229,243,362,365,368, but also some other patients presented with SRNS (9/28, 
32%)229,276,363, edema (3/28, 11%)243,276,364, CKD (3/28, 11%) 229,276 or hypertension (1/28, 
4%) 276,364 (Figure 1.13.D). The majority of the COQ8B patients had an adolescence onset 
(group 3), presenting mainly with SRNS (12/35, 34%), CKD (9/35, 26%), edema (9/35, 
26%), proteinuria (6/35, 17%), hypertension (5/35, 14%) and headaches (3/35, 9%) 
229,276,362–366. Other less common adolescent-onset first symptoms were muscle fatigue, 
heart failure and polydipsia plus polyuria (1/35, 3% each) (Figure 1.13.E). Adult-onset 
cases first manifested with SRNS (4/11, 36%), proteinuria (3/11, 27%), CKD (2/11, 18%), 
edema (2/11, 18%), hypertension (2/11, 18%), medullary nephrocalcinosis (MNC) (1/11, 
9%) and headaches (1/11, 9%) (Figure 1.13.F) 229,276,363,364.   
SRNS as the first symptom is equally frequent in all disease onset groups for COQ8B 
cases. Early diagnosis was mainly characterised by the detection of proteinuria before 
the nephrotic syndrome was established. Edema was found as the first manifestation in 
some cases, at any age of onset. Extrarenal symptoms as first symptoms were more 
common with a later onset of the disease. CKD or hypertension become more frequent 
as first symptoms when the beginning of the disease is later in life (Figure 1.13.C-F).  
c. Clinical manifestations of the disease  
COQ8B deficiency leads to a steroid resistant nephrotic syndrome (SRNS) (65/79, 82%) 
with variable neurological involvement (13/79, 16.5%) (Table 1.3). Variable associated 




8%), ID (4/79, 5%), headaches (4/79, 5%), HCM (2/79, 3%) or septal defects (2/79, 3%) 
(Figure 1.13.A).  
Patients presenting the earliest (group 1) manifested an infantile-onset steroid-
resistant nephrotic syndrome (3/4, 75%) with variable neurological involvement (2/4, 
50%) 243,276,363,366. They had edema (2/4, 50%), DD (1/4, 25%), ID (1/4, 25%) and 
hypercholesterolemia (1/4, 25%).  
Childhood-onset patients (group 2) manifested a steroid-resistant nephrotic syndrome 
(23/28, 82%) that progressed to an ESRD (17/28, 61%) in most of the cases 229,243,276,362–
365,367. Some of them also suffered from MNC (4/28, 14%), CKD (3/28, 11%), edema 
(3/28, 11%), hypertension (3/28, 11%), seizures (4/28, 14%), encephalopathy (1/28, 4%), 
ID (1/28, 4%), HCM (1/28, 4%) or septal defects (2/28, 7%). 
The majority of the COQ8B patients had an adolescent-onset (group 3) steroid-resistant 
nephrotic syndrome (31/35, 89%) that evolved to an ESRD in most of the cases (25/35, 
71%) 229,276,362–366. They had other renal affections, such as CKD (12/35, 34%), hematuria 
(5/35, 14%), MNC (2/35, 6%) or kidney dysfunction (1/35, 3%). Some of them also had 
edema (9/35, 26%), hypertension (6/35, 17%) or goiter (2/35, 6%). Some probands 
reported headaches (3/35, 9%), ID (2/35, 6%), seizures (2/35, 6%) or cardiac 
abnormalities (4/35, 11%).  
Adult-onset is less frequent (group 4) (11/79, 14% of the total number of COQ8B 
patients). They presented an adult-onset steroid-resistant nephrotic syndrome (8/11, 
73%) that evolved into an ESRD in some cases (5/11, 45%) 229,276,363,364. They had other 
renal affections, such as CKD (3/11, 27%), MNC (1/11, 9%) or isolated proteinuria (2/11, 
18%). Some of them also had edema (2/11, 18%), hypertension (2/11, 18%) or a dilated 
cardiomyopathy (1/11, 9%).  
All these patients had a steroid-resistant nephrotic syndrome, displaying multiple renal 
and some extrarenal features with variable frequency. DD and cognitive impairment are 
more frequent with the youngest ages of onset. Other symptoms, such as chronic kidney 
disease, hypertension or headaches, are more frequent the later in life the disease 
manifests (Figure 1.13.A).   
 




ii. CoQ10 treatment and effects 
CoQ10 treatment was administered to 29/79 (37%) of the COQ8B patients, representing 
all the four groups described (Tables 1.4 and 1.14). In the youngest onset group (group 
1), 4/4 patients were treated, and they improved proteinuria (3/4) and/or edema (1/4) 
229,276,363,366, while one did not respond to the treatment 243. In group 2, 12/28 patients 
were treated. Half of them improved the proteinuria condition (6/12) 229,276,362, one of 
them stabilized renal function 243, and another one did not obtain any benefits from the 
treatment 229,276, while the outcome of three of them was not described 229.  From the 
adolescence onset group 3, a few probands were treated (7/35). 4/7 improved 
proteinuria 229,276, while 3/7 did not benefit from the supplementation 229,276,366. 6/11 
patients of group 4 were treated, and while 2 of them did not experience any 
improvement, 3/6 improved proteinuria and 1/6 ameliorated albuminuria, had better 
physical fitness and reduced fatigue 229,276,364.  















Improvement of edema 
(1), No benefits (1) 
1 (1) c.532C>T p.Arg178Trp 366 
2 (2) c.748G>C p.Asp250His 243,366 






Stabilization of renal 
function (1), 
Improvement of 
albuminuria (1), No 
benefits (1), 
NK (3)  
1 (1) c.101G>A p.Trp34* 363 
3 (4) c.293T>G p.Leu98Arg 229,364 
1 (2) c.449G>A p.Arg150Gln 365 
1 (1) c.532C>T p.Arg178Trp 276,364 
1 (1) c.649G >A p.Ala217Thr 367 
3 (4) c.737G>A p.Ser246Asn 365,368 
1 (1) c.748G>T p.Asp250Tyr 367 
2 (2) c.748G>C p.Asp250His 243,362 
1 (2) c.759C>A p.Asn253Lys 365 
1 (2) c.857A>G p.Asp286Gly 276,363 
1 (1) c.929C>T p.Pro310Leu 364 
1 (1) c.954_956dupGAC p.Thr319dup 363 
1 (1) c.1041C>A p.Cys347* 362 
3 (4) c.1199dupA p.His400Glnfs*11 229,276 
4 (5) c.1339dupG p.Glu447Glyfs*10 229,364 
1 (2) c.1447G>T p.Glu483* 276,363 
1 (1) c.1468C>T p.Arg490Cys 365 






















No benefits (3) 
2 (2) c.293T>G p.Leu98Arg 229,364 
2 (2) c.532C>T p.Arg178Trp 276,363,364 
3 (4) c.645delT p.Phe215Leufs*14 276,363,364 
3 (3) c.737G>A p.Ser246Asn 365,366 
1 (2) c.748G>A p.Asp250Asn 364 
2 (2) c.748G>C p.Asp250His 362,366 
1 (1) c.759C>A p.Asn253Lys 365 
1 (1) c.857A>G p.Asp286Gly 276,363 
1 (1) c.958C>T p.Arg320Trp 276,363 
1 (1) c.1027C>T p.Arg343Trp 363 
1 (1) c.1041C>A p.Cys347* 362 
4 (5) c.1199dupA p.His400Glnfs*11 229,276,364 
7 
(11) 





2 (3) c.1430G>A p.Arg477Gln 229,276,363 













2 (2) c.293T>G p.Leu98Arg 229,364 
1 (1) c.958C>T p.Arg320Trp 276,363 
1 (1) c.1027C>T p.Arg343Trp 363 
1 (2) c.1199dupA p.His400Glnfs*11 229,276 





Abbreviations: F: Number of families with each variant, P: Number of patients with each variant, aa: amino 
acid, Ref: references. 
 
i. Pathogenicity of the mutations 
There are 24 reported COQ8B pathogenic variants (Figures 1.8, 1.13.G, Tables 1.14 and 
1.15). Most of these mutations were confirmed to be segregated on the different 
families (15/24, 63%). The pathogenicity of some of the mutations (8/24, 33%) was 
confirmed in a yeast model 276. The molecular effect of other variations on the disease 
have not been supported by any other evidence (8/24, 33%) than the in silico 
pathogenicity prediction, being all of them predicted pathogenic in the case of the 
missense variants, except for one mutation, the p.Ala498Glu, which was predicted as 




pathogenic by SIFT (0.03), but benign by Polyphen-2 (0.08). However, the integrated 
CADD score was above the threshold for pathogenicity, supporting a deleterious effect 
of this variant (Table 1.15).  
We classified the variants into the 4 age-of-onset groups (Figure 1.13.G). We will only 
discuss the most represented variants, which are the missense mutations c.293T>G 
(p.Leu98Arg), c.532C>T (p.Arg178Trp), c.737G>A (p.Ser246Asn) and c.748G>C 
(p.Asp250His); and the frameshift variants c.645delT (p.Phe215Leufs*14), c.1199dupA 
(p.His400Glnfs*11),  c.1339dupG (p.Glu447Glyfs*10).  
c.293T>G (p.Leu98Arg) was diagnosed in 8 patients from 4 families, all of them in 
homozygosis 229,364. They mainly presented during late childhood (4/8) or early 
adolescence (2/8), while in 2 cases, they were adults when they debuted (2/8).   
The c.532C>T (p.Arg178Trp) variant was found in 5 probands from 3 different families. 
When the mutation was in homozygosis, patients manifested between childhood (2/5) 
and adolescence (2/5) (7-14yo) 276,363,364, while only in one case, in heterozygosis with 
the p.Asp250His variant, the patient presented before 1 year of age 366. This mutation, 
c.748G>C (p.Asp250His), was present in 7 probands from 5 families. One homozygous 
patient also presented during infancy (2 yo), while his sister presented at 9 yo 243. Two 
siblings with this variant in heterozygosis with the non-sense variant c.1041C>A 
(p.Cys347*) presented when they were 10 and 12 yo 362. A heterozygous patient, with 
p.Asp250His and p.Ser246Asn variants presented when she was 11 years old 366. 
c.737G>A (p.Ser246Asn) mutation was identified in 7 patients from 6 families, the 
majority of them (4/7) presenting during childhood 365,368, while the rest (3/7) presenting 
during early adolescence (11-13yo)365,366. 
The frameshift variants c.645delT (p.Phe215Leufs*14), c.1199dupA (p.His400Glnfs*11), 
and c.1339dupG (p.Glu447Glyfs*10) were respectively found in 4 patients from 3 
families, 13 patients from 5 families and 20 patients from 7 families. All the patients with 
p.Phe215Leufs*14 mutation presented during adolescence 276,363,364. c.1199dupA 
(p.His400Glnfs*11) was always found in homozygosis and patients presented in a wide 
range of ages, since infancy (2/13) to adulthood (2/13), but the majority of them 
presenting during childhood (4/13) or adolescence (5/13) 229,276,363,364. c.1339dupG 




presented during adolescence (11/20)229,276,364. Some probands with this mutation also 
presented during childhood (5/20) or when they were adults (4/20).  
Finally, there are some variants found in homozygosis or heterozygosis in patients 
belonging to the different groups. We have classified them, but we cannot be sure of 
how they would contribute to the disease pathogenesis because of their low 
representation (Table 1.14).  
Table 1.15. Pathogenic variants of COQ8B gene found in patients.  
Gene/  
Protein 
Pathogenic variants Validation 





























  NM_024876.4 
NP_079152.3 
1 (1) c.101G>A p.Trp34* 2    - - low 34 363 
4 (8) c.293T>G p.Leu98Arg 5    Pathog. Probably - 28.6 229,364 
1 (2) c.449G>A p.Arg150Gln 6    Pathog. Probably - 29.0 365 
3 (5) c.532C>T p.Arg178Trp 7 S B F Pathog. Probably - 25.9 
276,363,364,
366 
3 (4) c.645delT 
p.Phe215Leufs
*14 
8 S  F - - - 31 276,363,364 
1 (1) c.649G >A p.Ala217Thr 8 S   Pathog. Probably - 28.9 367 
6 (7) c.737G>A p.Ser246Asn 9 S   Pathog. Probably - 27.0 365,366,368 
1 (2) c.748G>A p.Asp250Asn 9    Pathog. Probably - 26.1 364 
1 (1) c.748G>T p.Asp250Tyr 9 S   Pathog. Probably - 26.3 367 
5 (7) c.748G>C1 p.Asp250His 9 S   Pathog. Probably - 25.6 
243,362,366,
369 
2 (3) c.759C>A p.Asn253Lys 9    Pathog. Probably - 24.4 365 
1 (3) c.857A>G p.Asp286Gly 10 S  F Pathog. Probably - 29.7 276,363 




p.Thr319dup 11    - - - 23.5 363 
1 (2) c.958C>T p.Arg320Trp 11 S  F Pathog. Probably - 25.5 276,363 
1 (2) c.1027C>T p.Arg343Trp 11 S   Pathog. Probably - 29.0 363 
2 (3) c.1041C>A p.Cys347* 12 S   - - - 38 362,369 
5 (13) c.1199dupA 
p.His400Glnfs
*11 
13 S B F - - - 33 
229,276,363,
364 
7 (20) c.1339dupG 
p.Glu447Glyfs
*10 






15 S B  - - - 34 363 
2 (3) c.1430G>A p.Arg477Gln 15 S  F Pathog. Probably - 29.7 229,276,363 
1 (3) c.1447G>T p.Glu483* 15 S  F - - - 40 276,363 




p.Ala498Glu 15    Pathog. Benign - 24.0 364 
1. Two siblings  with this COQ8B variant in homozygosis also had an homozygous mutation in 
NPHS1 gene (c.1339G>A; p.Glu447Lys) 243. 
Reference sequences correspond to longest transcript. Abbreviations: F: Number of families with each 
variant, P: Number of patients with each variant, aa: amino acid, Pathog: pathogenic Ref: references. 





Primary CoQ10 deficiency patients show a wide and variable range of clinical 
manifestations. In this work, we have compiled all the reported cases published in the 
literature and classified them depending on the age of first presentation of the disease. 
The main conclusions are the following: 
i. Each COQ gene has a particular phenotypical spectrum of manifestations. 
However, even patients with mutations in the same gene can manifest different 
clinical presentation and course of the disease. 
ii. In general, the sooner the disease manifests, the more severe it is. Different 
clinical pictures emerge when patients for each COQ gene are classified by age of 
onset. 
iii. CoQ10 supplementation is a good therapeutic approach for primary CoQ10 
deficiency. However, some patients do not benefit from it, especially the most 
severe phenotypes (COQ2, COQ4). Renal function responds better to treatment 
than neurological function. 
iv. Genotype-phenotype correlations are difficult to stablish because of the low 
number of patients. Preliminary associations of mutations with clinical 
manifestations can be done. Some mutations seem to be more frequent in the 
different age of onset groups, especially for COQ2 and COQ6. Some less evident 












Primary CoQ10 deficiency study models 
2.1. Introduction. Primary CoQ10 deficiency models: Characterisation and 
therapeutic approach 
As discussed in Chapter 1, primary CoQ10 deficiency disorders are very complex and 
heterogeneous in terms of molecular causes, pathogenesis and clinical manifestations. 
This complexity is probably due to the wide range of cellular functions that CoQ exerts, 
as well as the big number of different components implicated in its biosynthetic 
pathway, some of which may even perform yet unknown additional roles in 
mitochondrial homeostasis.  
CoQ biosynthesis and functions are extensively conserved across the domains of life, 
from bacteria to eukaryotic multicellular organisms 381. We can take advantage of this 
conservation to deeper understand the human mitochondrial biology and disease, by 
investigating simpler model organisms.  
2.1.1. The use of primary CoQ deficiency models 
The use of model organisms has been proven effective to dissect the biosynthetic 
pathway and the functions of CoQ. What is more, disease modelling with simpler 
organisms is an extremely useful approach to elucidate the genetic causes and the 
pathogenesis of the disease, as well as to develop diagnostic tools or preclinical assays 
for potentially therapeutic molecules (Figure 2.1). 
Diagnosis and biochemical studies 
In vitro models of primary CoQ10 deficiency are useful tools to complement the genetic 
diagnosis, by biochemically determining the quinone content and the combined 
enzymatic activity of complexes I+III and/or II+III, which may all be reduced compared 
to controls. The biochemical diagnosis of CoQ10 deficiency is generally based on 
measurements of CoQ10 levels in muscle, which is an invasive technique and not always 
available. However, most of the patients with primary CoQ10 show reduced levels of 




CoQ10 in cultured skin fibroblasts, so these cells are starting to be used as a diagnostic 
tool for the biochemical characterisation of the CoQ10 biosynthetic defect by measuring 
the total CoQ10 levels by HPLC techniques. Skin fibroblasts offer an additional advantage 
for the molecular characterisation of the disease, since in vitro assessment of CoQ10 
biosynthetic rate is possible by measuring the incorporation of a labelled CoQ10 
precursor in this cellular model 177. Additionally, it is possible to identify the 
accumulation of abnormal metabolites generated by the defect in a particular COQ 
gene. These molecules could be considered specific molecular markers for the defective 
COQ function. As an example, 6-demethoxy-CoQ10 (DMQ10, COQ7 substrate) has been 
found in high amounts in fibroblasts from COQ7 and COQ9 patients 238,239,388. Western 
blot of whole cell lysates or purified mitochondria from these different models can show 
defects in the protein affected by the mutations. Interestingly, other COQ protein levels 
can also be affected.  
 
 
Figure 2.1. The use of model organisms for studying CoQ biosynthesis and primary CoQ deficiency.  
(A) Phylogenetic tree of the model organisms used for dissecting CoQ biosynthetic pathway, and for 
studying the physiological significance of a defect in this essential pathway. In vitro cell culture models 
are usually obtained from clinical patients or from deficient mouse models, or experimentally generated 
by knock-out/in/down mechanisms. Studying all these models has allowed us to expand the knowledge 
of CoQ biosynthesis biochemistry (B), but also, understanding the molecular and pathological relevance 







The pathogenesis of primary CoQ10 deficiency is very complex (See Chapter 1, section 
1.1.1). Different in vitro and in vivo models, from yeast to mouse and cell cultures, have 
contributed to expand our knowledge on CoQ deficiency pathogenesis.  
Assessing mitochondrial OXPHOS function has provided insights of the mitochondrial 
dysfunction caused by CoQ deficiency. This has been performed by measuring the 
enzymatic activity of the respiratory complexes, and/or analysing the oxygen 
consumption rate (OCR) by oxygraphy in living cells or in isolated mitochondria.  In 
addition, as CoQ is recognized as an important endogenous antioxidant, oxidative stress 
produced by this condition has been studied as a mechanism contributing to the 
pathogenesis 389. It has been shown that the reduced activity of the OXPHOS system and 
an increase of ROS are crucial factors involved in the pathogenesis of these disorders.  
The use of this models has allowed the molecular characterisation of other pathogenic 
consequences of reduced levels of CoQ. Some examples are the impairment of different 
pathways in which CoQ is an important cofactor, such as pyrimidine biosynthesis 266 or 
H2S detoxification 267.   
Therapeutic approach 
As described before, the only therapeutic option currently available for CoQ10 deficiency 
syndrome is CoQ10 supplementation. Patients generally respond quite positively to this 
therapy, but there is a significant group of probands for whom the treatment was not 
successful. In order to better understand this diversity of responses, different studies 
have evaluated the effects of CoQ10 supplementation as well as other compounds, such 
as CoQ10 analogues with different tail length, vitamin C, vitamin K2 or probucol in diverse 
CoQ deficient in vitro and in vivo models 181,287,390–395.  
Moreover, due to the high hydrophobicity and low bioavailability of CoQ10, new 
approaches are being developed to increase its levels in deficient in vitro and in vivo 
models. Some 4-hydrozybenzoate (4-HB) analogues have been proposed as bypass 
therapies, alternative to CoQ10 supplementation 289. These molecules are CoQ head 
precursors with additional chemical groups in some of the positions, which are the same 




than those found in the final molecule of CoQ (Figure 2.2). These water-soluble 
compounds with higher bioavailability than CoQ10 would bypass certain enzymatic steps 
disrupted by mutations in COQ genes. Their efficacy may differ depending on the 
stability of the CoQ biosynthetic complex 278 or the residual activity of the mutated 
enzyme 238, but also by the ability of COQ2 to use them as a substrate to which attach 
the hydrophobic tail 289. Some examples of such bypass molecules are vanillic acid (VA) 
and 3,4-dihydroxybenzoate (3,4-dHB), able to bypass COQ6 mutations, or 2,4-dHB for 
COQ7 defects (Figure 2.2).  
 
 
Figure 2.2. Schematic model of human CoQ10 biosynthesis pathway.  
Gray arrows represent enzymatic reactions and circled numbers represent the different COQ proteins 
that participate in each step. Circled question mark shows currently unidentified enzymes. Green boxes 
contain 4-HB analogues, defined as unnatural CoQ precursors, which are able to lead to CoQ production, 
bypassing defective COQ enzymes such as COQ6 (vanillic acid (VA)) or COQ7 (2,4-dihydroxybenzoate (2,4-
dHB). DDMQ: demethoxy-demethyl-coenzyme Q; DMQ: demethoxy-coenzyme Q; DMeQ: demethyl-
coenzyme Q (Adapted from Alcázar-Fabra et al., 2018112). 
 
The effectivity of VA and 3,4-dHB in restoring CoQ biosynthesis was first demonstrated 
in coq6 yeast mutant strains expressing pathogenic versions of human COQ6 342, while 
they were only effective in Δcoq6 strain after overexpression of Coq8 to stabilize the 
biosynthetic complex 396. Treatment with VA has also been tested in mammalian cell 
lines KO in COQ6, rescuing CoQ10 biosynthesis and ATP production, in a study that will 
be described in the results section of this chapter 165. Notably, VA also stimulates CoQ10 
synthesis and improves cell viability in COQ9 patient fibroblasts 388.  
2,4-dHB was also first tested in yeast. It was able to restore the CoQ6 defect in Δcoq7 





able to bypass the defective reaction in human fibroblasts with COQ7 238,239,388 and COQ9 
mutations 278,388, increasing CoQ10 and reducing DMQ10 levels. In vivo, it increased CoQ9 
levels and lifespan in Coq7 KO 398 and Coq9 defective mice (Coq9R239X) 278,399. Particularly, 
in this model, 2,4-dHB rescued the morphological and histopathological signs of 
encephalopathy, not by an increase of CoQ9 but a drastic reduction of DMQ9. 
Remarkably, the effectivity of 2,4-dHB depends on the nature of the COQ7 mutation and 
the residual activity of the protein 238, being more effective for more severe COQ7 
mutations with less residual activity. A similar effect has been observed for COQ9 in 
mouse, in which different mutations in Coq9 affect differently the stability of the CoQ 
biosynthetic complex 278, and 2,4-dHB supplementation is more effective when CoQ 
complex is more stable. 2,4-dHB was also administered to podocyte-specific Coq6 KO 
and Coq8b/Adck4 KO mice models, in which the treatment prevented focal segmental 
glomerulosclerosis, prolonging their survival 400,401. In the Coq6 study, 2,4-dHB 
treatment was also assayed in a migration assay of cultured podocytes from this mice, 
and compared with VA supplementation, 2,4-dHB was able to fully recover migration of 
podocytes, while VA only did it partially 400. 
It has also been reported that treatment with high doses of 4-HB, thus increasing COQ2 
substrate availability, restores CoQ10 synthesis in certain COQ2 deficient cell lines, which 
also suggests that these enzyme variants retain some residual activity 402. 
2.1.2. Models to study primary CoQ deficiency 
In vivo studies with animal models (such as the mouse Mus musculus 403 or the fish Danio 
rerio 363), and in vitro studies with mammalian cell cultures (mostly patient’s fibroblasts 
177,261,301 or cells from defective mice 238), have been used to study CoQ biology and 
disease. Additionally, other organisms like invertebrates lacking CoQ have been 
highlighted important functions of CoQ (the fruit fly Drosophila melanogaster or the 
nematode Caenorhabditis elegans 404–410). Even unicellular eukaryotic (the yeast 
Saccharomyces cerevisiae380,411380,411) or prokaryotic (the bacteria Escherichia coli 412,413) 
organisms have been proven very valuable in this context. Of course, the selection of 
the model organism is crucial, and the context must be considered in every case (Figure 
2.1). 




The models that are the most widely used for the study of primary CoQ deficiency 
disorder are yeast, mouse models and in vitro cell cultures (patient’s derived cells or 
other recombinant or KO cell lines). 
Saccharomyces cerevisiae 
Simple unicellular models, such as Saccharomyces cerevisiae and Escherichia coli, have 
been widely used in order to dissect CoQ biosynthetic pathway, to investigate the 
functions, structure and interactions of each protein involved in the process, and the 
functions of CoQ itself (Figure 2.1.B). In fact, coq genes were first discovered as a 
complementation group in yeast 414.  
Yeast is a powerful model for mitochondrial disease since it can grow in either a 
fermentative medium or a mandatory respiratory medium, using the mitochondrial 
respiration. Therefore, mutants in the respiratory function are easily obtained, 
maintained, and characterised. Examples for such mutants are the strains lacking one of 
the different coq genes, which are unable to synthesise CoQ6 and grow in a non-
fermentable medium. Thanks to the great conservation between yeast coq and human 
COQ genes, this eukaryotic unicellular organism has been widely used for evaluating the 
pathogenicity of the mutations found in primary CoQ10 deficiency patients. Yeast 
deleted-strains in almost all coq genes (coq1 241, coq2 232,241,277,328, coq4 251,341, coq6 
232,233,342, coq8 276,356,357, coq9 248)  have been used to better understand the 
pathogenicity of the mutation. The null mutants are transformed with the WT or mutant 
version of the respective gene (human or yeast gene), which is followed by a functional 
complementation assay, analysing the transformants ability to grow in a respiratory 
medium or to produce CoQ6.  
Yeast have also been proven a useful model for therapeutic assays. For example, the 
bypass therapy with 4-HB analogues with the defective chemical group was first assayed 
in yeast, as described above 342,395–397,415.  Very recently, yeast deficient in some coq 
genes (Δcoq6 and Δcoq4 strains with Coq8p overexpression) have been described to be 
a useful platform to perform a high throughput screening of natural extracts to identify 






Although studies in simple model organisms have been extremely useful, the generation 
of multicellular animal models deficient in CoQ is paramount to reveal the complex 
pathogenic consequences of CoQ deficiency in the physiological context of a whole 
animal. Mouse models recapitulating primary CoQ deficiency disease pathogenesis are 
extremely valuable, since their complexity, anatomy, physiology, and metabolism are 
relatively close to humans. In fact, they allow to study the tissue-specific damage that 
mutations in some COQ genes produce, providing deeper knowledge about CoQ 
biosynthesis and regulation in a whole organism. Furthermore, the use of mouse models 
is contributing to the development of new therapeutic approaches. Different mouse 
models with primary CoQ9 and CoQ10 deficiency have been developed and studied in 
CoQ biosynthesis research 403.  
i. Knock-out (KO) and Knock-in (KI) models 
The International Mouse Phenotyping Consortium (IMPC, www.mousephenotype.org) 
and the European Conditional Mouse Mutagenesis Program (EUCOMM), together with 
different gene specific studies have generated constitutive KO mouse models for the 
different Coq genes 403. In the case of Pdss1 (IMPC), Pdss2 417,418, Coq2 (EUCOMM), Coq3 
419, Coq4 (EUCOMM), Coq6 400, Coq7 419–421 and Coq8b/Acdk4 401, constitutive 
homozygous KO resulted in embryonic lethality. This suggests CoQ biosynthesis has a 
crucial role during development. Interestingly, the heterozygous Coq7+/– mice were 
viable and displayed an increased lifespan, lower levels of DNA damage in liver, 
decreased ROS levels, respiratory dysfunction and an altered distribution of CoQ9 and 
CoQ10 in submitochondrial membranes 419,422. Immunoblots showed the heterozygous 
mice had 50% of Coq7 signal in brain extracts, in comparison to the controls 420. The 
increase in lifespan was previously reported in clk-1 (ortholog of COQ7 gene) C. elegans 
null mutant 423. In contrast, Coq3+/- mice had a normal lifespan and had no defects in 
mitochondrial function or ubiquinone distribution 419. 
Contrarily, constitutive Coq8a/Adck3 424 and Coq9 278 knocking-out resulted in viable 
mice. Homozygous mice were born and recapitulated the clinical disorder. In the case of 
Coq8a/Adck3-/- mice, they displayed a cerebellar ataxia (ARCA2), mimicking 




COQ8A/ADCK3 patients’ main clinical phenotype 424. On the other hand, the effects of 
defects on Coq9 were studied in two different KI mouse models 278,279. The complete 
lack of Coq9 protein due to a very early nonsense mutation (Coq9Q95X) resulted in a 
moderate CoQ deficiency and a late-onset mild mitochondrial myopathy, with 
decreased levels of Coq7 and Coq5 proteins and, in agreement with what was observed 
in the Coq7+/– mice, an increase in lifespan. This mouse did not respond to 2,4-dHB 
supplementation. Contrarily, defects on Coq9 due to a late-truncation of the protein 
(Coq9R239X) produced a severe widespread CoQ deficiency associated with fatal 
encephalomyopathy, responding to 2,4-dHB supplementation. These mice had a generic 
decrease of Coq proteins, suggesting that the presence of a truncated Coq9 induces 
instability of the CoQ multiprotein complex and contributes in this way to the genetic 
and tissue-specific pathomechanisms of the disease 278,279. 
ADCK2 is a gene of a yet unknown function that is part of the ADCK family to which 
ADCK3 (COQ8A) and ADCK4 (COQ8B) also belong. Recently, it has been shown that 
ADCK2 haploinsufficiency reduces mitochondrial lipid oxidation and causes liver 
dysfunction and myopathy associated with CoQ deficiency in the skeletal muscle of an 
Adck2+/− mouse model 378. Fibroblasts from a patient with mutations in this gene also 
showed CoQ10 deficiency378. ADCK2 is proposed to be involved in organismal fatty acid 
metabolism and in CoQ biosynthesis in skeletal muscle378.  
ii. Conditional KO models 
To overcome the issue of embryonic lethality, some tissue-specific or adult-onset KO 
mice in some of the Coq genes were developed and studied. Conditional Pdss2 KO in 
kidney 393,418 and cerebellum 417 were generated, and they recapitulated the organs 
damage found in the patients. Conditional Clk-1/Coq7 KO in liver 425 revealed a defect in 
CoQ9, an accumulation of DMQ9 and a mild respiratory impairment in liver that was 
responsive to CoQ10 supplementation. An induced adult-onset global Coq7 KO mouse 
was also generated 398, developing a severe depletion of CoQ9 in almost all organs, with 
DMQ9 accumulation, gradual loss of mitochondrial function, gradual development of 
disease phenotypes and shortened lifespan. CoQ deficiency was not rescued by CoQ10 
treatment in this case, but it was partially recovered with 2,4-dHB. Podocyte-specific 





segmental glomerulosclerosis observed in the nephrotic syndrome caused by COQ6 and 
COQ8B/ADCK4 mutations in patients. In these two mouse models 2,4-dHB treatment 
ameliorated the kidney disease and prolonged their survival 400,401.  
iii. Spontaneous mutant models 
A mouse with a spontaneous missense mutation (p.Val117Met) in Pdss2 developed a 
kidney disease responsive to CoQ10 supplementation 287,394,418,426–428.  
In vitro cellular models 
Cell cultures of isolated mammalian cells are a fast and powerful tool to extract 
information from a eukaryotic system. However, the mechanisms studied in vitro occur 
in a simplified, highly controlled intracellular and extracellular environment, so 
conclusions must be drawn carefully.   
i. Patient’s fibroblasts 
Primary skin fibroblasts derived from patients carrying mutations in one of the COQ 
genes are a model widely used to study primary CoQ10 deficiency, especially for its 
biochemical diagnosis. They are very valuable, since they are easily obtained by less 
invasive techniques than muscle biopsies -which is preferred by families-, and they come 
directly from the studied patient. However, they have some limitations, after all the 
experiments are performed in optimum conditions outside their normal biological 
context and adaptations may occur. In addition, as they are primary cells, they can only 
divide a certain number of times, after which experiments should not be performed. Of 
note, due to the low number of described patients, the number of available cell lines is 
limited, and not a huge number of studies have been performed. They have also been 
used to study certain pathogenic mechanisms of the disease, as well as for in vitro 
assessments of efficacy of CoQ or 4-HB analogues supplementation (see section 2.1.1).  
ii. Human induced pluripotent stem cells model (iPSCs) 
One of the greatest breakthroughs that redefined the fields of stem cell biology, 
regenerative medicine and disease modelling was the discovery of the induced 
pluripotent stem cells (iPSCs) technology in 2006 by Shinya Yamanaka et al 429.  Fully 
differentiated adult somatic cells were reprogrammed into a pluripotent state, by using 




four defined transcription factors: Oct3/4, Sox2, c-Myc and Klf4. The resulting cells, the 
iPSCs, exhibited the morphology and growth properties of stem cells and had the 
capacity to differentiate into any cells of the three germ layers. The selection of the 
appropriate type of somatic cells, reprogramming factors and the method for delivering 
these factors to the cells are the most important parameters influencing the 
reprogramming process.  
This technology allows to create patient-specific and healthy donor iPSCs, suitable for 
disease modelling430. Moreover, it allows to obtain and work with hard-to-reach cell 
types, such as neurons, cardiomyocytes or myotubes, as well as to study their 
differentiation process and how the disease may alter it.  The development of this iPSC 
model, in combination with genome-editing strategies for correcting or introducing 
disease-causing mutations, has led to numerous advances in modelling neuro-
degenerative disorders, neuropathies, myopathies and mitochondrial diseases 430–434.  
However, the use of iPSCs has some disadvantages. They are expensive and complex to 
be generated. Besides, induction of pluripotency is accompanied by epigenetic 
reprogramming and metabolic shift from OXPHOS to glycolytic, and sometimes the 
nuclear and mitochondrial genomes have been reported to be genetically instable 434.   
In the context of primary CoQ10 deficiency, an iPSC model was generated from human 
dermal fibroblasts from a patient harbouring a heterozygous mutation in COQ4 gene 
(c.483G>C, p.Glu161Asp)435. The patient was a 4-year-old girl diagnosed with lethal 
rhabdomyolysis associated with CoQ10 deficiency. These iPSCs had impaired 
mitochondrial function and CoQ10 deficiency, which was rescued when the mutation 
was corrected by CRISPR/Cas9. Differentiation to neurons was not impaired in these 
iPSCs, while differentiation to skeletal muscle was compromised and the resulting 
muscle also displayed respiration defects. Remarkably, this was reproducing the disease 
phenotype observed in the patient, and the CRISPR/Cas9 corrected iPSCs did not show 
the defects436.        
iii. Continuous cell lines defective/overexpressing one COQ gene 
Continuous cell lines are a useful model often employed in research to study different 





big amount of material they can provide in a short time, their ease to use, and their high 
transfection efficiency. Thanks to this last point, knock-down (KD), KO, KI or tagged 
expression of COQ proteins have been achieved in cell lines in order to study CoQ 
biosynthesis (see also Chapter 3, CRISPR/Cas9). KO and KD have been used to study the 
functional defects of the lack of a certain COQ protein 165,315,394,437. Also, ectopic 
overexpression of the different tagged COQ proteins has been used for localisation of 
the labelled protein by microscopy 277 or mitochondrial fractionation 276,378 and for 
searching interactors of the tagged protein with other proteins 401,438. Some examples 
of cell lines commonly used are HeLa 277,394, HEK293 (and other lines derived from it) 
378,385,400,401,438, HepG2 438 or 143B 315,437 cells.  
HEK293 is a cell line derived from human embryonic kidney cells grown in tissue 
culture439. It is a hypotriploid cell line with a modal chromosome number of 64. These 
cells are popular for their ease of growth and high transfection efficiency, as well as their 
ability to produce exogenous proteins in large amounts. They are widely used in 
biomedical research in general, and have helped for great advances in mitochondrial 
research. For example, they have been used for mitochondrial localisation 
characterisation of the mammalian mitochondrial proteome by tagged protein 
expression and microscopy 69, or for the characterisation of functional and interaction 
partners of some unknown mitochondrial proteins -the COQs proteins among them- by 
tagged expression of these proteins in HEK293 cells, affinity purification of the tagged 
protein and mass spectrometry of the affinity enriched fraction (AE-MS)438. 
The Flp-In™ T‑REx™-293 cell line is derived from HEK293. It allows the rapid generation 
of stable cell lines that ensure homogenous expression of a protein of interest from a 
Flp-In™ expression vector. These cells contain a single stably integrated FRT site at a 
transcriptionally active genomic locus. Co-transfection of the Flp-In™ Cell Lines with a 
Flp-In™ expression vector and the Flp recombinase vector, pOG44, results in targeted 
integration of the expression vector to the same locus in every cell (the FRT site), 
ensuring homogeneous levels of gene expression. These cells have been used for 
mitochondrial protein expression, for example, in the recent generation of a high 
resolution human mitochondrial protein proximity map using BioID 440, characterising 




proteins belonging to the different mitochondrial compartments and sub-
compartments. 
2.2. Results and discussion 
In this chapter, we worked with different in vitro cellular models of primary CoQ10 
deficiency with three main objectives:  
i. Biochemical and molecular diagnosis of the primary CoQ10 deficiency, and report 
of new cases. 
ii. Determination of the pathogenesis and physiopathology of the mitochondrial 
defects associated to a primary CoQ10 deficiency. 
iii. Treatment evaluation with 4-HB analogues. 
For the completion of these objectives, several human cellular models with defects in 
one of the genes involved in CoQ10 biosynthesis were obtained.  
On one hand, in collaboration with different hospitals (see Table M.1), we received skin 
biopsies or fibroblasts of patients with clinical suspicion of suffering CoQ10 deficiency.  
After genetic tests to confirm the primary CoQ10 deficiency, due to mutations in one of 
the genes involved in CoQ10 biosynthesis, five patients were found to have compound 
heterozygous or homozygous mutations in COQ4 or COQ7 genes. These patients and the 
genetic defects producing their disease are being firstly reported in this PhD project. The 
studies on the fibroblasts have been performed with the three previously mentioned 
objectives in mind: diagnosis, study of the pathogenesis and therapeutic approach with 
4-HB analogues. 
On the other hand, HEK293T cells were genetically modified to knock out COQ6 or COQ4 
genes, and used as models of deficiency of these genes. The studies with HEK cell lines 
have been mainly performed with the objective of characterising the pathogenicity of 
the mutations, studying the physiopathology of the total defect of CoQ10 due to a total 
lack of one of the proteins involved in its synthesis (COQ6 or COQ4), as well as for 





Biochemical and physiological studies have been performed in order to determine how 
the mitochondrial function is altered. Additionally, some molecular studies have also 
been done in order to confirm the pathogenicity of the mutations.  
The first step consisted in confirming the CoQ10 deficiency by measuring steady state 
levels of CoQ10 in cells by HPLC. Sometimes, CoQ10 levels have already been measured 
in skeletal muscle from patients, before the arrival of the fibroblasts to our laboratory. 
Anyway, CoQ10 assessment in fibroblasts is very useful to corroborate the condition of 
CoQ10 deficiency. It would be also possible to detect the accumulation of intermediates 
of the synthesis, as it has been described for COQ7 and COQ9 patient fibroblasts388. To 
deeper investigate how this function is altered, we also measured CoQ10 biosynthetic 
rate, by analysing the incorporation of radiolabelled 4-HB, which is the precursor for the 
CoQ10 quinone head. This technique allows us to confirm the biosynthetic defect.  
Then, we measured the mitochondrial respiratory performance, by measuring the 
enzymatic activity of the respiratory complexes, and/or analysing the OCR by oxygraphy 
using a SeaHorse XF24 Extracellular Flux Analyzer in living cells. OCR measurement by 
the Seahorse XF Cell Mito-Stress Test uses modulators of cellular respiration that 
specifically target components of the electron transport chain (ETC) to reveal key 
parameters of the metabolic function: basal respiration, ATP-linked or coupled 
respiration, proton leak, maximal respiration, spare respiratory capacity, and non-
mitochondrial respiration (See Material and Methods, Section M2.5 for more details). 
For treatment evaluation, CoQ10 levels and mitochondrial performance have been 
assayed in cells after the administration of different analogues of 4-HB that could bypass 
the defective enzymatic step, in order to test their therapeutic potential effect. 
Primary deficiencies due to defects in COQ7, COQ6 and COQ4 genes have been studied 
in this chapter. 
2.2.1. Primary CoQ10 deficiency due to defects in COQ7 gene 
COQ7 is a di-iron oxidase responsible for the C6-hydroxylation of DMQ10. Mutations in 
COQ7 are very rare and only three cases have been reported in the literature so far (see 
Chapter 1, section 1.2.4). Here, we report two new patients with mutations in COQ7. 




One of them, P102, is similar to the patients reported in the literature, while the other 
one, P112, is strikingly different, with the disease onset during adolescence. 
Mutations in COQ7 gene produce different clinical manifestations 
P102 patient is a Spanish child who showed a pronounced neonatal generalized 
hypotonia. He developed hypoxic-ischemic encephalopathy during the neonatal period. 
He mainly had a neurological affection, with sensorineural hearing loss, and there were 
no signs of renal involvement. At the age of 8 months, he developed epileptic crisis with 
tonic movement in upper limbs. Because of the acute hypotonia, he could not hold his 
head at the age of two. At this age, he had lack of language and a severe intellectual 
disability, with cerebral atrophy. Metabolic studies showed persistently elevated 
lactate.  
In contrast, P112 presented a different and milder clinical picture. This patient is a 
Spanish 55-year-old woman who had walking difficulty since the age of 15 years. She 
had a pyramidal syndrome, with hearing loss and neuropathic gait. Up to now, all COQ7 
reported patients were paediatric patients presenting very early in life, being P112 the 
first patient with adolescence-onset and a mild progressive disorder.  
P102 and P112 have biallelic mutations in COQ7 gene 
Exome sequencing and bioinformatic analysis revealed these patients had potential 
pathological variations in the COQ7 gene.  
In the case of P102, a panel exome sequencing was performed, and after data analysis, 
two compound heterozygous mutations in COQ7 gene were found as candidates to 
produce the disease (Figure 2.3).  One of the variants is a deletion of one nucleotide, 
resulting in a frameshift (c.161_161delG, p.Val55Trpfs*94, NM_016138.5) in exon 2, 
with a premature stop codon 94 amino acid downstream the frameshift mutation. The 
variant is predicted pathogenic by CADD (score=29.4) tool. The other variant 
corresponds to a missense mutation (c.319C>T, p.Arg107Trp, NM_016138.5) in exon 3. 
This mutation has also been reported in another COQ7 patient 240 and it is predicted to 
affect the protein stability, changing a very conserved arginine (positive) for an 





(score=0.01), PolyPhen-2 (score=1) and CADD (score=33) tools (Table 1.10). Sanger 
sequencing confirmed the segregation of the variants in parental DNA. Both parents 
were heterozygous carriers of each of the mutated alleles. The frameshift variant was 
maternally inherited while the missense variant was carried by the father. 
 
Figure 2.3. Schematic representation of COQ7 mRNA (A) and protein (B).  
The localization of the two mutations from P102 patient are shown with red lines and boxes, showing the 
residue conservation in the alignment of COQ7 protein from different species (C). The localization of the 
mutation of P112 is shown with an orange box, being located in the translation initiation site (TIS). The 
rest of mutations shown (purple boxes) correspond to the 3 COQ7 patients reported previously 238–240. 
The multiple alignment was performed with the protein sequences obtained in Uniprot, using Clustal X2 
and BioEdit to visualize the results. UTR (untranslated region); MTS (mitochondrial targeting sequence; 
aa (amino acid); * (asterisk: single and fully conserved residue); : (colon: conservation between groups of 
strongly similar properties); . (period: conservation between groups of weakly similar properties). 
 
The nature of P112’s mutations is different. In this case, exome sequencing revealed a 
homozygous mutation in the translation initiation codon (c.3G>T, p.Met1Ile, 
NM_016138.5) (Figure 2.4). The change is predicted to be pathogenic by SIFT 
(score=0.00), PolyPhen-2 (score=1) and CADD (score=24.9) tools. This extremely rare 
case of primary CoQ10 is the first one reported to have a mutation altering the translation 
initiation codon of a COQ protein. 




Significance of the c.3G>T, p.Met1Ile mutation in P112 
Translation initiation in eukaryotic mRNAs mainly occurs via a scanning mechanism 
which identifies a start AUG codon in a Kozak context441. Mutations affecting this 
initiation codon will probably have important biological consequences, and there are 
several examples of different diseases caused by mutations in the initiation AUG codons 
442–449. The characterisation of the pathogenicity of mutations disturbing translation 
initiation codon is very useful to study not only the impaired biological process (in this 





Figure 2.4. Alternative translation initiation of COQ7.  
P112 c.3>G mutation in AUG (+1) could lead to alternative translation initiation in a downstream AUG 
(+114) (A). (B) The table indicates the probability of translation initiation in these two AUGs calculated by 
NetStart and ATGpr tools. Translation from AUG (+114) would give rise to a 179 amino acid long protein 
(COQ7 isoform 2), starting from Met39, and lacking the mitochondrial localization signal (MTS) (C). The 





The pathogenicity of the c.3G>T, p.Met1Ile mutation would mainly rely on the impaired 
translation of the protein, and not exclusively on the amino acid change from 
methionine to isoleucine. For this kind of mutation, it is possible that downstream AUG 
codons could be used as alternative translation initiation (ATI) sites, leading to shorter 
versions of the protein lacking the N-terminal region. ATI diversifies the proteome and 
may alter a protein’s function or cellular location 450. COQ7 isoform 1 has an MTS in the 
N-terminal of the protein, leading to a protein with mitochondrial localisation (Figure 
2.4.D and E). Of note, COQ7 protein has also been attributed a role in the nucleus, with 
the nuclear localisation signal (NTS) adjacent to the mitochondrial transit peptide 
(mitochondrial targeting sequence, MTS) 451.  However, this fact is still controversial 373.  
In this context, we subjected WT and mutated COQ7 mRNA sequence (NM_016138.5) 
to a translation initiation site (TIS) prediction using NetStart1.0 204 and ATGpr 205. COQ7 
translation initiation sites prediction did not give very high scores for any of the 
methionines, and the scores given by the two tools were not comparable to each other 
(Figure 2.4.A and B). However, ATG(+114) has one of the highest scores when ATG(+1) 
is mutated, so we could hypothesise that COQ7 translation can initiate from ATG(+114), 
besides from ATG(+1) (and specially in the context of the c.3G>T mutation). Translation 
from this site would lead to a 179aa protein that is annotated as COQ7 isoform2 and 
lacks the MTS (and the NTS) (Figure 2.4.C). This phenomenon would produce a protein 
with no mitochondrial (nor nuclear) localisation.  
It is also possible that the new non-AUG codon (in this case, AUU) could be also used for 
initiation of translation, but in a lesser efficient way, compared to the AUG codon 
449,452,453. In this case, COQ7 protein would be produced and probably translocated to 
the mitochondria, having no differences with a WT COQ7 protein after removal of the 
MTS. A reduction in the levels of WT COQ7 may not be deleterious, and even in some 
organisms it induces an increase in lifespan 422,454. We could speculate that this non-AUG 
translation could become less efficient with age 455, leading to a later onset of the 
disease.  
The effect of the p.Met1Ile mutation on COQ7 translation and localisation has not been 
experimentally studied yet, but it will provide important information about its 
pathogenicity. 




COQ7 patients’ fibroblasts have drastically reduced CoQ10 levels, impaired CoQ10 
biosynthesis and accumulation of DMQ10. 
In order to investigate the degree of affectation of CoQ10 biosynthesis due to these 
COQ7 mutations, total levels of CoQ10 were analysed in patients’ fibroblasts (Figure 2.5).  
P102 patient’s fibroblasts showed an 80% CoQ10 deficiency (Figure 2.5.A) and a high 
accumulation of DMQ10 (Figure 2.5.B), the natural substrate for COQ7 enzyme, which 
was undetected in cells from a neonatal control (HDF Neo). The identity of the DMQ10 
peak was confirmed by HPLC-coupled mass spectrometry, showing a prominent ion with 
a mass-to-charge ratio (m/z) of 850.70, which is compatible with the mass of DMQ10 
(M+NH4+). P112’s fibroblasts equally showed an 80% of CoQ10 deficiency (Figure 2.5.E) 
and a high accumulation of DMQ10, undetected in cells from an adult control (B003) 
(Figure 2.5.F). Accumulation of this molecule seems to be a hallmark for COQ7 
deficiencies, so it could be considered a molecular marker for this defect 388. COQ9 
deficiency has also been reported to show accumulation of DMQ10, which reflects its 
role in supporting COQ7 function 388. 
CoQ10 biosynthesis rate was also measured, by analysing the incorporation of 14C-4-HB 
to the quinone extract. While the control cells showed a radioactive CoQ10 peak, the 
fibroblasts from both patients only presented radioactivity corresponding to the DMQ10 
peak (Figure 2.5.D and H). This probably indicates that CoQ10 pathway is slow and the 
lack of a functional COQ7 enzyme is the bottleneck, provoking the accumulation of the 
radiolabelled substrate of COQ7, DMQ10. 
P102 and P112 show the same defects in terms of CoQ10 levels, biosynthesis rate and 
accumulation of DMQ10. However, it should be considered that fibroblasts were 
obtained from the patients with a great age difference. It is possible that CoQ10 levels 
and biosynthesis rate from the adult patient were not so highly impaired when the 
patient was younger. It is also possible that any systemic adaptation that could 
compensate the late-onset deficiency could be abolished in the context of an in vitro 







Figure 2.5. Quinone content in COQ7 Mutant Fibroblasts, P102 (A-D) and P112 (E-H).  
Both patient fibroblasts (P102: A; P112:E) show an 80% CoQ10 deficiency (Unpaired two-tailed t-test; p 
value<0.0001) and (B, F) a big accumulation of 6-demethoxyubiquinone (DMQ10) , the natural substrate 
for COQ7 enzyme, undetected (N.D.) in control cells. (C, G) The HPLC-ECD chromatogram showed the 
presence of the two peaks (DMQ10 peak, retention time (rt): 17.5min; CoQ10 peak, rt:18min) in lipids 
extracts from patients’ fibroblasts. It is also possible to see lower amounts of CoQ9 in controls and DMQ9 
in patients. The HPLC-radioactivity chromatogram (D, H) showed the incorporation of 14C-4-HB to the 
quinone extract; in controls, in a radioactive CoQ10 peak; in patients, in a radioactive DMQ10 peak.  




Patients’ fibroblasts respiration is impaired in different degrees 
Respiration studies in COQ7 mutant fibroblasts and controls were performed to evaluate 
the effect of the dysfunctional CoQ10 synthesis on the mitochondrial respiratory function 
(Figure 2.6).  
Patient P102 fibroblasts showed a marked decrease in CII+CIII activity, while isolated CIII 
was also reduced (Figure 2.6.A). However, these differences were not statistically 
significant. OCR profile showed a marked respiratory defect in patient’s fibroblasts. This 
phenomenon was mainly observed with the decrease of the maximal respiration rate, 
as well as the spare capacity (Figure 2.6.B and C) (see Matherials and Methods for more 
details). These results suggest that patient’s cells are less able to respond to energetic 
demands than control cells. These effects can be a combined action of CoQ10 deficiency 
and DMQ10 accumulation, as it has been proposed that DMQ10 could compete with 
CoQ10 to bind to CoQ10-binding sites in the MRC and inhibit electron transport 238,409,456. 
P112 fibroblasts also showed defects in CII+CIII and isolated CIII but a less severe 
respiratory impairment, measured by oxygraphy (Figure 2.6.E and F). Remarkably, these 
fibroblasts also showed an increased CIV activity. These fibroblasts have a mild 
respiratory defect, which fits with the fact that the patient had a milder disease. 
However, it is surprising because of the profound CoQ10 deficiency measured in 
fibroblasts, and the high levels of DMQ10 accumulated. In fact, both CoQ10 and DMQ10 
levels are comparable to those of P102 fibroblasts. However, respiratory efficiency is 
higher in P112 than in P102. This observation could rely on other compensatory or 
adaptation mechanisms still to be defined. Increased CIV activity in P112 fibroblasts 










Figure 2.6. Respiration Studies in COQ7 Mutant Fibroblasts, P102 (A-C) and P112 (D-F).  
(A, D) Mitochondrial Respiratory Chain (RC) activities were measured in patient’s fibroblasts and controls 
(Two-way ANOVA with Sidak’s multiple comparison test (p value<0.05 (*), <0.0001(****)). (B, E) Oxygen 
consumption rate (OCR) profile shows a respiratory defect in both patient’s fibroblasts. Arrows indicate 
the addition of the individual inhibitors. Quantitative data are graphed on C and F as mean ± SD (Two-way 
ANOVA with Sidak’s multiple comparison test (p value<0.0001(****)). OL (oligomycin 4 μM); FCCP 








COQ7 protein levels are drastically reduced in both patients, and P102 point mutation is 
predicted to alter the protein structure stability. 
COQ7 protein levels were analysed in whole cell lysates from controls’ and patients’ 
fibroblasts, revealing extremely low levels of the polypeptide in both the cases (Figure 
2.7.A and C).  
The low levels of the protein resulting from the c.161_161delG mutation in patient P102 
were expected and are explained by the frameshift mutation that produces an early 
STOP codon and, thus, does not produce any full length COQ7 protein. However, the 
missense mutation in this patient is predicted to give rise to a full-length COQ7 protein 
that should be detected by western blot. The inability to detect the protein could be 
explained by a dramatically decrease in protein stability induced by the mutation.  
Human COQ7 protein homology model was generated using a ferritin as template 
(PDB:5HJH, 224) (Figure 2.7.D). The mutated amino acid (p.Arg107Trp), labelled in red 
(Figure 2.7.D), was also found in another COQ7 patient 240 and it is predicted to affect 
the protein stability, changing a positive (arginine) for an hydrophobic (tryptophan) 
amino acid. It is also very close to the region that is proposed to interact with COQ9 
protein 224. We cannot know if these extremely low protein levels (probably because low 
protein stability) are the cause of the enzymatic defect, or if the mutation itself also 
alters COQ7 enzymatic function. What is clear is that the combination of these effects 
leads to a highly impaired COQ7 function. Other previously reported mutations in COQ7 
had been identified with the same extremely low expression feature. The mutations 
were p.Leu111Pro (very close to the here studied mutation) and p.Val141Glu (in the 
predicted di-iron center active site). After a treatment with a protease inhibitor, in order 
to prevent protein degradation, CoQ levels were not increased in those cases 238. 
P112 fibroblasts also show very low levels of COQ7 protein (Figure 2.7.A and C). This 
could be explained by the translation initiation defect induced by the homozygous 
mutation in the first codon. Localization studies have not been performed, but they 
would be interesting to decipher the mechanism by which COQ7 is translated (ATI or 







Figure 2.7. COQ7 and other COQ proteins levels in COQ7 Mutant Fibroblasts. 
Western blot analysis of COQ7 (A) and other COQ proteins (B) levels in whole fibroblasts lysates and their 
quantification (One-way ANOVA, Dunnett’s multiple comparison test, p-values<0.0001 (****))(C). An 
antibody against beta-actin (43KDa) was used as a loading control.  (D) Predicted structure of COQ7 
(PDB:5HJH, (Lohman et al., 2019)224) with different residues labeled: R107, the mutated amino acid  found 
in P102 patient (red); the region proposed to interact with COQ9 protein (pink)224; L111 and V141, amino 
acids found mutated in other patients (purple)238,239; the predicted di-iron center active site (E60, E90, 
H93, E142, E178 and H181) (green)457; other two amino acids reported important for protein activity (D50, 
R54) (blue) 458.  
 
We also checked the levels of other COQ proteins and they seem to be dysregulated, 
but this measurement was not significant. COQ4 and COQ5 seem to be upregulated, 
especially in P102 cells (Figure 2.7.B and C). This fact is probably caused by the low levels 




of COQ7, and would contribute to the instability and/or malfunctioning of the CoQ10 
biosynthetic machinery. We also tried to measure COQ6 and COQ2 levels, but the 
antibodies used did not show a clear signal. 
CoQ10 is increased with 2,4-dihydroxybenzoic acid treatment in a dose dependent manner, 
and DMQ10 is markedly reduced in both patient fibroblasts. 
We performed a supplementation with 2,4-dihydroxybenzoic acid (2,4-dHB), a structural 
analogue of 4-HB, that could be able to bypass the COQ7 deficiency. 2,4-dHB is a water-
soluble molecule that has the same structure than the quinone head precursor, 4-HB, 
and it also contains a hydroxyl group at C6, which is the position that COQ7 hydroxylates 
(Figure 2.8.A). With this molecule entering CoQ10 biosynthetic pathway, COQ7 activity 
would not be needed so it would be bypassed. It has already been demonstrated that 
2,4-dHB is able to increase lifespan and improve the phenotype in Coq7 398 and Coq9 
defective mice 278,399. It also has been proven to bypass the reaction in human fibroblasts 
with COQ7 238,239,388 and COQ9 mutations 278,388. Remarkably, the effectivity of 2,4-dHB 
to bypass COQ7 reaction depends on the nature of the COQ7 mutation itself and the 
residual activity of the protein 238. This has been already shown in fibroblasts from two 
different patients, in which 0.1mM 2,4-dHB supplementation during one week induced 
an increase in CoQ10 levels in the cells with the most severe CoQ10 deficiency (with a 
p.Val141Glu homozygous mutation in the predicted active site), while it did not have 
any effect in cells with a mild deficiency (with the p.Leu111Pro mutation). The treatment 
highly decreased DMQ10 accumulation in both cell lines 238.  
Particularly in our cases, we have observed that a 10 days treatment with 2,4-dHB is able 
to dose-dependent- and significantly increase cellular CoQ10 levels, while it has an 
inhibitory effect in controls (Figure 2.8.B and D). The effect on DMQ10 levels is even more 
drastic. DMQ10 levels are highly reduced at all concentrations of 2,4-dHB in both 
patients’ fibroblasts (Figure 2.8.C and E), while in controls it starts to be detectable only 









Figure 2.8. Quinone content after 2,4-dHB 
treatment in COQ7 Mutant Fibroblasts.  
(A) Structure of 2,4-dHB compared to 4-HB. 
P102 (B) and P112 (D) fibroblasts increase 
CoQ10 levels after 10 days of 2,4-dHB 
treatment, while in controls it has an 
inhibitory effect. DMQ10 levels are 
drastically reduced at all concentrations of 
2,4-dHB in P102 (C) and P112 (E). (One-way 
ANOVA with Dunnett’s multiple comparison 
test; each non-treated cell vs treated; p 
values: <0.05(*); <0.01(**); 0.001(***); 
<0.0001(****)).(F) Representative 




In comparison with the previously published treatments, in which only the cells from the 
V141E patient were increasing dose-dependently CoQ10 levels, higher concentrations of 
2,4-dHB were needed in order to see any effect on CoQ10 levels in P102. That could mean 




that the pathogenicity of the R107W mutation is probably in between the two mutations 
studied in the literature (V141E and L111P). For P112, which has a mutation probably 
affecting translation efficiency, treatment with 2,4-dHB (0.1mM and 5mM) significantly 
increases CoQ10 levels.  
The hallmark of 2,4-dHB treatment, more than increasing CoQ10, is significantly reducing 
the accumulation of DMQ10, which is probably in the core of the pathogenesis of the 
disease. This effect has been observed here and in all the other cases reported in the 
literature, with COQ7 and COQ9 patients’ fibroblasts or mice defective in the two same 
genes. In the case of the controls, an inhibitory effect of 2,4-dHB is always observed, 
leading to reduced levels of CoQ10. This could be probably due to a substrate 
competition between the 2,4-dHB and 2,4-dHB-derived molecules and the 4-HB 
endogenous substrate and intermediates, for the access to the enzymes upstream of 
the COQ7-hydroxilation step. 
Respiratory deficit is restored with 2,4-dihydroxybenzoic acid treatment. 
P102 showed a marked respiratory defect, while it was milder in P112 cells, as described 
before (Figure 2.6). After the 10 days of 2,4-dHB treatment, we observed a recovery in 
the respiratory capacity, being the response different in each patient fibroblasts (Figure 
2.9). 
P102 OCR showed a clear dose-dependent recovery after the treatment (Figure 2.9.A 
and C). The effects can be seen with the 0.1mM treatment, and they become more 
obvious with the high dose 5mM treatment. Especially, we can see a great recovery of 
the maximal respiration and the spare capacity. We can also observe an increase in the 
basal and coupled respiration rate. Controls show the opposite behaviour, being the 
treatment dose-dependently detrimental.  
In the case of P112, only 0.1mM of 2,4-dHB leaded to an improvement in mitochondrial 
performance (Figure 2.9.B and D). The treatment with the highest concentration, 5mM, 
did not influence in the OCR of these cells. This suggests that the dose of the treatment 
is important and specific for each cell line. The treatment is less detrimental for this 






Figure 2.9. Oxygen consumption rate (OCR) after 2,4-dHB treatment in COQ7 Mutant Fibroblasts.  
OCR profile shows a respiratory defect in P102 (A and C) and P112 (B and D) patients’ fibroblasts, and a 
recovery when they are treated with 2,4-dHB. Controls show the opposite behavior. Arrows indicate the 
addition of the individual inhibitors. (C, D) Seahorse quantitative data are graphed as mean ± SD ((n = 6–
17/group).  OL (oligomycin 4μM); FCCP (Carbonyl cyanide 4-(trifluoromethoxy)phenylhydrazone 1μM); 
Rot (rotenone 1μM); AntA (antimycin A 2.5μM).  
Two-way ANOVA with Sidak’s multiple comparison test:  
P102 vs HDF Neo (c, f:, p value<0.0001(****)).  
P112 vs B003 (j, l:, p value<0.0001(****)).  
Two-way ANOVA with Dunnett’s multiple comparison test:  
P102 vs 0.1mM treated P102 (a: p value<0.01(**), d: p value<0.0001(****), h: p value<0.001(***)) 
P102 vs 5mM treated P102 (b: p value<0.05(*), e: p value<0.0001(****), g: p value<0.0001(****), i: p 
value<0.05(*)) 
P112 vs 0.1mM treated P112 (k,m: p value<0.0001(****)) 
P112 vs 5mM treated P112 (non-significant) 





The benefits of 2,4-dHB treatment on mitochondrial respiratory rate can be explained 
by a combination of the induced CoQ10 increase and DMQ10 decrease. DMQ10 decrease 
is very drastic even with the lowest 2,4-dHB concentration (0.1mM), indicating that the 
treatment is inhibiting the natural CoQ10 biosynthetic pathway, from 4-HB to DMQ10, 
decreasing the DMQ10 accumulation. It seems CoQ10 production from 2,4-dHB 
(bypassing COQ7) would be slower than from 4-HB, and at this lowest concentration, 
CoQ10 synthesis from 2,4-dHB is not remarkable. When the concentration of the 
treatment is increased (5mM), the inhibition of the production of DMQ10 through the 
natural pathway stays the same, but more CoQ10 is being produced from 2,4-dHB. This 
can explain why the respiration rate is even better with this treatment (5mM) than with 
the 0.1mM in the case of P102. P112, however, behaves differently. The molecular 
mechanism explaining these differences needs further studies. Maybe other pathways 
or biological functions are responsible for this different behaviour.  
In the case of the controls, the picture is different. All the treatments lead to the same 
result on DMQ10 and CoQ10 levels. DMQ10 levels increase from not being detected, to be 
at the same levels than the treated patient cells, at least for the neonatal control. CoQ10 
levels decrease almost to the same levels than the 5mM treated patient cells. So, in this 
picture, control and patient cells treated with 5mM of 2,4-dHB have the same levels of 
DMQ10 and CoQ10, but the effect on the respiration capacity is totally different. 
Respiratory capacity of control cells is negatively affected with this treatment, while 
patient cells benefit from it. This could be explained as WT cells in normal conditions 
have higher CoQ10 levels and no detectable DMQ10, so they are adapted to this situation 
and the decrease in CoQ10 and increase in DMQ10 dysregulates the mitochondrial 
performance. In the patient’s cell lines, mitochondrial respiration would be adapted to 
be efficient enough in its basal conditions with a drastic CoQ10 deficiency and high 
DMQ10 accumulation, so they can significantly benefit when CoQ10 is slightly increased 





2,4-dihydroxybenzoic acid induces an increase in COQ7 protein levels 
Only P102 samples have been analysed in this section. Drastically reduced levels of 
mutant COQ7 protein are slightly increased with 2,4-dHB treatment (Figure 2.10). This 
effect is not only seen in the mutant protein, but also in the controls. This could mean 
that 2,4-dHB can be somehow stimulating COQ7 protein production or stabilising it. An 
effect on COQ7 expression has been observed previously in the literature 388, in controls 
and in COQ4 deficient fibroblasts. Also, COQ4 levels were increased with the treatment 
in controls and COQ9 and COQ7 deficient fibroblasts. COQ9 levels are increased as well 
in controls and COQ4 deficient fibroblasts with the treatment 388. The same effect was 
observed in COQ9 defective mice after 2,4-dHB treatment, in which this molecule 
increased COQs protein levels (COQ4, COQ5, COQ6, COQ8A) in some tissues 399. Other 
4-HB analogues have been proven to increase COQs proteins levels, such as VA. VA 
treatment increased COQ9, COQ7 and COQ4 levels in controls, COQ4 levels in COQ9 
deficient cells, COQ4, COQ7 and COQ9 in COQ7 deficient cells, and COQ7 and COQ9 in 
COQ4 deficient cells 388. Thus, regulation of other COQ proteins seems not to be a 
specific COQ7 phenomenon, but rather a generalised one.  
 
 
Figure 2.10. COQ7 protein levels in whole cell lysates of COQ7 
Mutant Fibroblasts. 
Western blot analysis of COQ7 protein levels in whole fibroblasts 
lysates (A) and their quantification (B). An antibody against beta-
actin (43 KDa) was used as a loading control. (One-way ANOVA with 
Dunnett’s multiple comparison test; each non-treated cell vs 








2.2.2. Primary CoQ10 deficiency due to defects in COQ6 gene 
COQ6 encodes a mono-oxygenase responsible for the addition of the hydroxyl group in 
position C5 of quinone ring 396. Patients with mutations in COQ6 present with a steroid-
resistant nephrotic syndrome (SRNS) associated with sensorineural deafness, and 
variable degree of encephalopathy (see Chapter 1, section 1.2.4) 233,459. In collaboration 
with Prof Leonardo Salviati’s group, we have studied CoQ10 deficiency in a continuous 
cell line lacking COQ6 protein. This cell line was generated in their laboratory, derived 
from HEK 293 cells by using the CRISPR/Cas9 technique. The results of this study have 
been recently published 165. In this section I present a brief summary of the research I 
have been directly involved in. 
COQ6 KO cells have extremely low CoQ10 levels and their CoQ10 biosynthesis is impaired, 
accumulating 4-HP10 
CoQ10 levels were markedly reduced in COQ6 KO cells compared to wild-type cells 
(Figure 2.11.A). Incorporation of 14C-labelled 4-HB to CoQ10 was virtually undetectable, 
indicating that the residual CoQ10 detected in these cells is not produced endogenously 
but it is derived from the medium (Figure 2.11.B). The chromatogram showed an 
additional radioactive peak only present in COQ6 KO cells, which eluted faster than 
CoQ10 (rt: 13 min). This peak was also observed with the ECD, meaning that this molecule 
has electrochemical activity. When the sample was oxidised before the injection in the 
HPLC, this 13 min rt peak shifted to a time very close but slightly before of the CoQ10 
peak (Figure 2.11.B). HPLC-coupled mass spectrometry of lipid extracts from WT and 
COQ6 KO cells allowed the characterisation of this compound as 3-decaprenyl-1,4-
benzoquinone (4-HP10), in agreement with the accumulation of 4-HP previously 
reported in yeast (Δcoq6 cells with coq8 OE 396 or expressing coq6 with point 
mutations342) and bacterial 460 models with a deficient C5 hydroxylation function.  
This result suggests that decarboxylation and hydroxylation of C1 can occur before or 
independently on C5 hydroxylation, and that this step is not dependent on COQ6 






Figure 2.11. Quinone content in COQ6 KO cells. 
(A) Total CoQ10 levels of HEK 293T COQ6 KO and wild 
type cells (Unpaired two-tailed t-test; p 
value<0.001). (B) Both cell lines were cultured with 
radiolabelled 14C-4-HB. Labelled quinones were 
detected by HPLC with a radio-flow detector (Rad), 
while total quinone content was detected by a 
electrochemical detector (ECD). COQ6 KO samples 
showed a preCoQ10 peak (rt 13 minutes), detected by 
Rad and ECD. This peak shifts to rt 18min when it is 
oxidised (right panels, with the oxidizing guard cell 
after the injector). This peak was identified as 4-HP10 
(by MS).  
 
Vanillic Acid Restores CoQ10 Biosynthesis and Cellular Respiration in COQ6 KO cells 
As presented in the introduction to this section, a possible therapeutic alternative to 
CoQ10 for COQ6 defects can be a bypass therapy based on vanillic acid (VA) 
supplementation (Figure 2.13.A). The capacity of VA to restore CoQ synthesis has been 
already proven in yeast expressing pathogenic versions of Coq6p. In this work, VA has 
been shown to restore CoQ10 production and mitochondrial respiration in a human cell 
line completely lacking COQ6 protein function.  





Figure 2.12. Proposed model of CoQ10 biosynthetic pathway in mammals.  
The fact that COQ6 KO cells accumulate 4-HP10 (red box) suggests that decarboxylation and hydroxylation 
of C1 can occur before or independently on COQ6 function (C5 hydroxylation).  
 
VA treatment is able to restore CoQ10 synthesis to WT levels (Figure 2.13.B) and, 
importantly, it also prevents the accumulation of the 4-HP10 intermediate. COQ6 KO cells 
are unable to respire, and after VA treatment, their OCR profile becomes very similar to 
the controls’ one (Figure 2.13.C and D). Treatment with VA is more efficient than CoQ10 
administration (Figure 2.13.C and D). This can be explained by the fact that VA 
supplementation allows CoQ production in the optimal concentrations and located in 
the natural environment, in the CoQ complex, next to the mitochondrial inner 
membrane, where it is needed for electron transport. In the case of CoQ10 
supplementation, is must arrive to this location to participate in this function. Although 
incorporation of CoQ10 in cell membranes after supplementation is demonstrated, its 
distribution and proper localisation could be suboptimal (See Chapter 4, section 4.2.3 







Figure 2.13. Quinone content and OCR after vanillic acid (VA) treatment in COQ6 KO cells.  
(A) Structure of VA compared to 4-HB. (B) COQ6 KO cells treated with VA have wild type levels of CoQ10, 
and the treatment does not show an inhibitory effect in controls (One-way ANOVA, Tukey’s multiple 
comparison test, p-value: <0.001 (***)) (C) Oxygen consumption rate (OCR) profile shows a total 
respiratory defect in COQ6 KO cells, and a partial recovery when they are treated with VA or CoQ10. VA 
treatment is more effective than CoQ10. Arrows indicate the addition of the individual inhibitors. OL 
(oligomycin 1μM); FCCP (Carbonyl cyanide 4-(trifluoromethoxy)phenylhydrazone 0.2μM); Rot (rotenone 
1μM); AntA (antimycin A 2.5μM).  
(D) Seahorse quantitative data are graphed as mean ± SD.  
Two-way ANOVA with Sidak’s multiple comparison test:  
COQ6 KO vs HEK WT (a, f, i:, p value<0.0001(****)).  
Two-way ANOVA with Dunnett’s multiple comparison test:  
COQ6 KO vs VA treated COQ6 KO (b, d, g, j:, p value<0.0001(****));  








2.2.3. Primary CoQ10 deficiency due to defects in COQ4 gene 
COQ4 is an essential protein for CoQ biosynthesis in eukaryotes. Its precise function is 
not known, but it has been shown that it interacts with other components of the CoQ 
biosynthetic complex. As for the other COQ genes, defects in COQ4 gene are a cause of 
CoQ10 deficiency. 35 patients from 26 families with COQ4 mutations (Figure 2.14) have 
been reported so far, presenting mostly as a fatal neonatal-infantile onset encephalo-
cardiomyopathy, and in a lesser percentage, as a childhood onset progressive 
spinocerebellar ataxia (see Chapter 1, section 1.2.4).  
Here, we report two new families with mutations in the COQ4 gene. One of them with 
one patient, P105, is similar to the majority of the patients reported in the literature. 
The second family is composed by two twin sisters (P108 and P109), with a milder 
progressive disease. To further investigate basic and disease-associated aspects of 
COQ4, we have also worked with a continuous cell line lacking this gene and the results 
will be detailed in Chapter 4. 
Mutations in COQ4 gene produce a severe disease with different clinical presentations 
P105 case was a girl from Denmark, who presented a birth-onset disease compatible 
with a COQ4 deficiency, but strikingly, instead of hypotonia, she showed hypertonia. She 
was suspected of a mitochondrial disease, so she started a CoQ10 treatment to try to 
avoid the worsening of the symptoms. Unfortunately, the development of the disease 
was very fast, and she died at the age of 16 months.  
P108 and P109 are two 14-years-old twin females who presented early-onset severe 
hypotonia, developmental delay and regression, seizures and hypertrophic 
cardiomyopathy. Plasma and cerebrospinal fluid lactate were normal and did not raise 
the suspicion of a mitochondrial disorder. P109 fatally progressed and recently died at 
17 years-old. 
Figure 2.14. Schematic representation of COQ4 mRNA (A) and protein (B).  
Mutations from P105 (orange), P108 and P109 (blue) patients are highlighted with boxes, showing the 
residue conservation in the alignment of COQ4 protein from different species (C). The rest of mutations 
shown (red boxes) correspond to the rest of COQ4 patients reported in the literature. The multiple 
alignment was performed with the protein sequences obtained in Uniprot, using Clustal X2 and BioEdit to 
visualize the results. UTR (untranslated region); MTS (mitochondrial targeting sequence; aa (amino acid); 
* (asterisk: single and fully conserved residue); : (colon: conservation between groups of strongly similar 










P105, P108 and P109 have biallelic mutations in COQ4 gene 
i. P105 case 
Exome sequencing of P105 revealed two heterozygous compound mutations in COQ4 
gene, and both parents were carriers of the mutations (Figure 2.14).  
One of the mutations (c.23_33delTCCTCCGTCGG, p.Val8Alafs*19, NM_016035.5) is a 
deletion of 10 nucleotides in exon 1, so a frame shift and an early truncated protein are 
predicted to be generated. This mutated allele is predicted to produce loss of function, 
since the defect occurs very early in the sequence, and the CADD in silico pathogenicity 
prediction tool also classify it as pathogenic (score=21.1) tool. To check its pathogenicity, 
COQ4 KO HEK cell line was transfected with this allele, and it was not able to restore 
CoQ10 biosynthetic function, confirming the lack of function of this aberrant allele (see 
Chapter 4, section 4.2.1). This mutation has been described previously in another COQ4 
patient with a birth onset encephalopathy with seizures, hypotonia and developmental 
delay. He also presented hearing loss and delayed visual maturation. He had 
hypertrophic cardiomyopathy and bradycardia, and he succumbed after a respiratory 
failure at 4 months of age. The other allele of COQ4 in this published case was also 
affected by the combination of two other mutations, c.311G>T and c.356C>T 
(p.Asp111Tyr and p.Pro119Leu)336.  
The other COQ4 mutation present in P105 is a point substitution in intron 5 (c.532+6 
T>A, p.?, NM_016035.5). This mutation is in the 5’ donor splice site of intron 5, so it may 
produce an aberrant COQ4 RNA splicing. This mutation is not described in the literature 
and nor present in the ClinVar database. Further details on this potential pathogenic 
variant will be provided in this section. 
ii. P108 and P109 cases 
Genetic tests revealed a novel homozygous mutation in COQ4 gene (c.437T>G, 
p.Phe146Cys, NM_016138.5) being both parents carriers of the mutation (Figure 2.14). 
This missense variant is located in exon 5, and it would probably affect protein stability, 
since it changes a very conserved phenylalanine (with an aromatic and hydrophobic side 
chain) to a cysteine (with a tiny sulfur-containing hydrophobic side chain). This mutation 





conflicting interpretations of pathogenicity. It is predicted to be pathogenic by SIFT 
(score=0), PolyPhen-2 (score=0.999) and CADD (score=29.2) tools. Sanger sequencing 
confirmed the segregation of the variants in parental DNA, being both parents 
heterozygous carriers. To check its pathogenicity, COQ4 KO HEK cell line was transfected 
with this allele. Overexpressing COQ4 with p.Phe146Cys mutation was able to restore 
COQ4 function and CoQ10 production to WT levels, indicating that this mutation is 
probably hypomorphic and it only partially affects COQ4 function (see Chapter 4, section 
4.2.1), which will also explain the milder phenotype of the siblings. 
Significance of the intronic c.532+6 T>A mutation in P105: Splicing alterations 
c.532+6 T>A is a point substitution mutation in intron 5, precisely, inside the 5’ donor 
splice site. Its pathogenicity may rely in the alteration of COQ4 pre-mRNA splicing.  
Pre-mRNA splicing is an essential process for the production of a functional protein. 
Mutations can alter this mechanism, affecting the RNA processing in different ways 
(skipped exons, alternative 5’ donor splice sites, alternative 3’ acceptor splice sites, 
retained introns and mutually exclusive exon usage) and these diverse molecular 
phenotypes can result in disease. Mutations that affect splicing of pre-mRNA account 
for at least 15% of disease-causing mutations with up to 50% of all mutations described 
in some genes 461.  
Understanding the molecular mechanisms through which a mutation is pathogenic is 
crucial for understanding the clinical phenotype, in order to advance for the 
development of novel therapeutic approaches. NGS has allowed identifying an 
enormous number of new genomic variants with unknown significance. The 
development of in silico prediction methods based on bioinformatical algorithms is very 
useful for a preliminary approach to classify the variants for later in vitro studies.  
In order to bioinformatically predict the spliceogenicity of the variant of interest, we 
have used a prediction tool called SPiCE 219. It works with two probability thresholds to 
set optimal sensitivity (ThSe=0.115) and specificity (ThSp=0.749). The tool provides a P 
probability for a given variant, that must be above the 2 optimal thresholds, to be 
classified as variant with high probability to alter splicing.  




SPiCE P for c.532+6 T>A variant is 73.382%, just below ThSp (74.9%) (Figure 2.15). It is in 
the region predicted to have medium probability to alter splicing, but very close to be 
considered to have high probability.  
 
 
Figure 2.15. NM_016035.5: c.532+6T>A variant 
spliceogenicity prediction by SPiCE program.  
(A) Graph shows that probability of c.532+6T>A variant to 
alter splicing is in the area considered of medium 
probability to alter splicing (grey), but close to the high 
probability (red).  (B) Table shows detailed information 
about the prediction. 
 
We have also used the RNAfold server206 to predict the secondary structure of the pre-
mRNA that would contribute a state of minimum free energy (Figure 2.16). As input, we 
have used a sequence containing the nucleotide that is found mutated in P105 patient 
and 100 (Figure 2.16.A) or 200 nucleotides (Figure 2.16.B) flanking it upstream and 
downstream. By comparing the WT and the mutant predicted RNA secondary structure, 
we find differences in the resulting structures. In both tested cases (100 or 200 
nucleotides flanking the mutation), the mutant sequence folding is different than the 
WT, changing the position and the pairing of some loops. Moreover, the mutant 
sequence also reduces the base pairing probabilities for several base-pairs that are not 
only close, but also far away from the mutation (Figure 2.16). Maybe, all these possible 








Figure 2.16. Minimum free energy structure of WT and c.532+6T>A mutant pre-mRNA.  
The minimum free energy RNA structure of a sequence containing the NM_016035.5: c.532+6 position 
and the upstream and downstream 100 (A) or 200 (B) flanking positions was calculated by using RNAfold 
server. WT (right) and c.532+6T>A mutant (left) structures are represented. The colour of each base pair 
indicates their probability to be paired (see colour legend). Blue arrows point the c.532+6 position. 
 
 




Further in vitro studies are needed to confirm the spliceogenicity of this variant, in order 
to confirm if its pathogenicity rely in the alteration of pre-mRNA splicing and to 
specifically identify which is the effect on COQ4 mRNA. The most commonly used in vitro 
methods for validating mutant mRNA are minigene constructs expression and RT-PCR 
analysis of the patient mRNA. The development of high throughput transcriptomics, 
such as RNA-Seq, has brought the possibility of studying alternative splicing events in a 
genome wide context, with computational tools that use the RNA-Seq data.  All these 
approaches show some advantages and some limitations. The minigene approach is able 
to analyse the transcript produced by a single allele, while this is not possible when 
analysing of the patients’ transcriptome by RT-PCR or RNA-Seq. In contrast, RT-PCR can 
analyse the effect of a certain mutation in the splicing of the whole transcript, while the 
minigene analyses each variant separately from the natural whole mRNA context. 
Moreover, RNA-Seq has the advantages of being high throughput and non-targeted 
462,463.  
i. Minigene constructs 
In collaboration with Dr Eva Trevisson’s laboratory in Padova, minigene constructs were 
used to analyse the spliceogenicity of this variant (Figure 2.17). The patient’s genomic 
DNA fragment carrying the c.532+6 T>A variant to analyse was amplified and 
subsequently cloned inside the ß-globin minigene contained in a pcDNA™3.1/Hygro(+) 
vector (Figure 2.17.A), as well as the equivalent WT sequence. The fragment amplified 
consisted in the exon closest to the intronic variant to analyse, in this case, COQ4 exon 
5, and a portion of 100 bp of flanking intronic regions upstream and downstream. WT, 
mutant and empty ß-globin vector were transfected in HEK293 cells that do not express 
ß-globin. 24 hours after transfection, total RNA was extracted, retrotranscribed and the 
resulting cDNA was amplified with a semiquantitative-PCR, using specific primers for the 











Figure 2.17. RT-PCR analysis of the COQ4 
(c.532+6T>A variant) minigene constructs 
expressed in HEK cells.  
(A) Schematic representation of the hybrid minigene 
constructs. The construct contains the closest exon 
to the variant, COQ4 exon 5, and part of the 
upstream and downstream introns. (B) Cells were 
transfected with the mutant and the wild type 
constructs, and results of RT-PCR are shown in the 
agarose gel. The relative amounts of the different 
forms were determined by densitometry. (C) 
Schematic representation of the spliced transcripts 
found. Ex, exon; C-, negative control of transfection; 
EV, transfection with empty β-globin-pCDNA3.1 
vector; WT, wild-type construct; MUT, construct 
carrying c.532+6 T>A variant. This experiment was 
performed by Dr Eva Trevisson’s group. 
 
 
Both the WT and the c.532+6 T>A variant in intron 5 yielded two products, but in 
different proportions (Figure 2.17.B and C). The mutated construct predominantly 
produced a fragment lacking exon 5 (87% of the total amplification), but also produced 
the WT fragment (13% of the total amplification). This splicing mutation seems to be an 
hypomorphic allele mutation, predominantly leading to exon 5 skipping, at least when 
it is studied in exon 5 context. Curiously, WT construct also led to the fragment lacking 
exon 5, but in a smaller proportion (16%), indicating this alternative splicing event can 
also occur with the WT sequence.  
 
 





In order to have a wider picture, we amplified COQ4 whole transcript from patient and 
control fibroblasts RNA (converted to cDNA). The semiquantitative PCR product was run 
into agarose gels, showing different results for controls and patient (Figure 2.18.A-C). 
Control samples showed a predominant band with COQ4 whole transcript length (Band 
1). In patient samples, this band was less intense, and several bands with lower 
molecular weight were more predominant. These 4 extra bands (Bands 2-5) were also 
present in control samples, but fainter. We interpreted these bands could be different 
molecular products of COQ4 pre-mRNA splicing, that are present naturally in the control, 
but enhanced in the mutant. It needs to take into account that we are looking at a 
picture of the effect of both mutations in the two COQ4 alleles. Our results suggest that 
the presence of the splicing mutation leads to unbalancing the normal splicing of COQ4, 
favouriting the presence of this alternative splicing. It is also possible that the frameshift 
mutation leads to NMD, which could affect the whole COQ4 transcript with that 
mutation, while the alternative spliced isoforms coming from the other allele would 
proportionally increase their presence. Of course, the final effect can be an addition of 
the effects of these two factors, or even others. 
Each of these bands was purified, subcloned and sequenced. Sequencing told us that, 
both in controls and patient, alternative COQ4 splicing occurs, producing different COQ4 
isoforms (Figure 2.18.D and Table 2.1). The first band (Band 2), included 2 different 
isoforms, one of them lacking exon 3 (p.Asp68Glyfs*34) and the other one lacking exon 
5 (p.Arg135Glyfs*5). Both of these isoforms would lead to a frameshift and truncated 
form of COQ4. The second band (Band 3) resulted to be COQ4 lacking both exon 3 and 
5, which would have the same frame shift than the one lacking only exon 3 
(p.Asp68Glyfs*34). The third band (Band 4) was identified as a COQ4 isoform lacking 
exons 3 to 5. This isoform was interpreted as a deletion of all the amino acids present in 
exons 3 to 5 (p.del68-177). The last band (Band 5) was sequenced as an unspecific 






Figure 2.18. RT-PCR analysis of COQ4 
transcripts in P105 and control fibroblasts. 
(A) Five (1-5) bands appeared in both P105 
and control cDNA samples. C+ is a positive 
control from a plasmid with full-length COQ4 
cDNA. (B) The relative amounts of the 
different forms were determined by 
densitometry and expressed as a percentage 
(B and C). (Two-way ANOVA, Sidak’s multiple 
comparison test, p-values: <0.001 (***)). (D) 
Schematic representation of the spliced 
transcripts found in each band. Iso, isoform. 
 
Curiously, the two most frequently excised exons (3 and 5) are preceded by the longest 
introns (1,995 bp and 6,271 bp, respectively). Maybe the presence of the mutation in 
the 5’ donor splice site of exon 5 is altering the pre-mRNA secondary structure and 
therefore, affecting the coordination of the splicing process across the whole COQ4 
transcript. This could result in the alteration of the order of intron splicing, or even to 
the inhibition of certain splice events, leading to the various effects that we have 
observed. 
















Iso a 1 Full length COQ4 mRNA 798 - 29.6 
Iso b 2 Missing Exon 3 701 Asp68Glyfs*34 10.7 
Iso c 2 Missing Exon 5 668 Arg135Glyfs*5 15.3 
Iso d 3 Missing Exons 3 and 5 571 Asp68Glyfs*34 10.7 
Iso e 4 Missing Exons 3 to 5 468 del68-177 17 
In order to characterise if these isoforms had COQ4 function, bands were cloned in 
pcDNA5, and transfected into HEK COQ4 KO cells. Only the whole COQ4 transcript 
expression was able to restore COQ4 function and CoQ10 production in these cells, 
meaning these isoforms can’t replace COQ4 function in CoQ biosynthesis when it is 
absent (See Chapter 4, section 4.2.1). 
iii. RNA sequencing 
Total RNA from patient and control fibroblasts was also subjected to RNA-Seq analysis, 
in order to validate the increased alternative splicing events that were observed with 
the minigene and the RT-PCR analysis. From the read histogram, we can see how P105 
sample shows lower number of reads of exon 3, mainly, and also exon 5 (Figure 2.19.A 
and B). Different splicing events were detected, and splice junctions reads were 
quantified (Figure 2.19.A, B and C). All splicing events were quantified as a percent 
spliced, which represents the percentage of a gene’s mRNAs transcripts that include a 
specific splice junction (Figure 2.19.D). These results are very similar to what was 
observed by RT-PCR and minigenes. Exons 3 and 5 are more frequently excised in cells 
from patient P105, which carry the c.532+6 T>A variant in intron 5.  
The splicing event found in the variant named Iso e (Table 2.1), from exon 2 to exon 6, 
was not found by the RNA-Seq. It is possible that the reads depth of this experiment was 
not enough to capture it. However, it is also possible that it is only produced anecdotally, 
and was only amplified by chance by the RT-PCR. Also, an alternative splicing event was 
also observed in the middle of intron 2, leading to a very short transcript. 
We are only seeing the final effect of the mutation (in combination with the 
c.23_33delTCCTCCGTCGG deletion mutation in the other allele). To exclude a general 
splicing defect, we checked splicing events in COQ2 and TFAM mRNAs and there were 
no differences between the control and P105 samples. To check both alleles were being 





the nucleotides that are deleted in one of the alleles of the patient, 
c.23_33delTCCTCCGTCGG, were measured and compared with the number of reads of 
the 10 nt downstream this deletion (control region, c.33-42). In the case of the WT, both 
regions had the same number of reads, while in the patient’s RNA, the control region 
had the double of reads than the deletion. This indicated that COQ4 mRNA is being 
produced from both alleles in a 1:1 proportion (Table 2.2).  
Table 2.2. Number of reads of the COQ4 c.23-32 and c.33-42 regions, to distinguish transcripts 

























chr9:128,322,881 T 47 274 
49 ± 1 281 ± 6 45% ± 1% 95% ± 2% 
chr9:128,322,882 C 48 275 
chr9:128,322,883 C 48 275 
chr9:128,322,884 T 49 278 
chr9:128,322,885 C 49 279 
chr9:128,322,886 C 49 279 
chr9:128,322,887 G 49 287 
chr9:128,322,888 T 49 283 
chr9:128,322,889 C 51 287 
chr9:128,322,890 G 52 289 
Control 
region 
chr9:128,322,891 G 104 290 
108 ± 3 297 ± 6 100% ± 3% 100% ± 2% 
chr9:128,322,892 C 104 291 
chr9:128,322,893 T 105 290 
chr9:128,322,894 C 107 294 
chr9:128,322,895 T 108 294 
chr9:128,322,896 G 109 299 
chr9:128,322,897 C 109 302 
chr9:128,322,898 G 112 304 
chr9:128,322,899 G 110 302 
chr9:128,322,900 G 112 303 
 
How the c.532+6 T>A variant (in combination with the c.23_33delTCCTCCGTCGG 
deletion mutation in the other allele) leads to an aberrant splicing alteration is unknown 
yet. Elucidating the mechanisms by which COQ4 pre-mRNA is spliced and the effects of 
this mutation could be a target for therapy design. 





Figure 2.19. RNA-Seq analysis of COQ4 transcripts in P105 and control fibroblasts.  
RNA-Seq histogram plots of control (A) and P105 (B) RNA samples. Height of the bars represents read 
coverage. Splice junctions are displayed as arcs, each one with its own number of reads. Canonical splicing 
events are indicated above the histograms, while alternative splicing events are displayed below the 
histograms. (C) Transcript models representing the different splice variants, according to the splicing 





COQ4 patients’ fibroblasts have drastically reduced CoQ10 levels, impaired CoQ10 
biosynthesis and accumulation of a specific intermediate. 
In order to investigate the degree of affectation of CoQ10 biosynthesis due to these 
COQ4 mutations, total levels of CoQ10 were analysed for all the three patients.  
CoQ10 concentration in skin fibroblasts was measured by HPLC, and, in the case of P105, 
we were able to analyse CoQ10 levels in skeletal muscle as well. In this patient, CoQ10 
levels in skeletal muscle (154.37 pmol CoQ10/mg of protein, control range 300-700) 
(Table 2.3) and skin fibroblasts (more than 50% of deficiency) were found to be severely 
reduced (Figure 2.20.A). Citrate synthase activity was also found to be slightly reduced 
in skeletal muscle (82.8 CS units/L, control range 88-240), indicating that this primary 
CoQ10 defect could lead to a defect in mitochondria in muscle (Table 2.3). In the case of 
P108 and P109, two different control fibroblasts were used, HDF Neo (neonatal control 
fibroblasts) and B003 (fibroblasts from a 20-year-old healthy person), because we did 
not have the information about the age of the patients when the skin biopsy was 
performed. P108 and P109 fibroblasts showed a 65% of CoQ10 deficiency comparing to 
HDF Neo control and a 53-55% of deficiency comparing to B003 control (Figure 2.20.C). 
Table 2.3. P105 CoQ10 levels in skeletal muscle. 
Skeletal muscle 
CoQ10 levels  
(pmol CoQ10/mg protein) 
CS activity 
(Units/L) 
P105 154.37 82.8 
Controls 300-700 88 - 240 
 
Incorporation of radiolabelled 4-HB, the quinone head precursor, revealed a drastic 
defect on CoQ10 biosynthetic rate in all the three patients’ fibroblasts, and the 
appearance of a radioactive peak different to CoQ10 (rt:13.5min), and different to the 
intermediates accumulated in the cases of COQ7 (DMQ10) and COQ6 (4-HP10) deficiency 
(Figure 2.20.B and D). This could indicate that CoQ10 synthesis is impaired at some 
specific step in which COQ4 would participate, assist, or be needed to.  
This is the first time that mammalian COQ4 deficiency is described to produce the 
accumulation of a yet unknown intermediate of the pathway, which provides key 
insights about COQ4 function in CoQ10 biosynthesis. Efforts on identifying this molecule 
will be described in next sections (see Chapter 4, section 4.2.1). 





Figure 2.20. Quinone content in COQ4 Mutant Fibroblasts, P105 (A, B) and P108 and P109 (C, D).  
(A) P105 shows CoQ10 deficiency in fibroblasts (Unpaired two-tailed t-test; p value<0.05 (*)). (C) P108 and 
P109 fibroblasts also show low levels of CoQ10 (Two-way ANOVA, Tukey’s multiple comparison test, p-
values: a= P108 vs. HDF Neo, p<0.0001 (****), P108 vs. B003, p<0.0001 (****); b= P109 vs. HDF Neo, 
p<0.0001 (****), P109 vs. B003, p<0.001 (***)). The HPLC-radioactivity chromatogram (B, D) showed the 
incorporation of 14C-4-HB to the quinone extract. While control cells show a radioactive CoQ10 peak, all 
patients’ fibroblasts present 2 peaks, one corresponding to CoQ10, and another probably corresponding 








Patients’ fibroblasts respiration is impaired in different degrees 
Respiration studies in COQ4 mutant fibroblasts and controls were performed, and P105 
and P108/P109 displayed a different behaviour. 
P105 fibroblasts showed a significant decrease in OCR, especially observed through a 
lower maximal respiration rate and spare capacity (Figure 2.21.A and B). This means that 
P105 cells are less able to respond to energetic demands than control cells, which may 
be due to CoQ10 deficiency, but also because of the accumulation of the unknown 
intermediate, as it occurs with DMQ10 in COQ7 and COQ9 deficiency. 
 
Figure 2.21. Oxygen consumption rate (OCR) in COQ4 Mutant Fibroblasts.  
OCR profile shows a respiratory defect in P105 (A) and P109 fibroblasts, but not in P108 (C). Arrows 
indicate the addition of the individual inhibitors. OL (oligomycin 4μM); FCCP (Carbonyl cyanide 4-
(trifluoromethoxy)phenylhydrazone 1μM); Rot (rotenone 1μM); AntA (antimycin A 2.5μM). 
(B, D) SeaHorse quantitative data are graphed as mean ± SD.  
(B) P105 vs. HDF Neo. Two-way ANOVA with Sidak’s multiple comparison test.  
p values<0.0001 (****).   
(D) Two-way ANOVA with Tukey’s multiple comparison test. p values:   
a: P108 vs. B003, p<0.05; P108 vs. HDFNeo, p<0.0001; P108 vs. P109, p<0.0001. 
b: P109 vs. B003, p<0.0001; P108 vs. P109, p<0.0001. 
c: P108 vs. B003, p<0.001; P108 vs. HDFNeo, p<0.0001; P108 vs. P109, p<0.0001. 
d: P109 vs. B003, p<0.0001; P109 vs. HDFNeo, p<0.05; P108 vs. P109, p<0.0001. 




In the case of P108 and P109, both cells behaved differently (Figure 2.21.C and D). P109 
presented lower maximal respiration rate and spare capacity compared to both controls 
used, while P108 had these two parameters in between the two controls. This 
characteristic fits with the fact that P109 fibroblasts grow slower and show a more 
senescent phenotype in culture, compared to P108 fibroblasts. Comparing both 
patients’ cells to B003 control, they have a decreased capacity to respond to energetic 
demands, which is indicative of reduced cell fitness or adaptability. When treated with 
5 μM of CoQ10 for 10 days, P109 experienced a slight improvement in maximal 
respiration and spare capacity, becoming more similar to P108 and controls (Figure 
2.21.D). 
COQ4 protein levels are drastically reduced in patients, and other COQ proteins are 
dysregulated.  
COQ4 protein levels were analysed in whole cell lysates from controls’ and patients’ 
fibroblasts, showing extremely low levels of mutant COQ4 protein in the fibroblasts of 
all patients compared to controls (Figure 2.22.A and B). In the case of P105, the very low 
levels of COQ4 protein agrees with the fact that the frameshift mutation is not predicted 
to produce any full length COQ4 protein, and it seems that it would happen the same 
with the splicing mutation. In the case of P108 and P109, the homozygous mutation 
could destabilize the protein, leading to its degradation, or could destabilize the mRNA, 
leading to NMD. 
We also checked the levels of other COQ proteins, since the alteration in one of the 
proteins of the CoQ10 biosynthetic complex could have effects on the stability of the rest 
of the proteins participating in the complex. Our results show that some of these 
proteins seem to be dysregulated (Figure 2.22.A and C-E). COQ7 is downregulated in 
comparison to controls, while COQ5 seems to be upregulated in P108 and P109 cells. 






 Figure 2.22. COQ4 and other COQ 
proteins levels in COQ4 Mutant 
Fibroblasts. 
Western blot analysis of COQ4 and other 
COQ proteins (A) levels in whole 
fibroblasts lysates and their 
quantification (B-E) (One-way ANOVA. 
Dunnett's multiple comparisons test, 
each patient vs. HDF Neo/B003, p 
values: <0.05(*); <0.01 (**)). An 
antibody against beta-actin (43KDa) was 










In this chapter, we worked with different in vitro cellular models of primary CoQ10 
deficiency: COQ4 and COQ7 patients’ fibroblasts and immortal HEK cell lines knocked-
out in COQ4 and COQ6. The main conclusions derived from this work are the following: 
i. New cases of primary CoQ10 deficiency due to mutations in COQ4 and COQ7 
genes have been described, widening the clinical phenotype attributed to these 
disorders. Unreported variants in COQ4 and COQ7 expand the genotype of these 
disorders.  
ii. Cell models with mutations in COQ4, COQ6 or COQ7 have low levels of CoQ10 and 
impaired biosynthesis, reduced CII+III activity and impaired respiratory 
performance. 
iii. Primary CoQ10 deficiency cell models accumulate diagnostic intermediates, 
specific for each COQ defect. COQ6 deficient cells accumulate 4-HP10, COQ7 
deficient cells accumulate DMQ10 and COQ4 deficient cells accumulate a yet 
unknown intermediate of CoQ10 synthesis.  
iv. Treatment with 4-HB analogues is effective in some of the primary CoQ10 
deficiency cell models. 2,4-dHB decreases DMQ10 accumulation, increases CoQ10 
levels and ameliorate respiratory function in COQ7 mutant fibroblasts. Vanillic 












Chapter 3.  
COQ4 gene and protein characterisation 
3.1. Introduction 
3.1.1. COQ4 yeast gene and protein 
COQ4 gene was first described  as one of the genes needed for CoQ6 production in the 
yeast S. cerevisiae 464. coq4 yeast gene, also known as YDR204W, is located in 
chromosome IV 858,137-859,144, and it spans 1,008 bp. The transcript 
(NM_001180512.1) produces a 335 aa-long protein (O13525) with a calculated 
molecular mass of 38.6 kDa. 
Work in yeast have provided comprehensive knowledge on CoQ biosynthesis in general, 
and coq4, in particular. coq4 null yeast has proven that coq4 is essential for CoQ 
production in yeast, but its exact function remains unclear. Coq4 yeast protein (Coq4p) 
has been shown to be peripherally associated to the matrix side of the mitochondrial 
inner membrane 464 and it has been suggested to play a structural role in stabilizing the 
CoQ biosynthetic complex, which contains most of the CoQ biosynthetic enzymes 465,466. 
The lack of coq4 in S. cerevisiae causes the instability of several Coq proteins, such as 
Coq7p and Coq3p and, importantly, the accumulation of hexaprenyl-hydroxybenzoate 
(HHB), an early precursor of the pathway (the molecule resulting when Coq2p binds the 
quinone head to the lipid tail) 467,468 (See Chapter 4, Section 4.1.5.).  
3.1.2. COQ4 human gene and protein 
Human COQ4 gene was first identified by Casarin and colaborators 469. It is located in 
the long arm of chromosome 9, specifically in the cytogenetic region 9q34.11 (Figure 
3.1.A). COQ4 genomic sequence spans chr9:128,322,544-128,334,072 (GRCh38.p13), in 
the forward strand (11,528 bp). Four different protein coding transcripts are annotated, 
but only the longest one is thought to produce a functional COQ4 protein (isoform 1) 
(Figure 3.1.B). This transcript (1,245 bp, NM_016035.5) encodes a 265 aa (7 exons) 
protein with a predicted molecular mass of 29.7 KDa (NP_057119.3) (Figure 3.1.C). 
Human COQ4 has 39% of identity and 55% of similarity with yeast Coq4p, and it is able 




to complement coq4 function in a coq4 null yeast mutant 469. Human COQ4 has a 
mitochondrial localization signal, leading to a mitochondrial targeted protein. Another 
transcription initiation site located within intron 1 was described to produce a shorter 
transcript and a shorter protein COQ4 (isoform 2). Isoform 2 starts at methionine 25 in 
exon 2, and it’s not targeted to mitochondria, as it lacks the amino acids that specify the 
predicted mitochondrial targeting sequence, so it would probably lead to a 
cytoplasmatic protein 469. This phenomenon is known as alternative translation 
initiation, and it can generate proteins targeted to different cell compartments, where 
they may exert different functions 450.  
 
 
Figure 3.1. Schematic representation of COQ4 
genomic localization (A), mRNA (B) and protein 
(C) sequences.  
Legend shows the scale of the sequences 
represented. UTR (untranslated region); MTS 
(mitochondrial targeting sequence; aa (amino 







COQ4 function in mammals is still unknown, but it has been identified as a part of a 
putative biosynthetic complex, with interactions with some COQ proteins (See Chapter 
4, sections 4.1.5 and 4.2.2.). For example, tagged COQ5 and COQ4 proteins co-
immunoprecipitated when co-expressed in HEK293 cells 470. Additionally, numerous 
interactions between different COQ proteins were also confirmed by cell-free protein 
expression and purification studies 438. Recently, a COQ4-containing protein complex in 
the range from 66 kDa to below 480 kDa was detected by 2D-BN-PAGE 315. Defects in 
COQ4 gene are a cause of CoQ10 deficiency, as we have seen in Chapter 1 (section 1.2.4) 
and 2 (section 2.2.3).  
Further insights in human COQ4 function are needed, in order to understand how this 
protein contributes to CoQ biosynthetic pathway, and how this process is altered in 
primary CoQ deficiency due to COQ4 mutations. This is crucial, so we could improve 
early diagnosis, therapeutic approaches and genetic advising. With this in mind, we can 
consider human cellular models a useful tool to better understand the disease 
mechanisms. Some examples of this models are skin fibroblasts from patients or 
immortal cell lines genetically modified to knock out the COQ gene we are interested in 
studying (see Chapter 2). Studies with immortal KO models can be greatly valuable, since 
these cells grow easily, and they can provide a homogeneous genetic background to 
study different defects. The recent advances in effective genome editing tools, such as 
CRISPR-Cas9, allows us to easily generate these models of extraordinary applicability in 
rare diseases research. 
3.1.3. Generation of KO models using the CRISPR/Cas9 system 
CRISPR (Clustered Regularly Interspaced Short Palindromic Repeats) sequences and Cas 
(CRISPR-associated) proteins are the two elements of an ancient microbial adaptive 
immune system 471–473, converted into the most powerful genome editing tool 474 (Figure 
3.2). The repeats (CRISPRs) are short, directly repeating nucleotide sequences flanked 
by short unique DNA fragments (protospacers), which have been acquired by bacteria 
from infections with invading phages. The CRISPR sequences are transcribed to make 
the pre-CRISPR RNA (pre-crRNA), which is then processed into individual crRNAs by a 
trans-activating crRNA (tracrRNA) with homology to the short palindromic repeat.  





Figure 3.2. Overview of CRISPR-Cas9 technique for gene editing, and the endogenous mechanisms of 
DNA repair of the cell (NHEJ/HDR).  
(A) The crRNA:tracrRNA from bacteria have been fused in a synthetic guide RNA (gRNA) to simplify its use 
for genome editing. (B) Cas9/gRNA complex produces a double strand break (DSB) at the target genomic 
locus, which have to be adjacent to a PAM (Protospacer Adjacent Motif; NGG in Cas9 from S. pyogenes). 
Repair will proceed through non-homologous end-joining (NHEJ) (C) or homologous directed repair (HDR) 





The tracrRNA helps recruit RNAse III and Cas9 enzymes, which together separate the 
individual crRNAs, forming the crRNA:tracrRNA:Cas9 complexes, each one having a 
specific crRNA sequence (protospacer). Each complex can bind infectious DNA 
molecules complementary to the crRNA’s protospacer, and the nuclease Cas9 produces 
a double strand break (DSB), cleaving and destroying the invader. After the DSB, the 
crRNA:tracrRNA:Cas9 complex unbinds. In Type II CRISPR systems, a potential target 
sequence is only valid if it contains a special Protospacer Adjacent Motif (PAM) directly 
after where the crRNA would bind. The most commonly-used Cas9 from Streptococcus 
pyogenes recognizes the PAM sequence 5′-NGG-3′ (where N can be any nucleotide base) 
(Figure 3.2). 
To translate a complex prokaryotic system into a simple genome editing tool, the crRNA 
and the tracrRNA were fused in a synthetic small guide RNA (gRNA), composed by a 
hairpin RNA structure linked to a 20 bp sequence homologous to the target DNA (Figure 
3.2.A). Then, the Cas9 nuclease can complex to the gRNA, and be guided to the genome 
region complementary to the gRNA, where it cleaves both strands of the DNA (Figure 
3.2.B). At this point, the cell will try to repair the break and that is when the potential 
for genome editing arises. The cells repair these DSBs by standard cellular repair 
mechanisms, either by non-homologous end joining (NHEJ), introducing small insertions 
or deletions into the sequence (Figure 3.2.C), or homologous directed repair (HDR), 
copying the genetic information from homologous DNA molecules (Figure 3.2.D). 
Depending on the mechanism used, the sequence at the repair site can be modified by 
indels, or new genetic information can be inserted 166,475. HDR needs the use of a repair 
template with the desired modifications (such as point mutations that affect the 
targeted sequence, and even the PAM, to prevent repeated cleavage of already repaired 
sequences (Figure 3.2.D). 
Knock-out generation benefits from the indels generated with NHEJ repair (Figure 3.2.C), 
that alter the original sequence, and by probability, can produce a shift in the ORF and 
a generation of a new stop codon, early in the protein. If the defects occur in all the 
alleles, the cell will not be able to produce the WT protein, meaning it will be knocked 
out for this gene 476.  




Cas9 generates DBSs in the region of the genome where the gRNA has guided to. 
However, off-target activity can also occur, sometimes very frequently, inducing 
mutations at sites other than the intended on-target site. One strategy to reduce this 
off-target activity is the use of two paired nickases, guided by two different gRNAs. Cas9 
nickase is a catalytically mutant Cas9 that is able to introduce a single-strand break (SSB) 
with the same specificity as a regular Cas9 nuclease. These SSBs can be repaired without 
inducing indels. In order to create DSBs, two paired nickases guided by two gRNAs 
targeting adjacent regions must be used. Because both nickases must effectively nick 
their target DNA, paired nickases have significantly lower off-target effects compared to 
the regular CRISPR/Cas9 system 477. 
3.2. Results and discussion 
We have previously seen that COQ4 is an essential protein for CoQ biosynthesis. In this 
Chapter we will extract as much information as we can from its gene and protein 
sequences, and we will generate a model to study COQ4 function. 
3.2.1. COQ4 in silico characterisation 
Gene sequence localization and genomic context 
COQ4 human gene is located in chr9:128,322,544-128,334,072 (GRCh38.p13), in the 
forward strand (Figure 3.1). Different transcripts are annotated. Five of them are protein 
coding, but only the longest one is thought to produce COQ4 protein (isoform 1). This 
transcript (1245bp, NM_016035.5) encodes a 265aa (7 exons) protein with a predicted 
molecular mass of 29.7 KDa (NP_057119.3).  
COQ4 (plus strand) shares 5’ regulatory region with TRUB2 gene (minus strand) (Figure 
3.3), which encodes a mitochondrial mRNA pseudouridine synthase essential for the 
mitochondrial 16S rRNA, thus, for mitochondrial protein translation 478,479. However, the 
functional significance of pseudouridinilation in mRNA is not characterised yet. This 
disposition is conserved throughout vertebrates, with some exceptions. The significance 
of this conservation is unknown, but it could suggest a shared or opposite regulation of 







Figure 3.3. Visualization of human COQ4 gene in its genomic context.  
Data obtained and visualised with UCSC genome browser, Genome Data Viewer (NCBI’s genome browser) 
and Ensembl Genome Browser. 
 
This head-to-head arrangement of gene pairs on opposite strands is not rare in the 
human genome. More than 10% of protein-coding genes are arranged this way, with 
transcription start sites (TSS) that are separated by less than 1,000 base pairs, being this 
percentage significantly larger than expected by chance 480. These gene pairs are termed 
‘bidirectional’, and the regions between the TSS of these gene pairs (their regulatory 
region) are known as bidirectional promoters. These sequences can regulate the genes 
in both directions. Bidirectional promoters are associated with gene pairs whose levels 
of transcription need to be expressed in a co-ordinately mechanism, such as genes co-
expressed in the same biological pathway. The bidirectional arrangement of promoters 
is also highly conserved among different species, which indicates functional 
importance481. 
Some data support the definition of this COQ4-TRUB2 region as a bidirectional 
regulatory region for both COQ4 and TRUB2. It has been described that TATA box 
occurrence in bidirectional promoters is significantly lower compared to the genome 
average, being the motif of TATA sequence mostly found in non-bidirectional promoters 




482. An in silico COQ4 promoter region study, revealed the absence of a classical TATA 
box, in line with the mentioned observation 469.  
Moreover, bidirectional promoters are GC rich, and CpG-islands are present in 90% of 
bidirectional promoters compared to 45% of non-bidirectional promoters 482. In the case 
of COQ4-TRUB2, the region annotated as promoter (regulatory build annotation by 
ENSEMBL) has a GC % of 53.73% (chr9:128,321,400-128,324,401), and a CpG island (with 
60.06% of GC) is annotated in this region (chr9:128,322,080-128,323,376 bp) (Figure 
3.3). 
A study performed in HeLa cells used RNA polymerase II (RPol II) ChIP-seq data to 
identify and classify the bidirectional promoters. The gene pair COQ4-TRUB2 has a very 
short TSS distance (93 bp). This gene pair was identified as one of the 932 pairs whose 
promoter was covering the two genes, inducing the expression of both of them. This 
was elucidated by the presence of a single central RPol II peak from ChIP-seq data 481. 
However, more studies would be needed to prove the co-expression of these two genes. 
COQ4 protein sequence conservation 
COQ4 protein sequence is highly conserved through the evolution (Figure 3.4). By 
analysing its sequence, it has no homology with any other known protein or domain that 
would indicate it has any specific enzymatic activity. It only has an inherent characteristic 
domain, so-called the COQ4 domain, which is very conserved, found in 1770 sequences 
from 1345 species (data from Pfam database 483). COQ4 gene has homologous 
sequences in all eukaryotic genomes, and some of them are also found in some bacteria, 
and cyanobacteria, even though some of these species do not even have any form of 
CoQ. This COQ4 domain has a very conserved putative catalytic zinc binding motif, 
HDxxH-(x)10-GE 466 (Figure 3.4).  
We predicted secondary structures (alpha helixes) from the sequence, and the position 
of these helixes seem to be conserved through COQ4 sequences from different species 

























































































































































































































































































































































































COQ4 protein 3D Structure 
COQ4 3D structure has not been dilucidated yet. Only two ortholog proteins from 
cyanobacterial genus Nostoc have been crystallised so far, which are Alr8543 (17.82% of 
identity and 44.36% of similarity with human COQ4, calculated by pairwise alignment) 
and Npun_R0350 (18.15% of identity and 48.75% of similarity with human COQ4, 
calculated by pairwise alignment).  
Structural properties of COQ4 orthologous proteins from Nostoc 
Alr8543 protein from the cyanobacteria Nostoc sp. (strain PCC 7120) was crystallised by 
X-Ray diffraction in a 2.4 Å resolution structure deposited in PDB as 6E12 (Figure 3.5.A). 
This protein crystallised as a homodimer, co-crystallising with a molecule of oleic acid in 
a deep binding pocket. Oleic acid is a mono-unsaturated fatty acid found to represent 
10% of the total fatty acid content in several species of cyanobacteria from genus 
Nostoc484. Additionally, a magnesium ion (Mg2+) was chelated by the putative zinc (Zn2+)-
ligand motif, HDxxH-(x)10-GE 466. The 6E12 PDB entry superseded the entry 3KB4, which 
crystallised similarly as a homodimer. This previous structure had co-crystallised with a 
molecule of geranylgeranyl monophosphate in the binding pocket, as well as the 
magnesium ion (Mg2+) 485 (Figure 3.5.B). On the other hand, Npun_R0350 from Nostoc 
punctiforme (strain PCC 73102) was crystallised by X-Ray diffraction in a 2.85 Å 
resolution structure found in the PDB entry 3MSQ (Figure 3.5.C). This protein crystallised 
as a homotetramer, without any ligands. It contains a helix predicted to be a 
transmembrane domain.  
We can see that the three protein structures have a similar globular structure (Figure 
3.5), and that the dimeric and tetrameric forms are compatible. The helixes and the 
structured regions are arranged in a not very different way in all the three crystal 
structures. To be able to study the structural features of COQ4 proteins, we selected 
Alr8543 protein model. One of the reasons of this choice is the structural arrangement 
of the residues coordinating the divalent cation. Since this motif seems to be important, 
based on its high conservation, we selected the structure in which these residues are 





putative binding pocket allows us to hypothesise that COQ4 may be able to bind lipids, 
such as the polyisoprenoid tail of CoQ.   
We thus analysed and visualised the conservation of the residues in the 6E12 structure 
(Figure 3.6). It can be observed that the most conserved features (in red) are the 
residues involved in the divalent cation coordination. The lipid binding pocket surface 
show a relatively high conservation while the rest of the protein surface shows regions 
with different degrees of conservation. 
 
Figure 3.5. Ribbons visualization of 3D structures from COQ4 homologous proteins from cyanobacteria 
from genus Nostoc.  
Ligands crystallised with the proteins are shown in different colours. Side chains of the residues that 
chelate the divalent cation are also displayed. (A) PDB: 6E12, (B) PDB: 3KB4, (C) PDB: 3MSQ. Alpha helixes 
are labelled in (A). 






Figure 3.6. COQ4 evolutionary residue conservation mapped onto COQ4 protein 3D structure. 
The residue conservation was calculated with AL2CO method and mapped onto 6E12 structure using 
Chimera software. (A, B) Protein surface view, from different angles. (C) Ribbons view. (D) Table with the 
COQ4 protein sequences used for the multialignment (H. sapiens, M. musculus, D. rerio, C. elegans, S. 
cerevisiae, Nostoc sp. (strain PCC 7120 / UTEX 2576) and Nostoc punctiforme (strain ATCC 29133 / PCC 
73102).  
 
Figure 3.7. 6E12 homodimer structure and interface. 
6E12 homodimer structure (A: surface, C: ribbons), and visualization of the opened interface, like a book 
(B: surface, D: ribbons). Contact residues are highlighted in different colours (pink and yellow) and listed 
in (E), with the corresponding residue in human COQ4 protein. The conservation of the residues with the 
human sequence is indicated in different tones of red: *(single and fully conserved residue); : (strong 












Regarding the possible oligomerization, this protein crystallised as a homodimer (Figure 
3.7). We cannot know if this is the physiological arrangement of the protein, but it should 
be taken into account that this structure should be only used within the context of a 
dimer. In this context, the monomers would reflect the phenomenon of induced fitting, 
by which they help each other to fold in a complementary manner, which would be 
different to the monomeric state. We were able to visualise the region involved in the 
dimerization and contact between the two chains of 6E12 structure (Figure 3.7.A-D), and 
we listed the amino acids that would be involved in this process (Figure 3.7.E). We could 
see how the hydrophobic residues are sequestrated at the binding interphase. If COQ4 
functions as a dimer, these residues would be important for its stability. It can be 
observed that most of these residues are conserved in the human sequence, or at least 
have the same chemical properties than the cyanobacterial ones (Figure 3.7.E). The α-
helixes that are mainly involved in these interactions are α1, α9 and α10, and some 
residues from α2 and α8 (see helixes labelling in figure 3.5.A). 
Interaction with ligands is also an important feature for protein function. We analysed 
the residues that interacted with the different ligands in the 3KB4 and 6E12 structures 
(Figure 3.8). The majority of the residues interacting with the two lipidic ligands were 
common for both structures, and some of them shared biochemical properties with the 
corresponding residues in the human COQ4 sequence (Figure 3.8.E). These residues are 
mainly belonging to α2 and α9, and some to α3 and α8. The residues chelating the 
divalent cation, located in α7 and α8, were the same in both structures (H120, H124 and 









Figure 3.8. 3KB4 (A) and 6E12 (B) structure and ligands. 
Ligands are in an orange box, which is zoomed in (C) and (D). In 
the zoomed regions, residues involved in ligand binding are 
labelled. In 3KB4 (C), residues binding geranylgeranyl phosphate 
molecule (in red) are marked in green, showing their side chains; 
and residues binding the Mg2+ ion (in green) are marked in pink. 
In 6E12 (D), residues binding oleic acid molecule (in dark blue) are 
marked in red, showing their side chains; and residues binding 
the Mg2+ ion (in green) are marked in cyan. Contact residues are 
highlighted in list (E), with the corresponding residues in human 
COQ4 protein. The conservation between them is indicated in 
different tones of red: *(single and fully conserved residue); : 
(strong similar properties); . (weak similar properties). 
 




Human COQ4 structure model 
We generated human COQ4 models by using the three previously mentioned structures 
as templates (Figure 3.9). There are some structural differences between the different 
models, but they are mostly compatible (Figure 3.9.D). We focused on the model that 
used 6E12 as template, and localised the features we know from the primary sequence, 
such as the exons, in an attempt to understand how each exon contributes to the protein 
structure (Figure 3.10).  
 
 
Figure 3.9. Human COQ4 protein models.  
Human COQ4 protein models using (A) PDB: 6E12, (B) PDB: 3KB4, (C) PDB: 3MSQ structures as templates. 
(D) Visualization of the three models matched together. They have been matched using the match 
command in Chimera software on the three residues that were found to bind a cation in the original 
Nostoc structures (H163, H167, E179), since they seem to be important for the function of COQ4. 







Figure 3.10. Distribution of exons in the structure of human COQ4 protein model.  
(A) Human COQ4 protein sequence representation, each coloured box representing a different exon. (B) 
Four views of the model from 6E12 and mapped exons. (C) Distribution of the different helixes through 
the structure.  Side C would correspond to the putative dimer interface. 
 
 
Information extracted previously from the Alr8543 protein structure has been 
annotated to this model in the Figure 3.11. If COQ4 had the same properties as Alr8543, 
we hypothesise that α1, α9 and α10 would be important for protein dimerization; 
helixes α2, α9, α3 and α8 would form a pocket with lipid binding capacity; and α7 and 
α8 would be involved in zinc or other cation binding. 
Additionally, we compared the human COQ4 model to the original structure, studying 
different properties of the protein surface. The representation of the spatial distribution 
of hydrophobicity, hydrophilicity and electrostatic potential on the molecular surface of 
proteins is critical for the understanding of the interaction with small molecules and 
other proteins.   





Figure 3.11. Putative features of COQ4 protein. 
Alpha-helixes have been labelled in the protein 
model (A) and represented in the linear primary 
sequence of COQ4 protein (B) (with the same 
exon colour code than in figure 3.10). Putative 
features have been added to the secondary 
structures representation (B) and to the 3D 
model (A) (dashed lines): Putative dimerization 
interface (orange dashed lines), putative lipid 
binding site (LBS, blue dashed lines), putative 
zinc binding motif (ZBM, green dashed lines) and 




The hydrophobicity properties of Alr8543 structure surface were displayed and 
compared with the human COQ4 model (Figure 3.12). Alr8543 crystal structure has a 
hydrophobic pocket in which the lipidic ligand was crystallised (Figure 3.12.A. Face A). 
Hydrophobicity in this pocket seems to be conserved in the human structure model, 
indicating that this pocket could conserve lipid binding properties (Figure 3.12.B. Face 
A). Another characteristic hydrophobic patch in Alr8543 surface is the dimer interface 
between two crystallised units of Alr8543 protein (Figure 3.12.A. Side C). The 
hydrophobicity of the surface of the putative dimer interface seems to be reproduced 
in the human COQ4 model (Figure 3.12.B. Side C). There are other hydrophobic patches 
on the surface of these structures, which are concentrated in Face A, Face B and Side C 
and almost absent in Side D (in both structures). These patches could be involved in 






Figure 3.12. Surface hydrophobicity of Alr8543 (A) and human COQ4 (B) protein structures. 





Electrostatic potential distribution on the molecular surfaces of Alr8543 and COQ4 
model are substantially different (Figure 3.13). However, conservation of the charges in 
the very conserved divalent cation chelating pocket as well as in the putative lipid 
binding pocket is high. Absence of positive or negative charges is observed in the 
putative dimer interface of both protein structures (Side C).  
 
Figure 3.13. Surface Coulombic electrostatic potential of Alr8543 (A) and human COQ4 (B)  
protein structures. 
These are only preliminary observations, since optimisation and energy minimisation of 
the model should be performed in order to be able to draw more conclusions about the 
protein structure and surface. Molecular dynamics modelling of the protein would 





Other features of COQ4 protein 
i. Mitochondrial localisation prediction 
Human COQ4 protein is a 265 amino acids polypeptide with a mitochondrial 
localization469. COQ4 is included in the MitoCarta2.0 inventory as one of the 1158 
human genes encoding proteins with strong support of mitochondrial localization69.  
Different in silico approaches classify COQ4 as a mitochondrial protein, with a 
mitochondrial localisation peptide in the N-terminal end of the protein. Uniprot 
database indicates a mitochondrial subcellular localisation by manual annotation with a 
mitochondrial localization signal corresponding to the first 30 amino acids of the protein 
(Figure 3.14).  MitoMiner 208 and MitoFates 209 bioinformatics tools predict a N-terminal 
cleavable targeting signal (presequence) with a high composition of arginine and no 
negatively charged residues (Figure 3.14).  
 
Figure 3.14. Human COQ4 contains mitochondrial localization signals.  
Prediction of a mitochondrial targeting signal and cleavage sites in COQ4 was performed using MitoMiner 
and MitoFates. Proteolytic cleavage site for mitochondria processing peptidase (MPP) was predicted at 
proline in position 21 (Φ(hydrophobic), β(basic)). 
 
This presequence is called mitochondrial targeting sequence (MTS) and is predicted to 
form an amphiphilic α-helix with positively charged residues on one side and 
hydrophobic residues on the opposite face. This helical structure is meant to be 
recognised by TOM20 in order to initiate the import of the protein to the mitochondria, 




through the TOM and TIM complexes. Upon import into mitochondria, this presequence 
is predicted to be cut by the heterodimer mitochondrial processing peptidase (MPP) in 
the mitochondrial matrix. The cleavage consensus site is predicted to be at proline 21 
(Figure 3.14). 
ii. Phosphorylation predictions 
Phosphorylation is an essential signalling process that is involved in the regulation of 
many cellular functions, such as bioenergetic metabolism, growth, differentiation or 
apoptosis. Mitochondrial phosphorylation is central to the regulation of the organelle 
functions, and proteins such as those belonging the respiratory chain 486,487 or pyruvate 
dehydrogenase subunits 488,489 are regulated by this post-translational mechanism. 
Phosphorylation plays a crucial role in CoQ biosynthesis. For example, phosphorylation 
of Coq3p, Coq5p, and Coq7p is altered in coq8 yeast 490,491. On the other hand, 
phosphorylation of Coq7p induces reduction of CoQ synthesis492. The phosphatase 
responsible for its dephosphorylation and activation is Ptc7p in yeast 493 and its 
homologous phosphatase in mammals is PPTC7494,495. Since phosphorylation seems to 
be an important process in the regulation of CoQ biosynthesis, and COQ4 has been 
defined as a regulatory protein, we were interested in determining if COQ4 was a 
phosphoprotein.  
In order to do so, human COQ4 sequence and some COQ4 ortholog sequences from 
model organisms with different phylogeny (mouse, zebra fish, yeast and worm) were 
aligned and subjected to different in silico analysis for phosphorylation prediction. 
Conservation in the position of the phosphorylation site could suggest that the function 
of the phosphorylation event is important for the organism. We selected potentially 
phosphorylatable residues, such as serine, threonine and tyrosine, which were 
conserved in at least 2 of these species (human’s, among these two).  
In total, 22 selected residues were analysed by seven different in silico phosphorylation 
prediction tools or phosphorylation databases. For each selected residue, a tools score 
was calculated, representing the number of tools for which the residue was positive for 






Table 3.1. COQ4 protein phosphorylation prediction. 
The tools score is coloured in a gradient from green (the highest values) to red (the lowest values). 
 
Phosphorylation at a site depends on many factors, including the structure and solvent 
accessibility of the phosphorylation site. Phosphorylation, as well as other post 
translational modifications, predominantly occurs in regions of intrinsic disorder 212. 
Disordered regions provide a flexibility that facilitates different conformational 
requirements for binding the modifying enzymes.  Intrinsically disordered regions are 
often found as flexible linkers or loops connecting domains 496.  
In order to introduce 3D structure information in our study, protein structures for 
human and mouse were modelled using the only homolog structure available at that 
time, PBD 3KB4. We considered the position of the residue in the 3D model, and 
depending on its structural position, it manually received a score. When the residue was 
on the surface of the protein, in a disordered region or loop, the score was the highest, 
and when it was totally buried in an ordered region of the protein structure, the score 
was the lowest (3D structure score: 0-2). We also considered the solvent accessibility 
predicted by JPred, giving the maximum score when the residue was exposed in a 
disordered region and the minimum score when it was buried and inside an ordered 
region (solvent accessibility score: 0-4).  
Selected conserved residues Tools score 3D structure score Solvent accessibility score 
Human Mouse Fish Worm Yeast Human Mouse Human Mouse Human Mouse 
S106 S107 - S76 T153 6 6 2 2 3.75 4 
S108 S109 S107 - - 5 6 2 2 4 3.5 
T107 - - - T154 5 - 2 - 4 - 
S31 S32 - - T77 5 5 1 1 3 3 
S122 S123 T121 T92 T169 4 5 1.5 1.5 2.5 2.75 
T77 T78 T76 T46 T123 4 4 1.5 1.5 2.75 2.25 
T140 T141 T139 - T187 4 4 2 2 3.75 3.75 
S45 T46 S44 - - 4 4 1 1 4 4 
S117 S118 - - - 4 4 2 1.5 4 4 
T144 T145 - - - 4 4 2 2 3 4 
S137 S138 T136 S107 S184 4 1 2 2 4 4 
T255 S256 - T225 T302 3 4 2 2 3.75 4 
T168 T169 T167 - - 3 3 0 0 0.25 0.25 
T190 T191 T189 - - 3 3 1.5 0.5 2 2 
T109 T110 T108 T79 - 3 2 2 2 3 4 
S56 - S55 S25 S102 2 - 1 - 3 - 
S210 S211 - - - 2 4 0.5 1.5 3.5 3.75 
S216 S217 - - - 2 3 0 0 1 4 
T44 T45 T43 - - 2 2 1 1 2 3 
T81 T82 T80 - - 2 2 0 0 2.75 1.75 
T3 T3 - - - 2 1 - - - - 
T174 T175 T173 T144 - 1 1 2 2 2.75 2.75 
- T247 - S216 T293 - 2 - 0 - 4 




We compiled the three scores for the 22 different residues and selected the ones with 
the highest scores. The tools score is considered to be the most relevant one, since it 
results from an assemblage of diverse in silico tools, each of them employing different 
algorithms to calculate the probability prediction, each of one with its advantages and 
limitations.  
The three amino acids with the highest scores were contiguous, in the positions 106 to 
108, serine, threonine and serine. Threonine 109 was also considered but reached 
significant lower scores. If we travel to the predicted 3D structure, we can localise these 
four residues in a loop, probably flexible, that would allow the conformational 
requirements of a post-translational modification such as phosphorylation (Figure 
3.15.B). Moreover, and interestingly, they are localised in the opposite side (Side D) to 
the putative dimerization interface (Side C) (Figure 3.11). This loop appeared after 
Nostoc in the evolution since it is absent from its sequence. In addition, the residues 
flanking this putative phosphorylation loop are very conserved (Figure 3.15.A), which 




Figure 3.15. Putative phosphorylation 
loop in COQ4 protein. 
Phosphorylation prediction revealed a 
putative phosphorylation loop (P-loop), 
which is conserved in terms of presence 
of at least 2 serine or threonine residues 
(A). Flanking residues of this putative 
phosphorylation loop have a high 
degree of conservation (A). If we localise 
these 4 residues in the 3D model, they 
are located in a probably flexible loop, 





Of note, there is evidence of phosphorylation in COQ4 but only from global 
phosphoproteomics MS assays, reported in PhosphoSitePlus. Four high-throughput 
studies found the same residue (from human, mouse and rat) in a phosphorylated state. 
S108 human residue was found phosphorylated in HeLa and K562 cells 497. It is conserved 
in mouse (S109), in which it was found phosphorylated in three different studies, in 
murine pancreatic cells 498, hearts 499 and kidneys 500. The same residue from rats (S108) 
was found phosphorylated in different rat tissues 501. For all these reasons, we selected 
these four residues for ulterior experimental studies (see Chapter 4, section 4.2.1). 
Mutations affecting COQ4: mutations found in patients  
35 patients from 26 families with COQ4 mutations have been reported to have a CoQ10 
deficiency. There are 22 published COQ4 variants associated to this disease in the 
literature. Here, we add 2 more to the list: the intronic mutation of P105 and the 
homozygous mutation of P108 and P109 (See Chapter 2, Section 2.2.3.). The reported 
mutations are distributed throughout the entire coding sequence (CDS), being less 
frequent in the first and last exons, and especially abundant in exon 5. All the residues 
involved in point mutations causing disease occur in conserved positions (Figure 2.14).  
Figure 3.16 shows the localization of the residues affected by missense (and one 
nonsense) mutations from all the published COQ4 patients in the 3D protein structure. 
We have classified the mutations in 2 groups, depending on the severity of the disease: 
early-onset severe multisystemic disorder (which corresponds to Group 1 and 2 of the 
age-of-onset classification done in Chapter 1) and milder disease with adolescence 
progression (which corresponds to Group 3) (see Chapter 1, section 1.2.4). We have 
added the homozygous mutation found in P108 and P109, F146C, to the less severe 
group, because the age of last examination of these patients was 17 years old. 
The mutations seem to accumulate in a face of the protein surface which contains the 
putative lipid binding pocket, face A (Figure 3.16). Additionally, the mutations classified 
in the milder disease group, except for the F146C mutation, appear to be buried in the 
protein structure, while the majority of the mutations classified in the severe group 
seem to be exposed on the surface of the protein. This may have a significance, 
reinforcing the idea that COQ4 surface interactions are important for its function. 





Figure 3.16. Patients’ mutations mapped on human COQ4 protein structure model (PDB template: 
6E12).  
(A). Surface models showing the mutated residues’ distribution on the surface of the protein (B). Mutated 





3.2.2. COQ4 cellular models’ generation 
COQ4 KO cell line was generated in a HEK 293T-Rex/Flp-In 
i. Selection of the cell line HEK 293T-Rex/Flp-In  
HEK 293T-Rex/Flp-In WT cell line was chosen to generate our COQ4 KO mutant cell line. 
Human embryonic kidney (HEK) 293T cells grow fast so big amounts of cells can be 
obtained in a short period of time and they can be efficiently transfected. Moreover, 
these cells are very convenient for biochemical approaches since they can be detached 
from the plate surface easily, considerably shortening the processing time for cell 
collection. The specific Flp-In genomic background was selected because it contains a 
single stably integrated FRT site at a transcriptionally active genomic locus. This feature 
would allow us to easily insert different versions of COQ4 gene in the COQ4 KOs genome 
by flippase (Flp)-FRT site directed recombination in this FRT-site and then, control their 
expression by inducing with doxycycline (See Materials and Methods, section M2.1 and 
Figure M.1 for more details). 
ii. Selection of the Paired nickases CRISPR/Cas9 3 plasmid strategy  
Paired nickases CRISPR/Cas9 3 plasmid strategy was used to generate the COQ4 KO in a 
HEK 293T-Rex/Flp-In WT background. Paired nickases strategy was selected over the WT 
Cas9 in order to decrease the number of off-targets. Cas9-D10A or Cas9 nickase is a 
catalytically mutant Cas9 that is able to introduce a SSB with the same specificity as a 
regular Cas9 nuclease. Two paired nickases guided by two gRNAs targeting adjacent 
regions were used in order to reduce off-target activity.  
iii. gRNA design and off target analysis 
Guide RNAs (gRNAs) were designed to target exon 2, to make sure the expression of 
COQ4 protein would be effectively disrupted. Exon 1 was not targeted in order to avoid 
a possible alternative translation initiation, which would more likely occur at the 
beginning of the transcript 450.  
 


































































































































































































































































































































































Four different sequences adjacent to PAMs were selected to design the gRNAs (Figure 
3.17). These gRNAs were designed to target COQ4 exon 2 (2 forward and 2 reverse), and 
4 different combinations of Forward and Reverse gRNA were used. Potential off-target 
sites were analysed computationally, and while each gRNA separately has predicted off-
target sites, the 4 pairs of gRNAs were considered to have high quality, with 0 predicted 
off-target sites. (Table 3.2). 
Table 3.2. Off-target analysis of selected gRNAs. 
 
Off-target analysis of single gRNAs 
gRNA Quality score On-target locus # of off-target sites 
gRNA1 97 (high) chr9:-131,085,324 29 (4 are in genes) 
gRNA2 49 (medium) chr9:-131,085,348 384 (56 are in genes) 
gRNA3 66 (high) chr9:+131,085,373 171 (67 are in genes) 
gRNA4 70 (high) chr9:+131,085,379 167 (85 are in genes) 
 
Off-target analysis of gRNAs pairs for paired nickases 
CRISPR 
pair 
gRNAs Nt between 
cleavage sites 
Quality score # of off-target sites 
CRISPR1 gRNA1+gRNA3 60 65 (high) 0 
CRISPR2 gRNA1+gRNA4 66 62 (high) 0 
CRISPR3 gRNA2+gRNA3 34 17 (medium) 0 
CRISPR4 gRNA2+gRNA4 40 35 (high) 0 
 
iv. Several clones with deletions at exon 2 of COQ4 were isolated and they 
did not express COQ4 protein 
WT HEK293T-Rex/Flp-In cells were transfected with 3 plasmids (pCMV-Cas9-nickase 
GFP, pU6gRNA1/2, pU6gRNA3/4) (Figure 3.18.A). 48h after transfection, they were 
FACS-sorted by GFP fluorescence (Figure 3.18.B), and the cells with high levels of GFP 
fluorescence were selected (Figure 3.19). The GFP-transfection efficiency was between 
20 and 25% (Figure 3.19.D). For each reaction, one pool and several individual clones 
were grown and genotyped by PCR amplification of the genomic targeted region (Figure 
3.18.C and D). This amplification would lead to a 499 pb fragment, according to the 
designed genotyping primers.  
 








Figure 3.18. Generation of COQ4 KO cells overview.  
(A) Wild type HEK293T-Rex/Flp-In cells were transfected with 3 plasmids (pCMV-Cas9-nickase GFP, 
pU6gRNA1/2, pU6gRNA3/4), and 48h after transfection, (B) they were FACS sorted for GFP fluorescence. 
Sorted pools were grown and genotyped by PCR amplification of the genomic targeted region (C). Clones 
from each pool were isolated, expanded and characterised (D). They were genotyped by PCR, pGEMT 
cloning and sequencing. COQ4 western blot analysis of total protein extracts of these cells was also 
































































































































































































































































































































































































































































































































































































































































































PCR revealed that COQ4 and positive control CRISPR reactions had some amplicons that 
were smaller to the expected size, indicating that deletions may have occurred (Figure 
3.20.A and B). Further genotyping techniques, as detecting mismatches or surveyor 
nuclease test, were not needed because all the CRISPR reactions tested appeared to 
produce a big deletion, easily detectable by PCR amplification.  
 
Figure 3.20. Identification of COQ4 KO cell lines.  
(A) PCR amplification of a genomic fragment containing the gRNAs binding site in COQ4 exon 2 revealed 
the presence of deletions in some pools of CRISPR transfected cells. C2 and C4 seemed to be the most 
efficient ones. Non-transfected cells (HEK) and cells transfected with the CRISPR negative control (C-) were 
used as negative controls. Genomic EMX1 fragment was also amplified in the cells that were transfected 
with the CRISPR positive control (gRNAs guided to a EMX1 genomic region) and with the C-. (B) The same 
PCR amplification was performed with genomic DNA from some cloned derived from C2 and C4 pools, 
and 5 of them showed a deletion in the amplified fragment. (C) This was confirmed by pGEMT cloning, 
colony PCR and sequencing. (D) None of the clones express COQ4 protein, analysed by immunoblots. 




At first, PCR amplification of pools revealed different efficiency of producing a deletion 
for the different gRNAs pairs, being CRISPR2 (C2) and CRISPR4 (C4) more efficient (Figure 
3.20.A). Then, 6 individual clones from these CRISPR reactions were genotyped by PCR 
(Figure 3.20.B). 5 of them showed a clear deletion in the targeted region, and this was 
confirmed by pGEMT cloning, colony PCR and sequencing (Figure 3.20.C and Table 3.3).  
One clone of CRISPR2, C22d showed a deletion of 66 nt between the 2 Cas9 cutting sites, 
and the other one, C24d, showed 2 different sequences, the same 66 nt deletion and 
also the original sequence with short deletions (8 and 2 nt) close to the cutting sites 
(Figure 3.20.C and Table 3.3). All analysed clones coming from CRISPR4 reaction 
harboured a deletion of 40 nucleotides (Figure 3.20.C and Table 3.3).  
All these deletions would produce a drastic change in COQ4 protein, that would lead to 
its lack of function (Table 3.3). In the clones from CRISPR2 reaction, the deletion causes 
a deletion of 22 amino acids in exon 2, probably leading to a non-functional COQ4 
protein. In the clones from CRISPR4 reaction, the deletion would produce a frameshift 
of the ORF and a premature stop codon, producing the lack of COQ4 in these cells. 
 Western blot analysis of total protein extracts of the cells showed an absence of COQ4 
protein in all mutant clones (Figure 3.20.D). From now on, all experiments have been 
performed with one of the obtained clones, 43d, which we are going to call COQ4 KO 
cell line. We chose this clone because it would have a frameshift and an early truncated 
protein, which is the most similar situation to a real knock-out. 
Table 3.3. COQ4 cDNA and predicted protein changes in CRISPR clones. 
Clones Deletion length cDNA mutation Predicted protein change 
22d 
24d 
66nt c.107_172del p.Leu37_Ala58del 




40nt c.133_172del p.Ser45Argfs*15 
COQ4 KO expressing different versions of COQ4 
In order to evaluate COQ4 function, we transfected COQ4 KO with different versions of 
COQ4. The transfections were performed by using a lipid-based reagent and pcDNA5 





variants were contained in the pcDNA5 plasmid (the transfected plasmids are detailed 
in Materials and Methods, Table M.12). After transfections, the expression of the 
transgene was induced with different amounts of doxycycline and measured by western 
blot. We were able to obtain different cell lines KO in COQ4, which stably expressed 
different versions of the gene. Details of levels and effects of expression of these ectopic 
COQ4 variants will be explained in the next sections (See Chapter 4, section 4.2.1).  
3.2.3. COQ4 molecular localisation characterisation 
As we just discussed, different in silico approaches classify COQ4 as a mitochondrial 
protein. Additionally, some experimental assays found it located inside the 
mitochondria 469. In order to experimentally test human COQ4 mitochondrial location in 
our cellular model, we have performed several experiments: immunofluorescence and 
colocalisation with mitochondrial proteins by confocal microscopy and cell 
subfraccionation and biochemical coexistence by western blot.  
For these experiments, we used a cell line previously generated, the HEK 293T-Rex/Flp-
In COQ4 KO cell line transfected with untagged COQ4 wt gene, as well as COQ4 gene 
tagged in C-terminal with a FLAG-Strep tag (COQ4-FS). These cells overexpress the 
transfected gene, expression that it dose-dependently induced with the addition of 
doxycycline (DOX) to the medium, since the transgene expression is regulated by a DOX 
inducible promoter.  
Tagged COQ4 colocalizes with TOM20 staining 
To start COQ4 localisation characterisation, we used a FLAG-tagged COQ4 WT protein in 
the HEK 293T-Rex/Flp-In human cell line. Cells were transfected and selected with 
hygromycin. 48h before the immune staining, cells were seeded onto poly-D-Lysine 
treated coverslips. 24h before the staining, the expression of the exogenous COQ4-FS 
was induced by adding 0.5ng/ml of doxycycline. The day after, cells were fixed and 
stained. COQ4 protein was visualised in green, by using a primary mouse antibody 
against FLAG tag, and the anti-Mouse Alexa488 antibody (Figure 3.21). As a mitochondrial 
marker, we used the outer membrane mitochondrial protein TOM20, stained in colour 
red (by using a primary TOM20 antibody with conjugated fluorescence). The nucleus of 
the cells was stained with DAPI (See Materials and Methods, section M3.4).   





Figure 3.21. COQ4-FS colocalizes with TOM20 staining.  
Immunofluorescence staining of HEK 293T-Rex/Flp-In cells (HEK wt), and the same cells transfected with 
a flag-strep tagged form of COQ4 (HEK COQ4-FS).  Overexpression of the transgene is observed after a 
doxycycline treatment (+DOX: 0.5ng/ml doxycycline during 24h). Images show that in induced cells 
(+DOX), COQ4-FS (green) localize to the mitochondria (TOMM20 red stain), while the non-induced cells 





Images of induced COQ4-FS transfected cells show that COQ4-FS green stain colocalizes 
to the TOM20 red stain, meaning that the overexpressed COQ4 protein seems to localize 
mainly to the mitochondria (Figure 3.21). As a negative control, non-transfected HEK 
cells as well as non-induced COQ4-FS transfected cells were also stained.  Anti-FLAG 
antibody seems to non-specifically recognize some areas in the cellular periphery, also 
in both the controls. Even if we know non-induced COQ4-FS transfected cells are also 
expressing COQ4-FS protein to some extent due to a leaky effect (see Chapter 4, section 
4.2.1 and Figure 4.8), they do not show the green and red colocalization pattern, but 
they are more similar to negative controls. This is probably is due to its leaky expression, 
that it is not enough to be visualized with the antiFLAG antibody. 
Endogenous and tagged COQ4 follow the same localization pattern than mitochondrial 
proteins after mitochondrial fractionation 
COQ4-FS transfected HEK cell line was expanded and fractionated in different 
subcellular compartments by differential centrifugation. Samples of total homogenate 
(nucleus free), cytosol, crude mitochondria, mitochondrial associated membranes 
(MAMs) and pure mitochondria were run in acrylamide gels and subjected to western 
blot (Figure 3.22). Mitochondrial external membrane protein TOM20 is predominantly 
in the mitochondrial fractions, and not in the cytosol. It also appears partially in the 
MAMs fraction, which has been described before 502. ATAD3A protein is mainly a 
mitochondrial IMM protein, where the N-terminal domain interacts with the OMM, 
being essential for mitochondria-ER contacts (See Chapter 5, section 5.1.6), and the C-
terminal domain localizes in a specific matrix compartment, where it is associated with 
nucleoids 175. It can be observed that it follows a mitochondrial localisation pattern, the 
same as TOM20, being also present in MAMs, which has been also reported before 4. 
Remarkably, both endogenous and tagged-COQ4 protein follow the same fractionation 
pattern than mitochondrial proteins TOM20 and ATAD3A, being predominantly present 
in pure mitochondria, but also a small fraction in the MAMs and in the cytosolic fractions 
(Figure 3.22). Lack of lactate dehydrogenase A (LDH-A) signal in pure mitochondria 503 
confirms the purity of the fractions.  





Figure 3.22. Endogenous and tagged COQ4 are enriched in mitochondrial fractions.  
Cellular and mitochondrial subfractionation of HEK 293T-Rex/Flp-In cells (HEK wt) (A and B), and the same 
cells transfected with a flag-strep COQ4 (HEK COQ4-FS) (C and D). TOM20 is a mitochondrial outer 
membrane protein, ATAD3 is a mitochondrial inner membrane protein and LDH-A is a cytosolic soluble 
protein. Endogenous COQ4 expression is very low (A), so the same blots with a higher concentration of 
the mitochondrial fractions (5x) are shown in B and D. H: Homogenate, C: Cytosol, CM: Crude 
Mitochondria, MAMs: Mitochondrial associated membranes, PM: Pure Mitochondria. 
 
 
Endogenous COQ4 and COQ4-FS are resistant to mild trypsin treatment. 
Whether the protein is in the mitochondrial matrix can be assayed biochemically by 
incubating mitochondria with trypsin (5mg/ml trypsin at 30ºC) in a hypotonic buffer. In 
this hypoosmotic conditions, mitochondrial outer membrane is firstly broken, and then, 
trypsin sequentially degrades the intermembrane space proteins, the external face of 
the IMM, the IMM and finally if incubated for enough time, the matrix (Figure 3.23.C). 
 Immunoblots show that endogenous COQ4 is protected from trypsin digestion in the 
same manner than HSP60, which resides in the mitochondrial matrix (Figure 3.23.A). 
This also occurs with the COQ4-FS tagged protein, meaning that it behaves similarly to 





time, we can see how proteins belonging to the mitochondrial outer (TOM20) or inner 
(TIM23, ATAD3A) membranes are being sequentially degraded with the same 
treatment.  
 
Figure 3.23. Endogenous and tagged COQ4 are protected from a mild trypsin treatment.  
Mild trypsin treatment of pure mitochondria sequentially degrades the different mitochondrial 
compartments: outer membrane (TOM20), intermembrane space, the inner membrane (ATAD3) and 
finally, the matrix (HSP60). Immunoblots show that endogenous COQ4 (A) and FS-tagged COQ4 (B) are 
both protected from trypsin digestion in the same way that HSP60, which is a matrix protein. (C) 
Schematic representation of the experiment, in which the combination of a hypoosmotic buffer and 
trypsin treatment (5mg/ml trypsin at 30°C), firstly breaks the outer membrane, and then the rest of 









In this chapter, we studied COQ4 gene and protein characteristics and we generated a 
COQ4 KO cell model. The main conclusions derived from this work are the following: 
i. Based on studies with COQ4 orthologues, it could be possible that human COQ4 
protein forms a homodimer, binds a lipid in a lipid binding pocket and chelates a 
divalent cation in the very conserved putative zinc-ligand motif, HDxxH-(x)10-GE.  
ii. It could be possible that human COQ4 phosphorylation in the residues S106, 
T107, S108 and T109 is important for COQ4 function. 
iii. Mutations from patients are distributed along the whole protein (in a human 
COQ4 protein model), mainly exposed on the surface of the protein in one face 
of the protein, indicating that COQ4 surface interactions in this face of the 
protein could be important for its function. 
iv. COQ4 has a N-terminal MTS, and the mature protein seems to reside inside the 
mitochondrial matrix. 
v. CRISPR-Cas9 paired nickases 3-plasmid assay is a useful method for generating a 










Chapter 4.  
COQ4 participation in CoQ10 Biosynthesis and  
mitochondrial respiratory chain 
4.1. Introduction. CoQ biosynthesis pathway from bacteria to eukaryotes 
CoQ is an isoprenoid quinone endogenously synthesized by organisms belonging to all 
domains of life 381. The length of the polyisoprenoid tail differs among species (6 
isoprene units in the yeast Saccharomyces cerevisiae, 8 units in the bacteria Escherichia 
coli, 9 or 10 units in mouse and 10 units in humans). The tail gives CoQ extremely 
hydrophobic properties, which therefore localizes in cellular membranes.  
In eukaryotes, CoQ is synthesized by a set of nuclear-encoded proteins that reside in the 
matrix side of the mitochondrial inner membrane, through a pathway that is not still 
completely understood. It has been proposed that, although most eukaryotic CoQ is 
produced in the mitochondria, some amount of CoQ may be generated in different 
cellular compartments, such as Golgi apparatus or ER 504,505, although it is controversial 
because the CoQ biosynthesis proteins are located inside mitochondria381.  
Most of the work on CoQ biosynthesis has been done in Saccharomyces cerevisiae, in 
which at least 13 yeast genes (coq1 – coq11, Yah1, Arh1) have been identified as players 
of the process. Some of the products of these genes assemble in a multienzymatic 
complex (CoQ complex) located in the matrix side of the IMM 292,464–466,506.  
Orthologues of most of the yeast coq genes have been identified in humans 380, but the 
assembly and regulation of the CoQ complex have not yet been wholly demonstrated in 
this case. A similar complex has been described in E.coli, with the peculiarity that it is 
described as a soluble cytosolic complex 413.  
The synthesis of CoQ occurs via the formation of highly hydrophobic intermediates. For 
this reason, lipid-binding proteins have a crucial role in chaperoning these 
intermediates, attaching the hydrophobic tails in their binding pockets 507. 
 




CoQ synthesis requires several processes to occur in order to get the final product. The   
biosynthesis pathway starts with the synthesis of the precursors of the quinone head 
(Figure 4.1) and the polyisoprenoid tail. Then, these two precursors are condensed to 
form the first lipophilic quinone intermediate of this pathway. Finally, a set of head 
group chemical modifications give rise to the final molecule of CoQ.  
 
 
Figure 4.1. 4-HB and pABA CoQ head precursors synthesis.  
(A) Chorismate is synthesized via the shikimate pathway in yeast and bacteria, and it is the precursor for 
phenylalanine, tyrosine, tryptophan and pABA. In bacteria, it can be directly transformed to 4-HB by UbiC 
or XanB2. (B) In yeast and mammals, 4-HB is synthesised from tyrosine (or phenylalanine) through some 
known and unknown steps. (C) Resveratrol, p-coumarate and kaemferol can also be used as 4-HB ring 
precursors. Black arrows indicate general pathways, while coloured arrows are pathways or reactions 
exclusive to bacteria (orange) or yeast (green). Dashed arrows indicate several reactions, while continuous 
arrows represent only one reaction. Coloured names of enzymes are unique for humans (blue), yeast 
(green) or bacteria (orange). Abbreviations: E4P, erythrose-4-phosphate; PEP, phosphoenolpyruvate; 4-







4.1.1. Synthesis of the precursors of CoQ 
Quinone head precursors synthesis 
4-Hydroxybenzoate (4-HB) is the main precursor of the benzoquinone ring. Yeast and 
bacteria can synthetize it de novo through the shikimate pathway via chorismate 508 
(Figure 4.1.A). This pathway is highly conserved in fungi, bacteria, and some plant 
species, but it is not present in mammals 509. Chorismate,  synthesized from erythrose-
4-phosphate (E4P) and phosphoenolpyruvate (PEP) also serves as precursor for aromatic 
amino acids (tryptophan, phenylalanine and tyrosine) and para-amino benzoic acid 
(pABA) biosynthesis 510. E. coli is able to directly transform chorismate to 4-HB, step 
catalysed by UbiC protein, the chorismate lyase 511.  Interestingly, other bacteria lack 
any UbiC gene or homologue and, instead, they have XanB2 protein, which converts 
chorismate to 3-HB and 4-HB with catalytic domains not related to UbiC 512. Mammals 
and yeast use tyrosine to produce 4-HB. The pathway converting Tyr to 4-HB is poorly 
characterized, and only the first and the last yeast enzymes have been identified in 
yeast, so far (Figure 4.1.B) 381. In this organism, tyrosine is first deaminated by the 
aromatic amino acid transaminases Aro8p or Aro9p, and after several unknown 
modifications to 4-hydroxybenzaldehyde (4-HBz), it is finally oxidized to 4-HB by the 
aldehyde dehydrogenase Hfd1 513,514. Human orthologs of Aro8p/Aro9p function in this 
pathway are not identified, but Aro8p/Aro9p homolog AADAT (mitochondrial alpha-
aminoadipate amino- transferase) and the tyrosine aminotransferase TAT are 
candidates 381. In the case of Hfd1, human ALDH3A1 (aldehyde dehydrogenase 3A1) is 
able to restore CoQ synthesis in yeast lacking Hfd1 513, but ALDH3A1 participation in 4-
HB production has not been demonstrated in mammals yet 381. Mammals can also use 
phenylalanine to produce CoQ, which is converted to tyrosine, and then to 4-HB 515.  
Resveratrol and para-coumarate can also be used as alternative ring precursors by 
bacteria, yeast and mammals, probably through 4-HB transformation (Figure 4.1.C) 515. 
The polyphenol kaempferol has also been described to be an alternative biosynthetic 
ring precursor. While in yeast its use was very limited, in mammals it has been shown to 
be a precursor of the ring, even inducing the increase of CoQ levels in mouse and human 
kidney cells 380,516. It has been recently shown that the B-ring of kaempferol is the part 




of the molecule entering CoQ biosynthesis (Figure 4.1.C) 517. It is cleaved by still 
unknown peroxidases, producing 4-HB which directly enters the CoQ biosynthesis 
pathway 517,518. This mechanism seems to be conserved in mammals and plants, but not 
in yeast 516–518.  
pABA is an alternative ring precursor for CoQ biosynthesis. Interestingly, only yeast but 
not mammals or bacteria (E. coli) are able to use this molecule to synthesise CoQ 
289,515,519,520. pABA is a well-known precursor of folate that has an amino group in C4, 
instead of the C4-hydroxyl group of 4-HB. In yeast, pABA is synthesized from chorismate, 
which is transformed to pABA by Abz1 and Abz2 enzymes in two steps via the 
intermediate 4-amino-4-deoxychorismate (Figure 4.1.A) 519. pABA is then imported to 
mitochondria, being the FOL1 gene product required for this import 519 for its use in CoQ 
biosynthesis. In the case of E. coli, pABA is synthesized from chorismate via the shikimate 
pathway. PabA and PabB convert glutamine and chorismate to glutamate and 4-amino-
4-deoxychorismate, which is subsequently transformed to pABA by PabC 521. It can be 
prenylated by UbiA, but it cannot progress down the whole CoQ biosynthesis pathway. 
Vertebrates cannot synthesize pABA, but it can be partially modified by COQ proteins. 
However, as it occurs in bacteria, this molecule cannot fully progress to CoQ, and it can 
inhibit CoQ production from 4-HB.  
Polyisoprenoid precursors synthesis and tail assembly 
The isoprene units of the tail come from the mevalonate pathway. It is a common 
pathway for the biosynthesis of a variety of isoprenoid molecules, like CoQ, cholesterol, 
dolichol, vitamin D and isoprenylated proteins (Figure 4.2). Pyruvate is decarboxylated 
to acetyl-CoA, and then, three molecules of acetyl-CoA are bound together to form 3-
hydroxy-3-methylglutaryl-CoA 522. This molecule is converted to mevalonate by the 
enzyme 3-hydroxy-3-methylglutaryl-CoA (HMG-CoA) reductase, which is a key step for 
the regulation of the whole pathway 522,523. Mevalonate can be phosphorylated by the 
mevalonate kinase and transformed to isopentenyl diphosphate (IPP). IPP is a building 
block for the production of farnesyl diphosphate (FPP) and geranyl diphosphate (GPP), 
and short-chain poly-prenyl diphosphate synthases (poly-PDS), such as FPP synthase and 





of precursors for CoQ side chain, dolichol and squalene (cholesterol precursor) 
biosynthesis, as well as for protein farnesylation and geranylgeranylprenylation 522.   
The mevalonate pathway takes place in the extra-mitochondrial membranes. In 
eukaryotes, the following steps of CoQ biosynthesis occur in mitochondria, associated 
to mitochondrial membranes, so a specific transporter for these molecules to 
mitochondria may exist in the IMM, but it is not known yet 381. It has been proposed that 
the ER-mitochondria contact sites are required for this transport, in order to proceed 
with CoQ biosynthesis1,2,320. The prokaryotic pathway is performed in the cytosolic 
compartment, with some steps associated to the cell membrane 413.  
Next, these isoprenoid units are assembled together by a trans long-chain poly-PDS:  
Coq1p in yeast 525, PDSS1 and PDSS2 in human 526, IspA and IspB  in E. coli 527. This long-
chain PDS adds IPP molecules to FPP, GPP or dimethylallyl diphosphate (DMAPP) in 
multiple steps. DMAPP is probably obtained through IPP isomerization by a yet unknown 
isomerase. If the isomerization occurs outside or inside the mitochondria is still 
unknown, but only two IPP isomerases (IDI1 and IDI2) have been described in mammals 
so far, which are products of a gene duplication and localize into peroxisomes 528,529. 
 
Figure 4.2. Mevalonate 
pathway.  
The end product of 
glycolysis, acetyl-CoA, is 
metabolized through the 
mevalonate pathway, also 
known as the isoprenoid 
pathway or HMG-CoA 
reductase pathway. These 
produce two five-carbon 
building blocks called 
isopentenyl pyrophosphate 
(IPP) and dimethylallyl 
pyrophosphate (DMAPP), 
which are used to make 
isoprenoids, essential 
biomolecules for the 
biosynthesis of cholesterol, 
dolichols and coenzyme Q, 
and for protein 
isoprenylation. (Adapted 
from Goldstein et al., 
1990523)  
 




Long-chain poly-PDS can be classified into homodimeric (octa-PDS IspB in E. coli, hexa-
PDS in S. cerevisiae), heterodimeric (hepta-PDS in B. subtilis) and heterotetrameric 
(deca-PDS PDSS1 and PDSS2 in humans, deca-PDS Dps1 and Dlp1 in S. pombe or nona-
PDS Pdss1 and Pdss2 in mouse) and this multimerization is essential for the CoQ side 
chain length determination 524,526,530. Thus, length of CoQ isoprenoid tail is determined 
by the specific long-chain poly-DPS and its multimerization, differing among species (8 
isoprene units in bacteria, 6 in yeast, mostly 10 (and some amount of 9) in humans, 
mostly 9 (and some of 10) in mice, etc.).  
4.1.2. Head precursor prenylation 
Head and tail are next conducted to the mitochondrial inner membrane by unknown 
mechanisms, probably involving ER-mitochondria contacts1, and Coq2p (in yeast)/COQ2 
(in humans), an integral protein of the IMM, condensates the two precursors 531,532. In 
the case of bacteria, UbiA is the polyprenyltransferase that binds head and tail, and it is 
embedded in the cell membrane 533. These polyprenyl-transferase proteins produce the 
first highly hydrophobic prenylated ring CoQ intermediate. In yeast, this intermediate 
(HHB) accumulates in most of the coq null mutants, as we will discuss later (section 
4.1.5).  
4.1.3. Modifications of the quinone ring: genes and proteins involved 
The resulting molecule undergoes subsequent modifications of the ring moiety 
performed by the Coq proteins in yeast and the COQ proteins in humans, which form a 
complex associated to the IMM. In prokaryotes, the following steps occur instead in the 
cytosol and are performed by the Ubi proteins forming a soluble multiprotein complex. 
Genes and proteins involved in this part of the pathway are presented in this section, 
referring to the human/S. cerevisiae /E. coli enzymes, in this order. COQ3/Coq3p/UbiG 
is an O-methylase which modifies C5 and C6 534–538; COQ5/Coq5p/UbiE C-methylates C2 
470,539,540 and COQ6/Coq6p/UbiI 396,460,541 and COQ7/Coq7p/UbiF 542–548 are hydroxylases 
modifying C5 and C6 respectively (Table 4.1). CoQ synthesis requires a C1-
decarboxylation and hydroxylation catalysed by enzymes that have not yet been 
identified in eukaryotes. In E. coli, UbiD and UbiX perform the C1-decarboxylation 549,550 





Table 4.1. Enzymes involved in CoQ biosynthesis. 
Reaction 
























C1-hydroxylation NK NK NK UbiH 551–553  
C2-methylation COQ5 Coq5 Coq5p UbiE 470,539,540  
C3- Prenylation COQ2 Coq2 Coq2p UbiA 531–533 
C5-hydroxylation COQ6 Coq6 Coq6p UbiI 396,460,541  
C6-hydroxylation COQ7 Coq7 Coq7p UbiF 542–548  
C5 and C6 
O-methylations 
COQ3 Coq3 Coq3p UbiG 534–538  
COQ3/Coq3p/UbiG 
COQ3 in eukaryotes (UbiG in prokaryotes) is an O-methyltransferase required for 2 steps 
in the biosynthetic pathway of CoQ, O-methylation of C5 and C6, after the hydroxylation 
of these carbons by COQ6 and COQ7, respectively 534,535,537,538. This enzyme methylates 
an early CoQ intermediate, the 3-polyprenyl-4,5-dihydroxybenzoic acid, as well as the 
final intermediate in the pathway, converting 2-polyprenyl-5-hydroxy-3-methyl-6-
methoxy-1,4-benzoquinone (6-demethyl-CoQ, DMeQ) to CoQ (Table 4.1). COQ3 
proteins are Class I S-adenosylmethionine (SAM)-dependent methyltransferases (SAM-
MTases) that use the methyl donor SAM as a cofactor and catalyse the transfer of the 
methyl group from SAM to oxygen, requiring a divalent cation for the reaction 381,411,554. 
UbiG crystal structure has been determined, and it displayed the typical class I SAM-
MTase Rossman-like fold, with some additional features characteristic of COQ3 proteins 
554. COQ3 proteins typically show three conserved regions. The first one is the classical 
glycine-rich motif (DXGXGXG) of class I SAM-MTases to interact with the methyl donor 
SAM. The other two are particular to COQ3 proteins: a short helix (α6) between β4 and 
α7 with unknown function, and an insertion of two hydrophobic helixes (α8, α9) 
between β5 and α10 that has been proposed to be essential for membrane binding.  
COQ5/Coq5p/UbiE 
COQ5 in eukaryotes (UbiE in prokaryotes) is a C-methyltransferase that methylates C2 
of the quinone ring, requiring SAM as methyl donor (Class I SAM-MTase) 470,539,540. COQ5 




catalyses the only C-methylation of CoQ biosynthetic pathway, the conversion of 2-
polyprenyl-6-methoxy-1,4-benzoquinone (2-demethyl-6-demethoxy-CoQ, DDMQ) to 2-
polyprenyl-3-methyl-6-methoxy-1,4-benzoquinone (6-demethoxy-CoQ, DMQ) (Table 
4.1). NADH has been reported to enhance the reaction through a yet unknown 
mechanism 539. Coq5p yeast protein has been crystallised as a dimer, and its structure 
shows a typical class I SAM-MTase Rossman-like fold, with some peculiarities 555. COQ5 
proteins have the typical glycine-rich SAM-binding site, in this case with a minor 
variation in the sequence: DVAGGSG. They also have a conserved insertion of two 
helixes (α6, α7) between β5 and α8, which participate in the hydrophobic interface of 
the dimer. Another feature that is conserved is a hydrophobic pocket predicted to be a 
putative DDMQ binding site 555. Interestingly, UbiE bacterial protein is only able to 
restore Coq5p methylation in yeast expressing an enzymatically inactive Coq5p enzyme, 
but not when they totally lack Coq5p protein 556. This fact indicates that besides the 
enzymatic function, Coq5p probably has an important function in stabilizing the other 
Coq proteins. 
COQ6/Coq6p/UbiI 
COQ6 in eukaryotes (UbiI in prokaryotes) is an evolutionarily conserved FAD-dependent 
monooxygenase required for the C5 hydroxylation (Table 4.1) 396,460,541. COQ6 proteins 
have three conserved motifs that are present in the larger family of flavin-dependent 
monooxygenases (FMOs): an ADP-binding motif, a NAD(P)H recognition and FAD-
pyrophosphate moiety binding site and a FAD-ribityl moiety binding motif 411,541.  Crystal 
structure of UbiI protein from E. coli has been partially resolved, revealing that it has a 
typical FAD-binding domain, similar to that of several FMOs 460. COQ6 enzymes catalyse 
the hydroxylation of 3-polyprenyl-4-hydroxybenzoic acid to 3-polyprenyl-4,5-
dihydroxybenzoic acid. The electrons required for the hydroxylation reaction are 
indirectly obtained from NAD(P)H via a ferredoxin/ferredoxin reductase system. In 
yeast, these are Yah1 and Arh1, encoding mitochondrial ferredoxin and ferredoxin 
reductase 520. FDXR and FDX1L are the human orthologues, but their possible implication 
in CoQ biosynthesis is unknown 381. Additionally, it has been shown that Coq6p acts as a 






COQ7 (Clk-1 or Cat5) in eukaryotes is a monooxygenase, member of the carboxylate-
bridged diiron hydroxylases family 542,543,547,558. It is responsible for the C6 hydroxylation 
of the quinone moiety in CoQ biosynthesis, catalysing the conversion of DMQ to DMeQ 
(Table 4.1), the penultimate step of the pathway 546. The protein seems to be associated 
to the IMM 547,559. The hydroxylation reaction catalysed by COQ7 has been proposed to 
occur through a DMQ substrate-gated reduction of the diiron centre by NADH (and not 
NADPH), and then, a subsequent dioxygen activation and DMQ hydroxylation 542,543. 
COQ7 protein structure has not been dilucidated yet, but structural models of COQ7 
protein from different organisms (human 224,543, S. cerevisiae 458, rat 558, P. aeruginosa 
547 have been obtained by using other diiron proteins as templates. They show to have 
a four-helix bundle, with a highly conserved diiron active site with the EXn1EXXH-Xn2-
EXn3EXXH binding motif 458,543,558. Each pair of helixes (α1 and α2; α3 and α4) contains a 
single iron binding site, that consists in one iron-coordinating E residue in the first helix 
(α1 and α3) and a EXXH motif in the second helix (α2 and α4), which chelate the iron 
atom. Then, there is a hydrophobic cavity leading to the diiron site, that could serve as 
DMQ binding pocket 547,558. UbiF is the monooxygenase that performs the C6-
hydroxylation in E. coli and other bacteria 548,551. It is an FMO, more similar to 
COQ6/Coq6p/UbiI, and unrelated to COQ7. Despite using different cofactors, UbiF 
performs the same function than COQ7/Coq7p and it is able to complement S. cerevisiae 
coq7 null mutants when it is targeted to the mitochondria 544. Also, Coq7 homologues 
from Pseudomonas aeruginosa, Thiobacillus ferroxidans, and C. elegans were 
demonstrated to complement an E. coli mutant with defects in UbiF 545,547.  
UbiD-UbiX system and UbiH 
In E. coli, the UbiD-UbiX system performs the C1-decarboxylation. UbiX is a flavin 
prenyltransferase that produces prenyl-FMN, a cofactor for UbiD decarboxylation 
reaction 549,550. UbiH is a FMO that hydroxylates C1 551–553. Eukaryotic homologues of 
these three proteins have not been yet found, suggesting that the reactions mechanisms 
in eukaryotes might be different from the bacterial ones.  




Order of the reactions in CoQ biosynthesis 
The accepted order of reactions involved in the modifications of the aromatic ring of 
CoQ is slightly different between eukaryotes and prokaryotes, and some steps are still 
unclear (Figure 4.3). It is possible that for some reactions the active site of the enzyme 
requires the presence of a chemical group previously added by a different Coq protein. 
This is obvious for Coq3 O-methylation, which requires a previous hydroxylation to 
perform the O-methylation. But this fact could be also true for other modifications, 
considering the chemical logic of the reactions and the possible regioselectivity of active 
sites 381. It is also possible that other enzymes could catalyse their reaction 
independently of other modifications, so they could occur before or after these other 
reactions.  
The accepted eukaryotic model after 4-HB prenylation by COQ2 starts with a C5 
hydroxylation of the head group performed by COQ6 411, followed by the O-methylation 
of these C5 group by COQ3. Next, unidentified decarboxylase and hydroxylase enzymes 
perform the C1-decarboxylation and hydroxylation. Then, COQ5 would C-methylate C2 
and COQ7 would hydroxylate C6. The last step of the pathway would be the O-
methylation of C6 by COQ3 (Figure 4.3 and Table 4.2). However, yeast and human COQ6 
knockout cells accumulate 4-HP, a compound that is decarboxylated and hydroxylated 
in position C1 of the ring. Therefore, these reactions (which are catalysed by still 
unidentified enzymes) must occur before or independently on C5 hydroxylation by 
COQ6 (Figure 4.3, Table 4.2 and Chapter 2, section 2.2.2) 165,396.  
In prokaryotes like E. coli, the sequence of reactions is described to be different. 4-HB is 
firstly synthetized by UbiC, directly from chorismate (Figure 4.1.A). Following 4-HB 
prenylation by UbiA, UbiX-UbiD system performs the C1-decarboxylation 549,550. Then, 
the monooxygenase UbiI performs C5-hydroxylation, and UbiG O-methylates this same 
position. Next, UbiH FMO hydroxylates C1, followed by C2-methylation by UbiE. Then, 
UbiF hydroxylates C6 and subsequently, UbiG O-methylates this position to form CoQ8 
(Figure 4.3 and Table 4.2) 512. Similar to what occurs in eukaryotes, E. coli defective in 
UbiI accumulates 4-HP8, indicating that UbiH is able to perform C1-hydroxylation in the 








Figure 4.3. CoQ biosynthesis pathway from 4-HB in human, yeast and bacteria. 
Human COQ proteins are indicated in blue, yeast Coqp proteins in green and bacterial Ubi enzymes in 
orange. Each intermediate compound is labelled with a number and described in Table 4.2. Human and 
yeast canonical pathway is the 1-2-3-4-9-10-11-12 pathway, while bacterial canonical pathway is the 1-5-
8-4-9-10-11-12. Pathways involving 5, 6 and 7 would be also possible, since human, yeast and bacterial 
models defective in COQ6/Coq6p/UbiI accumulate compound 6 (4-HP).  
 
 









1 3-polyprenyl-4-hydroxybenzoate DHB HHB OHB 
2 3-polyprenyl-4,5-dihydroxybenzoate DDHB DHHB DOHB 
3 3-polyprenyl-4-hydroxy-5-methoxybenzoate DHMB HHMB OHMB 
4 2-polyprenyl-6-methoxyphenol DMP HMP OMP 
5 2-polyprenyl-phenol DPP HPP OPP 




DHDP DHHP DHOP 















DMeQ10 DMeQ6 DMeQ8 
12 Coenzyme Q CoQ10 CoQ6 CoQ8 





Regarding the three hydroxylation reactions of the pathway, it has been shown that 
while in eukaryotes, two known (COQ6 and COQ7) and one unknown specialist 
hydroxylases participate in these three reactions, the picture in bacteria is more 
complex. There are some bacteria that have three specialist enzymes (like UbiF, UbiH 
and UbiI in E. coli or UbiH, UbiI and Coq7 in P. aeruginosa), while some other bacteria 
have one or two generalist enzymes of broader regioselectivity, able to perform 
hydroxylation reactions in different positions of the quinone ring in CoQ biosynthesis 
(like UbiM and UbiL FMOs) 551. Interestingly, a O2-independent CoQ biosynthesis 
pathway has been described in bacteria, in which the O2-dependent FMO hydroxylases 
are replaced by the Fe-S hydroxylases UbiU and UbiV 560,561. 
The use of pABA in CoQ biosynthesis 
Yeast can synthesise and use pABA for CoQ6 biosynthesis (Figures 4.1.A and 4.4.A), for 
which it is prenylated by Coq2p protein, competing with 4-HB for Coq2p active site 
519,520. C4 amino group must be then replaced by a hydroxyl group. The monooxygenase 
Coq6p is reported to perform C4 deamination and hydroxylation, in addition to C5 
hydroxylation, but at an undefined step 557. Specifically, C-terminal region of Coq6p is 
reported to be essential for C4 deamination, and Coq9p may have an indirect roll in this 
reaction, since some mutations in the C-terminal region of Coq6p or the lack of Coq9p 
promote severe defects in C4 deamination, while partially preserve C5 hydroxylation 
function 557. When the C4 deamination step is defective, 4-imino-6-demethoxyCoQ6 
(IDMQ6) is mainly accumulated, meaning that all Coq biosynthetic enzymes up to Coq7p 
(Coq2p, Coq6p, Coq3p (at least for the first reaction catalysed by Coq3), unknown C1-
decarboxylase and hydroxylase and Coq5p) can accommodate and transform substrates 
with a C4-amino group (Figure 4.4.A) 289,557. 
In E. coli, pABA is endogenously synthesised (Figure 4.1.A). It can be prenylated by UbiA, 
and then decarboxylated (by UbiD/X) and hydroxylated (by UbiI) to yield 2-amino-3-
octaprenylphenol (OAP), a “dead-end” aminated product that cannot progress further 
in the pathway (Figure 4.4.B) 515. This means prenylated pABA cannot be C4-deaminated 







Figure 4.4. The use of p-aminobenzoic acid (pABA) in CoQ biosynthesis.  
(A) S. cerevisiae (green) can use either 4-HB (4- hydroxybenzoate) or pABA for CoQ6 biosynthetic pathway. 
4-HB and pABA differ by the presence of a hydroxyl or an amino group at position C4. The C4-deamination 
reaction is performed by Coq6p and it occurs at an undefined step, being 4-imino-6-demethoxycoenzyme 
Q (IDMQ6) the most downstream amino-containing intermediate identified to date. (B) E. coli (orange) 
can transform pABA into 4-amino-3-octaprenyl-benzoate (OAB). UbiD and/or UbiX catalyze the 
decarboxylation of the aromatic ring forming 2-octaprenyl-aniline (OPA). UbiI adds the first hydroxyl to 
the ring to form 2-amino-3-octaprenylphenol (OAP). The pABA branch of the pathway stops at this step. 
R represents the polyprenyl tail, with 6 units of isoprene in yeast and 8 in bacteria. (Adapted from Ozeir 
et al., 2015 557 and Xie et al., 2015 515) 
 
 
Vertebrates cannot synthesize pABA. In mammalian cell cultures, pABA 
supplementation decreases CoQ total levels and leads to the accumulation of 4-imino-
6-demethoxycoenzyme Q (IDMQ) 289, similarly to what happened in yeast defective in 
the C4-deamination reaction 397. This fact suggested that IDMQ cannot be further 
modified by COQ7, and that deamination does not occur in cell cultures, interfering with 
endogenous CoQ biosynthesis. However, pABA supplementation in mice did not alter 
CoQ levels or accumulate IDMQ in the different tissues analysed, suggesting that pABA 
does not perturb CoQ biosynthesis in the context of a whole organisms, at least in 
mouse289.  




4.1.4. Other important non-enzymatic or uncharacterised proteins in CoQ 
biosynthesis 
There are other COQ/Coq/Ubi proteins that are essential for CoQ biosynthesis, but their 
precise molecular function is still unknown (Table 4.3). In eukaryotes, these are 
COQ4/Coq4p, COQ8A (or ADCK3/CABC1) and COQ8B (or ADCK4) /Coq8p, COQ9/Coq9p, 
COQ10A and COQ10B/Coq10p and Coq11p. In bacteria, there are three Ubi proteins of 
unknown function which are required for CoQ synthesis: UbiB, UbiJ and UbiK 512.  
Table 4.3. Other important functions involved in CoQ biosynthesis. 
Other important 











Coq8p UbiB 385,397,460 
Complex 







COQ9 Coq9 Coq9p UbiJ? 224,278,468,562–564,512 







Coq10p UbiJ? 565–568 
Decarboxylase or 
reductase? 
NK NK Coq11p NK 506 
COQ4/Coq4p 
COQ4 is essential for CoQ biosynthesis in eukaryotes. It has been proposed that COQ4’s 
function is related to the CoQ biosynthetic complex stabilization (Table 4.3) 465,466,469. 
COQ4 protein family has homologues in eukaryotes and also in some prokaryotes (See 
Chapter 3). These proteins have a conserved motif predicted to bind a divalent cation. 
For all the details about this protein and its features, please refer to Chapter 3. In the 
present chapter we will try to elucidate COQ4 molecular function in CoQ biosynthesis 





COQ8A and COQ8B/Coq8p/UbiB 
The ancient UbiB protein kinase-like (PKL) family is very conserved in archaea, bacteria, 
and eukaryotes. These proteins are needed for efficient CoQ production, but their 
molecular function still remains unclear (Table 4.3). E. coli UbiB was thought to be a 
monooxygenase performing the first hydroxylation of CoQ 569, but later studies revealed 
that UbiI performs this step 460. UbiB has three yeast (Coq8p, YLR253W and YPL109C) 
and five human orthologues (AarF Domain Containing Kinases, ADCK1-5) 385. Amongst 
these orthologues, only Coq8p in yeast and COQ8A (or ADCK3/CABC1) and COQ8B (or 
ADCK4) in humans have been reported to participate in CoQ biosynthesis. Human 
COQ8A and COQ8B protein sequences have a 44.23% of identity and a 66.12% of 
similarity, and patients with mutations in both genes have been found to present 
primary CoQ10 deficiency 112.  
The three other genes of the ADCK family (ADCK1, ADCK2 and ADCK5) have been 
suggested to be involved in the CoQ biosynthetic process and diverse functions have 
been shown for some of them. ADCK1 has been proposed to participate in the structural 
maintenance of mitochondrial membranes in muscle 570. ADCK2 has been described to 
participate in CoQ biosynthesis and in the fatty acid metabolism in skeletal muscle378, as 
well as in the distribution of CoQ from mitochondria to other membranes 571.  
Initially, Coq8p was thought to be a kinase participating in phosphorylation of Coq3p, 
Coq5p and Coq7p in yeast 397,490,491, since phosphorylation of these proteins is altered in 
a coq8 null mutant yeast. However, the crystallisation of COQ8A revealed a kinase-like 
fold protein with unique UbiB-specific features demonstrated to inhibit protein kinase 
activity. These features are an N-terminal domain that occupies the typical substrate 
binding pocket and a A-rich loop that replaces the canonical G-rich nucleotide binding 
loop and provides an unusual selectivity for ADP over ATP 385. Moreover, COQ8A/ADCK3 
has recently been shown to lack canonical protein kinase activity in trans 424 and  have 
an ATPase activity that is enhanced by binding cardiolipin containing membranes or 
small phenolic molecules resembling to CoQ pathway intermediates 572. It has been 
hypothesised that it could couple the hydrolysis of ATP to the extraction of the quinone 
heads of CoQ intermediates out of the membrane and allow their chemical modification 
316,413,572. Still, its mechanistic role is unclear and needs to be further studied.  





COQ9 are lipid-binding proteins present in a wide range of eukaryotes, but not in 
bacteria 468,562. COQ9 functionally and physically interacts with COQ7, to favour C6-
hydroxylation reaction, stabilizing CoQ biosynthetic complex 224,278,563,564. COQ9 
deficiency leads to a drastic reduction of COQ7 levels and activity, accumulating DMQ, 
in all models studied 278,388,397. It has also been reported that yeast Coq9p supports 
Coq6p in the deamination of the intermediates derived from pABA precursor 573. The X-
ray structure of human COQ9 protein was obtained, showing the presence of a 
conserved lipid-binding pocket, able to specifically bind aromatic isoprenes 224,564. The 
structure revealed structural homology to an ancient TetR family of transcriptional 
regulator (TFRs) with an amphipathic C-terminal helix. COQ9 protein structural and 
molecular dynamics studies suggested that this C-terminal hydrophobic helix controls 
membrane binding, and the association is favourited in cardiolipin-rich membranes. 
When COQ9 binds this part of the IMM, a local deformation occurs and lipids are 
orthogonally displaced, entering their hydrophobic tail inside the cavity of COQ9. 
Afterwards, COQ9 is able to lift the bound lipid off the membrane, and present it to 
COQ7, to promote C6-hydroxyltion 224. 
COQ10A and COQ10B/Coq10p/pasT   
COQ10 are mitochondrial proteins belonging to the START (steroidogenic acute 
regulatory protein-related lipid transfer) domain protein family, which have a 
hydrophobic tunnel specialised in binding lipids. Coq10p is not essential for CoQ 
biosynthesis since yeast null mutants present normal levels of CoQ 566. However, de novo 
CoQ biosynthesis and mitochondrial respiration of these mutants is less efficient than in 
WT yeast, and they are highly sensitive to H2O2. These defects can be restored by 
exogenous CoQ supplementation or Coq10p WT expression 565–567. Human COQ10A and 
COQ8B expression, CC1736 bacterial START domain protein from Caulobacter 
crescentus expression or yeast Coq8p overexpression were also able to rescue the 
respiratory defect and the sensitivity to oxidative stress in this mutant 565,566,574, and only 
partially the defect in de novo CoQ synthesis. Interestingly, levels of Coq10p protein are 





respiration, which is partially restored by Coq8p overexpression 567,575. S. pombe Coq10p 
protein has been demonstrated to specifically accommodate the quinone head ring of 
CoQ in a binding site included in the START domain 576. Very recently, an E. coli protein 
displaying the same functions of COQ10 proteins has been identified 560,577. E. coli 
mutants lacking pasT displayed the same pleiotropic phenotypes as yeast coq10 
mutants, including decreased membrane potential, increased sensitivity to oxidative 
stress, and modestly decreased ubiquinone biosynthesis. Moreover, these phenotypes 
were rescued by ectopic expression of human COQ10A 560,577.  
It is suggested that Coq10 proteins bind CoQ and late-stage CoQ-intermediates, 
probably chaperoning them to the sites where they are needed within the mitochondrial 
membranes, facilitating de novo CoQ biosynthesis and respiratory electron transport 
560,565–567,574,577.  
Coq11p 
Coq11p yeast protein was first found as a component of the CoQ biosynthesis complex 
by immunoprecipitation studies 506. It is present in fungal genomes and in 
photosynthetic genomes or genomes with a photosynthetic ancestor. Yeast coq11 null 
mutants have an impaired but not completely abolished CoQ biosynthesis, and they 
retain some respiratory growth. Coq11p is thought to be necessary for efficient de novo 
CoQ synthesis in yeast, with a predicted role as a FMN-dependent decarboxylase or 
reductase, but it has no clear human orthologue 506.  
Interestingly, coq11 gene was found to be fused to coq10 gene in some fungal genomes 
from Ustilaginaceae, suggesting some functional link between these two proteins 
506,574,578. Indeed, coq11 gene deletion in yeast has been recently reported to rescue the 
respiratory deficiency, sensitivity to oxidative stress and decreased de novo CoQ 
biosynthesis in coq10 null mutant. coq10 and coq11 double mutant showed increased 
CoQ levels in mitochondria, which were suggested to rescue the phenotype of coq10 
mutant 579. Coq11p is suggested to be a negative modulator of CoQ biosynthesis in yeast, 
but the mechanisms underlying this phenomenon are still elusive 579. It does not have a 
clear homologue in human, but it has been shown by a protein similarity network 
analysis that the taxonomy of Coq11p-like proteins include the short-chain 




dehydrogenases/reductases subfamily protein NDUFA9, an accessory CI subunit 
required for CI stability in humans 380,506. 
UbiJ and UbiK 
UbiJ 568 and UbiK 412 are bacterial proteins essential for CoQ biosynthesis. They have 
been found to physically bind to each other in a heterocomplex UbiK-UbiJ (2:1) that is 
able to bind lipids. UbiJ is a lipid binding protein capable of binding CoQ and CoQ 
intermediates. UbiK-UbiJ complex has been found part of a bigger 1-MDa multiprotein 
complex, in which 5 other Ubi proteins were also found (Ubi E, F, G, H, I), localised in the 
cytosolic fraction. UbiJ has a key role in binding the isoprenoid intermediates, through 
its SCP2 (sterol carrier protein 2) domain, inside the complex and is essential for complex 
formation. The current hypothesis is that UbiJ and UbiK assist several steps of CoQ 
biosynthesis by presenting intermediates to the Ubi enzymes inside the biosynthetic 
complex 560 
4.1.5. Structural organization of CoQ biosynthetic proteins: CoQ biosynthesis 
complex 
The enzymes modifying CoQ quinone head are described to form a multiprotein 
complex, the CoQ synthome or CoQ complex. There is evidence that yeast Coq3p-Coq9p 
proteins are organized in a complex located on the matrix side of the IMM 490,580, and 
this architecture seems to be conserved in mammals (Figure 4.5.B and C). As detailed in 
the previous section, in prokaryotes, an Ubi-metabolon has also been described, but in 
this case, in the cytosolic soluble fraction (Figure 4.5.D). Importantly, CoQ intermediates 
of the pathway are also needed for complex formation and stability. The organization of 
the CoQ biosynthetic proteins and CoQ intermediates in a complex would be essential 
for shielding the hydrophobic intermediates from the hydrophilic environment. 
Moreover, in addition to enhancing the catalytic efficiency of the pathway, by correctly 
orientating the substrates and active sites of the enzymes, or allowing the functional 
regulation of the different components, the complex would sequester the reactive 





Yeast CoQ complex 
The existence of a CoQ biosynthetic complex containing Coq3p-Coq9p proteins was first 
described in yeast. A common feature for coq3-coq9 null mutants was the lack of the 
final product CoQ and the accumulation of the same early precursor, hexaprenyl-
hydroxybenzoate (HHB), Coq2p’s product 467,468, instead of the substrate of the lacking 
enzyme (Table 4.4). This observation indicated that Coq proteins were needed not only 
for their enzymatic function but also for the activity and stability of the other Coq 
enzymes. This possibility was supported by the fact that some point coq mutants (coq5, 
coq6 and coq7) had a lesser drastic phenotype, accumulating their corresponding 
diagnostic intermediate. For example, some point mutations of Coq7p led to the 
accumulation of Coq7p substrate, DMQ6 (Table 4.4) 456,544,546. Moreover, this mutant but 
not the coq7 null mutant, was rescued by low copy expression of ubiF 544. Similarly, some 
respiratory deficient mutants with point mutations in coq5, affecting the catalytic 
activity, but not coq5 null mutant, were rescued by the expression of ubiE 556.  
Table 4.4. Intermediates accumulated in yeast defective in CoQ biosynthesis. 






















coq6 HHB 4-HP 4-HP/4-AP 342,396,467  
coq3 HHB HHB 
HHB (DMQ when 
VA added) 
397 
coq5 HHB DDMQ DDMQ 397,467,470  
coq7 HHB DMQ DMQ 397,415,467,546 
coq9 HHB - DMQ and 4-HP 397,468 
coq4 HHB HHB HHB/HHAB 397,467 
coq8 HHB - - 467 
coq10 HHB/HAB - - 565 
coq11 HHB and DMQ - - 506 
Moreover, in several of these mutants, the lack of one Coq protein (Coq3p, Coq4p, 
Coq6p, Coq7p or Coq9p) produced the depletion of other Coq polypeptides, while point 
mutations didn’t have such effect 464,468,544,556,563,580,581. All these data indicated that Coq 
proteins were also playing a structural role, besides their enzymatic one, forming a 
multiprotein complex, whose stability is essential for the function of the individual 
components.  




Importantly, it has also been demonstrated that some intermediates of the synthesis 
and CoQ itself are important integral components of the complex 395,415,424,465,506. 
Furthermore, it is known that CoQ intermediates are needed for complex formation and 
stabilization 1. In agreement with this, there are some Coq proteins that have been 
shown to directly bind lipids inside a lipid-binding domain of the protein. It is the case of 
Coq9p 224 and Coq8p 424, which both co-immunopurified with several intermediates of 
CoQ biosynthesis.  
Overexpression (OE) of Coq8p in some of the coq mutants stabilized the levels of other 
Coq polypeptides 397,575 and their organization as a complex 395, resulting in the 
accumulation of the respective substrates of the lacking enzyme, instead of HHB (Table 
4.4). Coq8p OE in coq null mutants has been then a useful tool for confirming the specific 
enzymatic activities of different components of the complex, such as coq7, which 
accumulates DMQ6 397,415, coq5, which accumulates DDMQ6 397,470 or coq6, which 
accumulates 4-HP6 396. Because of the complex-stabilising effect, OE of Coq8p has also 
been useful to explore the use of 4-HB analogues as bypass molecules for some specific 
Coq protein defects, such as vanillic acid in coq6 for Coq6p bypass 396 or 2,4-dHB in coq7 
for Coq7p bypass 397 (see Chapter 2), or even as a screening platform to look for new 
bypass molecules for some coq defects 416. As explained before, it has been 
hypothesised that Coq8p’s role in CoQ biosynthesis could be the extraction of the CoQ 
intermediates out of the membrane, coupled to ATP hydrolysis 316,413,572. In this context, 
Coq8p would act as a lipid chaperon, providing the lipid intermediates needed for 
complex nucleation and maintenance, but not being an integral component of the 
complex 1. In the condition of suboptimal complex stability, due to the lack of one of the 
components, Coq8p overexpression would rescue this instability, probably by providing 
more intermediates to nucleate and maintain the complex 1.  
Biochemical and proteomic analyses provided physical evidence of protein-protein 
interactions (PPI) between the complex Q components. Different co-
immunoprecipitation studies found that Coq3p-Coq9p co-precipitated together in 
different combinations 465,506,563, and one of them identified Coq11p as part of the 
complex 506. By size-exclusion chromatography, Coq3p, Coq4p, Coq6p and Coq7p were 





2D BN-PAGE assays also demonstrated that several Coq proteins (Coq3p, Coq4p, Coq5p, 
Coq7p and Coq9p) co-migrate as part of complexes with a molecular weight higher than 
1MDa 2,395,465,466,490,544,563,574. BN-PAGE separation profiles of Coq2p, Coq8p and Coq10p 
suggested that these proteins would probably not be integral and structural part of the 
>1MDa complex, but some weak or transient interactions between these proteins and 
the complex may be occurring 316,490.  
In vivo fluorescence microscopy in yeast has also provided evidence of CoQ complex 
formation, being Coq3, 4, 5, 6, 7, 9, and 11p the core components (Figure 4.5.C) 1. Tagged 
Coq proteins were visualised, and only some of them (Coq3p, Coq4p, Coq5p, Coq6p, 
Coq7p, Coq9p and Coq11p) were found to have a focal localisation into discrete foci in 
the IMM named CoQ domains 1. On the contrary, Coq1p, Coq2p, Coq8p and Coq10p had 
a uniform distribution within mitochondria. The lack of Coq1p-Coq9p totally prevented 
CoQ domain formation, while coq10 mutants were only partially affected, and coq11 
mutants just slightly affected in CoQ domain formation.  
Coq8p overexpression was also shown to rescue CoQ domain formation in coq5, coq6, 
coq7 and coq9 null mutants, but not in coq1, coq2, coq3 and coq4, in agreement with 
the previous biochemical data 1,395,397. In the case of coq1 and coq2, it is understandable, 
because the lack of these enzymes prevents the presence of prenylated intermediates, 
which are essential for CoQ domain formation 1,316. In the case of coq3 and coq4, the 
proteins coded by these genes are thought to be critical structural components of the 
complex 1,465,466, so that is the hypothetical reason why Coq8p overexpression do not 
rescue the CoQ domain formation. All these data fully agree with the previous 
biochemical data for CoQ complex formation, additionally suggesting that Coq8p is not 
an integral part of the CoQ complex, but it interacts with it dynamically, being essential 
for complex formation. 
Importantly, these CoQ domains are spatially and functionally related to ERMES 
(endoplasmic reticulum-mitochondria encounter structure) complex, also known as ER-
mitochondria contacts 1,2 and the loss of this structure impairs respiration through 
reduction of CoQ levels and accumulation of CoQ intermediates (See Chapter 5, section 
5.1.6). This could be a mechanism of secondary CoQ deficiency 316. 
  





Figure 4.5. Models of CoQ biosynthesis complex.  
(A) Human CoQ10 biosynthesis pathway and model of the biosynthetic complex. Blue arrows represent 
enzymatic reactions and circled numbers represent the different COQ proteins that participate in each 
step. Brown arrows indicate regulatory mechanisms. Circled question mark shows currently unidentified 
enzymes. (B) Model of human CoQ10 biosynthetic complex, containing at least COQ3–COQ9 and lipids, 
such as CoQ10 itself. Other CoQ biosynthesis complex models are also represented: yeast (C) and bacteria 
(D). CoQ10, coenzyme Q10; 4-HB, 4- hydroxybenzoate; DDMQ10, demethoxy-demethyl-CoQ10; DMQ10, 
demethoxy-CoQ10; DMeQ10, demethyl-CoQ10; IMS, inter-membrane space. (Adapted from Alcázar-Fabra 







Mammalian CoQ complex 
CoQ complex seems to be conserved in mammals. Unlike in yeast, only some mammal 
CoQ intermediates accumulation experiments have been performed, and only a few of 
them are in models with a total lack of a specific COQ protein (Table 4.5). Likewise coq6 
null yeast (overexpressing Coq8p or expressing mutated Coq6p), COQ6 KO human cells 
(HEK293) accumulated 4-HP10, but in this case with no need of COQ8 overexpression or 
inactive COQ6 expression 165. Something similar occurred in Coq7-/- embryos at E9.5 (the 
lack of Coq7 in these mice was embryonic lethal), which accumulated DMQ9 421. Two 
different KI mouse models with non-sense mutations in Coq9 (Coq9Q95X and Coq9R239X) 
also accumulated DMQ9 278,279. Patient fibroblasts with mutations in COQ7 or COQ9 
accumulated DMQ10 238,239,248,388. COQ4 patient fibroblasts also showed a small 
accumulation of DMQ10 388. Patient fibroblasts with mutations in COQ2 accumulated 
decaprenyl-pyrophosphate 241. COQ7 KD in 143B cells also accumulated DMQ10 315. 
Human fibroblasts KD of COQ3, COQ4, COQ5, COQ6, COQ7 and COQ9 genes (but not 
COQ2) also showed an accumulation of DMQ, being observed the highest accumulation 
in the COQ7 KD 388. 
Table 4.5. Intermediates accumulated in mammalian models defective in CoQ biosynthesis. 




Point mutations  
(Patient cell line) 
COQ2 - - Decaprenol 241 
COQ6 4-HP - - 165 
COQ3 - DMQ - 388 
COQ5 - DMQ - 388 
COQ7 DMQ DMQ DMQ 238,315,388,420,421,425 
COQ9 DMQ DMQ DMQ 248,278,279,388 
COQ4 - DMQ - 388 
 
Depletion of specific COQ proteins has been observed in some mouse models with 
primary CoQ deficiency. Coq3-9 proteins were depleted across different tissues in 
Coq8a-/- mice at different degrees 424, and the same was observed in Coq9 mutant mice 
278,564. This phenomenon has also been studied in some human cell lines. COQ4, COQ7 
and COQ9 levels were measured in patient fibroblasts with mutations in COQ4, COQ7 
and COQ9 388. In these specific cell lines, defects in COQ9 led to a depletion in COQ4 and 
COQ7; mutations in COQ7 also depleted COQ4 levels but not COQ9; and COQ4 deficiency 




did not affect COQ7 or COQ9 levels 388. In human 143B cells, the KD of some of the PDSS 
and COQ genes resulted in the alteration of other COQ protein levels 315. In these cells, 
the KD of some genes, such as PDSS1, PDSS2 and COQ3, produced a general depletion 
of COQ3-COQ9 proteins. In contrast, knocking-down the rest of the COQ genes had a 
more discreet effect, reducing or increasing the levels of other specific COQ 
polypeptides. For example, COQ4 KD displayed an overproduction of COQ5 and COQ6, 
while COQ7 KD only showed an overproduction of COQ4. In contrast, COQ5 KD produced 
a reduction in COQ7; COQ6 KD, a reduction in COQ3 levels and COQ9 KD, a decrease in 
COQ5 levels. In these studies, KD of COQ2 and COQ8A did not show an effect in other 
COQ proteins levels 315.  
COQ PPI have also been described in mammalian cells. COQ8B co-immunoprecipitated 
with COQ6 and COQ7 in cultured human podocytes 363 and with COQ5 in HEK293 
overexpressing COQ8B-FLAG 401. Tagged COQ5 and COQ4 proteins 
coimmunoprecipitated when coexpressed in HEK293 cells 470, and COQ8A-FLAG co-
purified with COQ5-HA when co-expressed in COS cells 424. Wider affinity enrichment 
mass spectrometry (AE-MS) studies of HEK293 and HepG2 cells expressing the different 
tagged-COQ proteins revealed a highly interconnected CoQ biosynthetic complex, with 
a big number of PPI between the different components 438,514. Interestingly, the 
abundance of PPI involving COQ8A and COQ8B were reciprocally regulated depending 
on the cellular metabolic status, being COQ8A interactions more abundant when cells 
were grown in galactose medium, while COQ8B’s were predominant in cells grown in 
dextrose medium 438.  
Cell-free protein translation and co-immunoprecipitation showed that nearly all COQ 
proteins were unstable alone but stabilised when co-expressed in pairs 438. With this 
same approach, a complex containing COQ3, 4, 5, 6, 7 and 9 was purified in vitro, 
indicating that the presence of these six core components is enough to produce the 
complex (Figure 4.5.C) 438. These 6 core components are the same that, in yeast, were 
reported to localize in the foci so-called the CoQ domain (in yeast, Coq11p is also part 
of these CoQ domains) 1,438. COQ8A and COQ8B seem to interact with the different COQ 
proteins of the complex in a more dynamic way, and are required for its stability and 





Also, 2D BN-PAGE experiments showed the presence of different COQ proteins (PDSS2, 
COQ3, COQ4, COQ5, COQ6, COQ7 and COQ9) in high-molecular weight complexes in 
human osteosarcoma 143B cells 315,437, but smaller than the ones found in yeast. These 
proteins were mainly found in a dissociated state, but some high-molecular weight 
signals were observed. PDSS2 was observed in two major complexes of approximately 
146KDa and 242KDa, and very faint signals up to 1MDa. One of the two small complexes 
were hypothesized to be the heterotetramer configuration of PDSS2 in association with 
PDSS1, maybe with contacts with other proteins too 315. COQ3 was found in small 
complexes from 66 to 146KDa, and COQ7 also around the 146KDa marker with some 
faint signals up to 242KDa 315. COQ4 and COQ6 were found in a range from 66 to 480KDa 
315, and COQ5 in the range of 242KDa to 400KDa 437. COQ9 was found in complexes of 
66KDa-146KDa 437. The presence of the different proteins in fractions of diverse 
molecular weight would support the idea of a dynamic CoQ biosynthetic complex in 
mammals. CoQ complex configuration should be studied under specific metabolic 
conditions in order to better understand its assembly and regulation. 
As in yeast, some COQ proteins have been shown to bind lipids or small molecules, like 
CoQ precursors, which are thought to be integral and important componets of the 
complex as well 224,424,564. For example, mouse Coq8a was found to bind lipid membranes 
424 and its human homologue was able to bind small molecules like CoQ-intermediates 
and phenol derivatives 572. Human COQ9 protein co-crystallised with phosphorylated 
lipids 564 and co-immunopurified with aromatic isoprenes 224. 
The CoQ domains observed in yeast were also observed in human osteosarcoma U2OS 
cells by immunohistochemistry and fluorescence microscopy. Endogenous human COQ9 
localized to discrete foci that colocalised to Mitotracker Red staining 1.  
Bacterial CoQ complex 
The structural organization of the CoQ biosynthetic proteins is evolutionary very 
conserved, and the pathway in E. coli has been equally studied, to characterize the Ubi 
proteins and how they function as a metabolon. Mutations varying from point mutations 
to total ablation of some ubi genes resulted in the accumulation of various CoQ 
intermediates of the pathway (Table 4.6) 512, such as OHB for UbiD and UbiX 




mutations550, OPP for UbiB 569, UbiJ 568, UbiK 412, UbiG 538 and UbiH 552 mutations, 4-HP8 
for UbiI mutations460, DDMQ8 for UbiE mutations 540 or DMQ8 for UbiF mutations 548.  
Table 4.6. Intermediates accumulated in bacterial models defective in CoQ biosynthesis. 
Bacteria Intermediate accumulated 
References 
Mutated gene Null mutant Point mutant 
UbiC - None + Low CoQ 511 
UbiA - No prenylated quinones 533 
UbiD OHB + Low CoQ - 550 
UbiX OHB + Low CoQ - 550 
UbiI 4-HP + Low CoQ - 460 
UbiG - OPP and DMeQ 538 
UbiH - OPP, OHP, OMP 552 
UbiE DDMQ DDMQ 540 
UbiF DMQ DMQ 548 
UbiB OPP OPP 569 
UbiJ OPP - 568 
UbiK OPP - 412 
Recent studies reported that Ubi proteins are organised into a multiprotein complex of 
1MDa 413,507. Surprisingly, this complex seems to be in the cytosolic fraction, forming a 
stable and soluble metabolome able to transform a highly hydrophobic molecule in a 
hydrophilic environment 413 (Figure 4.5.D). The seven core components of this complex 
are five Ubi enzymes (UbiI, G, H, E, and F) and two accessory factors (UbiJ and UbiK) 413. 
This complex would catalyse OPP transformation to CoQ in the cytosol. UbiJ is a lipid-
binding protein capable of binding CoQ and CoQ intermediates, through its SCP2 
domain, inside the complex, and is essential for complex formation 412,568. 
4.1.6. Regulation of CoQ biosynthesis 
Little is known about the regulation of CoQ biosynthesis. Still, such a complex pathway 
must have an elaborated regulatory mechanism operating at very different levels: 
nuclear transcriptional factors, posttranscriptional and post-translational modifications, 
or even assembly of the complex in time and space might be important for the 
regulation of this process.  
Transcriptionally, several nuclear transcription factors have emerged along the last 
years as candidates for regulating the expression of the COQ genes, such as PPARα 582, 
RXRα 583 or NFκB 584. However, an in-depth study of promoters and regulatory sequences 





peroxisome proliferators, by dimerizing with another receptor, the retinoid X receptor 
(RXRα, β or γ). This heterodimeric complex, when it is active, induces a wide range of 
lipid anabolic and catabolic processes, and increases CoQ content in all tissues except 
for the brain. In a PPARα null mouse, CoQ, cholesterol or dolichol levels are the same 
than in a WT mouse, so the constitutive synthesis of these lipids is not affected. 
However, while a WT mouse experiences an increase in CoQ levels upon administration 
of a peroxisome activator, the PPARα null mouse is unable to induce CoQ synthesis, 
indicating this receptor participates in CoQ induction via peroxisome proliferators, but 
it is not essential for constitutive CoQ synthesis 582,583. RXR is able to form dimers with a 
number of other receptors, such as retinoic acid receptor, vitamin D receptor, thyroid 
hormone receptor, PPAR, RXR itself and other orphan receptors. The RXRα was found 
to be essential for CoQ biosynthesis regulation by studying a hepatocyte-specific RXRα 
deficient mouse. These mice had 50% of CoQ WT levels in liver, while cholesterol and 
dolichol were unchanged. In vivo CoQ biosynthesis rate was reduced when compared to 
controls, but the CoQ induction after peroxisome proliferators was not affected. All 
these observations indicated that RXRα is important for constitutive CoQ biosynthesis 
and not for induction by peroxisome proliferators 582,583. NFκB was found to upregulate 
the expression of COQ7 gene, and therefore CoQ synthesis, by binding to COQ7 gene’s 
5’ flanking region. This activation was found to occur under stress conditions, such as 
treatment with cancer drugs like camptothecin 584,585. In contrast, the tricyclic 
antidepressant amitriptyline has been proposed as an antitumoral drug that down-
regulates CoQ biosynthesis in cancer cells, by reducing COQ4 mRNA levels, and COQ4 
and COQ6 protein levels by unknown mechanisms 586. However, this treatment also 
upregulated COQ7 mRNA and protein levels, similarly to camptothecin treatment, and 
it has been suggested that this is probably caused by the increase in ROS through 
activation of NFκB 584,586. 
At the post-transcriptional level, several studies have identified some RNA binding 
proteins (RBPs) which modulate the stability of COQ transcripts, regulating therefore 
their ability to be translated. The yeast RBP Puf3p has been reported to bind coq5 mRNA, 
and control its translation, to avoid the detrimental overproduction of this protein 587. 
Moreover, it also binds to other mRNAs of proteins related to mitochondrial biogenesis 




for their repression during fermentation, which means that Puf3p is involved in a 
regulatory network that coordinates CoQ production and mitochondrial biogenesis 587. 
Some human RBPs have also been found to be involved in CoQ biosynthesis regulation. 
It is the case of HuR and hnRNP C1/C2, which have been reported to bind to COQ7 mRNA 
3’ UTR with opposite regulatory outcomes 588. HuR enhances COQ7 mRNA stability and 
helps maintain physiological COQ7 mRNA, COQ7 protein levels, and CoQ10 biosynthesis; 
while hnRNP C1/C2 binds to COQ7 mRNA by interacting with HuR and triggers its 
degradation 588. These findings suggest that RBPs have crucial roles in regulating CoQ 
biosynthesis. 
There is also evidence showing that CoQ biosynthesis can be regulated at a post-
translational level. For example, yeast Coq5p requires to be processed at the N-terminus 
directly by the mitochondrial protease Oct1p (human orthologue MIPEP) to improve its 
stability in yeast 589. The unprocessed Coq5p protein has a reduced half-life and leads to 
a decrease in CoQ levels 589. Yeast Coq7p is also post-translationally regulated by a 
phosphorylation cycle, being active when it is dephosphorylated by the mitochondrial 
phosphatase Ptc7 in yeast (human orthologue PPtc7) 493. However, the kinase 
responsible for its phosphorylation is not known yet. Additionally, human COQ7 activity 
also depends on the interaction with COQ9 protein, which seems to present the lipid 
cargo DMQ to COQ7 to allow its modification 224,564. Additionally to Coq7p, Coq3p and 
Coq5p also seem to be regulated by phosphorylation modifications by an unknown 
kinase 397,490,491. Coq8p seems to indirectly participate in these phosphorylations, since 
phosphorylation states of these proteins are altered in a coq8 null mutant yeast 
397,490,491. However, COQ8 lacks canonical protein kinase activity in trans 424 and have an 
ATPase activity instead 572.   
4.2. Results and discussion 
In this chapter, we will focus on the molecular characterisation of human COQ4, and 
how it is involved in the CoQ biosynthesis process and in the mitochondria respiratory 
chain. In order to do so, we will study in-depth our COQ4 KO cellular model, and how 
CoQ biosynthesis and mitochondrial respiration are affected in this model. Also, we will 





4.2.1. COQ4 is essential for CoQ10 synthesis in human cells 
COQ4 KO cells show drastically reduced CoQ10 levels, impaired CoQ10 biosynthesis and 
accumulation of a specific intermediate  
CoQ10 levels were measured in the five COQ4 KO clones previously described (See 
Chapter 3, section 3.2.2), lacking COQ4 protein expression (Figure 3.20.D). CoQ10 levels 
were extremely reduced, near to be undetectable, in COQ4 KO cells compared to WT 
cells (Figure 4.6). This means that CoQ10 biosynthetic pathway is highly impaired in these 
cells.  
In order to analyse how this pathway was affected, we measured the incorporation of 
14C-labelled 4-HB to CoQ10, which was virtually undetectable (Figure 4.6.B). This suggests 
that the residual CoQ10 detected in these cells is not produced endogenously but it is 
derived from the medium, in agreement with what we observed in COQ6 KO cells. 
Moreover, the chromatogram showed an additional radioactive peak in COQ4 KO 
sample (rt: 13.5 min), which eluted faster than CoQ10 (rt:17.5-18 min), which is probably 
an intermediate of CoQ10 synthesis (Figure 4.6.B). This peak was also observed in 
samples from patients’ fibroblasts with mutations in COQ4 (see Chapter 2, section 2.2.3, 
Figure 2.18).  
The pre-CoQ10 peak was electrochemically active, since it was also observed with the 
ECD, like the intermediates found in the cases of COQ6 (4-HP10) and COQ7 (DMQ10) 
deficiency (see Chapter 2, sections 2.2.2 and 2.2.1, respectively). However, in contrast 
with the COQ6 and COQ7 deficiency intermediates, COQ4 deficiency pre-CoQ10 peak did 
not shift when the sample passed through the oxidizing guard cell before entering the 
chromatographic column (Figure 4.6.B). This probably indicates that this molecule would 
need a greater potential to be oxidised or that it is already in the oxidized form.   





Figure 4.6. Quinone content in COQ4 KO cell lines.  
(A) All COQ4 KO clones had almost null levels of CoQ10 in total lipid extracts (One-way ANOVA, Dunnett’s 
multiple comparison test (each KO vs. WT); p value<0.0001). (B) Both cell lines were cultured with 
radiolabelled 14C-4-HB. Labelled quinones were detected by HPLC with a radio-flow detector (Rad), while 
total quinone content was detected by a electrochemical detector (ECD). COQ4 KO samples showed a pre-
CoQ10 peak (retention time: 13.5 minutes), detected by Rad and ECD and not detected in WT. This peak 
do not shift when it is subjected to oxidation by the guard cell (right panels, with the oxidizing guard cell 
after the injector).  
HPLC-coupled MS and mass scanning of lipid extracts from WT and COQ4 KO cells was 
performed to characterise this compound. A list with all the possible intermediates of 
the pathway, according to the current knowledge for CoQ biosynthesis in mammals, was 





compounds (Table 4.7, for abbreviations of the compounds’ names, please refer to Table 
4.2). This list was used as the input for the mass spectrometry experiment, meaning that 
if the mass found in the samples was not previously in the list, we would not be able to 
identify the compound. 
Table 4.7. List of possible intermediates of CoQ10 biosynthesis, input for MS identification. 
Abbreviation Formula M (u) [M+NH4]+ Redox state 
DHB C57H86O3 818,657695 836,692069  
DDHB C57H86O4 834,65261 852,686983  
DHMB C58H88O4 848,66826 866,702634  
DMP C57H88O2 804,678429 822,712804  
DPP C56H86O 774,667865 792,702239  
4-HPox C56H84O2 788,64713 806,681504 ox 
4-HPred C56H86O2 790,66278 808,697154 red 
DHDPox C56H84O3 804,642045 822,676419 ox 
DHDPred C56H86O3 806,657695 824,692069 red 
DDMQ10 C57H86O3 818,657695 836,692069 ox 
DDMQ10H2 C57H88O3 820,673344 838,707719 red 
DMQ10 C58H88O3 832,673344 850,707719 ox 
DMQH2 C58H90O3 834,688995 852,723369 red 
DMeQ10 C58H88O4 848,66826 866,702634 ox 
DMeQ10H2 C58H90O4 850,68391 868,718284 red 
CoQ10 C59H90O4 862,68391 880,718284 ox 
CoQ10H2 C59H92O4 864,69956 882,733934 red 
 
Six different samples from WT and COQ4 KO cells were analysed and some intermediate 
candidates were obtained (Figure 4.7 and Table 4.8). While in WT samples we found 
CoQ10 in its oxidized (m/z 880.7 [M+NH4+]) or reduced (m/z 882.7 [M+NH4+]) form, in 
COQ4 KO we found molecules with different m/z ratio. In 4 out of 6 samples, we found 
an ion with m/z 866.7 [M+NH4+], corresponding to the formula C58H88O4. There are two 
intermediates from the list with that formula. One of them is 3-decaprenyl-4-hydroxy-
5-methoxybenzoate (DHMB), product of COQ3. The enzyme that decarboxylates it in C1 
is still unknown, so it could be a good candidate. However, with the same C58H88O4 
formula there is 2-decaprenyl-5-hydroxy-6-methoxy-3-methyl-1,4-benzoquinone 
(DMeQ10), product of COQ7 and substrate of COQ3. We have also found in 3 out of 6 
samples a m/z of 868.7 [M+NH4+], compatible with the reduced form of this last 
molecule, 2-decaprenyl-5-hydroxy-6-methoxy-3-methyl-1,4-hydroquinone (DMeQ10H2). 
Another m/z found in 1 out of 6 sample was 836.7, which can correspond to the formula 
C57H86O3 [M+NH4+]. There are two molecules of the list with this formula, 4-hydroxy-3-




decaprenylbenzoic acid (DHB) and 2-decaprenyl-6-methoxy-1,4-benzoquinone (DDMQ). 
DHB is an early intermediate, product of COQ2, which can be modified by COQ6 or the 
unknown carboxylase previously mentioned; and DDMQ appears later, product of COQ3 
or an unknown hydroxylase, which is afterwards methylated by COQ5. Ubiquinol was 
also found in 2 out of 6 samples (m/z 882.7 [M+NH4+]). 
 
Table 4.8. MS candidates for pre-CoQ10. 









1 CoQ10H2 C59H92O4 [M+NH4+] 9.3 113.6 882.7334 882.7251 
2 CoQ10 C59H90O4 [M+NH4+] 2 101.6 880.7177 880.7195 
3 CoQ10 C59H90O4 [M+NH4+] 1.4 102.1 880.7177 880.7165 
4 
CoQ10H2 C59H92O4 [M+NH4+] 6 127.4 882.7334 882.7281 
CoQ10 C59H90O4 [M+NH4+] 2.3 16.9 880.7177 880.7197 
5 
CoQ10H2 C59H92O4 [M+NH4+] 6 127.4 882.7334 882.7281 
CoQ10 C59H90O4 [M+NH4+] 2.3 15.8 880.7177 880.7197 
6 CoQ10H2 C59H92O4 [M+NH4+] 6.3 105.7 882.7334 882.7278 
COQ4 
KO 
1 DHB or DDMQ10 C57H86O3 [M+NH4+] 6.8 101 836.6915 836.6858 
2 
DHMB or DMeQ10 C58H88O4 [M+NH4+] -3 63.2 866.7021 866.7047 
DMeQ10H2 C58H90O4 [M+NH4+] -4.7 28.8 868.7177 868.7218 
3 
DHMB or DMeQ10 C58H88O4 [M+NH4+] -4.9 98.1 866.7021 866.7063 
DMeQ10H2 C58H90O4 [M+NH4+] -6.5 66.5 868.7177 868.7234 
4 DHMB or DMeQ10 C58H88O4 [M+NH4+] 3.3 98.2 866.7021 866.6993 
5 CoQ10H2 C59H92O4 [M+NH4+] 2.8 124.6 882.7334 882.7358 
6 
DHMB or DMeQ10 C58H88O4 [M+NH4+] 8.7 76 866.7021 866.7096 
DMeQ10H2 C58H90O4 [M+NH4+] 3.9 80.4 868.7177 868.7212 




Figure 4.7. Candidates for pre-CoQ10 identity.  







We obtained some candidates to be possibly accumulated in COQ4 KO cells. However, 
the confidence of the results was not very high (mSigma<50 indicates high probability 
of correct formula, and in most of the results it was >50) (Table 4.8). Additionally, we 
were unable to distinguish between molecules with the same molecular formula. It 
should be bear in mind that only the results that were compatible with the initial list of 
known intermediates were obtained, meaning we were very limited in terms of possible 
outputs. It is possible that the molecules we were looking for are not in the list, since 
the pathway is not entirely deciphered yet. For this reason, nuclear magnetic resonance 
(NMR) experiment in our pre-CoQ10 compound was decided to be performed, to 
elucidate the exact structure of the intermediate. Significant amounts of the pure 
compound are needed to this end, so currently the pre-CoQ10 peak is being purified by 
HPLC in order to get enough material to be subjected to NMR analysis.  
Treatment with 4-HB analogues and other quinone molecules did not have any effect on 
CoQ10 biosynthesis in COQ4 KO cells 
In an effort to explore potential bypass therapies for COQ4 defects, and at the same 
time, to gain more insight on the role of this protein, we used COQ4 KO cell model to 
test whether some molecules could rescue CoQ synthesis in the absence of the protein. 
COQ4 KO and control cells were treated with diverse 4-HB analogues that would 
potentially bypass some CoQ biosynthesis defects (VA for C5-hydroxylation (COQ6) and 
O-methylation (COQ3); 2,4-dHB for C6-hydroxylation (COQ7)) and other molecules that 
could serve as bypass molecules for the still unknown C1-decarboxylation step 
(hydroquinone (HQ) or 2-methoxy-hydroquinone (2-moHQ). The effect on CoQ10 
biosynthesis was measured for all the treatments (Table M.2). None of the compounds 
had a great impact on CoQ10 biosynthesis in COQ4 KO cells or controls (not shown). 
These results confirm that COQ4 has a different enzymatic role from COQ6 or COQ7 and 
does not act by supporting their function. Although HQ and 2-moHQ are structurally 
equivalent to the C1 decarboxylation and hydroxylation putative resulting 
intermediates, none of them were able to rescue the synthesis of CoQ in COQ4 KO cells. 
In order to enter the CoQ pathway, both molecules should be prenylated. It is possible 
that COQ2 is enzymatically unable or do not recognize the structure of HQ or 2-moHQ, 
since they are not 4-HB analogues 289. 




WT versions of tagged or untagged COQ4 restore CoQ levels and biosynthesis in COQ4 KO, 
regardless of expression levels 
The whole COQ4 cDNA sequence was amplified by PCR and cloned into a pcDNA5 
plasmid, using HindIII and XhoI restriction enzymes (restriction sequences were included 
in the PCR primers, Table M.11, primers #1 and #2). An intermediate T-A cloning of the 
PCR bands in pGEMT plasmid was performed. pGEMT plasmids with the different inserts 
were sequenced and, when the sequences were correct, they were double digested with 
HindIII and XhoI, as well as pcDNA5 plasmid was. COQ4 sequences were finally 
subcloned in pcDNA5, and confirmed by restriction enzyme digestion and sequencing. 
Tags were introduced by different approaches. Flag-strep (FS) tag was already included 
in the backbone sequence of the pcDNA5 plasmid, so for FS tagging, COQ4 was cloned 
without stop codon. For HA tagging, HA sequence was included, together with a stop 
codon, in the reverse PCR primer (Table M.11, primer #3), and then, the resulting 
fragment of DNA was digested and cloned into pcDNA5 in the same way than COQ4.  
WT COQ4 protein expression in COQ4 KO cells was achieved after co-transfection of 
pcDNA5 carrying COQ4 sequence (untagged or FS/HA tagged) together with pOG44 in 
these cells (see Materials and Methods, section M2.3 and Figure M.1). Cells expressing 
these 3 different forms of WT COQ4 were obtained after transfection. Since the 
sequences introduced are under the expression of a tetracycline/doxycycline inducible 
promoter, induction tests were performed, by incubating the cells with different 
concentrations of doxycycline for 24h, before harvesting them. Expression was checked 
by western blot of total cell lysates. Of note, for all these 3 cell lines, COQ4 protein 
expression was observed even for not induced samples, and the levels of non-induced 
expression were some fold higher than endogenous COQ4 expression in HEK WT cells 
(Figure 4.8.A). This means our models are overexpressing COQ4, even without induction 
by doxycycline. Induction leads to an even higher overexpression of the transgene.  
CoQ10 levels in COQ4 KO cells transfected with COQ4 WT cDNA were comparable to WT 
levels, which are very low in both non-induced and induced samples (Figure 4.8.B). 
Achieving COQ4 protein expression to levels comparable to endogenous expression, 
thus, is enough to restore CoQ10 biosynthesis. Notably a significant overexpression of 





tagged COQ4 behave similarly to untagged COQ4, meaning the tags do not impede 
COQ4 function in CoQ10 biosynthesis.  
Importantly, accompanying the rescue of CoQ10 levels, pre-CoQ10 intermediate 
accumulation is suppressed when COQ4 expression is restored (Figure 4.8.C). This result 
supports the idea that pre-CoQ10 is an intermediate of the pathway. 
 
Figure 4.8. COQ4 KO transfected with WT versions of the gene recovers COQ4 protein expression and 
CoQ10 levels.  
(A) Levels of COQ4 proteins in WT, COQ4 KO and COQ4 KO transfected with untagged or FS/HA tagged 
WT COQ4. Membranes developed with antibody against each tag or anti COQ4. Cells were incubated with 
0.1ng/mL of doxycycline (DOX) for 24h. (B) CoQ10 levels in the same cells with or without doxycycline 
induction. (C) Representative HPLC-ECD chromatograms from WT, COQ4 KO and COQ4 KO + COQ4-HA 
samples, showing the CoQ10 and the pre-CoQ10 peaks. 
 
Mutations in the phospho-loop do not affect COQ4 function in CoQ synthesis in COQ4 KO 
cells overexpressing the mutant versions 
We selected the amino acids Ser106, Thr107, Ser108 and Thr109 as a putative 
phosphorylation loop, based on in silico phosphorylation prediction studies previously 
detailed (see Chapter 3, section 3.2.1 and Figure 3.15). S108 has also been found 
phosphorylated in global phosphoproteomics mass spectrometry assays 497–501. 




Modifying this loop with different mutations would allow us to determine if these amino 
acids and their phosphorylation state contribute to COQ4 function in CoQ10 biosynthesis 
(Figure 4.9).  
Site-directed mutagenesis to study protein phosphorylation is widely used (Figure 
4.9.A). Ser/Thr to Ala mutation is considered to prevent phosphorylation of the mutated 
residue. On the contrary, Ser/Thr mutations to Asp/Glu residues are used to mimic 
constitutive phosphorylation in Ser/Thr. It has even been proposed  that Asp/Glu 
residues are in some cases ancestral precursors of phosphorylation sites 590.  
Thus, to study the putative phosphorylation loop, we performed site-directed 
mutagenesis in pcDNA5 plasmid containing WT COQ4-FS cDNA sequence to obtain 
different mutant versions of the gene (M1, M2 and M3) (Figure 4.9.C) with primers 
described in Table M.11 (primers #22 to #29). M1 has the four amino acids of the loop 
(Ser106, Thr107, Ser108 and Thr109) converted to Ala, so they would no longer be 
phosphorylatable. M2 has a point substitution of the residue that has been found 
phosphorylated before (Ser108) to a constitutively negatively charged Glu, to mimic this 
phosphorylation. In M3, all amino acids are mutated to Ala, except for this Ser108, that 
is mutated to Glu. These different versions of the COQ4 gene were transfected in COQ4 
KO cells, and after selection with hygromycin, they were analysed. If phosphorylation in 
these residues was important for CoQ biosynthesis, we would expect different outcomes 
for each of the mutants. 
CoQ10 levels in COQ4 KO cells transfected with COQ4 phospho-mutants were similar in 
M1, M2 and M3 and comparable to WT levels (in all the samples, non-induced and 
induced) (Figure 4.9.D). Inducible expression of the transgene was checked by 
immunoblotting (Figure 4.9.E). Results suggested that these mutations in COQ4 do not 
affect CoQ synthesis, at least in this model and in the conditions we tested. These 
mutations are not loss-of-function; however, we cannot discard they are hypomorphic 
and the high levels of expression do not allow to determine their residual activity. 
Further studies would be needed to ultimately unveil the significance of these residues 








Figure 4.9. COQ4 KO transfected with phospho-mutant versions of the gene recovers COQ4 protein 
expression and CoQ10 levels.  
(A) Changes of serine (Ser) and threonine (Thr) after phosphorylation (left) and mutations for 
phosphorylation (Glu, glutamic acid) and non-phosphorylation (Ala, alanine) mimics (right). (B) 
Conservation of the region of the putative phosphorylation loop, between brackets (positions 106, 107, 
108 and 109 in human sequence). (C) Changes in this region introduced by site-directed mutagenesis. (D) 
CoQ10 levels in WT, COQ4 KO and COQ4 KO cells transfected with WT and mutant M1, M2 and M3 versions 
of COQ4. (E) Levels of COQ4 proteins in the same cells, developed with antibody against FLAG tag. Before 
these experiments, cells were incubated with doxycycline (DOX) for 24h. 
 
 




COQ4 KO cells overexpressing COQ4 protein with mutations found in patients have 
different outcomes in terms of CoQ biosynthesis 
i. Some patient variants restore CoQ biosynthesis in COQ4 KO cells, while others 
do not. 
Several mutations in COQ4 have been reported in patients with CoQ deficiency (Figure 
2.13), being distributed throughout the whole structure of the protein (Figure 3.17). We 
wanted to analyse the effect of these mutations on COQ4 function using a homogeneous 
background, in this case, the COQ4 KO cell line. We selected all the variants affecting the 
coding region (excluding intronic mutations) and introduced them into pcDNA5 plasmid 
containing HA-tagged WT COQ4 cDNA sequence by site-directed mutagenesis 
(Val8Alafs*19, Leu52Ser, Gly55Val, Pro64Ser, Arg66Gln, Asp68His, Thr77Ile, Leu82Gln, 
Asp111Tyr, Pro119Leu, Asp111Tyr + Pro119Leu, Gly124Ser, Arg141*, Arg145Gly, 
Phe146Cys, Gln157Lys, Arg158Gln, Thr174del, Arg240Cys) with primers described in 
Table M.11 (primers #30 to #65). Some of the variants in Figure 2.13 have not been 
included in this study because they were reported after the design of the experiment 
(Gly178Glu, Trp184Arg, Ala199Thr). The different versions of the COQ4 gene were 
transfected in COQ4 KO cells, and after selection with hygromycin, they were analysed. 
As all these mutations have been detected by NGS in patients in a primary CoQ10 
deficiency disease context, we expected they would probably affect COQ4 function in 
CoQ10 biosynthesis.  
We checked the inducible expression of the different mutated COQ4 versions by 
immunoblot (Figure 4.10.A). Most of them had a leaky expression of the genes and 
achieved a high level of COQ4 protein after induction with doxycycline. Some of them 
showed very low (Val8Alafs*19, Asp111Tyr + Pro119Leu, Arg240Cys-1) or even null 
(Arg141*) levels of COQ4 expression.  
Figure 4.10. COQ4 KO transfected with COQ4 mutant versions from patients recovers COQ4 protein 
expression and CoQ10 levels in different degrees.  
(A) Levels of COQ4 proteins in HEK WT (WT), COQ4 KO (KO) and COQ4 KO transfected with WT COQ4 (WT) 
or with COQ4 mutated variants from patients. Membranes developed with antibody against COQ4. Before 
these experiments, cells were incubated with doxycycline (DOX) for 24h. CoQ10 (C) and pre-CoQ10 (B) 
levels in HEK WT, COQ4 KO and COQ4 KO cells transfected with WT and patients’ mutant versions of COQ4 
(Two-way ANOVA, Dunnett’s multiple comparison test (each transfected cell line (induced+non-induced) 
vs. WT); p values: ****, p<0.0001; ***, p<0.001; **, p<0.01). Grey area represents CoQ10 levels range 












We analysed CoQ levels in all these COQ4 KO transfected cells (Figure 4.10.C), and also 
quantified the levels of the pre-CoQ intermediate, which seems to be a marker of COQ4 
deficiency (Figure 4.10.B). Surprisingly, most of the mutations were able to restore WT 
levels of CoQ, to the same extent than the WT gene did (Leu52Ser, Pro64Ser, Arg66Gln, 
Asp68His, Leu82Gln, Asp111Tyr, Pro119Leu, Gln157Lys). At the same time, these 
mutations abolished pre-CoQ accumulation, in line with what we observed when we 
transfected with the WT protein. The rest of the mutations had other different effects.  
There were 6 mutations that produced a significant decrease in CoQ levels and, 
parallelly, an increase in pre-CoQ accumulation (Val8Alafs*19, Arg141*, Arg145Gly, 
Arg158Gln, Thr174del, Arg240Cys-1). Two of them are mutations not expected to 
produce any functional COQ4 protein: the frameshift (Val8Alafs*19, one of the 
mutations of P105, see Chapter 2, section 2.2.3), and the non-sense (Arg141*) 
mutations, which create premature STOP codons. Null or almost null levels of COQ4 
protein were observed by immunoblot of cells carrying these two mutations. The 
deletion mutation (Thr174del) produces a protein, observed by western blot, but 
extremely low levels of CoQ. The negative effect of this mutation can be explained by its 
localisation in the protein structure, inside the loop between helixes α7 and α8, in which 
the putative Zinc-binding motif is located (Figure 3.16). The lack of this threonine 
probably affects the correct orientation and function of the Zinc-binding motif. The rest 
of the mutations producing a decrease in CoQ are 3 missense mutations (Arg145Gly, 
Arg158Gln, Arg240Cys). Among them, Arg145Gly mutant is the one with the highest 
levels of CoQ and the only one with no pre-CoQ accumulation. Regarding COQ4 protein 
expression, Arg145Gly and Arg158Gln produced COQ4 protein levels comparable to the 
rest of the mutations, but Arg240Cys levels were very low. In order to check if the 
decrease of CoQ in this mutant (Arg240Cys-1) was an effect of the low expression, we 
re-cloned the mutated gene in pcDNA5 with FS tag and transfected COQ4 KO cells again 
(Arg240Cys-2). In this second mutant clone, COQ4 protein levels were higher and CoQ 
levels were now in a WT range.  
There is another set of 5 mutations that produced a surprising phenotype in COQ4 KO 
cells: an increase in CoQ levels (Gly55Val, Thr77Ile, Asp111Tyr + Pro119Leu, Gly124Ser, 





“Milder disease” group described in Chapter 3, section 3.2.1 (Figure 3.17). It is 
challenging to explain how could mutations that produce primary CoQ deficiency in 
patients produce an increase in CoQ levels in the COQ4 KO cellular model. However, we 
should bear in mind that variants are overexpressed in the KO mutants, and, although 
mutated, the high load of protein could compensate for a putative reduced enzymatic 
activity. There is also the possibility that these mutations would affect somehow COQ4 
regulation, that could be differentially exerted in a patient or an immortal cell line’s 
context. Our observation raises concerns about the general use of this kind of models to 
study the pathogenicity of different mutations. Our results would suggest that this 
approach is only useful to determine the pathogenicity of very drastic mutations with 
no residual COQ4 activity. For the rest of the cases, it would be difficult to distinguish 
between the non-pathogenic and the hypomorphic variants. The latter would have a 
decrease in protein activity but could act as WT COQ4 when they are overexpressed.  
For example, P108 and P109 patient fibroblasts, which harbour the Phe146Cys 
homozygous mutation, show extremely low levels of COQ4 protein, accumulation of the 
intermediary and reduced levels of CoQ (Chapter 2, section 2.2.3 and Figure 2.19.A and 
B). However, COQ4 KO models expressing this variant accumulate high amounts of 
protein and recover CoQ biosynthesis. The mutation may lead to an unstable mRNA or 
protein, and the degradation at one of those levels in fibroblasts. Artificially high 
amounts of protein would compensate for the COQ4 enzymatic defect. Alternatively, it 
could be possible that this mutation did not affect the activity, but only the stability of 
the protein and a high and continuous expression would compensate for the rhythm of 
degradation. 
Endogenous expression under the natural promoter of the patient's variants in a 
homogeneous background would help to clarify these cases, but it would need 
techniques such as CRISPR-Cas-driven modification of the genome. 
ii. Para-amino benzoic acid (pABA) treatment can help us determine COQ4 
patients’ mutations pathogenicity and COQ4 function 
Para-amino benzoic acid (pABA) has an amino group in C4, instead of the C4-hydroxyl 
group of the CoQ head precursor. Yeast, but not mammals, bacteria (E. coli) or the plant 
A. thaliana are able to use this molecule to synthesise CoQ (see the introduction of this 




chapter, section 4.1.1). In vertebrates, it is not synthetized endogenously, and in 
mammalian cell cultures, pABA supplementation decreases CoQ total levels and leads 
to the accumulation of 4-imino-6-demethoxycoenzyme Q (IDMQ), which seems to be a 
dead end product 289.  
We performed a very preliminary assay of pABA supplementation in WT, COQ4 KO cells 
and COQ4 KO cells expressing some of the COQ4 patient variants (Leu52Ser and 
Phe146Cys). pABA supplementation would reduce the rate of endogenous CoQ10 
synthesis from 4-HB, by competing for COQ2 active site to be prenylated 289. We wanted 
to check how these different variants would perform in a context of low CoQ10 synthesis, 
and thus, if there were any differences between variants’ residual activity to produce 
CoQ10.  
However, by analysing CoQ10 levels, we did not observe any difference between the WT 
and the cells expressing the patients’ variants. In terms of CoQ10 final product content, 
CoQ10 was equally inhibited in the three cell lines, and with the different times of 
inhibition (Figure 4.11.A). We could also see a peak probably corresponding to DMQ10, 
that usually appears upon CoQ10 inhibition by pABA 289. This peak has a retention time 
slightly shorter than CoQ10. On the other hand, DMQ10 content was higher in WT than in 
the cells expressing mutant COQ4, and it increased with the time of the treatment 
(Figure 4.11.C). Even if CoQ10 levels are the same in the three cell lines, the increased 
amount of DMQ10 in the controls would suggest that COQ4 WT protein is working more 
efficiently than the mutated COQ4 proteins to produce DMQ10 (together with the rest 
of COQ proteins). The lack of DMQ10 accumulation in COQ4 KO cell line is suggesting that 
COQ4 functions upstream DMQ10 formation. 
 
 
Figure 4.11. Para-amino benzoic acid (pABA) treatment has different effects on quinone content of 
COQ4 KO transfected with COQ4 mutant versions from patients.  
Quantification of different quinones after pABA treatment: CoQ10 (A), pre-CoQ10 (B), DMQ10 (C) and 
IDMQ10 (D) peaks (Two-way ANOVA, Dunnett’s multiple comparison test (each pABA treated cell line vs. 
WT with the same treatment for CoQ10 (A), DMQ10 (C) and IDMQ10 (D); each pABA treated cell line vs. the 
same untreated cell line for pre-CoQ10 (B)); p values: ****, p<0.0001; ***, p<0.001; **, p<0.01; *, p<0.05)). 











Additionally, we could see how pABA is also modified to a dead-end product that is 
accumulated (putatively IDMQ10, based on the bibliography 289). It appears as a peak 
after CoQ10 in the chromatograms (Figure 4.11.D). It is possible that the accumulation of 
IDMQ10 and the probable inability of COQ7 to transform it are the reasons why DMQ10 
is also being accumulated. The presence of this putative IDMQ10 peak in all cells except 
from the COQ4 KO cells indicates that COQ4 protein (WT or mutated) is able to modify 
the amino containing prenylated quinone. This post- CoQ10 peak is higher in WT than in 
cells expressing mutated COQ4, similarly to what was observed with DMQ10 
accumulation. This fact is in agreement with the suggestion that WT COQ4 is functioning 
more efficiently to modify the amino-containing prenylated quinone than the mutated 
COQ4 proteins.  
In the case of COQ4 KO supplemented with pABA, the COQ4-specific intermediate we 
observed before (pre-CoQ10 peak) was reduced, and another peak slightly after 
appeared instead (Figure 4.11.B and E). This fact probably indicated that when using 
pABA as a substrate, the intermediate accumulated due to the lack of COQ4 is different 
than the endogenous one, and probably this difference is the presence of the amino 
group instead of the hydroxyl. This fact supports the idea that COQ4 acts directly or 
indirectly upstream DMQ10 production.  
We did not obtain clear results of pathogenicity of patients’ mutations in COQ4 when 
expressing the variants in a COQ4 KO HEK cell line, presenting most of the variants WT 
levels of CoQ10. With this preliminary study of pABA supplementation we have been able 
to determine that Leu52Ser and Phe146Cys mutations in COQ4 affect COQ4 function, 
since COQ4 KO cells overexpressing these variants are less efficient in producing late 
intermediates of the pathway, such as DMQ10 or the dead-end product when using 
pABA, IDMQ10. A more comprehensive study including further variants is planned to be 
performed, to be able to check the pathogenicity and functionality of the mutations 





COQ4 Isoforms lacking exon 3, 4 and 5, in different combinations, fail to restore CoQ 
biosynthesis in a COQ4 KO cell line 
Different COQ4 isoforms not previously described were found expressed in fibroblasts 
(see Chapter 2.2.3, Table 2.1 and Figure 2.17). COQ4 mRNAs lacking several exons in 
different combinations were found in fibroblasts from controls and from P105 patient 
(who carried the splicing mutation c.532+6 T>A). In fibroblasts from this patient, mRNAs 
lacking exon 3, exon 5, both exons 3 and 5 or exons from 3 to 5, were found to be 
relatively more abundant than the canonical COQ4 mRNA, compared to controls. We 
wanted to check if these putative isoforms were functional and whether they could play 
a similar role than COQ4 in CoQ10 biosynthesis. For this purpose, we subcloned the cDNA 
obtained from fibroblasts in pcDNA5 and transfected them into HEK COQ4 KO cells.  
Only the WT COQ4 cDNA expression was able to restore COQ4 function and CoQ10 
production in these cells (Figure 4.12.A). Also, the WT COQ4 expression suppressed the 
intermediate accumulation, while expression of the different isoforms did not (Figure 
4.12.B). These results would suggest that these isoforms are unable to replace COQ4 
function in CoQ10 biosynthesis when it is absent.  
 
Figure 4.12. Quinone content of COQ4 KO cells transfected with COQ4 isoforms found in P105 patient’s 
and control’s fibroblasts.  
Quantification of CoQ10 (A) and pre-CoQ10 (B) show that only the full length isoform (iso a) is able to restore 
CoQ10 WT levels (A) and abolish pre-CoQ10 accumulation (B) in induced and non-induced samples.  
 
 





However, we were not able to detect any COQ4 isoform protein levels by western blot, 
even after doxycycline induction. These isoforms are indeed predicted to lead to 
significant changes in COQ4 protein sequence (Table 2.1), and it is probable that all these 
aberrant forms of COQ4 are readily degraded in the cells. Future experiments will 
include inhibition of proteasome to check a putative accumulation of the small proteins. 
In any case, further phenotyping of these cells to check plasmid integration into the cells’ 
DNA or the RNA isoforms expression levels will help to elucidate whether the isoforms 
are definitively unable to substitute COQ4 function in CoQ10 biosynthesis. 
4.2.2. Effects of COQ4 deficiency in mitochondrial respiration 
CoQ-dependent enzymatic activities of combined respiratory complexes are markedly 
reduced in COQ4 KO cell, while isolated activities are normal. 
Respiration studies in COQ4 KO cells and controls were performed to test the effect of 
the lack of COQ4 or the consequent dysfunctional CoQ10 synthesis on the mitochondrial 
respiratory function. Activities of individual respiratory chain enzymes were normal, 
COQ4 KO only showed a slight tendency to have decreased CI activity and increased CII 
activity (Figure 4.13.A). However, combined activity of CI+III and CII+III were markedly 
reduced in these cells, consistent with a severe defect in CoQ10 levels (Figure 4.13.B). 
This deficiency was restored with the expression of COQ4 WT gene. Reduced CoQ-
dependent respiratory activities is the typical phenotype of a CoQ10 deficiency, 
indicating these defects are mostly due to the severely reduced levels of CoQ10 in COQ4 
KO cells.  
COQ4 KO cells show a defective cellular respiration, that is completely restored with COQ4 
gene expression or exogenous CoQ10 supplementation 
Cellular respiration in living cells was measured by using the Seahorse XF24 Extracellular 
Flux Analyzer. COQ4 KO cells showed a completely deficient OCR profile, with all 
respiratory parameters’ levels near to zero (Figure 4.14). This result suggested these 






WT COQ4 gene transfection restored all the respiratory parameters to WT levels. The 
same rescuing effect was observed in COQ4 KO cells treated with 5µM of CoQ10 for 96h 




Figure 4.13. Mitochondrial Respiratory Chain (RC) activities in COQ4 KO cells and the same cells 
transfected with WT versions of the gene.  
(A) Isolated RC activities of COQ4 KO were normal compared to controls, while (B) CoQ10 dependent 
activities (CI+III and CII+III) were significantly reduced. Specific activities are represented as a normalized 
value (by the specific activity of citrate synthase (CS)) and relative to WT (Two-way ANOVA with Tukey’s 
multiple comparison test (p values: ****, p<0.0001; ***, p<0.001; **, p<0.01; *, p<0.05)).  
 
 





Figure 4.14. COQ4 KO cells have a 
respiratory deficiency that is 
rescued with COQ4-WT 
expression or CoQ10 
supplementation. 
(A) Oxygen consumption rate 
(OCR) profile shows a profound 
respiratory defect in COQ4 KO 
cells, restored with WT COQ4 
expression or CoQ10 
supplementation (5µM for 96h). 
Arrows indicate the addition of 
the individual inhibitors: OL 
(oligomycin 1μM); FCCP (Carbonyl 
cyanide 4-(trifluoromethoxy) 
phenyl-hydrazone 0.2μM); Rot 
(rotenone 1μM); AntA (antimycin 
A 2.5μM). Quantitative data are 
graphed on B as mean ± SD  
(Two-way ANOVA with Tukey’s 
multiple comparison test (p 
value<0.0001(****)). 
 
4.2.3. COQ4 interacts with the rest of the COQ proteins in a dynamic complex 
It is clear that CoQ biosynthesis is performed by a complex of proteins in yeast, and in 
recent years, there is increasing evidence of the formation of such a complex in 
mammals as well. As a part of our research in COQ4 protein function, we wanted to 
investigate if COQ4 protein is present in protein complexes, and which are its partners. 
In order to do so, we performed BN-PAGE and immunocapture of COQ4, with or without 
SILAC labelling. We were especially interested in determining the composition of the 
CoQ10 biosynthesis complex in human cell lines. 
Identification of protein complexes containing COQ4 protein by BN-PAGE 
Cell pellets of HEK WT, COQ4 KO and COQ4 KO expressing different tagged versions of 
COQ4 WT protein were enriched in mitochondria with a digitonin treatment. Then, they 
were prepared for Blue Native-PAGE, solubilizing with two non‐denaturing detergents, 
n‐dodecyl‐β‐D‐maltoside (DDM) and digitonin. 2D‐BNGE membranes were probed for 





Complexes I, II, III, IV and V (Mitoprofile), as a control of the size of the complexes. The 
results of the digitonin solubilized mitochondrial enriched pellets are shown in Figure 




Figure 4.15. 2D BN-PAGE of digitonin-solubilised samples.  
Digitonin-solubilised pellets from WT (A), COQ4 KO, and COQ4 KO transfected with WT COQ4 (C) or COQ4-
FS (D) were run in 1D-BN-PAGE and lanes were subjected to a 2D-SDS-PAGE. Western blot and 
immunodetection was performed with antiCOQ4 antibody (left) and a cocktail of antibodies against 
subunits of the mitochondrial respiratory complexes I, II, III, IV and V (Mitoprofile, right). 
 
 




COQ4 protein (developed with an anti-COQ4 antibody, 25KDa) migrated to the bottom 
of the gel (low molecular weights) in both WT and COQ4 KO expressing WT COQ4 
samples (Figure 4.15.A and C). These results suggested that COQ4 is not stably 
interacting in high molecular weight complexes in our experimental conditions. If COQ4 
was part of a complex, its interactions would be transient (or stimulated in some specific 
metabolic states) or they would be unable to be maintained in the solubilization or the 
electrophoresis conditions. To test if this low molecular weight conformation was due 
to the metabolic state of the cells, the same experiments were performed by treating 
the cells with a low glucose medium for 24h to boost respiration and, thus, the need of 
CoQ biosynthesis. No differences were observed by comparing the high glucose to the 
low glucose conditions (not shown).  
Comparing these two blots with COQ4 KO blot, there are two main differences (Figure 
4.15.A-C). On one hand, as expected, COQ4 KO blots lack the 25KDa band corresponding 
to COQ4 protein, which corroborates that our model is a total knock out of COQ4 
protein. On the other hand, a 50 KDa band is differentially detected also at the low 
molecular weights’ region. We could not confirm the nature of this band, but we could 
speculate that it could be a very stable dimeric form of COQ4 (resistant to SDS 
treatment), that it is not forming higher molecular weight complexes. These 50KDa 
band, not present in COQ4 KO cells, could not be distinguished by SDS-PAGE probably 
because of the presence of another overlapping 50KDa band result of an unspecific 
binding of the anti-COQ4 antibody (which can be observed by BN-PAGE, at the 50KDa 
size, but running in high molecular weight complexes).  
COQ4 KO expressing FLAG-strep (FS)-tagged COQ4 behave slightly different in 2D BN-
PAGE experiments (Figure 4.15.D). COQ4-FS was detected by an anti-FLAG antibody, 
with the expected size (around 30KDa). It was detected in the low molecular weight 
region of the gel, similar to the localization of WT COQ4 in HEK WT samples. However, 
when we developed the blot with an anti-COQ4 antibody, we saw some differences 
compared to the untagged COQ4 protein. Overexpression of COQ4-FS led to a big 
accumulation of tagged COQ4 at around 30KDa. Surprisingly, a band corresponding to 
the size of untagged COQ4 also appeared, forming complexes of higher molecular 





antibody, suggesting that FS-tagged COQ4 was probably being processed to remove the 
tag. These COQ4-containing high molecular weight complexes observed could be an 
artifact related to the processing of the tag, which would not occur naturally or could be 
real complexes only visible now because of the high expression of the protein. Despite 
this model being useful for recovering COQ4 function in CoQ biosynthesis, this 
anomalous behaviour in terms of protein complexes should be considered. The 
unspecific 50KDa detection at high molecular weights is still there, but the one at low 
molecular weights is not detectable. Maybe the processing of the tag is needed for the 
putative dimerization and functionality.  
Quantitative proteomics with SILAC labelling after immunocapture of COQ4 revealed 
measurable interactions with mitochondrial chaperones and actin related proteins 
To characterise the interaction partners of COQ4 protein, we carried out a comparison 
of COQ4 immunopurified from digitonised cells of COQ4 KO overexpressing COQ4 
(tagged or untagged) and COQ4 KO cells as a negative control for COQ4 expression. They 
were analysed by quantitative mass spectrometry (MS) using stable isotope-labelled 
amino acids in cell culture (SILAC). Three different experiments were performed, with 
immunocapture of COQ4-FS with antiFLAG beads, untagged COQ4 with antiCOQ4 
antibody crosslinked to agarose beads, and COQ4-HA with antiHA beads. Each of these 
three experiments were performed in duplicates with reciprocal isotopic labelling 
between the COQ4 expressing cell line and the COQ4 KO.   
Firstly, we performed the immunocapture of FLAG-tagged COQ4 from a 1:1 mix of 
mitoplasts from COQ4 KO and COQ4 KO overexpressing COQ4-FS, differently labelled. 
COQ4-FS enrichment was checked by immunoblot (Figure 4.16.A). The mass 
spectrometric analysis of affinity-purified COQ4 and associated partners identified 148 
different proteins, but only 73 of them were quantifiable (Figure 4.16.B). From these 73, 
only three of them showed a significant enrichment in the COQ4-FS overexpressing 
sample over the negative control. The first one was COQ4 itself, which demonstrated 
that the immunocapture worked, as we had already seen by western blot. Then, only 
HSPA9 (HSP70) and HSPD1 (HSP60) were significantly enriched in COQ4-FS eluates 
(Figure 4.16.B). They are both mitochondrial heat-shock chaperones with important  





Figure 4.16. COQ4 co-purified with mitochondrial chaperones and actin related proteins, measured by 
quantitative proteomics with SILAC labelling.  
Immunocapture of COQ4 (FS-tagged (A, B) or untagged (C, D)) was checked by immunoblot (A, C). Before 
the experiments, expression of COQ4 was induced with 24h of doxycycline 0.1 ng/mL. Scatterplots show 
the log2 and −log2 H/L ratios obtained after mass spectrometry analysis of anti-FLAG (B) or anti-COQ4 (D) 
co-immunoprecipitation fractions of bidirectional SILAC labelled COQ4 KO and COQ4 KO expressing COQ4-
FS (B) or COQ4 WT (D). Each point represents a specific protein. COQ4 protein is plotted with a rhombus 
and co-immunopurified proteins with circles. Statistically significant interactions are plotted in blue 
(based on significance B, Perseus analysis platform). Crosses represent exogenous contaminants. SM, 






functions in stress response, maintenance of the mitochondria and correct folding of 
imported proteins591,592. This would suggest that the overexpression of COQ4-FS is 
producing stress, and these proteins are interacting with the excess of tagged COQ4 to 
fold it correctly. Going back to the BN-PAGE results, maybe the complexes we were 
observing were related with this kind of interactions (Figure 4.15.D). However, it could 
be possible that these significantly quantified interactions are meaningful, and there is 
some relationship between COQ4 or CoQ biosynthesis with mitochondrial heat shock 
proteins. More in-depth studies would be needed to confirm this. 
After observing that COQ4-FS overexpression could be producing artifacts, we purified 
untagged COQ4 from COQ4 KO overexpressing untagged COQ4 and COQ4 KO as 
negative control (Figure 4.16.C). MS identified 217 different proteins and only 96 of 
them were measurable (Figure 4.16.D). Five of them showed a significant enrichment in 
the COQ4 overexpressing sample. Again, the most enriched one was COQ4 itself, proving 
that the immunocapture worked. The other four significantly enriched proteins were 
ACTR2, ACTR3, ARPC3 and ARPC4, four of the seven subunits of the ARP2/3 complex 
(Figure 4.16.D). This actin-related complex mediates actin polymerization in the 
cytoplasm (essential for the cytoskeleton function, cell shape and motility) and the 
nucleus (provides the motility needed for gene transcription and DNA repair). The 
hypothetical relationship between COQ4 and these complex from non-mitochondrial 
cell compartment would require further studies. 
The third assay tried to increase the number of interactions found, by treating purified 
mitochondria with a disuccinimidyl suberate (DSS) before immunocapture. DSS is a non-
cleavable and membrane-permeable crosslinker that contains an amine-reactive (NHS) 
ester at each end of an 8-carbon spacer arm. NHS esters react with primary amines at 
pH 7-9 to form stable amide bonds, along with the release of the N-hydroxysuccinimide 
leaving group (Figure 4.17.A). Proteins generally have several primary amines in the side 
chain of lysine (K) residues and the N-terminus of each polypeptide that are available as 
targets for NHS-ester crosslinking reagents. With DSS crosslinking, we expected to 
capture also transient or very dynamic interactions with COQ4. We did a test with 
different times and concentrations of DSS, crosslinking isolated mitochondria of COQ4 
KO expressing COQ4-HA. We could see the formation of new bands with increasing the 




concentration and time, while at the same time, the single protein was disappearing 
(Figure 4.17.B). We hypothesized that the new bands were COQ4-HA crosslinked to 
other proteins which it interacts with. We decided to continue with the SILAC-MS 
experiment, to identify these captured associations. We treated isolated mitochondria 
from SILAC labelled cells with DSS (1mM, 30min), performed the immunocapture (Figure 
4.17.C) and analysed the eluates by MS. MS only identified 81 different proteins, only 5 
of them being measurable. Only COQ4, HSPA9 (Hsp70) and HSPD1 (Hsp60) were 
significantly enriched in COQ4-HA eluates, the same results obtained in the first 
experiment (Figure 4.17.D). 
 
Figure 4.17. COQ4 co-purified with mitochondrial chaperones, measured by quantitative proteomics 
with SILAC labelling after crosslinking of crude mitochondria.  
(A) Disuccinimidyl suberate (DSS) crosslinker. (B) Crude mitochondria were SDS treated with different DSS 
concentrations an times, and after SDS-PAGE and antiHA immunodetection, new bands of high molecular 
weight were detected. (C) Immunocapture of DSS treated (1mM, 30min) mitochondria from SILAC 
labelled cells was performed and checked by immunoblot. Before the experiments, expression of COQ4 
was induced with 24h of doxycycline 0.1 ng/mL. (D) Scatterplot show the log2 and −log2 H/L ratios 
obtained after mass spectrometry analysis of the co-immunoprecipitation fractions of bidirectional SILAC 
labelled COQ4 KO and COQ4 KO expressing COQ4-HA and crosslinked (D). Each point represents a specific 
protein. COQ4 protein is plotted with a rhombus and co-immunopurified proteins with circles. Statistically 
significant interactions are plotted in blue (based on significance B, Perseus analysis platform). Crosses 
represent exogenous contaminants. C, cytosol; M, mitochondria; SM, soluble material; UM, unbound 





None of the three experiments detected any of the COQ proteins, putatively forming 
the CoQ biosynthesis complex. The inability to detect any interaction partners for COQ4 
could be due to the fact that COQ proteins are expressed in very low levels in the cell, 
or that these interactions are not stable in the conditions we used for the affinity 
purification, even if crosslinked. 
COQ4-FS copurified with COQ3-COQ9 proteins, and with other mitochondrial and non-
mitochondrial proteins. 
We performed a less restrictive qualitative proteomic analysis without SILAC (Figure 
4.18). Mitoplasts from COQ4 KO and COQ4 KO overexpressing COQ4-FS (induced with 
doxycycline) were subjected to affinity purification with anti-FLAG beads in native 
conditions. Subsequent analysis of the eluates was performed by MS. The experiment 
was performed twice, and we only considered the identified proteins as positive results 
when they were found in both experiments in the pulled down COQ4-FS sample (and 
not in the negative controls).  
 
Figure 4.18. COQ4 co-purified with COQ proteins and other mitochondrial proteins. 
(A) Immunocapture of COQ4-FS was checked by immunoblot. Before the experiments, expression of 
COQ4 was induced with 24h of doxycycline 0.1 ng/mL. (B) The elution fraction was subjected to mass 
spectrometry analysis, and identified proteins (by gene names) were plotted in Venn diagrams. 138 
proteins were considered positive in both experiments. SM, soluble material; UM, unbound material; E, 
elution fraction. 




In the first experiment, 929 proteins were identified in the COQ4-FS sample and 212 in 
the negative control (COQ4 KO), from which 184 were common to both samples. The 
second experiment identified 480 proteins in the COQ4-FS sample and 339 in the 
negative control, being 216 common to both samples. Combining the results of both 
experiments, we observed that 138 proteins in total were identified as potential 
interactors of COQ4, since they were found in the two COQ4-FS samples, and not found 
in any of the negative controls (Figure 4.18.B). By manually analysing these proteins, we 
eliminated 7 of them that were duplicated in the list. We subjected the protein list (by 
gene names) to a Gene Ontology (GO) PANTHER overrepresentation analysis, by cellular 
component, biological process and molecular function.  
Among the 131 positive results, 37 were mitochondrial proteins (Table 4.9). We could 
see this mitochondrial enrichment by the cell component GO analysis. Interestingly, 
mitochondrial subcompartments like mitochondrial nucleoids and respiratory 
complexes were overrepresented. ER, Golgi and lysosomes also seemed to be significant 
locations for COQ4 identified putative partners. In general, cell component GO terms 
that were overrepresented were mainly related to membranes (plasma, mitochondrial, 
vesicle membranes) and to complexes that are mainly localised in membranes, such as 
ATPase or GTPase complexes (Figure 4.19.A). We have to take into account that the 
immunoprecipitation of COQ4 was performed with digitonised cells (mitochondria 
enriched fractions) as starting material, so the enrichment in mitochondrial and 
membrane proteins probably derives from this approach. Molecular function GO 
analysis showed that the detected proteins mainly exert the following functions:  
aminoacyl tRNA editing, transferase activity, ion transport across the membrane, 
oxidoreductase activity, purine nucleotide (ATP, ADP, GTP, GDP) binding, GTPase and 






Figure 4.19. Gene Ontology (GO) terms enrichment in COQ4 co-purifing list of proteins.  
Representative GO cell component (A) and molecular function (B) terms enriched in putative COQ4 
interaction partners.  
 
 




Table 4.9. Mitochondrial proteins identified in COQ4-immunopurified eluates. 







COQ3 ATP5F1A PRDX3 POLDIP2 FASTKD4 
COQ4 COX4I1 PYCR2 LONP1 FASTKD5 
COQ5 NDUFA2   NIPSNAP1 
COQ6 NDUFS1   AARS 
COQ7 NDUFS7   DARS2 
COQ8B UQCRC1   VARS2 
COQ9     
Pyruvate, TCA and other 
mitochondrial metabolism 






Protein import to 
mitochondria 
D2HGDH HADHB MCCC2 FKBP8 TIMM44 
DLD IVD PYCR2 TRAP1 TIMM50 
GLUD1  GLUD1  GRPEL1 
IDH3B  GLUD2  HAX1 
GLUD2     
 
Importantly, amongst the mitochondrial-positive results, all the COQ proteins putatively 
forming the CoQ biosynthetic complex (COQ3, COQ5, COQ6, COQ7, COQ8B and COQ9) 
were identified as COQ4 interactors (Table 4.9). The fact that they all co-purified with 
COQ4-FS provides strong evidence for the mammalian CoQ biosynthesis complex and 
its composition. Biological process GO analysis also showed an enrichment in 
ubiquinone biosynthetic process terms (Figure 4.20.A). We found COQ8B and not 
COQ8A in our experiments. It has been suggested that they are reciprocally regulated 
depending on different metabolic conditions 438, and it is possible that in our model, the 
kidney HEK293 cell line, the COQ8 protein that is mostly working is COQ8B. Notably, this 
observation fits with the fact that the most predominant clinical phenotype of COQ8B 
patients is a nephrotic syndrome, meaning that COQ8B function is more important in 
kidney than in other organs.  
In addition to the COQ proteins, other mitochondrial proteins involved in different 
processes were identified as candidates for COQ4 interaction partners (Table 4.9 and 
Figure 4.20.B). Six of them are components of the mitochondrial respiratory chain, from 
CI (NDUFA2, NDUFS1, NDUFS7), CIII (UQCRC1), CIV (COX4l1) and CV (ATP5F1A). Some 
proteins involved in pyruvate metabolism, TCA cycle, fatty acids beta-oxidation and 
amino acids biosynthesis and catabolism were also identified (D2HGDH, DLD, GLUD1, 
GLUD2, IDH3B, HADHB, IVD, MCCC2, PYCR2). Proteins involved in protein import to 







Figure 4.20. Biological processes and mitochondrial functions enriched in COQ4 co-purifing list of 
proteins.  
(A) Representative GO biological process terms enriched in putative COQ4 interaction partners. (B) 
Representative functions of the 37 identified mitochondrial proteins. 
 
 




mitochondria (TIM44, TIM50, HAX1, GRPEL1). Proteins related to mtDNA metabolism 
and maintenance (POLDIP2, LONP1), mitochondrial RNA processing (FASTKD4, FASTKD5, 
NIPSNAP1) and mitochondrial translation (AARS, DARS2, VARS2) were also found. We 
also detected chaperones or proteins involved in protein folding (TRAP, FKBP8). The 
biological process GO analysis showed an overrepresentation of these different 
mitochondrial functions in the list of COQ4 potential partners: aminoacyl-tRNA 
metabolism, mitochondrial respiration, 2-oxoglutarate metabolism, ketone and 
glutamine biosynthesis, etc (Figure 4.20.A).  
Besides mitochondrial proteins, other proteins localised to the cytosol or other parts of 
the cell (plasma membrane, ER, Golgi, lysosome, vesicles, nucleus, cytoskeleton) were 
also found. Moreover, cell component GO analysis showed an overrepresentation of 
these cellular locations. ATPases from non-mitochondrial membranes (ATP12A, ATP1A1, 
ATP1A2, ATP1A3, ATP1A4, ATP1B3, ATP2A2, ATP5F1A, ATP6V1A), proteins related to 
cytoskeleton (tubulins), Ras-related proteins, guanine nucleotide-binding proteins, 
cytoplasmic ribosomal proteins and heat shock proteins were also identified as potential 
COQ4 partners. However, the functional significance for many of these interactions 
would need deeper analysis. 
COQs proteins levels are altered in COQ4 and COQ6 KO cells 
Almost all COQ proteins (only with the exception of COQ8A) co-purified with COQ4, 
providing more evidence to the existence of a COQ multienzymatic complex. It has been 
suggested that its stability is essential for CoQ biosynthesis. The presence of all 
components of the complex seems to be essential for maintaining this stability, meaning 
that these proteins are important building blocks of the complex, besides their catalytic 
activity.  
Our COQ4 KO and COQ6 KO cell lines (see Chapter 2, section 2.2.2, for more details of 
COQ6 KO cell line) are unique models of human cell lines completely lacking one of the 
components of this complex. We wanted to determine if the stability of the rest of the 
COQ proteins was affected by the lack of one of these two proteins.  We subjected total 





using antibodies against COQ4, COQ5, COQ6 and COQ7 proteins, and the constitutive β-
actin as a loading control (Figure 4.21).  
In these blots, we can see how COQ4 and COQ6 are indeed knocked out in COQ4 and 
COQ6 KO cells, respectively (Figure 4.21). But they are not the only COQ proteins with 
altered levels. COQ4 KO cells show significantly high levels of COQ5 and COQ7 proteins, 
while COQ6 levels also seem to be slightly incremented. Similarly, COQ6 KO cells show 
a significant overexpression of COQ4 protein, COQ5 is only slightly increased, and COQ7 
remains the same than in controls. The lack of COQ4 or COQ6 proteins seems to induce 
an increase of other COQ proteins (Figure 4.21), maybe as an attempt to compensate 
for the lack of these two components for the stabilisation of the complex.  
Similar effects have been observed before in the literature, using human 143B cells 315. 
In these cells, COQ4 KD showed an overproduction of COQ5 and COQ6, and COQ6 KD, 
only showed a reduction in COQ3 levels 315. 
 
 
Figure 4.21. Western blot analysis of COQ4 and other COQ proteins in whole cell lysates. 
Western blot analysis of COQ4 and other COQ proteins (A) levels in whole cell lysates and their 
quantification (B-E) (Two-tailed unpaired t-test, each KO vs. HEK WT; p values: <0.05(*), <0.001 (***), 
<0.0001 (****)). An antibody against β-actin (43KDa) was used as a loading control.  
 
 




Exogenous CoQ10 enters mitochondria upon treatment and produces some changes in 
COQs proteins levels in COQ4 and COQ6 KO cells 
We wanted to check if supplementation of exogenous CoQ10 had an effect on COQ 
proteins levels, in order to understand if the specific COQ proteins overproduction we 
were observing was due to the lack of the final product or to the absence of one of the 
components of the CoQ complex and its instability. We treated controls, COQ4 KO and 
COQ6 KO with 5µM of CoQ10 for 96 hours. We first checked if exogenous CoQ10 was able 
to enter the mitochondria, for which cell subfractionation was performed and CoQ10 
levels were measured in the mitochondrial fraction. CoQ10 levels were similar in the 
three treated cell lines, and around 7 times higher than WT levels (Figure 4.22.B). This 
result was indicating that a big amount of exogenous CoQ10 was reaching the 
mitochondria. Then, we subjected mitochondrial protein to western blotting, to 
measure COQ4, COQ5, COQ6 and COQ7 proteins’ levels, and TOM20 as a mitochondrial 
control.  
CoQ10 treatment seems to have a greater effect in terms of COQ proteins levels in the 
COQ6 KO (Figure 4.22). In these cells, the high amounts of COQ4, COQ5 and COQ7 are 
reduced when treated with exogenous CoQ10. CoQ10 supplementation does not show a 
significant effect in the regulation of other COQ protein levels in COQ4 KO cells, except 
for a slight decrease in COQ5 levels. Our results could indicate that CoQ10 treatment is 
more likely to stabilize a complex lacking COQ6 than a complex lacking COQ4, maybe 








Figure 4.22. Western blot 
analysis of COQ4 and other 
COQ proteins in mitochondria. 
Western blot analysis of COQ4 
and other COQ proteins (A) 
levels in mitochondria of CoQ10 
treated and untreated cells and 
their quantification (B-E). 
Treatment conditions: 5µM of 










A COQ4 KO cellular model has been useful to dissect human COQ4 function in CoQ 
biosynthesis. The main conclusions derived from this work are the following: 
i. COQ4 protein is essential for CoQ10 biosynthesis in human cells. The lack of COQ4 
leads to drastically reduced CoQ10 levels, which causes a great respiratory defect 
that is rescued with CoQ10 treatment or WT COQ4 expression.  
ii. Impaired CoQ10 biosynthesis due to the absence of COQ4 protein produces the 
accumulation of a specific intermediate, which could be considered as a marker 
for CoQ10 deficiency in human cells.  
iii. COQ4 may act directly or indirectly upstream DMQ10 production. 
iv. Mutations in the phospho-loop do not affect COQ4 function in CoQ10 synthesis, 
at least in the tested conditions. 
v. Most of the mutations described in patients are hypomorphic, and when 
overexpressed in COQ4 KO cells they cannot be distinguished from the wild type 
version of the protein. 
vi. COQ4 Isoforms lacking exon 3, 4 and 5, in different combinations, do not have 
the same function than full-length COQ4 in CoQ10 biosynthesis. 
vii. COQ4 protein interacts with COQ3-COQ9 proteins in a dynamic complex, and the 
lack of COQ4 or COQ6 proteins alters the levels of other COQs proteins, probably 
modifying the stability of the biosynthetic complex.  
viii. Other mitochondrial proteins involved in different processes were identified as 
candidates for COQ4 interaction partners. They were involved in different 
functions, such as OXPHOS, pyruvate metabolism, TCA cycle, fatty acids beta-
oxidation, amino acids biosynthesis and catabolism, protein import to 
mitochondria, mtDNA metabolism and maintenance, mitochondrial RNA 










Chapter 5.  
COQ4 involvement in mtDNA metabolism  
5.1. Introduction. Human mtDNA and its metabolism  
The human mitochondrial genome is a 16,569 bp-long circular and double-stranded DNA 
molecule. It exists in multiple copies in the mitochondrial matrix, in both somatic tissues 
and germ cells 9. According to the endosymbiotic theory, mitochondria originated from 
α-proteobacteria that were endocytosed by a primitive archaebacterium during the 
eukaryotic evolution 593. The observed similarities between mtDNA and the bacterial 
chromosome probably derive from the endosymbiotic origin of mitochondria.  
The mtDNA molecule is very compact since most of the mitochondrial genes were lost 
or transferred to the nucleus throughout evolution. Mitochondrial genes retained by 
different organisms are variable. The reason why some of the genes were maintained in 
an organelle-specific genome like the mtDNA is unclear, but it is possible that the local 
regulation of gene expression is key for the control of the energy production metabolism 
and the redox state of mitochondria 594. Also, it has been hypothesized that highly 
hydrophobic proteins, such as CYTB or COXI, are difficult to import across the outer 
membrane and correctly insert them in the IMM 594,595.  
5.1.1. Organization of the mitochondrial genome: mitochondrial genes 
The mitochondrial genome has a remarkable economy of sequence, with a compact 
gene organization in which there are no introns and almost no intergenic regions or non-
coding regions 596. In humans, only 37 genes are encoded by the mtDNA; 13 of them 
correspond to structural subunits of the MRC (transcribed in 11 mRNAs and translated 
to 13 proteins) and the rest code for RNA components of the mitochondrial translation 
machinery: 22 mitochondrial transfer RNAs (mt-tRNAs) and 2 mitochondrial ribosomal 
RNAs (mt-rRNAs, 12S and 16S) (Figure 5.1.A) 9,596.  






Figure 5.1. The human mitochondrial genome and its metabolism.  
(A) mtDNA sequence structure, with the different genes coloured (see legend). (B) Transcription from LSP 
and HSP promoters produces long polycistronic transcripts. (C) These long transcripts must be cleaved 
and processed to produce mature rRNAs, tRNAs and mRNAs. (D) Mitoribosomes are assembled with 
rRNAs and proteins, and the translation machinery produces the mtDNA-encoded proteins, that are 







The 13 mtDNA-encoded subunits of the MRC represent a small fraction of the OXPHOS 
subunits, but they are nevertheless essential for the correct functioning of the OXPHOS 
system.  These genes include 7 subunit of complex I (ND1–6, ND4L), 1 subunit of complex 
III (cytochrome b), 3 subunits of complex IV (COXI, COXII and COXIII) and 2 subunits of 
the ATP synthase or complex V (ATP6 and ATP8) 9,67. The rest of the structural subunits 
of the respiratory complexes (around 77), as well as all the factors needed for the correct 
assembly of the respiratory complexes (around 57 known so far), are encoded by the 
nDNA (Table 5.1 and Figure 5.1) 9,36. 
Table 5.1. Number of nDNA- and mtDNA-encoded subunits and assembly factors for each 
mitochondrial respiratory complex.  
Polypeptides CI CII CIII CIV CV 
mtDNA-encoded subunits 7 0 1 3 2 
nDNA-encoded subunits ~38 4 10 10 ~14 
nDNA-encoded  
assembly factors 
~11 ~4 ~9 ~30 ~3 
Colours are the same than in Figure 5.1. CII do not have subunits encoded by the mtDNA. 
5.1.2. mtDNA inheritance and segregation 
The mtDNA is almost exclusively maternally inherited. While oocytes contain around 105 
copies of mtDNA, mtDNA copy number is actively downregulated in spermatogenesis, 
so the sperm cell contains around 100 copies of mtDNA 597. Moreover, sperm 
mitochondria that may enter the oocyte are specifically marked for degradation after 
fertilization 9,598,599. When the mechanisms of selective elimination of paternal 
mitochondria are defective, paternal mtDNA transmission can occur, but this is a rare 
phenomenon 600–603. 
MtDNA molecules from the oocyte segregate into the daughter cells after fertilization, 
and mtDNA replication in the embryos starts after implantation 9,604. There are 
mechanisms that prevent the transmission of mtDNA mutations in the germline.  The 
mtDNA bottleneck phenomenon occurs in the early development of the oocyte, and it 
highly reduces the number of different molecules of the pool of maternal mtDNAs which 
will be transmitted to the next generation 605. Moreover, mtDNA mutations affecting 
codons of the protein-coding genes or the tRNAs are negatively selected in the female 
germline or during embriogenesis, respectively, phenomenon known as purifying 
selection 606,607. The molecular mechanisms underlying these two levels of purifying 





selection are still elusive. Moreover, females with mtDNA mutations in the germline are 
reported to have a reduced fertility 607.  
Conversely to what happens in the germline, in somatic tissues, mtDNA molecules 
segregate randomly to the daughter cells during mitosis, by a process of relaxed 
replication 9. This means there is non-stringent control of mtDNA replication during the 
cell cycle, which could lead to different mtDNA molecules replicating at different rates, 
within the same cell 607. 
Heteroplasmy and mutation rate 
Given that mitochondria enclose multiple copies of mtDNA and each cell can contain a 
variable number of these organelles, there can be several hundreds or thousands copies 
of mtDNA per cell 66. Therefore, if there is a mutation in the mtDNA, it can be present in 
just a fraction of the mtDNA molecules. The homoplasmic state is when all the cells or 
the tissues contain the same identical copy of mtDNA, while various levels of 
heteroplasmy can occur when there is a mix of different molecules of mtDNA. Generally, 
we refer to heteroplasmy when there is a mix of wild type mtDNA molecules and 
mutated mtDNA molecules with a disease-causing mutation 66,608,609. In this case, the 
mitochondrial dysfunction and the clinical phenotype associated to this condition will 
depend on the proportion of wild type and mutated mtDNA genomes (heteroplasmy 
load), and it will appear only when the proportion of WT mtDNA drops below a threshold 
level. This phenomenon is known as mitochondrial threshold effect, and it can be 
specific for the mutation, the tissue or even the patient 66,610. 
Besides, mtDNA has a high mutation rate, 10-17-fold higher than nDNA mutation rate. 
It can be explained by different factors: mtDNA is less protected by a chromatin-like 
packaging than nDNA, it resides in an environment with high exposure to oxidative 
stress and there are less mechanisms of mtDNA repair in mitochondria. This 
mutagenesis can lead to the phenomenon of heteroplasmy 66. Also, paternal mtDNA 





5.1.3. mtDNA expression and maintenance 
The two strands of the human mtDNA have different nucleotide composition so they are 
designated heavy (H) and light (L), since they can be separated by CsCl density 
centrifugation gradients 611. The H-strand is rich in guanines, and it contains most of the 
coding material (12 of the 13 protein-coding genes, the two rRNAs, and 14 of the 22 
tRNAs) (Figure 5.1.A). In contrast, the L-strand encodes one protein (ND6) and eight 
tRNAs. There is only one major non-coding region (NCR), 1.1 Kb long, which contains cis-
elements for replication and transcription 612. Promoters of both H and L strands are 
located in the NCR, as well as the origin of mtDNA replication of the strand H (OH). 
Moreover, it has been observed that, in vertebrates, many molecules of mtDNA contain 
a short and stable triple-stranded region, or displacement loop (D-loop), located in the 
NCR 9,612–615. The proportion of molecules containing a D-loop is very variable, ranging 
from 10% to 90% in different cell lines and times 613. The third strand of the D-loop, the 
7S DNA, is  around 650 bp long in humans, and its synthesis is thought to be primed 
using the 7S RNA molecules (of about 200 nt) derived from transcription from the light 
strand promoter 614. The precise function of the D-loop is not clear, but it could be 
related to mtDNA replication from OH origin, mtDNA recombination, membrane 
association or topology, or even mitochondrial dNTP pools metabolism 613.  
The regulation of mtDNA expression and maintenance is a complex process since it 
involves many different levels, such as mtDNA replication, mtDNA transcription, the 
processing of primary transcripts, RNA modification and stability and the translation by 
mitochondrial ribosomes (Figures 5.1 and 5.2). The structural organization of these 
machineries within the mitochondria is essential for a tight regulation of the different 
processes. In this chapter, we provide an overview of these processes and how they are 
structurally and functionally regulated in the different compartments within the 
mitochondria.   
mtDNA replication 
mtDNA replication is a key  process that occurs independently of the cell cycle 66. Human 
mtDNA molecules have two origins of replication, one for each strand: OH (origin of H-
strand synthesis), at the NCR, and OL (origin of L-strand synthesis), within a tRNA cluster 





around 11,000 bp downstream of OH 612 (Figure 5.1.A). L-strand transcription generates 
the RNA primers needed for replication initiation. The mtDNA replication machinery 
involves several proteins: the mtDNA polymerase (POLG) 9,612, the DNA helicase 
TWINKLE 616, the mitochondrial single-stranded DNA-binding protein (mtSSB) 9, and 
probably other factors 612,614,617.  
Several modes of mtDNA replication have been proposed to operate in mammalian 
mitochondria:  
i. Strand displacement replication (SDR) or strand asynchronous replication: The 
initiation of the replication occurs at the OH 9,612,618. Then, the replisome 
proceeds unidirectionally to produce the nascent H-strand. The displaced, 
parental H-strand is stabilized by mtSSB. When the second origin (OL) is displaced 
as a single-stranded template, DNA replication of the other strand begins in the 
opposite direction, with no generation of small replication intermediates (RIs). 
For this purpose, mitochondrial RNA polymerase (POLRMT) produces small 
primers at the loop originated at OL, which are used to initiate L-strand DNA 
synthesis 619. The mtDNA replication is carried out by POLG. TWINKLE is required 
for DNA unwinding when replication initiates at the H-strand 9.   
ii. Bootlace/RITOLS strand-asynchronous replication: The finding of RNA hybridized 
to the parental H-strand, led to propose that Ribonucleotides are Incorporated 
ThroughOut the Lagging Strand (RITOLS) 615,620,621. Replication of this mode 
initiates with the synthesis of an H-strand, similarly to SDR. H-strand DNA 
synthesis (leading-strand synthesis) proceeds unidirectionally, but RNA is 
incorporated to the lagging strand, instead of being coated by mtSSB. Delayed L-
strand DNA synthesis is initiated at OL and proceeds unidirectionally, removing 
RNA lagging strands in the process. 
iii. Strand coupled replication (SCR): Conventional coupled leading and lagging 
strand DNA synthesis, similar to nuclear DNA replication 612,615. Characterisation 
of RIs from this process suggests that the synthesis of the leading and the lagging 
strands are synchronous and both strands are essentially composed of DNA. 






Transcription from the light-strand promoter (LSP) and the heavy-strand promoter (HSP)  
produces polycistronic RNA precursors that are almost the same size of the mtDNA 9,622 
(Figure 5.1.B). This transcription is carried out by the mitochondrial RNA polymerase 
POLRMT, which specifically binds the sequence of the LSP and HSP. The process requires 
the presence of mitochondrial transcription factor A (TFAM) and the mitochondrial 
transcription factor B2 (TFB2M) to start transcription. TFAM binds sequence-specifically 
to mitochondrial promoters and creates a 180° bend in DNA. Then POLRMT is recruited 
by TFAM and the DNA sequence. When the polymerase binds to the DNA-TFAM 
complex, it undergoes a conformational change that allows its interaction with TFB2M, 
forming the initiation of transcription complex. After the initiation of transcription, 
elongation goes on with the help of the mitochondrial transcription elongation factor 
(TEFM), which interacts with the catalytic C-terminal domain of POLRMT and is thought 
to be an accessory subunit of the polymerase 623. A second heavy-strand promoter was 
proposed to be at the boundary between the tRNAPhe and the 12S rRNA genes and 
mainly dedicated to producing the two rRNAs for mitochondrial ribosomes 624. However, 
recent research suggested that H strand transcription occurs only from HSP, and rRNA 
abundance may be due to different turnover rate 622. In any case, when transcription is 
terminated, the RNA precursors must be processed via endonucleolytic cleavage to 
release the individual mRNAs, tRNAs and rRNAs (Figure 5.2.C). 
mtRNAs processing 
Mt-RNA processing and maturation occurs in specialized compartments in the 
mitochondria, known as mitochondrial RNA granules (MRG), in close proximity to the 
mtDNA nucleoids 440,625,626.  
Most of the tRNA genes are flanking rRNA and protein-coding genes, and it is described 
that polycistronic RNA processing is performed by the recognition and cleavage of these 
tRNA, known as the tRNA punctuation model 627, which leads to the release of the rRNAs 
and mRNAs. The cleavage is performed by two enzymes that recognise tRNAs ends and 
catalyse 5′ and 3′ cleavage, respectively: a mitochondria-specific protein-only RNase P 
complex and the RNase Z endonuclease ELAC2 626,628,629.  For the genes that are not 





localized in these tRNAs junctions, other proteins have been identified to be responsible 
for their processing, such as FASTK, FASTKD4, FASTKD5 and GRSF1. After 
endonucleolytic cleavage, the individual mRNAs, tRNAs and rRNAs are post 
transcriptionally modified. Curiously, two mRNAs are bicistronic (mRNAs for ND4/ND4L 
and ATP6/ATP8) 623.  
The mRNAs are added a 3’ poly-A tail by the mitochondrial poly(A) polymerase (mtPAP) 
and stabilized by binding to factors like the PPR-containing proteins (such as LRPPRC) 
622,630,631. tRNAs undergo nucleotide modifications, such as the 5-formyl modification of 
the cytosine residue in the wobble position of the anticodon in human mt-tRNAMet by 
NSUN3 and ABH1 626. Some mRNAs, tRNAs and rRNAs are also pseudouridylated in 
specific positions by different pseudouridine synthases (PUS1, RPUSD3, RPUSD4, and 
TRUB2), but the exact function of these modifications is still not clear 478,479,626,632. rRNAs 
are also modified with methylations by methyltransferases (TFB1M, NSUN4, MRM1, 
MRM2, MRM3, TRMT61B), being these modifications important for mitoribosome 
assembly, which occurs also in the MRGs 595,626,630,633.  
mtRNA translation 
Translation of the mt-mRNAs takes place in the mitochondrial matrix by the 
mitoribosomes and different proteins associated (Figure 5.1.D). All these protein factors 
are transcribed in the nucleus, translated in the cytosol and imported to the 
mitochondria via the translocases of the outer and inner membrane (TOM and TIM, 
respectively) complexes.  
Proteins involved in the mtRNA translation are the 80 or more mitoribosomal proteins 
(MRP), aminoacyl synthetases (ARSs), the already mentioned tRNA modifying enzymes, 
translation initiation (IF2mt and IF3mt), elongation (EFG1, EFG2, EF-Tsmt, and EF-
TUmt/TUFM), termination (mtRF1a, mtRF1, C12ORF65 and ICT1) factors, and two 
mitoribosome recycling factors (mtRRF1 and mtRRF2) 630.  
Firstly, MRPs bind to rRNAs 12S and 16S to form the mature mitorribosomes subunits, 
28S and 39S, respectively. Then, mitochondrial protein synthesis occurs in four major 





Initiation is the rate limiting step, in which IF3mt binds the 28S subunit and the mRNA. 
When a proper start codon is found, formyl-Met-tRNA bind to the first codon and IF2mt 
associates to form the initiation complex. This allows the binding to the 39S subunit to 
form a 55S monosome and releases the initiation factors.  
The machinery proceeds then to elongation, in which a charged aminoacyl-tRNA enters 
the A site of the monosome (in a ternary complex with EF-TUmt-GTP). If the 
codon:anticodon pairing is correct, EF-TUmt hydrolyses GTP and EF-TUmt-GDP is 
released. Then, the nascent amino acid chain is transferred from the tRNA in the P site 
to the new aminoacyl-tRNA in the A site by peptidyl-transferase activity of the 39S 
subunit. Then, the monosome moves along the mRNA towards the 3’ direction by the 
action of EFG1 in a GTP-dependent manner, allowing a new codon to enter the A site. 
At this point, EF-TUmt-GTP is regenerated by EF-TSmt and binds a new aminoacyl-tRNA.  
Elongation cycle continues until a termination codon is recognized in the A site. When 
this occurs, the termination factor mtRF1a-GTP binds to the complex, which leads to 
hydrolysis of the peptide bond between the nascent chain and the tRNA in the P site 
thereby releasing the mature polypeptide from the ribosome. Other factors homologous 
to mtRF1a (ICT1, C12ORF65, and mtRF1), may also be involved in translation 
termination.  
When translation is terminated, mtRRF1 and mtRRF2/EFG2 bind to the A site and 
dissociate the 55S monosome, releasing the mRNA and tRNA and allowing 
mitoribosome recycling 624,634.  
5.1.4. Coordination of nDNA and mtDNA gene expression 
As we have seen, mitochondria need much more than the 37 genes on the mitochondrial 
genome to work. Actually, it has been estimated that these organelles contain around 
1,500 proteins, which are needed for all the different processes that occur inside them 
69,440,635. All these proteins are encoded by the nuclear genome, and must be translated 
on the cytosol and imported to mitochondria. For the correct functioning of all 
mitochondrial processes, an accurately regulated coordination of mtDNA and nDNA 
expression must exist. The coordination of mitochondrial-nuclear DNA expression can 
operate in different levels.  





There is a set of transcription factors, called coactivators, that regulate both nuclear and 
mitochondrial gene expression in response to environmental changes or external stimuli 
(i.e. caloric intake or exercise).  In this context, there is a change in the gene activation 
program that affects both mitochondrial and nuclear gene expression. For example, the 
peroxisome-proliferator-activated receptor coactivator-1 (PGC-1) is considered a 
universal regulatory system for mitochondrial biogenesis in vertebrates 636. 
However, since mitochondrial genomes encode a small subset of proteins, precise 
mRNA-specific mechanisms have evolved. mRNA-specific nuclear encoded translation 
activators can regulate the synthesis of a specific mitochondrial protein by regulating 
their abundance in mitochondria. In yeast, many transcript-specific activators have been 
described 637. However, only one mitochondrial translation activator has been identified 
in mammalian mitochondria, the TACO1 gene encoding a translational activator of COXI. 
This suggests the mechanisms of mammalian mitochondrial gene regulation are 
significantly different from the yeast ones 626. 
Also, translational activators can directly regulate mitochondrial gene expression by 
evaluating the efficiency of OXPHOS complex assembly. A failed assembly would lead to 
a decrease in the synthesis of the key subunit. These feedback mechanisms have been 
extensively studied in yeast, but less is known about the mammalian system. A study in 
human mitochondria described that mitochondrial translation displays plasticity and 
adapts to the availability of nDNA-encoded complex subunits 638. According to their 
findings, the translation of COXI is paused in the absence of COXIV, and, interestingly, 
ribosomes carrying nascent COXI peptides prime complex IV assembly. Whether this 
kind of feedback mechanism, with translation coupled to complex assembly, exists for 
the rest of the mitochondrial encoded MRC proteins remains to be elucidated 626.    
5.1.5. Packaging mtDNA into mitochondrial nucleoids 
MtDNA molecules need to be compacted to fit inside the mitochondrial network. 
MtDNA is organized into compact nucleoprotein complexes named nucleoids, which are 
considered to be the mitochondrial genetic segregating unit (Figure 5.2) 639. They can be 
visualized as punctate foci evenly distributed inside the mitochondria (Figure 5.2.A). 





organization of the nucleoids have been elucidated 640–643. Mitochondrial nucleoids are 
slightly elongated with a size around 0.1 µm of diameter. Depending on the cell type, 
there is a wide range of nucleoids per cell. It has been shown that each mammalian 
mitochondrial nucleoid contains only one copy of mtDNA, which is compacted with 
different proteins 641,643.  
TFAM is the major constituent of the mammalian nucleoid and sufficient for nucleoid 
compaction, while other proteins can associate to it temporarily for replication or 
transcription purposes (Figure 5.2.B and C) 641,644.  When it binds to mtDNA, it produces 
a U-turn bend, facilitating the folding of the mtDNA molecule 645. TFAM is very abundant 
in mammalian cells, present in about 1,000 molecules per mtDNA molecule 641.  
Different degrees of nucleoid compaction have been observed at different physiological 
TFAM/mtDNA ratios (Figure 5.2.C) 639,643,646. When TFAM/mtDNA ratio is high, the 
nucleoids are fully compacted, and their transcription and replication is blocked 646. This 
means that nucleoid compaction by TFAM protein levels is an important mechanism for 
control of mtDNA expression, selecting which nucleoids undergo transcription or 
replication 9,643–646.  
Besides TFAM, a large number of other mitochondrial proteins have been found to be 
part of the nucleoids, exerting different functions. Mitochondrial transcription 
(POLRMT, TFB2M, TEFM) and replication (POLG, Twinkle, mtSSB) machineries are 
prominently represented (Figure 5.2.B). The MRGs are located in close proximity of the 
nucleoids, so various RNA-metabolism proteins have been found in nucleoid-rich 
preparations 647.  
Nucleoids distribution depends on the mitochondrial fusion and fission dynamics, 
probably by nucleoid attachment to the IMM, and coordinated with mtDNA replication 
3,648,649. For this purpose, ER-mitochondria contact sites are essential. In fact, the subset 
of nucleoids that is replicatively active has been shown to be associated with the IMM 
through cholesterol-rich areas within these ER-mitochondria contact sites (Figure 5.2.B) 
4. These membrane-attached nucleoids are also rich in ATAD3 protein, which is a AAA 
(ATPases Associated with diverse cellular Activities) only present in multicellular 
eukaryotes 650–652.  






Figure 5.2. Mitochondrial DNA organisation in nucleoids.  
(A) Mitochondrial nucleoids visualised by fluorescence microscopy as punctate foci (antiDNA stained in 
green). AntiTOM20 stained in red shows the mitochondrial network and DAPI blue staining shows the 
nucleus of HEK cells. (B) Schematic representation of transcriptionally (left) or replicatively (right) active 
nucleoids, in close contact with IMM and ER-mitochondria contacts, with different proteins associated 
(not in scale) (image elaborated with data from different references, see main text). (C) Different degrees 
of compaction of mtDNA by TFAM association. At intermediate stages, mtDNA can still be used for 
replication and/or gene expression. At the tightly packaged stage, TFAM blocks DNA unwinding and makes 
mtDNA inaccessible to the replication and transcription machineries (Adapted from Gustafsson et al., 
20169).  
 
5.1.6. ER-mitochondria contact sites and relationship with mtDNA 
Membranes from two different organelles can be tightly connected through specialized 
structures named membrane contact sites, which are maintained via dynamic protein-
protein and protein-lipid interactions. These contact sites have essential functions in 
intracellular signalling, mediating a wide range of cellular processes, which include 
calcium homeostasis, lipid metabolism, membrane biogenesis and organelle 
remodelling 653. ER-mitochondria contact sites are unique microenvironments for the 





associated to different processes, such as cellular and mitochondrial calcium 
homeostasis, mitochondrial division and motility, apoptosis, autophagy and lipid 
metabolism and trafficking (Figure 5.3) 15,654,655.  
Mitochondrial division and distribution of nucleoids 
ER-mitochondria contact sites are also important for mitochondrial dynamics. It has 
been demonstrated that mtDNA replication marks the site for ER-recruitment, 
coordinating mitochondrial genome replication and segregation to mitochondrial 
division 3. ER binding to this site drives pre-constriction of the membrane, and oligomeric 
forms of dynamin-like protein 1 (Drp1) accumulate in a ring-like structure. GTP-
hydrolysis leads to Drp1 conformational change, enhancing membrane constriction. The 
composition in phospholipids of the OMM also regulates Drp1 assembly and activity. 
Then, Dnm2 is recruited to the constriction site and terminates membrane scission 23. 
The molecular mechanism explaining how mitochondria-ER contacts occur at the 
replicative mtDNA spots remains to be completely elucidated.  
Moreover, it has been proposed that ER-mitochondria contacts promote mtDNA 
nucleoids active transportation via KIF5B-driven mitochondrial dynamic tubulation. The 
MICOS (mitochondrial contact site and cristae organizing system) complex links 
nucleoids to Miro1, a KIF5B receptor on mitochondria, at the ER-mitochondria contact 
sites. This active transportation of nucleoids is distinct from mitochondrial fusion or 
fission and is an essential mechanism for the proper distribution of nucleoids in the 
peripheral zone of the cell 656. 
Lipids metabolism and trafficking and its importance for mtDNA maintenance 
The proper distribution and abundance of different lipids in the mitochondrial 
membranes allow the correct assembly of membrane protein complexes, cristae 
biogenesis, fusion/fission of mitochondrial membranes and even mtDNA maintenance.  
Some lipids are synthesised in the mitochondria, but the majority of them come from 
the ER. ER-mitochondria junctions are sites for non-vesicular lipid transport to allow 
mitochondrial membrane biogenesis 657–661.   
 





i. Mitochondrial cholesterol 
Cholesterol is an important lipid of all membranes, and its distribution influences 
membrane fluidity, curvature, permeability and membrane protein function. De novo 
sterol synthesis takes places in the ER, through the mevalonate pathway, and 
afterwards, it is rapidly distributed to other organelles and membranes 662. It is imported 
to the IMM mainly through the ER-mitochondrial contacts by a complex formed by the 
translocator protein (TSPO) and VDAC in the OMM, and the ATPase family AAA domain-
containing protein 3 (ATAD3) bridging to the IMM (Figure 5.3.A) 661–663.  
 
Figure 5.3. ER-mitochondria contact sites and CoQ biosynthesis.  
(A) Schematic representation of ER–mitochondria contact sites. The ER– mitochondria contact sites in 
mammalian cells are not yet completely defined. Shown are several of the relatively better understood 
components and their functions associated. (B) Diagram of current model of CoQ biosynthetic pathway 
in eukaryotes. In the inner mitochondrial membrane (IMM), a cohort of Coq proteins (Coq3–9 and Coq11) 
are assembled into a supramolecular complex, the CoQ complex. This complex is localized into discrete 
foci, called mitochondrial CoQ domains, which are positioned close to the ER– mitochondria contact sites. 
In addition to the protein constituents, generation of polyisoprenylated UQ intermediates is also required 
for the formation and stabilization of the CoQ synthome and the CoQ domains. Coq proteins with known 





Cholesterol levels in mitochondrial membranes are extremely low, being concentrated 
in the ER-mitochondria contact sites, in association with ATAD3 and membrane attached 
nucleoids (Figure 5.2.B) 4. Yeast do not have cholesterol, but the structurally similar lipid 
ergosterol. It has been reported that ergosterol reduction impairs mtDNA maintenance 
in these microorganisms 664. Abnormal levels of cholesterol in mitochondria have been 
observed in a wide range of pathological conditions with a mitochondrial dysfunction 
and an impaired mtDNA maintenance. One example is ATAD3 dysfunction.  
ATAD3 membrane proteins are specific to multicellular eukaryotes. They are encoded 
by the ATAD3 gene cluster, composed of three paralogs formed by tandem duplication 
(ATAD3A, ATAD3B and ATAD3C). ATAD3A and ATAD3B differ in a stop-loss mutation in 
ATAD3B that makes the protein 62 aa longer. ATAD3C is not known to be expressed 665. 
ATAD3A is a transmembrane ATPase that anchors in the IMM and spans to the OMM 
175,644,666. It is predicted to form hexamers. The N terminus of ATAD3 contains 50 aa that 
have been proposed to be inserted into the OMM and associated to organelles such as 
the ER 175. Interestingly, ATAD3 has been found associated to membrane-attached 
nucleoids 4,650 and proposed to be important for mtDNA maintenance and cholesterol 
levels in mitochondrial membranes 665,667.  
Several patients have been reported with a wide variety of disease-causing mutations in 
the ATAD3 gene cluster, including biallelic hypomorphic variants, biallelic deletions, 
monoallelic dominant-negative missense variants and monoallelic de novo dominant-
negative duplications. This genetic variety also produces a broad phenotypic spectrum: 
pontocerebellar hypoplasia 667, hereditary spastic paraplegia 668, syndromic neurological 
disorder (peripheral neuropathy, hypotonia, cardiomyopathy, optic atrophy, cerebellar 
atrophy, and seizures) 669–671 or an ataxic syndrome (with CAt and DD)672.  
At the cellular level, defects in ATAD3 impair mitochondrial structure and function in 
different ways, leading to loss of cristae 673, dysfunctional mitochondrial morphology 
and dynamics 663,668, mtDNA abnormalities, perturbed cholesterol distribution, reduced 
steroid hormone formation and OXPHOS dysfunction 4,663,667–669,673. It is not clear if the 
origin of these defects is the lack of a functional ATAD3 protein or the changes in 
membrane structure caused by altered cholesterol levels, or even a combination of both 
phenomena. 





ii. Coenzyme Q 
Remarkably, CoQ biosynthesis has also been related to ER-mitochondria contact sites. 
CoQ head-modifying enzymes have been found to resolve in discrete loci, so-called CoQ 
domains, adjacent to ER-mitochondria contact sites (Figure 5.3.B) 1,2,316. Yeast defective 
in ER-mitochondria contact site components display defects in CoQ domain copy 
number and CoQ biosynthesis. They have increased cellular CoQ levels and 
accumulation of early and late CoQ biosynthetic intermediates in whole cells, while in 
mitochondria, CoQ and some late intermediates were significantly reduced 2. These 
findings suggest that ER-mitochondria contacts could function to control the spatial 
organization of CoQ biosynthesis and distribution within mitochondrial and 
extramitochondrial membranes, being essential for CoQ homeostasis and cellular 
respiration 1,2,316.  
CoQ levels and mtDNA maintenance have been linked in the context of disease, being 
mtDNA depletion syndromes the most common cause of secondary CoQ deficiency (See 
Chapter 1, section 1.1.2). A reciprocal effect has been observed in the literature, in a 
yeast model, in which several coq null mutants (coq2, coq4 and coq10) had an increased 
mtDNA instability 674.  
Moreover, CoQ and cholesterol share part of their biosynthetic pathways and levels of 
both molecules could be coregulated in the cells. Recently, cellular models of 
pharmacological inhibition of COQ2 protein displayed high levels of cholesterol 675. The 
same happened in a KD of UBIAD1, a nonmitochondrial prenyltransferase involved in 
CoQ synthesis in the Golgi 676. In a disease context, Niemann-Pick disease type C is a 
cholesterol trafficking disorder that causes high levels of cholesterol in endosomes and 
mitochondria 661,677; and, in line with the previous section, mtDNA abnormalities, such 
as aggregation 667. Some patients with this disorder presented also a secondary CoQ10 
deficiency, probably due to a downregulation of the mevalonate pathway caused by 
high cholesterol 291,301,313. Similarly, low CoQ10 levels were detected in fibroblasts from 





Other functions of ER-mitochondria contacts 
ER-mitochondria contact sites are where Ca2+ is released from the ER to the 
mitochondria (Figure 5.3.A). The Ca2+, released from inositol-triphosphate receptors 
(IP3Rs) at the ER, passes the OMM through VDAC and the IMM via the mitochondrial 
calcium uniporter (MCU) 15,655. HSPA9/HSP70/GRP75 protein links IP3R and VDAC 678, 
and the OMM protein TOM70 also binds to IP3R 502. Dimerization of mitofusin 2 (MFN2) 
also controls the tethering of ER to OMM 679,680. Mitochondrial Ca2+ uptake has been 
linked to energized mitochondria, by enhancing the activity of TCA cycle 
dehydrogenases required for OXPHOS. Mitochondrial Ca2+ and ER-mitochondria 
contacts are also involved in the control of apoptosis and ROS signalling 15,681–683.  
5.2. Results and discussion 
All biological processes occurring inside the mitochondria are tightly interconnected and 
regulated, functionally and spatially. This regulation involves a complex interaction 
between mtDNA replication and transcription machinery, functional components of the 
ETC, the structural conformation of IMM, selective clearance of mitochondria, nuclear 
gene expression, and probably other cellular processes.  
CoQ biosynthesis is a crucial process in mitochondria that has been recently linked to 
ER-mitochondria contact sites 1,2, a mitochondrial location in which other important 
mitochondrial functions take place, as presented in the introduction above. Very 
interestingly, it has been described in yeast that several coq null mutants (coq2, coq4 
and coq10) have an increased mtDNA instability, compared to controls, with a high rate 
of rho- cell formation 674. The authors proposed that this mtDNA instability was due to 
elevated ROS production in cells defective in CoQ function. 
COQ4 deficiency leads to a respiratory defect due to an impaired CoQ biosynthetic 
process. We wanted to further investigate if CoQ deficiency due to COQ4 defects, 
specifically, or CoQ biosynthesis defects, in general, may lead to an impairment in other 
important mitochondrial functions related to mtDNA metabolism, such as replication, 
maintenance or expression.  
Moreover, in the InterPro database of protein families, the Coq4 domain (IPR007715) 
(which includes the whole Coq4 protein sequence), appears in architecture with other 





types of domains in some proteins. The most frequent functions of these other domains 
are RNA metabolism and metal binding, which may be related with COQ4 function.   
5.2.1. mtDNA copy number is decreased in cells lacking COQ4 
We subjected our COQ4 KO model to mtDNA copy number measurements. We used 
different probes for real-time PCR to quantify mtDNA and nDNA, obtaining the same 
results for all of them. MtDNA copy number seems to be reduced in cells lacking COQ4 
protein, with varying percentage of deficiency (between 25 and 60%), depending on the 
mitochondrial and nuclear probes used (Figure 5.4.A). This deficiency shows a trend to 
be rescued with the overexpression of different forms of COQ4, such as WT COQ4 with 
or without a FLAG tag, or COQ4 with mutations in the putative phosphorylation loop 
(Figure 5.4.B), which were shown no to have any effect in CoQ biosynthesis as well.  
 
 
Figure 5.4. mtDNA copy number in 
COQ4 KO cells and COQ4 KO cells 
transfected with different COQ4 
variants. 
(A) mtDNA copy number of the 
different COQ4 KO cell lines and HEK 
WT control. (Two-way ANOVA, 
Tukey’s multiple comparison, p-
values < 0.05 (*), < 0.01 (**)). (B) 
mtDNA copy number of COQ4 KO 
(43d) cell lines, the same KO 
transfected with different versions 
of COQ4 gene and HEK WT cells. 
(One-way ANOVA, Tukey’s multiple 








5.2.2. mtDNA transcription is not altered at the level of transcripts in COQ4 KO 
cells 
Another critical and tightly regulated phenomenon related to mtDNA metabolism and 
the correct functioning of mitochondria is mtDNA transcription. Transcripts of several 
mtDNA-encoded subunits of the respiratory chain complexes were measured by qPCR, 
using the actin transcript as a constitutive control for normalization. The expression of 
the nDNA-encoded SDHB subunit of CII was equally measured. No significant changes in 
mtDNA transcription were found between the cells lacking COQ4 and the controls, or 
between the expression of nDNA-encoded SDHB and the mtDNA-encoded transcripts 
(Figure 5.5). These results indicated the transcription of mtDNA is not affected in COQ4 
KO mutant cells.  
 
 
Figure 5.5. Mitochondrial transcripts expression in COQ4 KO cells, relative to HEK WT control.  
Quantitative PCR of several transcripts of mtDNA-encoded (ND1 for Complex I, CYB for Complex III, COXI 
for complex CIV and ATP6 for Complex V) and nDNA-encoded (SDBH for Complex II) subunits of the 
respiratory chain complexes, using the actin transcript as a constitutive control for normalization. (Two-
way ANOVA, Tukey’s multiple comparison, p-values > 0.05 (non significant)).  
 
  





5.2.3. COQ4 KO cells have a slight increased translation of mtDNA-encoded COXI 
protein 
We wanted to analyse the participation of COQ4 protein in the translation of 
mitochondrial proteins. The small number of proteins encoded by mtDNA (13 
polypeptides) makes it easy to label, detect, and quantify these mitochondrial 
translation products. With this purpose, cells were incubated with [35S]-methionine, 
which is incorporated into newly synthesized proteins. To avoid the labelling of new 
cytosolic proteins, cells were treated with emetine, a cytoplasmic translation inhibitor, 
before the addition of radioactive methionine. After a 60 min pulse with the labelled 
amino acid, cells are harvested, washed, lysed, and finally subjected to SDS-PAGE, to 
later detect the radioactively labelled polypeptides. The in vivo mitochondrial protein 
labelling assay was carried out 3 times, testing mitochondrial translation in HEK WT cell 
line, COQ4 KO (with a low number of passages and with a high number of passages since 
the ablation of COQ4 gene), and COQ4 KO complemented with COQ4-FS.  
We observed that the COQ4 KO cells showed a significant specific increase in the 
translation of COXI, which was rescued by WT COQ4 gene expression (Figure 5.6.A-C). 
Steady-state levels of COXI were also analysed by Western Blot, being the same in all 
cell lines (Figure 5.6.D). Maybe the increase in translation could be due to a slower 
turnover rate of this protein in the COQ4 KO cells, compared to the controls, but the 
significance of these results and the eventual molecular mechanism of this phenomena 
remains to be elucidated.  
A slight but not significant decrease in the translation of ATP6 and ATP8 was also 
observed, but cells expressing COQ4-FS did not revert this effect (Figure 5.6.A-C). 
Interestingly, the same phenotype was described for a TRUB2 gene KD (Antonicka et al., 
2015), a gene that shares a 5'UTR region with COQ4. In order to check that the ablation 
of COQ4 gene did not have an effect on TRUB2 expression, causing an indirect impact 
on mitochondrial translation, we performed a western blot of TRUB2 protein. TRUB2 
levels were the same in all cells (Figure 5.6.D), so this effect could be related to the lack 









Figure 5.6. Increased COXI and slightly decreased ATP6 and ATP8 translation in COQ4 KO cells, compared 
to controls.  
(A) L-[35S]-Methionine labelling (pulse of 1 hour) of mtDNA-encoded proteins in control HEK WT, in COQ4 
KO (43d) with high (HP) and low (LP) number of passages after COQ4 ablation, and in COQ4 KO cells 
transfected with COQ4-FS. (B) Densitometric profile of each lane of the gel and (C) densitometric 
quantification of the signal intensities of the labelled peptides (Two-way ANOVA Dunnett’s multiple 
comparisons test, all samples vs. HEK WT; p-values<0.05 (*)). (D) Immunoblot of total lysates of the same 
cells, showing COQ4, TRUB2, COXI and β-tubulin levels. 
 
 





5.2.4. Recovery after EtBr depletion 
Next, we were interested in understanding if the correct functioning of CoQ biosynthetic 
function was also important for the balance of mtDNA maintenance and replication, and 
for the cellular response to mtDNA stress. With this purpose in mind, we treated COQ4 
KO and control cells with ethidium bromide (EtBr) at concentrations that induced a loss 
of mtDNA, to study the effects of mtDNA depletion in both genomic backgrounds.  
EtBr is a DNA intercalator that preferentially binds to the mtDNA, disrupting its tertiary 
structure and leading to inhibition of its replication and transcription, but not stopping 
cell proliferation. Thus, cells continue to divide and, consequently, mtDNA is diluted into 
the daughter cells. This is a reversible process since upon withdrawal of the intercalator, 
cells are able to restore mtDNA replication if they still have some molecules of it 684.  So 
that, after a certain time, cells will have recovered their initial levels of mtDNA, with a 
recovery rate that may be different for different cell types. 
It has been shown in the literature that, upon EtBr intercalation, not only the DNA 
topology changes, but it also neutralizes the charge of mtDNA and alters the binding 
ability for TFAM 685. The release of TFAM into the mitochondrial matrix would lead to its 
specific degradation by Lon protease. After the loss of TFAM, mtDNA nucleoids tend to 
cluster, as a protecting mechanism for newly replicated mtDNA against intercalators 
mediating genotoxic stress 685. This clusters mostly contained nucleoids in a replicative 
state, while the nucleoids which were not in replication tended to remain outside the 
clusters 685. Nucleoid clustering has been also observed under other circumstances of 
mtDNA stress, such as POLG 614, TWINKLE and TFAM overexpression 686 or TFAM or CLPX 
protease downregulation 687,688.  
We wanted to test the effect of COQ4 deficiency in the response to mtDNA stress caused 
by EtBr treatment, in order to understand if COQ4 in particular, or CoQ biosynthesis in 





COQ4 KO recovers faster the mtDNA copy number after depletion induced by ethidium 
bromide (EtBr) treatment 
MtDNA depletion was induced with with EtBr up to a 10% of the initial amount of 
mtDNA. After removing the intercalator, cells were let to recover mtDNA over time, and 
the recovery rate was quantified. Wild type cells, COQ4 KO, and COQ4 KO transfected 
with different versions of COQ4 gene (COQ4-FS, COQ4, COQ4 M1-FS, COQ4 M2-FS and 
COQ4 M3-FS) were used in this assay. Firstly, the optimal duration of the EtBr treatment 
was determined  to be 4 days for the cells to reach the 10% of the initial mtDNA. For the 
following experiments, cells were treated for 4 days and thenwashed and re-seeded. 
Every 24h, up to 7 days, two samples were collected, for DNA and protein extraction. 
The experiment was performed in triplicate, and with two conditions, with doxycycline 
and without doxycycline (which induces the expression of the transfected gene) (Figure 
5.7). 
 
Figure 5.7. Increased mtDNA recovery rate in COQ4 KO ethidium bromide mtDNA-depleted cells, 
compared to controls.  
Cells were treated for four days (96h) with 100 ng/mL) of ethidium bromide (EtBr), for mtDNA depletion, 
until they had a 10% of the initial copy number. After withdrawal of the treatment (wash, t=0), mtDNA 
was recovered at different rates by the different cell lines. mtDNA copy number was measured at each 
time-point by quantitative PCR, using the nuclear gene (APP) for normalisation (Two-way ANOVA 
Dunnett’s multiple comparisons test, all samples vs. HEK WT; p-values<0.05(*), <0.001 (***), <0.0001 
(****)). 
 





Strikingly, after quantifying the recovery rate of mtDNA (measured by qPCR MT-
COXI/APP), we observed that the lack of COQ4 accelerated the recovery of mtDNA, 
reaching 50% of the initial copy number approximately 48 hours earlier than wild type 
cells or COQ4 KO cells transfected with any of the versions of the gene. The latter 
recovered more slowly than wild type cells (Figure 5.7). The results were the same in the 
presence or absence of doxycycline (Figure 5.7). This surprising phenomenon has not 
been observed before in the literature. It could be directly related to the lack of COQ4, 
indicating that this protein could have some regulatory function in this process; or 
indirectly, related to the lack of CoQ10, the lack of a functional CoQ10 biosynthetic 
complex or the accumulation of specific lipidic intermediates. Alternatively, it could also 
be caused by differences between COQ4 KO cells and controls in the protective 
mechanism of nucleoid clustering that is caused by TFAM loss after EtBr intercalation, 
as described in the literature 685; or even a differential efficiency in mitochondrial 
biogenesis in the two cell lines.  
Several proteins, COQ4 amongst them, are lost and then recovered at different times 
during the mtDNA depletion and recovery process induced by EtBr treatment and 
withdrawal. 
In order to gain further insight into the changes in mtDNA and mitochondrial mass 
following EtBr exposure, levels of proteins involved in different mitochondrial processes 
were analysed in the different conditions. In particular, levels of mitochondrial 
transcription factor (TFAM), proteins involved in mitochondrial RNA processing and 
translation (TRUB2, LRPPRC, TUFM, MRPS18B), subunits of the respiratory complexes 
encoded by the mtDNA (COXI, COXII) or the nDNA (NDUFS3, NDUFA9) and controls for 
mitochondrial mass (HSP60, VDAC1) were assayed. Steady-state levels of these proteins 
were analysed before the treatment (Figure 5.8), and during depletion (Figure 5.9) and 
recovery of mtDNA (after EtBr treatment and withdrawal) (Figure 5.10), at different time 
points.  
The levels of all these proteins before the EtBr treatment were the same in COQ4 KO 







Figure 5.8. Steady-state levels of 
proteins involved in different 
mitochondrial processes were 
the same in COQ4 KO and 
controls. 
Western blot and 
immunodetection analysis of 
SDS-PAGE of total lysates from 
HEK WT, COQ4 KO and COQ4 KO 
transfected with COQ4 (FS-
tagged or untagged), before 
ethidium bromide treatment. 
 
 
Consistent with the reduction in mtDNA content during EtBr treatment, the steady state 
levels of TFAM decreased in COQ4 KO and in controls, being slightly faster degraded in 
COQ4 KO cells (Figure 5.9). TRUB2, the mitochondrial mRNA pseudouridine synthase 
whose coding gene shares 5’ UTR with COQ4 gene, was very rapidly depleted in all the 
three cell lines. LRPPRC, a protein involved in RNA metabolism, was partially degraded 
with the 4 days treatment, similarly to what happened to the mitochondrial ribosomal 
protein S18B (MRPS18B). The mitochondrial translation elongation factor TUFM was 
only very slightly degraded at 4 days of treatment, being in COQ4 KO slightly more 
abundant than in the controls. MRC subunits were also affected by mtDNA depletion, 
especially the mtDNA encoded COXII. COXII was very rapidly degraded, and this 
degradation seemed to be somehow slower in COQ4 KO. nDNA encoded complex I 
subunit NDUFA9 was slowly degraded in the three cell lines. HSP60 levels did not 
experienced major changes during depletion, suggesting the mitochondrial mass was 
not being affected, at least at 4 days of treatment with EtBr (Figure 5.9).  






Figure 5.9. Protein levels during mtDNA depletion caused by ethidium bromide treatment. 
 (A) Western blot and immunodetection analysis of SDS-PAGE of total lysates from HEK WT, COQ4 KO and 
COQ4 KO transfected with COQ4-FS, at different time-points of mtDNA depletion. B: before depletion, d: 
days with ethidium bromide treatment.  
 
After the removal of EtBr and during the mtDNA recovery phase, the proteins measured 
behaved in accordance with the mtDNA content and the faster recovery of mtDNA in 
COQ4 KO (Figure 5.10.A). Proteins that were lost (or partially degraded) during the 
depletion phase, were gradually recovered (TFAM, TRUB2, LRPPRC, MRPS18B, MT-COII), 
being the recovery faster in COQ4 KO cells. Other proteins that were only partially 
degraded behaved differently. This is the case of nDNA encoded complex I subunits 
NDUFA9 and NDUFS3, which continued to be degraded after EtBr withdrawal, and then, 
they experienced a delayed recovery that was similar in the three cell lines. Interestingly, 
COQ4 protein was also modulated in a similar way than NDUFA9 and NDUFS3 (nDNA-
encoded complex I proteins). This effect is independent of the endogenous genomic 
locus and promoter, because it also occurred in COQ4 KO cells overexpressing COQ4 
(tagged and untagged) from a different locus of the genome (Figure 5.10.B). This 





degradation of the transcript. The delayed depletion and repletion of nuclear-encoded 
proteins directly involved in energy production (MRC components, or CoQ biosynthesis) 
is probably a mechanism to adapt to the retarded mtDNA-encoded protein synthesis. 
 
Figure 5.10. Protein levels during mtDNA recovery after ethidium bromide treatment.  
Western blot and immunodetection analysis of SDS-PAGE of total lysates from HEK WT, COQ4 KO (A) and 
COQ4 KO transfected with COQ4-FS or untagged COQ4 (B), at different time-points of mtDNA recovery. 
B: before depletion, t=0: withdrawal of ethidium bromide treatment.  





Faster mtDNA recovery in COQ4 KO is not due to the lack of CoQ10, and also occurs in a 
COQ6 mutant (+/- CoQ10) 
We wanted to unravel if the faster recovery was directly due to the absence of COQ4, 
or it was produced by other causes, such as the consequently significant CoQ10 
deficiency, the lack of a functional CoQ biosynthetic process derived from the lack of 
COQ4, or the perturbance in lipids metabolism. To distinguish whether the increased 
rate of recovery was derived from the lack of CoQ, mtDNA depletion and recovery 
experiments were assayed in control and COQ4 KO cells, with or without CoQ10 
supplementation. To better understand if the effect was due specifically to the lack of 
COQ4 or the accumulation of specific intermediates, a COQ6 KO cell line was also tested 
for mtDNA recovery rate.  
 
Figure 5.11. Increased mtDNA recovery rate in COQ4 KO and COQ6 KO ethidium bromide mtDNA-
depleted cells, compared to controls (with no effect of CoQ10 treatment).  
Cells were treated for four days (96h) with 100 mg/mL) of ethidium bromide (EtBr), for mtDNA depletion, 
until they had a 10% of the initial copy number. After withdrawal of the treatment (wash, t=0), mtDNA 
was recovered at different rates by the different cell lines. CoQ10 treatment was performed at 5μM during 
the recovery phase. mtDNA copy number was measured at each time-point by quantitative PCR, using 
the nuclear gene (APP) for normalisation, and represented as a percentage relative to mtDNA copy 
number before EtBr treatment. (Two-way ANOVA Dunnett’s multiple comparisons test, all samples vs. 
HEK WT. p-values<0.05(*), <0.01 (**), <0.001 (***), <0.0001 (****):  
a: COQ4 KO (*), COQ6 KO (**), COQ4 KO + CoQ10 (**), COQ6 KO + CoQ10 (****); 
b: COQ4 KO (****), COQ6 KO (****), COQ4 KO + CoQ10 (****), COQ6 KO + CoQ10 (****); 
c: COQ4 KO (****), COQ6 KO (****), COQ4 KO + CoQ10 (**), COQ6 KO + CoQ10 (****); 
d: COQ4 KO (***), COQ6 KO (****), COQ4 KO + CoQ10 (non-significant), COQ6 KO + CoQ10 (****); 





Our results show that the mere lack of CoQ10 does not influence the rate of mtDNA 
recovery in COQ4 KO, since the same phenotype was observed when cells were 
supplemented with 5µM of CoQ10 during the recovery phase (Figure 5.11). Very 
interestingly, a faster recovery of mtDNA in COQ6 KO cells (+/- CoQ10) was also observed, 
indicating that both COQ4 and COQ6 KO cell lines have something in common that 
induces a rapid repletion of mtDNA copy number after EtBr-induced depletion (Figure 
5.11). Determining the cause of this phenomenon would shed light into the possible link 
between CoQ biosynthesis and mtDNA metabolism, a currently unexplored field.  One 
possibility is that the disassembly of the CoQ biosynthetic complex itself could influence 
mtDNA metabolism. 
5.2.5. Study of mitochondrial cholesterol and nucleoid proteins distribution 
Considering the shared pathway between CoQ and cholesterol biosynthesis, and the link 
between mitochondrial cholesterol and replicative nucleoids, we wanted to explore if 
these relationships could be a clue for explaining the phenotype of fast mtDNA recovery 
after EtBr induced depletion.  
Mitochondrial cholesterol concentration is the same in COQ4 KO cells and controls 
Given that CoQ and cholesterol biosynthesis have in common the mevalonate pathway, 
a blockage in CoQ synthesis could lead to an accumulation of isoprenoid precursors in 
mitochondrial or extramitochondrial membranes that may increase cholesterol 
synthesis. In fact, higher levels of cholesterol have been observed in cellular models 
upon pharmacological inhibition of COQ2 protein by the addition of 4-nitrobenzoic acid 
(4-NB) 675, and in a KD of UBIAD1, a nonmitochondrial prenyltransferase involved in CoQ 
synthesis in the Golgi 676.  
As we have seen in the introduction, mitochondrial cholesterol has been shown to be 
concentrated in the membrane fractions where replicative nucleoids attach 4. We 
hypothesised a possible cholesterol raise could increase the number of cholesterol 
platforms in mitochondria membranes, which would anchor more replicatively-active 
nucleoids. In order to test this, we measured total cholesterol levels in mitochondria, 
comparing the COQ4 KO cell line to controls.  





In terms of total mitochondrial cholesterol concentration, the two cell lines have the 
same concentration in pure mitochondria (Figure 5.12.A). This finding made us conclude 
that cholesterol levels in mitochondria may not be the reason of the fast mtDNA copy 
number recovery in COQ4 KO cells, compared to controls. However, we cannot rule out 
the possibility that small changes in concentration or distribution in specific domains in 
the IMM would be responsible for the modulation of cholesterol platforms and mtDNA 
stability. 
COQ4 KO cells seem to have a slightly altered nucleoid structure in mitochondria 
It has been suggested that cholesterol distribution in specific structures in the ER-
mitochondria contact sites is important for the association of replicative mtDNA 
nucleoids 4. Additionally, the CoQ biosynthesis machinery also localises in focal regions 
within ER-mitochondria contacts and, in yeast, the lack of Coq4p or Coq6p abolishes this 
focal localisation 1,2. 
We wanted to examine if the lack of COQ4 protein had an effect on the distribution of 
nucleoid components and cholesterol within IMM. Thus, pure mitochondria from COQ4 
KO and controls (HEK WT and COQ4 KO transfected with WT COQ4) were subjected to a 
DDM solubilization and a top-down fractionation on an iodixanol density gradient 
(Figure 5.12.B).   
TFAM, ATAD3 and COQ4 were localized in the different fractions of the gradient (Figure 
5.12.C). TFAM was considered a marker of mtDNA (and nucleoids), as it has been 
suggested to possibly be the only factor that is permanently associated with mtDNA 641. 
ATAD3 was measured as an indicator of membrane-bound nucleoids, that are 
considered to be in a replicatively-active state 644,650. ATAD3 is also thought to determine 
mitochondrial localization of cholesterol in this same area 4. 
TFAM staining showed two distinct protein populations in mitochondria (Figure 5.12.C). 
The majority of the TFAM signal was part of high-density structures (being detected 
mainly in fractions 8 and 9). Likewise, a small proportion of TFAM staining was found in 
less dense fractions (12, 13 and 14). This distribution was in accordance with the 
literature, where dense structures are considered nucleoids containing mtDNA, TFAM, 






Figure 5.12. Cholesterol levels in mitochondria, and distributions of proteins and cholesterol on top-
down iodixanol gradients of total mitochondrial DDM lysates.  
(A) Cholesterol levels in pure mitochondria of HEK WT and COQ4 KO cells (non-significant differences by 
unpaired two-tailed t-test). (B) Total pure mitochondrial DDM lysates from HEK WT, COQ4 KO and COQ4 
KO transfected with COQ4 cells were separated on top-down iodixanol gradients. (C) Western blot and 
immunodetection analysis of SDS-PAGE of each fraction of the iodixanol gradients. (D) Cholesterol 
quantification in each fraction of the gradients, represented as a percentage of the total cholesterol 
measured. 





The less-dense structures found in iodixanol gradients could be nucleoids associated 
with a lower amount and diversity of proteins or even free TFAM (we did not measure 
mtDNA presence). In our system, TFAM signal found in less dense structures (fractions 
12, 13 and 14) is higher in COQ4 KO cells than in controls. This would suggest that in a 
steady-state situation, COQ4 KO cells have more nucleoids in a non-replicative state and 
not attached to membranes, or that they have more free-TFAM. 
ATAD3 protein was mainly found in dense fractions, being mostly in fractions 7 to 9, co-
fractioning with TFAM-dense structures. Also, a small part appeared in less dense 
fractions (10 to 13) (Figure 5.12.C). This results agreed with previous observations 
described in the literature, in which they propose that TWINKLE-containing mammalian 
nucleoids attach to the IMM by ATAD3, in association with ER-mitochondrial junctions4. 
ATAD3 found in dense structures (fractions 7 to 9) is relatively less abundant in COQ4 
KO cells. This could mean that in a steady-state situation, COQ4 KO cells have less ATAD3 
coordinating nucleoids organisation, and more free-ATAD3.  
COQ4 signal was also measured and found in the same low-density fractions than TFAM 
(13 and 14) in controls (Figure 5.12.C). This distribution of COQ4 protein probably 
indicates that it is not part of high-density complexes with nucleoids or other proteins, 
and is probably not tightly attached to the membrane. On the contrary, it is located in 
low-density fractions, cosedimenting with a fraction of TFAM that may correspond to 
nucleoids in a non-replicative state and/or not attached to membranes.  This 
colocalisation could have some importance in the context of a regulation between 
mtDNA expression and CoQ10 biosynthesis. 
Cholesterol levels were also measured in each of the fractions. In the literature, 
cholesterol was found in the low-density fractions of a flotation gradient (bottom-up) 
from mitochondrial membranes preparations, Triton X-100 solubilized 4. In this type of 
gradients, IMM-associated nucleoids also migrated from the bottom of the tube to the 
low-density fractions. In our experiments, we used DDM lysates from total mitochondria 
separated by top-down iodixanol density gradients. Cholesterol was found next to the 
top of the gradient, in low-density fractions (12 to 14), and not in the fractions 
associated to ATAD3, in all the 3 cell lines (Figure 5.12.D). It is possible that the technical 





account that we made gradients from total pure mitochondria instead of membrane-
enriched samples, performed DDM instead Triton X-100 solubilisation and used top-
down gradient instead of bottom-up flotation gradient.  
We repeated the experiments with a digitonin pre-treatment before running the 
gradient, to produce a mitochondrial membrane pellet sample and a supernatant 
sample containing soluble components. The membrane-rich pellet sample was 
solubilised with DDM, and both the pellet and the supernatant were fractionated on 
top-down iodixanol density gradients.  
 
Figure 5.13. Distribution of proteins and cholesterol on top-down iodixanol gradients of membrane and 
soluble fractions of pure mitochondria.  
Pellet and supernatant preparations from digitonin treated purified mitochondria from HEK WT and COQ4 
KO cells were separated on top-down iodixanol gradients and their protein (A) and cholesterol (B) 
contents were analysed.  
 
The pellet fraction, rich in mitochondrial membranes, showed the same distribution of 
TFAM and ATAD3 observed with total mitochondria (Figure 5.13.A). We could see that 
TFAM and ATAD3 were more abundant in less dense fractions in the COQ4 KO cell line 
compared to the control. COQ4 was not detected in the control pellet, probably 
indicating COQ4 is not tightly associated with the membranes. Cholesterol was almost 
undetected and equally distributed along the fractions in the pellet samples, contrarily 
to what was observed in the literature (Figure 5.13.B). It seems the digitonin treatment 





removed the cholesterol from the membrane fraction, or that the combination of 
digitonin and DDM treatment totally solubilise cholesterol from the membranes. 
Technical improvements should be performed in order to confidently measure 
cholesterol in this kind of samples. 
In the supernatant samples, TFAM and ATAD3 became more soluble, part of less dense 
fractions in both COQ4 KO cells and controls. Soluble TFAM was no longer at high density 
8 and 9 fractions, but it moved to fractions 9 to 13. ATAD3 spread to low-density 
fractions, but it was still more abundant in fractions 8 and 9. Curiously, cholesterol was 
detected in supernatant fractions (which were not treated with DDM), being 
concentrated in fractions 8 and 9, following ATAD3 distribution, with no significant 
differences between COQ4 KO and control. This result fits with the literature 4.  
With these very preliminary experiments, we have observed that mitochondrial 
cholesterol does not seem to change its levels or localisation in the absence of COQ4, 
although cholesterol distribution in compromised cells by mtDNA depletion should be 
further investigated. However, there seem to be slight differences between COQ4 KO 
and control cells in terms of nucleoid proteins (TFAM and ATAD3) distribution in density 
gradients. Maybe these subtle changes are behind the COQ4 KO fast mtDNA recovery 
after induced depletion. However, there is still a lot of work to be done to better 







CoQ biosynthesis is an essential process taking place inside the mitochondria and 
influencing its physiology. When CoQ is altered, it could affect other essential 
mitochondrial functions such as mtDNA metabolism. The main conclusions derived from 
this work are the following: 
i. The lack of COQ4 leads to a slight decrease of mtDNA copy number, with no 
effect on mtDNA transcription and a very subtle effect on mtDNA-encoded 
proteins synthesis. 
ii. The lack of COQ proteins, such as COQ4 or COQ6, induces a faster mtDNA 
recovery rate after depletion induced by ethidium bromide (EtBr) treatment. 
This phenomenon does not seem to be due to the lack of CoQ10. 
iii. Faster mtDNA recovery rate is not due to mitochondrial cholesterol total levels, 
which overall are not altered in cells lacking COQ4.   
iv. Density gradients of pure mitochondria show that the lack of COQ4 slightly alters 
nucleoid structure in mitochondria. ATAD3 and TFAM show a wider distribution 
towards the low-density fractions when COQ4 protein is missing.  
v. COQ4 protein is found in low-density fractions of a density gradient, 
cosedimenting with a fraction of TFAM that may correspond to nucleoids in a 
non-replicative state and/or not attached to membranes.  This colocalisation 
could have some importance in the context of a regulation between mtDNA 
expression and CoQ10 biosynthesis. 
  

















D1. Primary CoQ10 deficiency 
D1.1. Phenotypic variability and attempt for genotype-phenotype associations 
Primary CoQ10 deficiency is a rare mitochondrial disorder caused by mutations in one of 
the nuclear genes participating in the CoQ10 biosynthesis pathway, such as PDSS1, 
PDSS2, COQ2, COQ4, COQ5, COQ6, COQ7, COQ8A/ADCK3, COQ8B/ADCK4 or COQ9 
112,225. Patients show a broad spectrum of clinical manifestations, with different organs 
and tissues affected in a variable way, mainly depending on the affected gene and 
probably on many other factors still to be completely defined. The most affected organs 
and systems are the central and peripheral nervous system, kidney, heart and skeletal 
muscle, but other more heterogeneous findings have also been reported. 
In this work, we have compiled and analysed the patients described in the literature so 
far for each mutated gene, according to the age of onset of the disease. We have studied 
the manifestations of the disease, the pathogenic mutations present in each family and 
other aspects, such as the response to CoQ10 treatment (Chapter 1). In this context, we 
have been able to describe the main phenotypic patterns of primary CoQ10 deficiency 
for each mutated gene, depending on the age when the patient first manifested the 
condition. These patterns are summarised in Table D.1. We have also checked for 
putative associations between some specific variants and these clinical phenotypic 
patterns. 
Mutations in some COQ genes produce a multisystemic affection. This is the case of 
PDSS1, PDSS2, COQ2, COQ4, COQ7 and COQ9 pathogenic variants, which are also the 
ones that produce a disease that manifests the earliest in life. The most predominant 
phenotype in PDSS2 and COQ2 patients is the renal affection mainly with some 
neurological manifestations 242,245,277,323,324. COQ4 patients mainly displayed 
encephalopathy with cardiomyopathy in many cases 250–252,336. The number of patients 
with mutations in PDSS1, COQ7 and COQ9 is too low to achieve a general conclusion, 
but they generally presented a multisystemic disease 238–241,246,248,256,322.  





Pathogenic variants of other COQ genes show a more specific phenotype. Patients with 
mutations in COQ6 manifest a nephrotic syndrome, with sensorineural hearing loss in 
many cases 233,235. COQ8B/ADCK4 patients had a steroid-resistant nephrotic syndrome, 
with multiple renal and some extrarenal features with variable frequency 229,363,364. The 
hallmark phenotype of patients with pathogenic variants of COQ8A/ADCK3 is  cerebellar 
ataxia, often associated with cerebellar atrophy and other neurological abnormalities 
like epilepsy or movement disorders 274,275,357. Only one family with a mutation in COQ5 
has been described so far, having an ataxic phenotype similar to COQ8A’ s one 326. Only 
one patient with ADCK2 haploinsufficiency has been described, presenting at adult age 
a mitochondrial myopathy378. 
Age of onset of the disease is very variable among the different families, ranging from 
birth to early childhood (PDSS1, PDSS2, COQ2, COQ4, COQ5, COQ6, COQ7, COQ9), from 
childhood to adolescence (COQ8A, COQ8B), or even during adulthood (COQ8A, COQ8B). 
Generally, the disease seems to be more severe when the first symptoms appear earlier 
in life. We classified the clinical cases described in the literature according to their age 
of onset, as an attempt to draw more specific clinical patterns between patients with 
mutations in the same gene. We have done this for the genes for which the total number 
of families with affected individuals was higher than 20 (COQ2, COQ4, COQ6, COQ8A 
and COQ8B). After the classification, we observed how different phenotypic clinical 
patterns appeared in some of the age of onset groups, which are detailed in Table D.1 
and Chapter 1 (Section 1.2.4).  
Many mutations associated with primary CoQ10 deficiency are rare or private. We have 
analysed, for each gene, the most common ones, and how they are distributed within 
the different age-of-onset groups of patients (Table D.1). For some genes, like COQ2 and 
COQ6, some specific variants are clustered in the different age-of-onset groups (Table 
D.1). Based on some functional studies found in the literature, it seems that the residual 
activity of the mutated protein is essential for determining the severity of the disease 
232,277. A profound functional study on how all these mutations affect protein 
functionality could shed light to this hypothesis. No clear associations have been 






This distinction of different phenotypic patterns depending on the mutated gene, the 
age of onset of the disease and the pathogenic variants has been previously observed in 
several specific studies, focused in one particular gene or clinical case. We believe its 
application to the whole group of primary CoQ10 patients can be clinically useful for the 
early diagnosis and management of patients with primary CoQ10 deficiency suspicion. 
To contribute to this purpose, we have also built a web-based database that will grow 
with all the published primary CoQ10 deficiency clinical cases and their features: 
https://coq-biology.github.io/clinic-CoQ-defects. Heatmap representation of the 
frequency of symptoms will give a visual and convenient overview of the disease 
according to the affected gene, which we think will be useful in a clinical context.  
Table D.1. Main clinical phenotypes of primary CoQ10 deficiency patients, classified by the 












All (3) 1 yo 
Only two families with different 





All (7) 6 mo 
multisystem disorder with mainly 
renal involvement and a wide range 
of neurological manifestations 
c.1145C>T (p.Ser382Leu) (2) 
COQ2 
(30) 
1 (13) 2 wo 
early-onset severe multisystemic 
disorder, mainly with renal and CNS 
involvement 
c.287G>A (p.Ser96Asn) (5) 
2 (6) 9 mo 
infancy-onset SRNS that was 
accompanied by some neurological 
symptoms 
c.740A>G (p.Tyr247Cys) (2), 
c.823A>G (p.Thr275Ala) (2) 
3 (9) 34 mo 
infancy or childhood -onset isolated 
SRNS 
c.533A>G (p.Asn178Ser) (8) 
4 (2) 17 yo 
Adolescence-onset SRNS with a 
mild CNS involvement 
c.1019G>C (p.Gly340Ala) (1) 
COQ4 
(35) 
1 (25) 2 wo 
Neonatal or infantile-onset 
encephalo-cardiomyopathy 
c.370G>A (p.Gly124Ser) (9),  
c.402+1G>C (3), 
c.718C>T (p.Arg240Cys) (3) 
2 (4) 6 mo infantile-onset encephalopathy 
c.370G>A (p.Gly124Ser) (3), 
371G>T (p.Gly124Val) (2) 
3 (5) 6 yo 
childhood-onset progressive 
spinocerebellar ataxia 
c.190C>T (p.Pro64Ser) (1), 
c.230C>T (p.Thr77Ile) (1),   






early childhood cerebellar ataxic 
phenotype 
- 
Abbreviations: P: number of patients; F: number of families; SRNS: steroid resistant nephrotic syndrome; 









Table D.1. Main clinical phenotypes of primary CoQ10 deficiency patients, classified by the 













1 (15) 1 yo 
infantile-onset SRNS, sometimes 
with SNHL and CNS affection 
c.763G>A (p.Gly255Arg) (2),  
c.1078C>T (p.Arg360Trp) (3), 
c.189_191delGAA (p.Lys64del) (3), 
c.782C>T (p.Pro261Leu) (3) 
2 (12) 5 yo 
childhood-onset SRNS, sometimes 
with SNHL 
c.1058C>A (p.Ala353Asp) (4), 
c.189_191delGAA (p.Lys64del) (3), 
c.782C>T (p.Pro261Leu) (3) 
COQ7 
(3) 
All (3) 4 mo 
neonatal-infancy onset 
multisystemic disorder with CNS, 





All (7) 1 mo 
neonatal-infancy onset 
multisystemic disorder, with CNS, 




1 (24) 19 mo 
infantile-onset cerebellar ataxic 
syndrome with intellectual 
disability and developmental delay 
c.1027C>T (p.Gln343*) (3),  
c.1823C>T (p.Ser608Phe) (2) 
2 (32) 6 yo 
childhood-onset cerebellar ataxic 
syndrome with cognitive 
impairment, tremor and speech 
difficulties 
c.901C>T (p.Arg301Trp) (4), 
c.895C>T (p.Arg299Trp) (3), 
c.1331_1332insCACAG 
(p.Glu446Alafs*33) (3),  
c.1844G>A (p.Gly615Asp) (3), 
c.1750_1752delACC (p.Thr584del) 
(3)  
3 (9) 14 yo 
adolescence-onset cerebellar ataxic 
syndrome with tremor, speech 
difficulties and myoclonus 
- 
4 (6) 22.5 yo 
adult-onset cerebellar ataxic 





1 (4) 17 mo 
infantile-onset SRNS with variable 
involvement of other organs 
c.748G>C (p.Asp250His) (2), 
c.1199dupA (p.His400Glnfs*11) (2) 
2 (28) 7.3 yo 
infantile-onset SRNS with variable 
involvement of other organs 
c.1339dupG (p.Glu447Glyfs*10) (4), 
c.293T>G (p.Leu98Arg) (3), 
c.737G>A (p.Ser246Asn) (3), 
c.1199dupA (p.His400Glnfs*11) (3), 
c.748G>C (p.Asp250His) (2) 
3 (35) 14.3 yo 
adolescence-onset SRNS with 
variable involvement of other 
organs 
c.1339dupG (p.Glu447Glyfs*10) (7), 
c.1199dupA (p.His400Glnfs*11) (4), 
c.737G>A (p.Ser246Asn) (3), 
c.645delT (p.Phe215Leufs*14) (3) 
 
4 (11) 24 yo 
adult-onset SRNS with variable 
involvement of other organs 
c.1339dupG (p.Glu447Glyfs*10) (4) 
 Abbreviations: P: number of patients; F: number of families; SRNS: steroid resistant nephrotic syndrome; 







D1.2. Expanding phenotypes and genotypes 
We also worked with primary fibroblasts from previously unreported cases of primary 
CoQ10 deficiency. In this context, we contributed to the biochemical diagnosis of the 
CoQ10 deficiency in fibroblasts from 5 patients with CoQ10 deficiency, with biallelic 
mutations in COQ7 and COQ4 genes (Chapter 2, sections 2.2.1 and 2.2.3). They had low 
levels of CoQ10 and impaired biosynthesis, reduced CII+III activity and impaired 
respiratory performance. 
P102 and P112 are two patients with new pathogenic variants in COQ7. P102 presented 
clinical manifestations similar to the three COQ7 patients reported in the literature. They 
all showed early-onset multisystemic disease, mainly with neurological involvement. In 
contrast, P112 presented an adolescence-onset and a mild progressive disorder with a 
pyramidal syndrome, hearing loss and neuropathic gait, expanding the phenotype of the 
disease with a strikingly different one. Interestingly, the genotype of this patient is also 
very different from all primary CoQ10 deficiency patients reported to date.  P112 has a 
homozygous mutation in the translation initiation codon (c.3G>T, p.Met1Ile, 
NM_016138.5). This extremely rare case of primary CoQ10 deficiency is the first one 
reported to have a mutation altering the translation initiation codon of a COQ protein. 
The pathogenicity of the mutation may primarily rely on the efficiency of COQ7 
translation or even in the mislocalization of the protein, rather than on a dysfunctional 
COQ protein. This fact should be taken into account for the possibility to design 
personalised therapeutic options. 
P105, P108 and P109 are three patients with new pathogenic variants in COQ4.  P105 
presented a birth-onset disease compatible with a COQ4 deficiency, but manifesting 
hypertonia instead of hypotonia. She died prematurely at the age of 16 months old. 
P108 and P109 presented early-onset severe hypotonia, developmental delay and 
regression, seizures and hypertrophic cardiomyopathy. P109 died at the age of 17 years 
old. All these patients presented new pathogenic variants in COQ4 gene. One of the 
mutations found in P105 is a point substitution in intron 5 (c.532+6 T>A, p.?, 
NM_016035.5), specifically in the 5’ donor splice site. We have observed that this 
mutation produces an aberrant COQ4 mRNA splicing pattern, inducing the skipping of 
exons 3 and 5, mainly. In this case, we observe how the pathogenicity of the mutation 





would rely on the process of splicing of the COQ4 pre-mRNA, that would reduce the 
levels of properly spliced variants and, consequently, would impact the rate and 
efficiency CoQ10 biosynthesis process. As explained before, it is important to consider 
this fact for possible and personalised therapeutic options in this kind of mutations. 
D1.3. Intermediates of the pathway as diagnostic markers 
CoQ is synthesised by a multienzymatic complex composed by different proteins 
involved in the process. Defects in one of these components sometimes lead to the 
accumulation of specific intermediates in certain yeast, bacteria and mammalian models 
(Chapter 4, section 4.1.5 and Tables 4.4, 4.5 and 4.6)). However, not a great number of 
studies of the accumulated intermediates have been performed in human models of 
primary CoQ10 deficiency disease. DMQ10, the substrate of COQ7 enzyme, has been 
found accumulated in several models of CoQ10 deficiency. Specifically, it has been 
described as a diagnostic intermediate for COQ7 and COQ9 deficiency, in primary 
fibroblasts from patients with mutations in these two genes 239,388. Interestingly, it was 
also found in lower amounts in patient fibroblasts with mutations in COQ4 388.  
In this work, we equally found high amounts of DMQ10 accumulated in patients with 
mutations in COQ7. Moreover, we were able to find other diagnostic intermediates 
accumulated in models with defects in COQ6 and COQ4 proteins. Human COQ6 KO cells 
accumulate 4-HP10 intermediate 165, in agreement with the accumulation of 4-HP 
reported in yeast 342,396 and bacterial 460 models deficient in C5 hydroxylation function. 
Human COQ4 KO cells also accumulate a not previously reported specific intermediate 
that we have been able to observe in the HPLC chromatograms. Consistently, patient 
fibroblasts with mutations in COQ4 equally show this peak. Currently, we are trying to 
identify this molecule which could be a very valuable marker for the diagnosis  of CoQ10 
deficiency due to COQ4 mutations.   
D1.4. Primary CoQ10 deficiency: a treatable disorder  
Supplementation with CoQ10 or derivatives is the only therapeutic option currently 
available for CoQ10 deficiency. Patients generally respond quite well to CoQ10 
supplementation, but in some cases, the treatment does not have any effect. The 






the irreversible damage in critical tissues has not been completely established yet 255. 
However, no other clear predictors of treatment response have been identified.  There 
are difficulties that hinder our understanding of this variable response to treatment.   
CoQ10 treatment and the patient’s response to it has been described in almost half of 
the reported primary CoQ10 deficiency cases in the literature. However, among these 
reports, response to treatment has been measured in different and not standardised 
ways, generally as an amelioration of the specific reported symptoms. Due to the small 
number of patients and the diversity of the reports, it is difficult to establish quantitative 
data regarding the response to CoQ10 treatment.  
Moreover, CoQ10 delivery in muscle and brain tissue is generally limited, due to its high 
molecular weight and lipophilicity. However, at high doses, dietary supplementation has 
been proved to increase CoQ10 levels in all tissues, especially in the case of certain lipid-
soluble formulations 280,281,689. For these reasons, patients are worldwide treated with 
very different doses and formulations of CoQ10. Doses range from 5 mg/kg/day 285 to 30-
50 mg/kg/day for both adults and children 286. Different formulations of CoQ10 are now 
available and being used in a clinical context. There are CoQ10 drugs both in the oxidized 
and the reduced forms, with different properties. All this variability may also contribute 
to the differences in treatment response.  
Alternatively to CoQ10 supplementation, some soluble 4-HB head precursor analogues 
have been proposed as potential therapeutic molecules with higher bioavailability than 
CoQ10 289. These molecules provide the defective chemical group and can reactivate 
endogenous CoQ biosynthesis. Currently, they have not been yet utilised for patients’ 
treatment, but they have been proven useful in yeast, mammalian cell cultures and 
mouse models of primary CoQ10 deficiency 238,239,342,399–401. In this work, we have 
observed that vanillic acid treatment is more effective than CoQ10 treatment in a COQ6 
KO human cell line 165. We have also observed how 2,4-dHB treatment is generally 
beneficial in fibroblasts from patients with mutations in COQ7. Taking these facts 
together, 4-HB analogues could be considered as promising potential therapeutic agents 
for specific defects in CoQ10 biosynthesis. However, the conditions of the treatment 
should be personalised for each patient, since these molecules seem to be more 
effective when the CoQ10 biosynthetic defect is more severe.  





D2. Investigating COQ4 function  
D2.1. COQ4 function in CoQ10 biosynthesis and mitochondrial respiration 
COQ4 protein has an essential role in CoQ10 biosynthesis. It was first described and 
studied in yeast, in which it was suggested to play a structural role in stabilizing the CoQ 
biosynthetic complex 465,466. In our work, we have demonstrated that human COQ4 
protein is essential for CoQ10 biosynthesis in human cells (Chapter 4, section 4.2.1). The 
lack of COQ4 leads to drastically reduced CoQ10 levels (Figures 4.6, 4.8 and 4.14), which 
causes a great respiratory defect that is rescued with CoQ10 treatment or WT COQ4 
expression. Moreover, knocking-out COQ4 protein produces the accumulation of a 
specific intermediate, as described in section D1.3. It is possible that the lack of COQ4 
and its structural function in the CoQ10 biosynthesis complex derives in a destabilisation 
of contacts between the different COQ proteins, ending up in the accumulation of an 
intermediate molecule of the pathway. Other possibility is that, in addition to the 
important structural function of COQ4, it could have other roles directly or indirectly on 
a specific enzymatic reaction in the pathway and its defect would lead to the 
accumulation of the intermediate.  
We have used our CRISPR/Cas9 produced COQ4 KO to try to study other aspects related 
to COQ4 function. We predicted the presence of a potential phosphorylatable loop, 
composed of the residues S106, T107, S108 and T109 andused site-directed 
mutagenesis to study this possible protein phosphorylation, changing Ser/Thr to Ala to 
prevent phosphorylation, and Ser/Thr to Glu to mimic constitutive phosphorylation. 
Expression of these mutants on a COQ4 KO background recovered COQ4 function, 
restoring CoQ10 levels, at least in the conditions tested (Figure 4.9). It could be also 
possible that these variants affect somehow COQ4 function, but our system is not fine 
enough to distinguish differences in residual activity due to a high expression of the 
transgene. Further studies would be needed to ultimately unveil the significance of 
these residues in CoQ10 biosynthesis regulation under different conditions.   
We also expressed COQ4 carrying the pathogenic variants found in patients in the COQ4 
KO background, in order to analyse the pathogenicity of the mutations. Surprisingly, 






recovering CoQ10 biosynthesis in the COQ4 KO cells when overexpressed (Figure 4.10). 
The expression system we used seem to be unable to discern different levels of activity 
of the mutated COQ4 proteins. However, it seems to be useful for examining the 
pathogenicity of loss-of-function variants. For the rest of mutations, we propose a 
combination of the mutant COQ4 variant overexpression and a pABA treatment that 
partially inhibits CoQ10 biosynthesis from 4-HB (Figure 4.11). This combined system 
could help us to elucidate the pathogenicity of the mutations found in patients, by 
understanding the levels of residual activity that the mutant proteins may have.  
Treatment with pABA also helped us in the task of investigating COQ4 function. When 
comparing pABA-treated COQ4 KO cells with WT cells or cells expressing a WT or mutant 
version of COQ4, we could observe how all of them, except COQ4 KO, presented an 
accumulation of DMQ10, due to a partial inhibition of the endogenous CoQ10 synthesis 
from 4-HB (Figure 4.11). This fact supports the idea that COQ4 may act directly or 
indirectly upstream DMQ10 production, or that its specific function precedes DMQ10 
formation, since it is not found when COQ4 is totally abstent.  
D2.2. COQ4 forms a dynamic complex with COQ3-9 proteins, essential for CoQ10 
synthesis 
CoQ6 biosynthesis complex has been extensively studied in yeast, in which it is described 
to be composed by Coq3p-Coq9p proteins. Some recent studies identify Coq8p 
dynamically interacting with the complex, but not as an integral component 1,316,438. 
There is increasing evidence of the formation of such a complex in mammals as well. 
With this work, we aimed to provides further insights about the CoQ10 biosynthesis 
complex and its composition in humans. Specifically, we were interested in studying 
COQ4 interaction partners. In order to do so, we performed BN-PAGE and 
immunocapture of COQ4, with or without SILAC labelling (Chapter 4, section 4.2.3).  
BN-PAGE and blots of COQ4 protein showed that this protein migrated to the bottom of 
the gel, in low molecular weights (Figure 4.15.A and C). These results suggested that 
COQ4 is not stably interacting in high molecular weight complexes, at least in our 
experimental conditions of cell growth, or even solubilization or electrophoresis. 
Additionally, 2D BN-PAGE showed a 50 KDa band at the low molecular weights’ region, 





in the controls but not in the COQ4 KO. We could speculate that it could be a very stable 
dimeric form of COQ4 (resistant to SDS treatment), that it is not forming higher 
molecular weight complexes.  
We were able to identify proteins that copurified with COQ4 after immunocapture. 
Interestingly, all the COQ proteins (except for COQ8A) were found significantly 
overrepresented in the eluates of COQ4 purification (Table 4.9). The fact that they all 
co-purified with COQ4-FS provides evidence for the mammalian CoQ biosynthesis 
complex and its composition. Moreover, we observed by Western blot that the lack of 
COQ4 or COQ6 proteins alters the levels of other COQs proteins, probably modifying the 
stability of the biosynthetic complex.   
Interestingly, recent studies in yeast localised the CoQ-head modifying enzymes in 
discrete loci named CoQ domains, spatially and functionally related to ERMES1,2,316. A 
similar distribution of COQ9 protein was also observed in human cells1. Further research 
is needed to analyse if this relationship between ER-mitochondria contacts and CoQ10 
biosynthesis is also conserved in mammals and to understand its implications. 
D2.3. Studying the relationship between CoQ10 biosynthesis and mtDNA 
metabolism.  
Different studies have reported an important link between ER-mitochondria contacts 
and proper nucleoids distribution in mitochondria 3,656. Remarkably, the cholesterol 
content in these areas seems to be key for mtDNA replication of membrane-attached 
nucleoids 4. Moreover, CoQ biosynthesis has also been related to ER-mitochondria 
contact sites, since CoQ head-modifying enzymes resolved in discrete loci, the so-called 
CoQ domains, adjacent to ER-mitochondria contact sites 1,2,316. Besides this newly 
described spatial localisation in mitochondria, CoQ and cholesterol also share part of 
their mevalonate-derived lipid chain biosynthesis in the ER 522,523. Therefore, all these 
processed must be tightly regulated, and it is possible that if one of them is altered, the 
others can be affected. 
That is why we wanted to further investigate if CoQ deficiency due to COQ4 defects, 
may lead to an impairment in other important mitochondrial functions related to 






context, we found that the lack of COQ4 led to a slight decrease of mtDNA copy number, 
with no effect on mtDNA transcription and a very subtle effect on mtDNA-encoded 
proteins synthesis (Chapter 5, sections 5.2.1, 5.2.2 and 5.2.3). 
However, regarding mtDNA replication, we observed a surprising phenotype in the 
COQ4 and COQ6 KO cells (Chapter 5, section 5.2.4). The lack of these two COQ proteins 
induced a faster mtDNA recovery rate (compared to controls) after depletion induced 
by ethidium bromide treatment indicative of a more efficient mtDNA replication. This 
phenomenon does not seem to be due to the lack of CoQ10 because it was equally 
observed after CoQ10 supplementation. We suspected it could be rather related to an 
altered mitochondrial cholesterol content or distribution that may affect mtDNA 
replication. Reduced CoQ biosynthesis may lead to an accumulation of upstream 
intermediaries that would be available for more cholesterol biosynthesis and/or more 
stable cholesterol platforms in the IMM. However, we found that total cholesterol levels 
were not altered in mitochondria, although this does not rule out the possibility of 
changes in the micro-domains of cholesterol platforms. To study cholesterol 
distribution, as well as the distribution of related proteins within mitochondria, we 
performed very preliminary studies using density gradients.  Interestingly, we found 
subtle differences between COQ4 KO and control cells in terms of nucleoid proteins 
(TFAM and ATAD3) distribution in these gradients, which maybe are behind the COQ4 
KO fast mtDNA recovery after induced depletion. However, there is still a lot of work to 
be done to better understand the relationship between CoQ biosynthesis and mtDNA 
metabolism. Super-resolution microscopy of nucleoids may help us describe these 
possible differences in nucleoids structure and distribution, which we think is essential 
for the next steps of this project. Many mtDNA depletions are associated with CoQ 
secondary reduced levels. The understanding of the possible mtDNA metabolism and 
CoQ biosynthesis interplay in mitochondria would represent a milestone for unveiling 
the complexity of mitochondrial and specifically CoQ deficiencies conditions. 
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